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Abstract 
The process of parturition resulting in the delivery of a newborn is a 
fundamental event ensuring survival of the species.  In humans, the main clinical 
problems of parturition include activation of the process too early or too late 
resulting in the delivery of pre-term and post-term infants, both with their own 
implications for future health for the mother and baby.  Additionally, where 
parturition systems are not activated correctly, dysfunctional labour with the 
resulting need for caesarean delivery (CS), in addition to atonic post-partum 
haemorrhage can also ensue.  Overall, in the UK up to 40% of pregnancies are 
affected by one of these problems.  However, the exact processes involved in 
the initiation and maintenance of parturition in the human are not fully 
understood.  With such an important event, influences are most likely to be 
multi-factorial, with hormonal, mechanical, inflammatory, biochemical and 
maternal environmental factors playing a part. 
The aims of this thesis were to investigate influences on parturition in human 
pregnancy.  Firstly, the myometrial transcriptional effects of long term exposure 
to the uterotonic oxytocin (OT) were examined.  Further investigation of the 
myometrial and maternal peripheral response to uterine contractions in-vitro 
and in-vivo was also made with particular reference to the role of inflammation 
and myocyte damage.  Additionally, the influence of maternal factors, 
particularly obesity, on the myometrial in-vitro contractile function and 
response to OT was studied. 
Initially, 150 gene arrays were produced using the Illumina platform.  The 
samples were derived from myometrium taken at pre-labour CS which 
subsequently underwent functional contractility experiments in an organ bath.  
Five drug environments were studied, namely OT, acetic acid (OT vehicle), ML7 
(a tocolytic acting via inhibition of myosin light chain kinase), ML7 & OT and 
finally DMSO (ML7 vehicle).  Additionally, five time-points of 0, 1, 2, 4, and 6 
hours after drug addition were used, resulting in 5 samples for each drug and 
time combination.  The results indicated that despite a clear enhancement of 
myometrial contractile activity by OT, this functional response does not appear 
to be mediated by cellular transcription.  However, there was a clear 
contraction and time dependent transcriptional wave, with overrepresentation 
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of genes associated with inflammation and cellular damage/apoptosis, and 
down-regulation of pathways concerning cellular metabolism. 
These findings were confirmed by QPCR on further myometrial samples 
undergoing additional in-vitro functional studies.  In addition to the temporal 
and contractile association with the inflammatory response, our data suggest 
inflammation occurs in response to myocyte cellular damage regardless of mode 
of damage e.g. contractile or chemically induced.  This was demonstrated by 
inflammatory upregulation in myometrium exposed to the tocolytic agents 
nifedipine and ritodrine, which is not seen in response to ML7.  Additionally, the 
myometrial inflammatory response was enhanced by the infective agent LPS.  
However, contrary to other proposals, the enhanced inflammatory response of 
the myometrium did not alter or promote the in-vitro contractile ability of the 
myometrium or its response to OT.  This myometrial transcriptional data 
therefore suggests that the inflammatory response of labour is associated with 
contraction, chemical or infection induced myometrial cellular damage, but 
would not be considered necessary for a contractile response. 
Our in-vivo study of peripheral changes in the maternal circulation again 
supported our in-vitro myometrial data.  Data showed that the effect of 
pregnancy at term was limited to increased white cell count driven by a 
neutrophilia, with no suggestion of leukocyte priming prior to labour.  
Additionally, term pregnancy is associated with an increase in CRP, an increase 
in GCSF (corresponding with the neutrophilia) in addition to suppression of the 
chemokines CCL11 and CCL22.  Subsequently, we found that repeated blood 
samples taken at 2 hourly intervals during term labour induced dramatic changes 
in inflammatory cells and inflammatory mediators in the maternal circulation.  
Importantly, these changes occur in a co-ordinated time and contraction 
dependent manner, with the degree of inflammation associated with the length 
of time in labour and the degree of myocyte damage as measured by circulating 
CK and Mb. 
Our study of the influence of maternal factors on myometrial contractile ability 
and response to OT examined in-vitro myometrial contractility of 609 
myometrial strips from 85 women.  We demonstrated that maternal obesity does 
not impair spontaneous or OT induced myometrial contractions in-vitro.  
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Furthermore, maternal age, ethnicity, parity, previous caesarean delivery, 
gestation at delivery and birthweight do not influence in-vitro myometrial 
spontaneous or OT induced contractile activity.  This therefore suggests that the 
observed implication of these maternal and infant factors on parturition in-vivo 
(high rates of induction of labour, high rates of intrapartum caesarean delivery 
and post partum haemorrhage) cannot be explained by an effect on myometrial 
contraction per se.  This therefore merits further investigation as to alternative 
mechanisms to ultimately promote and effective, uncomplicated and safe labour 
and vaginal delivery for at risk mothers. 
In summary, this thesis provides evidence that the myometrial contractions of 
human labour, whether spontaneous or OT induced are capable of inducing a 
temporal wave of transcriptional changes associated with the processes of 
inflammation, cellular damage/apoptosis with inhibition of cellular metabolic 
processes.  In addition, maternal peripheral circulating factors mirror the 
myometrial transcriptional changes.  These changes are highly comparable with 
those seen in response to exercising skeletal muscle, and in this model have 
been shown to play an important role in muscle repair and remodelling after 
exercise.  Therefore, we would suggest that the inflammatory reaction typically 
associated with human labour occurs as a non-specific response to contraction 
induced cellular damage and may play a role in postpartum repair and 
remodelling of the uterus.  
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Chapter 1  
General Introduction and themes of thesis 
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1 Introduction 
1.1 Human parturition 
The process of human parturition leading to delivery of a newborn infant is 
essential to secure the survival of mankind.  Worldwide figures indicate that 
during the year 2012 there will be an estimated 134,475,000 live births adding to 
the population, with 774,000 in the UK1.  Despite parturition being such a 
fundamental event, the exact processes involved in the initiation and 
maintenance of human parturition are not fully understood. 
In humans, normal pregnancy is classically considered as spanning 40 weeks from 
the date of the last menstrual period (LMP), with term being considered at any 
time after 37 completed weeks.  During pregnancy it is essential that the 
contractile apparatus of the uterus remains relaxed and quiescent to 
accommodate the growing foetus with the cervix remaining rigid and closed.  
Successful parturition is achieved at term when the cervix starts to soften 
(ripen) with breakdown of the collagen fibres.  At the same time the uterus 
becomes more responsive and active with the resultant contractile activity 
typically required for labour and delivery of the newborn.  After delivery the 
uterus involutes with eventual return of normal function and preparation for 
future pregnancy.  The typical stages and timeline for the uterus in pregnancy 
are illustrated in Figure 1. 
 
Figure 1 Phases of myometrial activation 
Depiction of the typical stages and approximate timing of the activity of the contractile 
apparatus during pregnancy and parturition. 
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1.2 The clinical problems 
The clinical implications of incorrect activation of myometrial associated 
parturition pathways can be considered as three categories; activation too early, 
activation too late or dysfunctional activation either during labour or in the 
post-partum period.  These are summarised below in Figure 2.   
 
Figure 2 Phases of myometrial activation 
Graphical depiction of timing of inappropriate activation of parturition pathways resulting in 
clinical problems with the mother or infant. 
It is estimated that overall in the UK up to 40% of pregnancies may be affected 
by incorrect activation of parturition pathways2-8, with each described in more 
detail in the following sections. 
It remains unclear as to why aberrant activation of myometrial associated 
parturition pathways occurs, however, knowledge regarding these processes 
including modulating factors has the potential to help prevent abnormal 
activation and promote safe, effective and efficient parturition and delivery of 
the newborn infant. 
1.2.1 Activation too early 
Activation of the parturition processes prior to 37 completed weeks of pregnancy 
is considered too early and may result in the delivery of a pre-term infant.  It is 
estimated that 1 in 10 of all babies born world wide are born prematurely, with 
rates ranging from 4% to 20%2.  Scottish figures for 2010 indicate preterm 
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delivery affected 7.5% of all births and 6% of all singleton births3.  English data 
show similar figures with the rate of preterm delivery standing at 7.3% of live 
born singletons 2010-20114.  Additionally, recent data reviews have suggested 
preterm birth rates appear to be increasing, both in developed and developing 
populations5. 
The implications of pre-term delivery can be severe with estimate of 1million 
children per year dying worldwide as a result of prematurity, with risks of severe 
physical and mental disabilities or difficulties inversely related to gestation in 
those who survive2 6-11.  Additionally there are long term implications for both 
the mother and wider family following the birth of a pre-term infant10 12-14.  In 
terms of the economic costs, infants born prematurely commonly require 
intensive neonatal care input along with lifelong supportive costs for any 
residual physical or learning difficulties 10 11 15-17. 
It must be acknowledged that premature delivery does not necessarily occur as a 
result of pre-term labour, with approximately 30% of premature deliveries being 
iatrogenic18.  In these situations, early delivery either by induction of labour or 
caesarean delivery, is expedited as a medical response when there is maternal 
or foetal risk if the pregnancy were to continue, many of which are linked to 
hypertensive or pre-eclamptic pathologies18 19. 
The remaining 70% of preterm deliveries occur secondary to either pre-term 
labour with intact membranes and premature activation of the uterine 
contractile machinery (40-45%), or following premature rupture of membranes 
(25-30%)18 20.  In approximately 50% of those experiencing spontaneous preterm 
birth no identifiable cause is found.  Therefore, the aetiology can be considered 
multifactorial with risk factors including multiple pregnancy, maternal body 
mass index (BMI), maternal age, previous or familial history of premature birth, 
cervical dysfunction, maternal ethnicity, maternal infection, antepartum 
haemorrhage, cigarette smoking, high alcohol consumption, use of recreational 
drugs, socioeconomic status and maternal stress18 19 21-31. 
It remains unclear as to whether the processes of term and preterm labours can 
be considered identical with the only difference being gestation.  The 
occurrence of increased uterine contractility and cervical ripening and dilatation 
are certainly common to both situations.  However, the concept of the ‘preterm 
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parturition syndrome’ has been proposed where preterm activation of the 
contractile machinery is influenced by pathological signalling pathways 
influenced by intrauterine infection, uterine ischaemia, uterine overdistension, 
abnormal allogenic recognition, allergic-like reaction, cervical disease, and 
endocrine disorders 23.  Many of the factors suggested to be involved in this 
pathological activation are discussed later in this chapter. 
1.2.2  Activation too late  
As term approaches most women will labour spontaneously.  In the United 
States, prolonged or ‘post-dates’ pregnancies are estimated to affect 5-10% of 
all pregnancies, and where no obstetric intervention is undertaken estimated 
rates of 18% of all singleton pregnancies last >41 weeks, 10% (range 3% to 14%) 
>42 weeks and 4% (range 2% to 7%) continue beyond 43 weeks32.  English data for 
2010-2011 indicate that deliveries after 42 weeks account for 3.6% of all live 
births and 2.3% of all births with spontaneous onset4.  Additionally, at >42 weeks 
gestation, 33.9% of deliveries at this gestation will occur following spontaneous 
onset of labour compared with 79.0% at 40 weeks gestation4. Conversely, 34.3%, 
19.6% and 11.9% of all inductions of labour occur beyond at 40, 41 and 42 week 
gestation respectively, with 56.5% of all labours at >42 weeks requiring induced 
onset4. 
Post dates pregnancies have implications for both the mother and the infant.  
Post dates pregnancy increases the rates of antepartum and intrapartum 
stillbirth33-35, perinatal death and morbidity many of which are related to 
meconium aspiration36-40.  Some have also shown increased risks of shoulder 
dystocia, intrapartum caesarean section for both foetal distress and failure to 
progress in labour, instrumental deliveries, severe perineal trauma and injury, 
and post partum haemorrhage (PPH)38 40-44.  Additionally, new data suggest that 
post-term birth may also affect development of the child in later life, with 
increased risks of behavioural and emotional problems in childhood45. 
Interestingly, family history tends to increase the incidence of post dates 
pregnancy, with both maternal and paternal influences if they themselves were 
born postdates46.  This suggests that the contractile mechanisms and 
responsiveness of the myometrium may be genetically determined. 
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It is recommended practice in the UK to offer induction of labour to women with 
uncomplicated pregnancies between 41+0 and 42+0 weeks gestation44.  As 
discussed earlier, induction of labour is also undertaken at earlier gestations for 
other clinical reasons where the mother or infant may be compromised18 19.  
Therefore, overall, induction of labour accounted for 22.5% of all live births in 
Scotland 20103.   
However, induction of labour (IOL) is not without risks itself.  The process can 
last longer47 and be perceived to be more painful than spontaneous labour, 
increasing the need for regional analgesia48.  Additionally, there are risks of 
uterine hyperstimulation and rupture.  Induction of labour may not always work, 
and some have suggested higher rates of intrapartum caesarean delivery or 
assisted vaginal delivery in those undergoing elective induction of labour 
compared with expectant management48-54.  However, this may be influenced by 
parity, maternal age, cervical length or medical interpretation of length of 
labour rather than the induction process itself47 52 55 56.  IOL also has both 
physical and emotional implications for the mother57. 
1.2.3 Dysfunctional activation 
Dysfunctional activation of the myometrial contractile machinery can result in 
two main clinical problems.  Firstly, dysfunctional labour may present as poor 
uterine contractility which may result in the need for an assisted vaginal 
delivery (forceps or ventouse) or delivery by intrapartum caesarean section.  
Secondly, failure of contraction mechanisms post delivery can result in atonic 
post partum haemorrhage (PPH) with excessive blood loss following delivery. 
Overall caesarean section (CS) rates remain high at 26.6% of live births in 
Scotland with 11.3% of all deliveries classed as elective CS and 15.3% as 
emergency CS3.  Failure to progress in labour has been identified as a major 
aetiological factor in the decision to perform an emergency CS, and is cited as a 
primary indication in up to 53% of intrapartum CS deliveries in singleton cephalic 
pregnancies58-61.  This occurs despite augmentation of labour with the uterotonin 
Syntocinon® as up to 81% of these women have received oxytocin (OT) prior to 
CS7 14.   
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There are specific maternal and pregnancy characteristics which appear to 
negatively influence and tend to suppress uterine contractility in-vivo.  These 
include maternal BMI62-67, maternal age68-71, nulliparity72 73, previous mode of 
delivery74-78, gestation79 80 and birthweight79.  The mechanisms for this negative 
influence of patient characteristics upon myometrial contractile function remain 
uncertain. 
PPH is one of the most common obstetric emergencies and haemorrhage at 
anytime in pregnancy represents the sixth leading cause of maternal mortality in 
the UK during 2006-200981.  PPH is defined as a loss of >500ml of blood from the 
genital tract which can either be within 24 hours of delivery (primary PPH) or 
between 24 hours and 12 weeks post delivery (secondary PPH).  The rate of PPH 
in England is approximately 12%4.  In addition major obstetric haemorrhage is 
considered to be the loss of ≥2500mls of blood or the requirement of a 
transfusion of ≥5units of blood.  Rates of major obstetric haemorrhage have 
increased in Scotland, with an incidence of 3.7 per 1000 live births in 2003-2005 
and 5.18 per 1000 live births in 2009.  Notably, atony of the uterus secondary to 
dysfunction of the contractile mechanisms rendering the uterus unable to 
contract sufficiently to control bleeding is responsible for up to 50% of PPH 
cases82 83.   
Overall, it remains unclear as to why aberrant activation of myometrial 
associated parturition pathways occurs with the clinical outcomes described 
above.  The next section will attempt to summarise current knowledge of the 
contractile apparatus involved in parturition and factors known to influence 
activation of contractile pathways. 
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1.3 The Uterus and parturition related contractile 
machinery 
The uterus is a hollow fibromuscular organ which sits within the female pelvis, 
bounded anteriorly by the bladder and posteriorly by the rectum84.  It is subject 
to multiple changes throughout a woman’s life; cyclical changes related to 
menstruation, accommodation of the growing foetus during pregnancy, force 
generation during labour and subsequent post partum remodelling.  In terms of 
size, in the nulliparous adult, the uterus is approximately 6-8cm long, 5cm wide, 
with the walls being 2.5 cm thick and can weigh up to 70 grams85.  During 
pregnancy, hyperplasia and cellular hypertrophy of the uterus result in an 
enlargement of four to five times with a final weight of approximately 1000 
grams and the ability to accommodate a total volume of up to 5 litres85 86. 
Anatomically, the uterus can be considered in two parts; the upper muscular 
uterine body (or corpus) and the lower fibrous uterine cervix84 87 (Figure 3).  Of 
note is the area described as the isthmus in the non-pregnant uterus; an area 
0.5-1.0cm long which is still considered part of the corpus and is bounded 
superiorly by the anatomical internal os and inferiorly by the histological 
internal os84 87-89(Figure 3).  It is the isthmus which is thought to expand after 28-
30 weeks gestation to approximately 2.5cm in length and is at this point referred 
to as the lower uterine segment, an anatomical area important in caesarean 
delivery.  Of note, despite being thinner walled than the upper uterine corpus 
during pregnancy, the lower segment consists of approximately 70-80% uterine 
myocyte90 91, and displays a similar in-vitro contractile ability to samples from 
the upper segment92. 
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Figure 3  Gross anatomy of the human uterus 
Reproduced from Anatomy of Uterus, Harold Ellis87 
During pregnancy, the expulsive forces of the muscular corpus must be balanced 
against the resistance or competence of the cervix in order to facilitate in-utero 
development of the infant until term with subsequent changes in the balance of 
forces allowing for delivery.  The current knowledge regarding influences on this 
change in balance between the cervix and the uterine body will be further 
discussed in the remainder of this chapter. 
1.3.1 The uterine cervix 
In many aspects, the cervix appears to be a continuation of the uterus (Figure 
3).  However it differs in its constitution with sparse contractile myocytes and a 
preponderance of fibrous connective tissue89 93-95.  It is this connective tissue 
which contributes to the tensile structure of the cervix during pregnancy.  At 
term the connective tissue degrades, softening the cervix, thus allowing 
‘ripening’ and dilatation to facilitate passage and delivery of the neonate.  This 
cervical remodelling occurs not only during the active phase of labour, but also 
towards term, with additional changes during postpartum repair93 96 97.   
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The most abundant protein within the cervix is collagen which contributes to the 
firm tensile structure93 94.  Cervical collagen is made up from Type I and Type 
III93 with evidence of Type IV collagen in association with smooth muscle cells 
and blood vessels94 95.  During ripening, there is a loss of tissue integrity mainly 
through changes to collagen fibril structure, disorganisation of collagen bundles, 
oedema and an increased volume of glycosaminoglycans93 96.  An important 
constituent of the extracellur matrix are the glycosaminoglycans, particularly 
hyaluronan and proteoglycans (versican, decorin, biglycan, fibromodulin and 
asporin)93 96.  These are thought to modulate the disruption and disorganisation 
of the collagen bundles, promote the accompanying increase in water content 
and oedema of the cervix typically seen during cervical remodelling93 94 96. 
Additionally, elastin fibres comprise 0.9-2.4% of cervical connective tissue in the 
pregnant and non-pregnant state and may also contribute to the recoil of the 
cervix during pregnancy and in the post partum remodelling period96.  The 
contractile myocytes within the cervix account for between 8.9- 15.5% of the 
cervix from the distal to proximal end95 98.  The cervical myocytes are capable of 
both spontaneous and drug induced contractile activity, however since they are 
sparse in number, it is probable their only function may be protection of 
surrounding blood vessels and closure of the cervix post delivery89.  
1.3.2 The uterine corpus 
The uterine corpus is the upper largest part of the uterus which connects 
inferiorly with the isthmus and cervix and on each side with a fallopian tube 
(Figure 3).  Anatomically, the fundus is considered the area of the corpus above 
the entrance of the fallopian tubes87.  The uterine body is made up of 3 layers, 
the outer perimetrium (covers the outer peritoneal surface of the uterus), the 
inner endometrium (consisting of ciliated columnar epithelium) and the middle 
thicker layer of myometrium (the muscular portion of the uterus).   
As this thesis is concerned with uterine contractility, the following section 
considers the contractile apparatus specific to the myometrium. 
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1.4 Myometrium – the uterine contractile machinery 
1.4.1 Anatomical organisation 
The myometrium is the largest layer of the uterus and provides the contractile 
element essential to the normal functioning of the female reproductive tract.  It 
consists mainly of contractile muscle cells (myocytes) interspersed with 
connective tissue, blood vessels, lymphatic vessels and nerves99.  In pregnancy 
the walls of the uterus are approximately 7mm thick and remain relatively 
stable across gestation from 26 weeks100.  It is this myometrial layer of the 
uterine wall which undergoes cellular hyperplasia and hypertrophy during 
pregnancy.  
Little definite evidence regarding the organisation of the myometrial cells in the 
human uterus in both the pregnant and non-pregnant state is known.  In other 
animals, particularly those with two uterine horns, for example rodents and 
rabbits, there appears to be two distinct muscular layers with an outer 
longitudinal and an inner circular layer99 101-103.   
 
Figure 4  Layers of the myometrium 
Proposed organisation of the layers of muscle fibres within the myometrial layer of the 
uterus body Layers of myometrium showing the three layers of smooth muscle fibre. Image 
downloaded from http://medical-dictionary.thefreedictionary.com/myometrium104 
Some consider the muscular fibres of the myometrium in humans to be arranged 
in three layers; the thin outer layer (stratum supravasculare) consisting of 
longitudinal fibres, the thickest middle layer (stratum vasculare) of swirling 
intertwined fibres surrounding blood vessels and the thin inner layer (stratum 
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subvasculare) which appears to have circular fibres85 99 105 (Figure 4).  This 
arrangement is thought to determine the force and direction of contractions 
during labour85.  Additionally the arrangement of the inner layer surrounding 
blood vessels is thought to play a protective role in stemming bleeding after 
delivery of the placenta85. 
However, others have not found the layers in the human uterus to be so distinct 
and alternative suggestions of a myometrial junctional layer in women of 
reproductive age have been made106 107 108(Figure 5).  This junctional layer has 
been studied mainly in the non-pregnant uterus where in-vivo imaging has shown 
peristaltic waves which vary in direction (cervico-fundal or fundo-cervical) 
dependent on the stage of the menstrual cycle109 110.  The inner zone of 
myometrium has been found to have a higher smooth muscle density with a 
higher ratio of nucleus to cytoplasm within these cells suggesting both structural 
and cellular differences between the inner and outer zones of the 
myometrium111 112. The role of the junctional layer during pregnancy and 
parturition is uncertain, and MRI imaging of the myometrium during pregnancy 
has suggested that zones become indistinct from early gestation, with a return 
normal within 6 months post delivery113.  Therefore, activity of the junctional 
layer may be limited to the non-pregnant state. 
 
Figure 5  Layers of the myometrium 
Illustration of the alternative layers of myometrium with the existence of the inner junctional 
or subendometrial myometrial zone and an outer myometrial zone.  Image reproduced from 
Aguilar et al106 
Further MRI studies in combination with computational modelling have 
attempted to describe the directionality of myometrial myocyte fibres105 (Figure 
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6).  This suggests that fibres run mainly in a circular direction implying a 
cylindrical form to the uterus with longitudinal fibres at the fundus105.  Further 
computational modelling of the uterus using a combination of in-vivo imaging 
and pressure monitoring techniques with in-vitro physiology studies hope to 
determine the organisation of fibres and functional direction of contractile 
forces for both the pregnant and non-pregnant uterus105 114 115. 
 
Figure 6  Global myometrial fibre structure of the uterus (dorsal view).   
Circular direction of fibres at the cervix and surrounding the uterine cavity are illustrated 
with a suggestion of longitudinal fibres at the fundus.  Red coloured fibres indicate 
transverse, left to right direction, green indicates through plane and blue top-down 
direction.  Fibre direction is computed from MR images using the FACT algorithm (fibre 
assignment by continuous tracking)  Further details and image from Weiss et al105 
1.4.2 Myometrial myocytes and intracellular mechanics 
The main cellular constituent of the myometrium is the contractile myocyte.  As 
in other smooth muscle organs, these are spindle shaped cells which are 
connected to each other via gap junctions and form smooth muscle bundles with 
the exact arrangement and orientation of these bundles not completely certain 
as described above116 (Section 1.4.1).  Smooth muscle, including myometrium, 
differs from skeletal muscle as contractions are involuntary and the cells are 
adapted for long sustained contractile activity. 
In the myometrial smooth muscle cell as in other myocytes, contractions are 
dependent on the final common pathway of an interaction between actin and 
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myosin causing shortening of the cell116.  Unlike skeletal muscle where actin 
filaments are attached to Z-lines and therefore allow contraction in one 
longitudinal direction, the actin filaments of smooth muscle cells are anchored 
to dense bodies which are scattered through the cytoplasm of the cell106 101 
117(Figure 7A and Figure 7B).  This is thought to facilitate the ability of the 
myocyte to stretch and accommodate contents of the hollow organ whilst 
maintaining contractile ability and strength.  The dense bodies are attached via 
intermediate filaments to dense bands which are found around the 
circumference of the cell attached to the plasma membrane and therefore aid 
the shortening of the cell during a contraction117 (Figure 7A & Figure 7B). 
 
Figure 7  The myometrial smooth muscle cell contractile machinery 
(A) myocytes packed into bundles connected by GAP junctions.  (B) Single myometrial 
smooth muscle cell illustrating presence of actin and myosin filaments attached to dense 
bodies within the cytoplasm.  Dense bodies are connected via intermediate filament (blue 
dotted line) to dense bands on cell membrane.  (C) Single actin and myosin complex 
attached to a dense body in the relaxed state.  In the presence of increased intracellular 
calcium, a calcium-calmodulin complex is formed which in turn activated the enzyme 
Myosin Light Chain Kinase (MLCK).  Activated MLCK catalyses the phosphorylation of 
myosin causing cross bridge formation between actin and myosin filaments and change in 
the direction of the neck region of the myosin.  This results in a contraction by shortening 
of the distance between the two anchor points (dense bodies) (D).  Contractions are 
terminated when the phosphorylation is reversed, a process facilitated by Myosin Light 
Chain Phosphatase (MLCP)106 
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Common to all types of muscle cells, contractions are under the control of 
intracellular calcium ([Ca2+]i,) levels (Figure 7).   With an increase in [Ca
2+]i, a 
calcium-calmodulin complex is formed which binds to the calmodulin-binding 
site on myosin light chain kinase (MLCK), thus activating its enzymatic activity.  
This activation of MLCK promotes phosphorylation of the 20kDA regulatory 
myosin light chains in turn initiating actin-myosin ATPase on myosin heavy chains 
allowing cross bridge formation with actin thereby facilitating cellular 
contraction.  It has been suggested that this is the common final pathway in 
myocyte contractions since in-vitro, MLCK inhibitors have rendered both rat and 
human myometrial samples unable to contract, even when exposed to the 
uterotonin oxytocin or in response to cellular depolarisation by Potassium 
Chloride (KCl) 118.   
Additionally, it has been shown that in contrast to the non-pregnant state, 
myometrium during pregnancy has the ability to produce a higher level of tissue 
stress or contraction for any given level of myosin light chain phosphorylation119, 
thus suggesting there is adaptation of the contractile mechanisms during 
pregnancy which favour a pro-contractile phenotype. 
Phosphorylation of the myosin heads is reversed as the intracellular calcium 
concentrations decrease and by actions of the enzyme Myosin Light Chain 
Phosphatase (MLCP).  Calcium is then extruded from the cell by sodium/calcium 
counter transporter (Na/Ca exchange) and Ca-ATPase transporter or 
replenishment of the intracellular calcium stores of the sarcoplasmic 
reticulum106 120. 
Additionally, the contractile response to the influx of a certain amount of 
calcium can be variable, this is especially noticeable after cellular stimulation 
with uterotonic agents, for example OT106.  This is known as calcium 
sensitisation and the process is mediated by an impairment of MLCP activity, 
thereby facilitating phosphorylation of the MLC and cross-linking with actin.  The 
process appears to be mediated via the receptor coupled activation of Rho-
kinase (ROK) by RhoA-GTP and CPI-17 (17-kDa-protein-kinase C-potentiated 
inhibitor) by DAG-PKC 106 117 121-126 
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1.4.3 Action potential generation  
Myometrial smooth muscle, both pregnant and non-pregnant has the ability to 
produce spontaneous contractile activity without hormonal or neuronal 
stimulation, while maintaining the ability to respond to endogenous or 
exogenous agonists.  Spontaneous contractile activity is preceded by 
depolarisation of the cell116 127 (Figure 8).  The resting membrane potential is 
maintained by trans-membrane ionic gradients of Calcium (Ca2+), Sodium (Na+), 
Chloride (Cl-) and Potassium (K+), created by energy dependent pumping of ions 
against their respective electrochemical gradients combined with ion-specific 
permeability of the plasma membrane.  Concentrations of Ca2+, Na+ and Cl- are 
lower within the intracellular environment, and K+ higher in the intracellular 
space. It is movement of these ions across the cell membrane via specialised 
membrane ion channels which initiates cell depolarisation, AP generation, 
voltage-gated calcium entry and contractile activity.   
Action potentials in the contracting myometrium have a specific shape which 
determines calcium entry with consistent increases in [Ca2+]I
 preceding 
contractile force generation, with a return to baseline [Ca2+]I
 prior to 
relaxation127 128.  The levels of [Ca2+]i determine the extent of the contractile 
force generated by the myometrium.  In the presence of a depleted extracellular 
calcium environment, force is greatly reduced where increases in [Ca2+]i are 
dependent on calcium release from the sarcoplasmic reticulum
128.  Additionally, 
changes in  [Ca2+]i tend to follow a pattern of an initial fast increase with 
cellular depolarisation followed by a plateau phase and fast repolarisation and 
reduction in [Ca2+]i, and this seems to determine the pattern of contractile force 
generated127 128 (Figure 8).  An example of the action potential generated by the 
myocyte, the corresponding intracellular Ca2+ levels and the contractile force 
produced by the cell is illustrated in Figure 8115. 
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Figure 8  Smooth muscle action potential 
The relationship between the action potential (green line), [Ca2+]i (blue line) and force 
generation (red line) in smooth muscle.  Reproduced from Taggart et al115 
Additionally, it is of interest to note that the resting membrane potential in the 
myometrial myocyte alters with gestation129.  During pregnancy the membrane 
potential becomes progressively more negative (i.e. cell membrane is 
hyperpolarised) peaking in mid-pregnancy at the reversal potential for potassium 
(-80 mV).  As term approaches, resting membrane potential depolarises to near 
threshold at approximately -55 mV129.  This implies that the myometrial cells are 
more difficult to depolarise at earlier gestations and therefore are intrinsically 
less excitable during the quiescent phase of pregnancy than towards term129.  
1.4.4 Ions and Ion Channels 
Contractile activity in the myocyte is dependent on depolarisation of the cell, 
with ultimate increases in intracellular calcium levels which facilitate the MLCK 
mediated final pathway of actin and myosin cross-linking.  The control of 
membrane potential via the influx and efflux of ions across the cell membrane 
requires the involvement of specialised ion channels. 
In the human myometrial cell the inward depolarising current is carried mainly 
by the influx of calcium (Ca2+), with potassium (K+) efflux concerned with 
repolarisation to the resting state.  Ca2+ influx is mediated mainly via opening of 
the voltage gated L-type calcium channels found in the cell membrane allowing 
rapid influx of calcium and an increased [Ca2+]i with maximal opening at 0mV
116 
130-132.   There may be an additional contribution via T-type low voltage activated 
calcium channels132 133 and also from the calcium stores in the sarcoplasmic 
reticulum, however, in experimental situations where the sarcoplasmic 
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reticulum was the main source of calcium, contractile activity fell to 
approximately 26% of that observed with Ca2+ influx from the extracellular 
environment128.  Following the Ca2+ influx, the cell becomes repolarised 
primarily by outward movement of K+ via Ca2+ sensitive K+ channels (BKCa or 
maxi-K) and voltage gated K+ channels (KV)
116 130.  Initially, the membrane 
potential is maintained at around -20 mV for the duration of the contraction 
with subsequent full repolarisation to -55mV106 116. 
Other ions and ion channels, namely sodium and chloride, also play a part in the 
maintenance of resting membrane potential and cell excitablility116 130.  In 
particular, chloride channels may be involved in the generation of the plateau 
phase of the action potential particularly in response to the agonist oxytocin130 
134.  However, sodium and chloride involvement in action potential development 
and contractile activity overall does not appear to be to the same degree as 
calcium and potassium.   
1.4.5 Uterine pacemaker cells 
It has been proposed that similar to cardiac smooth muscle, contractions of the 
myometrium are under the control of pacemaker type cells which are capable of 
spontaneous depolarisation with the subsequent propagation of an action 
potential through the uterine tissue.  However, unlike in cardiac muscle 
pacemaker cells have never been defined within the uterus, either histologically 
or anatomically.  It has therefore been proposed that the spontaneous electrical 
activity of the myometrium is an inherent property of these smooth muscle cells 
with cells able to depolarise at random and act as a pacemaker for that 
particular contraction.  This would certainly be supported by in-vivo human data 
suggesting the ‘hot spots’ of activity can develop at any point within the 
myometrial tissue, thereby further negating the proposal of a fixed area of 
pacemaker type cells135.  Additionally, virtual modelling of the gravid uterus has 
suggested that a heterogeneity of excitable cells throughout the uterus in 
addition to cellular communication via gap junctions is essential for the types 
and force of contraction required by the uterus for the process of parturition136.  
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1.4.6 Gap junctions and action potential propagation 
In the myometrium, it is essential that a co-ordinated contraction of many 
muscles cells produces sufficient contractile activity in the correct direction for 
progress in labour and delivery of the infant.  Therefore the cells have 
developed a way to work in concert via GAP junctions (connexins).  These are 
connecting channels which allow the flow of intracellular ions thus causing mass 
depolarisation and a synchronous tissue contraction.  It has also been suggested 
that differential expression of connexins through the myometrial tissue may play 
a role in determining directionality of electrical activity and therefore 
contractility of the uterus116.  Additionally, the speed of action potential 
propagation in the labouring uterus (0.25m/s) is faster than in the non-labouring 
uterus (0.1m/s), with the increase most probably facilitated by increased gap 
junction formation114.  In the myometrium the main gap junction proteins are 
connexin-43, connexin-26, connexin-40 and connexin-45116.  The numbers of 
connexin-43 gap junctions tends to increase at term137-140 while the expression of 
connexin-26 tends to fall138 and is thought to be influenced by both hormonal 
exposure141 142 and stretch142.  Certainly absence of connexin-43 is associated 
with delayed parturition in the mouse model143 suggesting this may be 
considered the most important myometrial connexin protein with a role in 
facilitating sufficient myometrial contractile activity necessary for labour.   
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1.5 Modulators of contractile activity 
Despite much research into the parturition associated contractile pathways, the 
exact mechanisms involved in the initiation and propagation of labour in the 
human remain uncertain.  The following section will address the two main 
agonists, namely oxytocin and prostaglandins, which can directly promote 
contractile activity in the myometrium.  Additionally, some of the known factors 
which are thought to modulate myometrial contractile ability and either 
positively of negatively influence the progression of human parturition will be 
discussed. 
1.5.1 Oxytocin  
Oxytocin (OT) is involved in many aspects of human reproduction with functions 
in the promotion of uterine contractility during labour and the postpartum 
period, in addition to involvement in the milk let down reflex allowing delivery 
of milk to the neonate during suckling.  OT is a small nonapeptide hormone 
released by the posterior pituitary (Figure 9), with evidence for autocrine and 
paracrine production in gestational tissues towards term91 144 145.   
 
Figure 9  Chemical structure of Oxytocin 
 
In terms of oxytocin in human parturition, ‘extracts of the posterior pituitary’ 
were first found to promote contractility of the pregnant animal uterus in 1906 
by Dale146 147.  In 1909, Blair Bell first began to use the ‘extract’ in clinical 
obstetric practice to control uterine bleeding during post partum haemorrhage 
Claire A Higgins, 2012   Chapter 1, 44 
and bleeding secondary to placenta praevia and caesarean section148.  In modern 
obstetrics, Syntocinon®, a synthetic oxytocin is widely used to induce and 
modulate uterine contractions to facilitate labour and delivery of the infant, in 
addition to its role in the prevention and treatment of post partum haemorrhage 
where it is routinely given to women in order to aid delivery of the placenta in 
the third stage of labour. 
With regard to the role of OT in the modulation of myometrial contractile 
activity, its overall effect is to increase contraction frequency, duration and 
force.  This enhancement of myometrial contractility is achieved by increasing 
the frequency of cellular action potential generation, extending the plateau 
phase of the action potential and promotion of calcium sensitisation (impairment 
of MLCP activity via activation of rho-associated kinase (ROK) by GTP-rhoA and 
CPI-17 by DAG-PKC 121)106 116 125 126 149.  An illustrative example of the alteration to 
the contractile force produced by the myometrium in response to a single 
addition of OT is illustrated in Figure 10. 
 
Figure 10  Trace of myometrial contractile activity 
Illustration of myometrial contractile activity from organ bath experiment.  The first 2 
contractions indicate the contractile force of non-agonist induced spontaneous myometrial 
activity, while the subsequent two contraction curves indicate the changes which occur in 
response to stimulation with OT.  OT increases the amplitude, duration and rate of 
contraction while decreasing the rate of relaxation. The latter observation is most probably 
due to OT-induced sensitisation of contractile machinery to Ca2+ 
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OT stimulation of myometrial cells facilitates two types of contractions which 
are typical of smooth muscle organs.  Firstly, the phasic contraction with an 
intermittent contraction and relaxation phase, an example of this type of 
contractile activity is illustrated in Figure 10.  Phasic contractions of the uterus 
are suitable for the process of labour and the passage of the neonate, with the 
intermittent relaxation phase necessary to restore blood flow both to the active 
myometrium in addition to the placenta and the neonate.  In response to OT, 
the phasic contractions tend to increase in frequency, amplitude and overall 
force, with a prolonged contraction pattern.  The second type of contraction 
seen in smooth muscle is the sustained tonic contraction.  In the myometrium 
this is essential in the postpartum period to prevent haemorrhage particularly 
from vessels at the newly exposed myometrium at the site of placental bed 
detachment.  In response to OT stimulation, the onset of this tonic contraction is 
hastened and the contraction is maintained124 150. 
To produce its effects on the myometrium, OT acts via the cell surface seven 
transmembrane G-protein coupled oxytocin receptor (OTR).  Evidence suggests 
that with increasing gestation, the concentration of OTRs on the myometrial 
cells increases, particularly towards term151-153.  As discussed earlier, 
contractility of the myometrial myocyte hinges on the interaction and cross 
linking of myosin with actin154 which is ultimately dependent upon increased 
intracellular calcium.  OT facilitates an increase in intracellular calcium as it 
binds the OTR resulting in activation of phospholipase C isoforms β1, β2 and β3 
via Gαq.  This catalyses the hydrolysis of phosphatidylinositol 4,5-bisphosphate 
(PIP2) with a resultant increase in inositol-1,4,5-triphosphate (IP3) and 1,2-
diacylglycerol (DAG)155.  IP3 acts on the sarcoplasmic reticulum to release its 
calcium stores, thereby increasing the availability of cytoplasmic calcium156.  
The increased cytoplasmic calcium has a direct effect upon calcium-sensitive 
cationic channels which depolarise the cell and open voltage gated L-type 
calcium channels and calcium can influx from the extracellular environment134.  
The other second messenger DAG is thought to activate plasma membrane 
calcium channels in addition to mediating effects via protein kinase C (PKC)155 
157.  The subsequent influx of large quantities of calcium binds to the calcium 
binding protein calmodulin which acts to initiate activity of the enzyme MLCK 
thereby facilitating the final common contraction pathway of actin and myosin 
cross-linking via myosin light chain phosphorylation.  Activation of the OTR and 
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the cascade of intracellular events culminating in an increase in intracellular 
calcium and cellular contraction are depicted in Figure 11.  
 
Figure 11  Intracellular events following OTR stimulation with OT (contraction pathway) 
Diagram of the intracellular events which occur to produce a contractile response to OT 
activation of the oxytocin receptor (OTR) on a myometrial cell. 
In addition to the above contraction pathway, OT is known to increase the 
sensitivity of the contractile machinery to calcium by altering the activity ratio 
of MLCK (pro-contraction) and MLCP (pro-relaxation) via activation of Rho-kinase 
(ROK) by RhoA-GTP, and also activation of CPI-17 (17-kDa-protein-kinase C-
potentiated inhibitor) by DAG-PKC pathway 116 121 124 149 158.  This overall results in 
suppression of MLCP activity and allows the plateau phase typical of an agonist 
induced contraction to occur.  The exact mechanisms by which OTR activation 
leads to ultimate activation of Rho-kinase and CPI-17 are not fully certain, but 
most likely ROK activation occurs via OTR associated G-protein activation which 
facilitates conversion of RhoA-GDP to RhoA-GTP enabling activation of Rho-
kinase106 124.  Concerning the activation of CPI-17, the 2nd messenger DAG is 
involved in the activation of protein kinase-C (PKC) which promotes CPI-17 
activity, in addition to CPI-17 activation by Rho-kinase106 125 126.  A diagram of the 
pathways involved in OT and agonist induced calcium sensitisation in uterine 
smooth muscle is illustrated in Figure 12. 
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Figure 12  Intracellular events following OTR stimulation with OT 
Diagram of intracellular events occurring in response to OT activation of the oxytocin 
receptor (OTR) on a myometrial cell culminating in cellular contraction.  In addition, the 
mechanisms of calcium sensitisation in response to OT are illustrated with suppression of 
MLCP activity via 1.Rho-kinase and 2.DAG/PKC activation of CPI-17.  
The responsiveness of myometrium to contractile agonists, particularly OT is 
increased with gestation124.  In many animals, including humans, OTR number 
and expression of the OTR gene increases, peaking in the myometrium prior to 
the onset of labour, with a return to low levels post partum153 159.  This 
subsequent decrease in OT binding is thought to be a result of OT exposure 
causing internalisation and downregulation of OTR mRNA transcription160 161 and 
may represent a process of cellular contractile regulation.  Additionally, OTR 
expression has been found to increase in human amnion tissue prior to labour, 
with the OT stimulation thought to be involved in prostaglandin production162 
suggesting a complimentary role for OT in uterine stimulation.  The expression 
of both OT and OTR in myometrial tissue appears to be under regulation from 
the sex steroids oestrogen and progesterone, with oestrogen mediating the 
increase in both OT and OTR expression and progesterone increasing OT but 
decreasing OTR expression160 161.  Uterine stretch is also thought to increase OTR 
expression both in cultured human myometrial cells and pregnant uterine horns 
of rats and sheep compared to the non-pregnant horn161 163,and OT levels are 
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influenced by cervical stretch (the Ferguson reflex) particularly during delivery 
of the neonate164-166.   
During pregnancy, the uterus is exposed to endogenous oxytocin, which similar 
to other animals appears to be released in a pulsatile manner increasing towards 
term and particularly during labour167.  During labour itself, circulating OT levels 
peak during delivery and expulsion of the foetus which may be part of the 
Ferguson reflex (distension of the cervix or vagina causing increased uterine 
contractility)164-166.  Certainly in the animal model, mechanically mediated 
stretch of the cervix during delivery of the pups appears to stimulate afferent 
nerves to the hypothalamus with subsequent release of OT into the 
circulation168-171.  In primates, the oxytocin pulses observed during pregnancy 
have a diurnal variation, peaking nocturnally during periods of darkness, which 
correlates with observed increases in periods of myometrial activity during these 
hours and can be inhibited by administration of an OT antagonist172.  Gestational 
and diurnal variations in labour onset, and non-labour antenatal uterine activity 
(Braxton Hicks contractions) are also seen in human pregnancy173-178 and may be 
explained by a diurnal variation in OT release179 
It is also thought that prolonged antenatal and intrapartum exposure to OT may 
facilitate changes to the myometrial proteome and promote a pro-contractile 
profile.  There is a suggestion of global protein changes after one hour of OT 
exposure in fresh term myometrial samples which were contracting in an organ 
bath environment180.  This has shown up-regulation of the expression of 13 
proteins associated with 5 functional classes, namely cytoskeletal function 
(septin-2, cytokeratin-19, desmin, transgelin) contractile/oxidative stress 
(annexin A3, heat shock protein 70, protein disulfide isomerise, thioredoxin), 
extracellular matrix (Osteoglycin, BIGH3), energy metabolism (EH domain 
protein 2, triose phosphate isomerise, pyruvate kinase) and protein synthesis 
(EF1γ)180.  However, the protein changes identified by this approach are subject 
to method related selection bias and it is unclear whether the changes in 
expression are due to post-translational modifications or new gene expression.  
It is therefore important to study gene and protein expression independently, 
with gene arrays assessing a wider range of molecular changes.  This is 
addressed within the work presented in Chapter 3 of this thesis. 
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Despite an important functional contractile role for OT, there does seem to a 
suggestion of redundancy, with OTR null mice still able to labour at the correct 
gestation, but with subsequent death of the pups due to absence of milk let-
down during suckling181.  Additionally, evidence has suggested that despite the 
increase in the concentration of OTRs on the myocytes at term, the ability of the 
myometrium to achieve phasic contractions is dependent on the working of the 
intracellular contractile machinery rather than exposure to oxytocin182.   
1.5.2 Prostaglandins  
Prostaglandins (PGs) are biologically active lipid hormones which have both 
autocrine and paracrine actions.  In terms of parturition, along with OT, 
prostaglandins are considered to be one of the main myometrial contractile 
agonists with an additional role in cervical ripening and softening to allow 
passage of the neonate.  Prostaglandin (PG) F2α, PGE2 and PGI2 (prostacyclin) are 
made endogenously by the uterus.  In particular, within the myometrium, there 
has been localisation of enzymes involved in the synthesis of PGs, namely 
cyclooxygenase (COX) and prostacyclin synthase to the myocytes with gestation 
dependent increases183-185. 
With regard to PG use in obstetric practice, Misoprotol (PGE1 synthetic agonist) 
is used to facilitate cervical softening prior to surgical termination or for 
induction of contractions during medical terminations of pregnancy.  
Dinoprostone (PGE2 synthetic agonist) is used for cervical ripening during the 
process of induction of labour, and Carboprost (PGF2α synthetic agonist) is used 
in the treatment of postpartum haemorrhage to promote a tonic uterine 
contraction186 187. 
Endogenous PGs are derived from arachadonic acid (AA), which is a constituent 
of the cell membrane.  After the initial step of AA release from the cell 
membrane via phospholipase-A2 (PLA2), the conversion of AA to PGs is mainly 
mediated by the COX enzymes COX-1 and COX-2, with specific synthase enzymes 
determining the final type of prostaglandin formation188-192.  Of note, 
intracellular AA is suggested to play a direct part in the activation of Rho-kinase, 
which as described above can mediate calcium sensitisation and thus 
contractility of the myometrial cell149. 
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PG receptors are coupled to G-proteins with a specific second messenger 
system191.  The main function of PGF2α appears to be in the stimulation of 
myometrial contractile activity.  The exact mechanism of action is uncertain 
however, stimulation of the PGF2α receptor (FP) mediate cell membrane 
depolarisation and a rise in intracellular calcium via influx from the extracellular 
environment, thus resulting in contractile activity116 191.   
The second main prostaglandin PGE2 has varying actions dependent on receptor 
sub-type.  Activation of the PGE2 receptors E1 and E3 tend to stimulate 
contractility of the uterus (E1 via calcium mobilisation, E3 via inhibition of 
cAMP)191, and E2 and E4 tend to relax the muscle via stimulation of cAMP116 191 193 
194.  The receptor sub-types have been traditionally thought to vary in expression 
throughout the uterus with E1 and E3 found to be fundal promoting contractile 
activity, and E2 and E4 in the lower segment and cervical tissue promoting 
relaxation116 194 195.  However, contractile response to PG has more recently been 
found to be consistent between paired samples from the upper and lower 
uterine segments196.  Prostacyclin (PGI2) is thought to play a role in uterine 
relaxation, however this can be negated by PGF2α or OT, and production of PGI2 
does not appear to alter with gestation194.   
Similar to OTR regulation, expression of receptors for PGF2α and PGE2 appear to 
change throughout pregnancy with decreases of up to 45% in the pro-contractile 
receptors FP and EP3 during pregnancy compared with non-pregnant 
myometrium197.  In addition FP and EP receptor expression appear to be 
influenced by the sex steroids oestrogen and progesterone190 198.  The production 
of prostaglandins within gestational tissues is influenced by gestation, labour and 
also inflammatory cytokines188-191 199 200 and is discussed further later in this 
chapter. 
1.5.3 Interchangeable role of the uterine contractile agonists 
oxytocin and prostaglandin 
The two main agonists of myometrial contractile activity, namely OT and PG are 
described above.  With such an important physiological process as parturition, 
there are advantages to having an element of redundancy between stimulating 
mechanisms.  This is certainly demonstrated where the parturition process in OT 
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null mice has been examined.  Surprisingly for such a powerful agonist, these 
mice laboured spontaneously with no evidence of prolonged active phase and 
were able to deliver viable pups at the normal expected gestation181. 
Additionally, the role of OT was studied in rats which had undergone disruption 
of the pelvic nerves thereby interrupting signalling via afferent pathways in 
response to cervical dilatation at delivery of the pups168 201.  Repeated sampling 
and measurement of OT levels were certainly decreased in these rats, indicating 
the role of the Ferguson reflex, however blood OT was not completely abolished 
and administration of exogenous OT did not appear to reduce delivery time168.  
This suggests alternative pathways for both OT release and expulsion of pups in 
the absence of surge in circulating OT168 171. 
In terms of parturition in PG knock out mice, modulation of various PG specific 
pathways including PGF2α receptor (FP) null mice and COX-1 null mice, labour is 
delayed since PGs are essential for luteolysis and in its absence, there is no 
decrease in circulating progesterone levels, an essential event for labour onset 
in the mouse202-205.  However, where ovaries are removed to mimic the 
progesterone drop, labour and delivery of the pups occurs as normal189 202-204 206.  
Again, as with the OT null mouse, this suggests that myometrial stimulation by 
PGs is not essential for the process of parturition. 
The effects of manipulating both OT and PG in the same mouse have been 
studied using the COX-1/OT null mouse.  These mice demonstrate an ability to 
establish labour at the correct time (most probably due to the absence of the OT 
luteotropic effects allowing progesterone levels to fall), however, the process of 
parturition is prolonged203 205.  Taken together with evidence from the single 
knock-out mice, this suggests that OT and PG can be considered interchangeable 
as myometrial agonists, however, in the absence of both, contractile and labour 
difficulties occur.  The importance of both agonist systems was further 
supported by studies in sheep where simultaneous administration of an OT 
antagonist and a COX-2 antagonist has the ability to suppress the onset of 
induced labour and prevent progression where pre-term labour contractility had 
already been established207 208. 
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1.5.4 Inflammation, infection and modulation of myometrial 
contractile activity 
The concept of labour as an inflammatory event is well established209-217, with 
8189 citations found via Pubmed using the basic search criteria ‘labour’ and 
‘inflammation’ (search performed July 2012).  In 1981, Liggins first proposed 
that inflammatory cells were responsible for mediating changes in the cervix, 
leading to cervical remodelling and ripening218.  Indeed, increases in numbers of 
immune cells (mainly neutrophils and macrophages) in response to labour are 
present within gestational tissues including the myometrium and cervix219-221.  
There is also a co-ordinated increase in cell adhesion molecules, cytokines and 
chemokines within these tissues suggesting the uterus can exert control over the 
inflammatory process in labour220-223.  Certainly, from within our department, in-
vivo gene array transcription data from the cervix and myometrium has shown 
labour is associated with a core inflammatory response, with particular increases 
in the chemokines CXCL3, CXCL5, CXCL8, CCL2 and CCL20211. 
In addition to a role in leukocyte chemoattraction, inflammatory cytokines also 
have the ability to stimulate production of prostaglandins (mainly via COX-2 
stimulation) in the amnion, chorion, decidua and myometrium, which can occur 
both in the presence and absence of infection induced cytokine upregulation and 
can lead to uterine contractility188 199 224 225.  It is of interest to note that COX-2 
expression in myometrium is low during gestation and increased at the time of 
parturition (COX-2 is an inducible enzyme and upregulation is secondary to 
substances which can be associated with perceived cell damage e.g. cytokines, 
mechanical stretch, infection, hypoxia), where COX-1 (constitutively expressed 
in tissues) tends to remain stable throughout204 226-229.  In terms of the 
relationship between inflammation and contractility, it follows that increased 
cytokines and PGs would positively enhance myometrial contractile activity, and 
this has been the basis of current theories regarding initiation of both term and 
in particular pre-term labour210 216 217 230-236. 
This obviously makes inflammation a possible target through which uterine 
contractions and human labour may be manipulated; suppressing the 
inflammatory process to prevent contractility in the case of pre-term labour or 
enhancing inflammation in an attempt to promote a contractile phenotype 
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where induction of labour is undertaken in the post-dates pregnancy233 237 238.  
However, dampening of the inflammatory response by systemic administration of 
COX inhibitors in pregnancy has proven to be inconsistent in preventing pre-term 
labour and delivery239-241.  Furthermore, despite some evidence of prolonging 
gestation with COX inhibitors, they also demonstrate a poor neonatal side-effect 
profile, particularly concerning neonatal morbidity including necrotizing 
enterocolitis, premature closure of ductus arteriosis in utero, impairment of 
renal function and oligohydramnios241.  
It also remains unclear as to whether activation of inflammatory pathways 
precedes labour and can therefore be regarded as a stimulant of labour, or 
whether inflammation occurs as a response to labour.  In humans this is difficult 
to determine, and in-vivo studies have examined tissues taken at caesarean 
delivery prior to the onset of labour and those taken intrapartum at both term 
and pre-term gestations211 213 242-246.  However, there are inevitable problems 
with these comparisons in that there will be normal variation between subjects 
at the same gestation, and reasons for undergoing caesarean delivery at term 
and pre-term will differ and may contribute to variations.  Even in mouse 
models, the mechanisms of cervical ripening differ between those mediated by 
progesterone withdrawal and infection, with an inflammatory cell mediated pro-
inflammatory response and significant upregulation of COX-2 in response to 
infection247.  This suggests an alternative mechanism for ripening in the non-
infective, spontaneously labouring cervix at term247 248.  Furthermore, evidence 
also suggests that smooth muscle contractility may potentially be suppressed by 
inflammatory mediators249 250.  In intestinal smooth muscle studies, IL1β and 
TNFα are associated with suppressing the activity of CPI-17, thereby preventing 
calcium sensitization with resultant bowel dysmotility249 250. 
The transcription factor, Nuclear Factor-кB (NF-кB) has been proposed to have 
an essential role in the activation of inflammatory pathways in non-gestational 
and gestational tissues, and hence may play a part in control of parturition226 237 
251-255.  Specifically, NF-кB acts to promote the transcription of cytokine, 
chemokines including TNFα, IL-1β, CXCL8(IL-8) and inflammatory related 
enzymes including COX-2, and inhibition of NF-кB leads to decreased PG 
production226 227 251 255 256.  Additionally, NF-кB has been found to be induced in 
response to not only cytokines, but also mechanical uterine stretch with a 
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suggestion of involvement in the promotion of OTR transcription226 254.  It has 
also been proposed as a possible target for tocolytic therapies in the prevention 
of pre-term labour and potentially would display a better side effect profile in 
the manipulation of inflammation than the COX inhibitors237 254, certainly 
evidence suggests progesterone may exhibit anti-inflammatory actions via 
suppression of NF-кB257.  However, there is evidence of alternative transcription 
factors involved in the inflammatory response in some cell types258 259, 
suggesting that blockage of NF-кB alone may not be sufficient to suppress the 
inflammatory and contractile response in uterine tissue. 
In terms of infection associated inflammation, the clinical concern is of 
premature activation of uterine contractile activity resulting in pre-term labour 
which has been associated with infection (maternal systemic or local 
intrauterine infection) in up to 40% of cases18 235 260-262.  Certainly, in the mouse 
model, exposure to the TLR-4 agonist lipopolysaccharide (LPS) is a recognised 
method whereby pre-term labour is successfully induced263.  Infection is a 
classically recognised stimulus for mounting an inflammatory response264 265.  
Therefore, based on infection induced inflammation, the inflammatory response 
has been proposed as being pivotal in the initiation and propagation of human 
labour (term and pre-term) 210 216 217 230-236.   
The theory regarding pathways involved in infection driven parturition hinges on 
an infective stimulus recruiting leukocytes to the affected tissue which in turn 
increases cytokine production and initiation of prostaglandin production199 231.  It 
would therefore follow that using antibiotics to reduce bacterial load would 
potentially reduce inflammation and therefore inhibit the contractile response.  
However, despite the use of antibiotics (particularly in human pre-term labour 
and prevention of preterm labour with intact membranes) leading to reduced 
maternal intrauterine infections, there has been no concomitant reduction in 
preterm birth, delivery within 48 hours or perinatal mortality rates261 266 267.  It 
has been suggested that these results may reflect firstly an inability of the 
antibiotic to penetrate and treat the infected tissues, or perhaps in these 
situations the inflammatory response is already established which cannot be 
altered by removal of the infective stimulus261.  However, it has been proposed 
that treatment of culture proven infections in the antenatal period may have a 
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preventative effect on the development of infection associated preterm labour, 
particularly in high risk women231 261 268-271. 
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1.5.5 Tocolytics and modulation of myometrial contractile activity 
Where premature activation of myometrial contractile pathways occur, attempts 
can be made to suppress contractile activity via the administration of tocolytic 
agents.  Discussed below are those specifically relevant to or examined within 
the main body of this thesis. 
1.5.5.1 Myosin Light Chain Kinase inhibitors 
There are a number of myosin light chain kinase (MLCK) inhibitors including 
wortmannin and ML9 available which have been used in vitro to demonstrate the 
importance of the contractile common final pathway via MLCK. 
During the course of this thesis, we chose to use ML7 (1-(5-Iodonaphthalene-1-
sulfonyl)-1H-hexahydro-1,4-diazepine hydrochloride, molecular weight 452.7, 
Sigma UK I2764), a selective MLCK inhibitor due to its specificity and its ability 
to inhibit contractile mechanisms of our myometrial samples (for details see 
Chapter 2, Section 2.3.3.2)272-275.  Since MLCK is an essential component of the 
contractile pathway, inhibiting the activity of this enzyme will prevent 
phosphorylation of myosin light chain thereby preventing actin and myosin cross-
linking and ultimately preventing cellular contraction (Figure 11). 
ML7 is not used in clinical practice since MLCK inhibition would have profound 
effects on other contractile cells including cardiac, gastrointestinal and vascular 
smooth muscle myocytes and certainly blocking contractility of these cells in-
vivo would most likely be fatal.  However, it does provide an excellent substance 
to use in the study of contractile pathways in-vitro with the advantage of little 
interruption to upstream cellular events. 
1.5.5.2 Calcium channel antagonists (Nifedipine) 
Nifedipine is a calcium channel antagonist and acts to reduce the entry of 
calcium into the cell via blockage of the L-type voltage gated calcium channels 
calcium186 187.  As discussed earlier, the main source of calcium entry is via the L-
type calcium channel, are therefore blocking this channel with nifedipine leads 
to significant reduction in the cells ability to increase intracellular calcium 
levels.  Since calcium is essential for the contractile machinery, reduced levels 
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of intra-cellular calcium therefore lead to suppression of myocyte contractions 
(Figure 13).  Nifedipine is used in clinical practice as a tocolytic in the treatment 
of established pre-term labour (unlicensed in the UK) and has been 
recommended by a Cochrane Review as ‘preferable to other tocolytic agents, 
mainly betamimetics’239 276. 
1.5.5.3 β2 adrenergic receptor agonist (Ritodrine, Terbutaline) 
Ritodrine acts as an agonist at the cell surface β2 adrenergic receptor which 
promotes smooth muscle relaxation and is therefore considered as a uterine 
tocolytic.  It exerts relaxatory effects on smooth muscle mainly by increasing 
levels of cyclic –AMP and its activation of cAMP-dependent protein kinase-A 
(PKA).  PKA acts to alter intracellular events including opening of Ca2+ sensitive 
K+ channels (BKCa or maxi-K) leading to cell membrane hyperpolarization thereby 
rendering depolarization and entry of calcium to the myocyte more difficult 
(Figure 13)116.  In addition it inhibits MLCK activity and gap junction 
permeability, further promoting cellular relaxation116 186 187.  Ritodrine is used in 
clinical practice licensed in the UK as a tocolytic in the treatment of established 
pre-term labour and has been shown to decrease the number of women in 
preterm labour delivering within 48hrs239 277, however there is insufficient 
evidence for its use in prophylactic or maintenance therapies278 279. 
1.5.5.4 Potassium channel opener (Levcromakalim) 
Levcromakalim is an ATP-dependent potassium channel (K) opener and works to 
hyperpolarize the cell membrane, therefore making it more difficult for the cell 
to depolarize with the net effect of promoting relaxation in smooth muscle 
(Figure 13)280.  In the clinical situation it has been used as an antihypertensive 
medication, and has been proposed as a possible tocolytic280 281. 
1.5.5.5 Progesterone 
Progesterone is a sex steroid hormone which has been considered to act as a 
suppressor of uterine contractility.  It has also been suggested that pre-
treatment of myometrium in-vivo with progesterone can render the myometrium 
less sensitive to the uterotonic effects of oxytocin and more sensitive to the 
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effects of tocolytics, including β2-agonists282 283, nifedipine and indomethacin284.  
However, this is not replicated by all studies, and importantly, in-vivo pre-
treatment with progesterone does not seem to affect response to uterotonins or 
tocolysis285 286.  Additionally evidence for its use in-vivo has been conflicting with 
no difference in rates of preterm delivery in twin pregnancy287 and inconsistency 
of contractile inhibition in in-vitro and in-vivo singleton models285 287-291.  The 
mechanisms by which progesterone can have a tocolytic effect is unknown, and 
had previously been thought to be via manipulation of potassium channels 
however we were unable to confirm this proposal285.  The effects therefore, may 
be mediated by systemic inflammatory suppression or reduction in PG production 
via suppression of NF-кB257 285. 
1.5.5.6 Oxytocin receptor antagonist (Atosiban) 
Atosiban is an OTR antagonist which has been shown to inhibit myometrial 
contractions in vitro292 (Figure 13).  Evidence of its success as a tocolytic in 
clinical practice has been variable293, but has been shown to reduce the number 
of women  giving birth within 7 days when treated for pre-term labour239.  There 
is currently insufficient evidence to support its use in the prophylaxis of preterm 
labour294.  
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Figure 13 Mode of Action of Tocolytic agents 
Graphical illustration of mode of action for selected methods of tocolysis namely Atosiban, 
Nifedipine, Levcromakalin, Ritodine and ML7.  All apart for ML7 and levcromakalim are used 
in clinical practice in the UK for the management of preterm labour. 
Overall, in terms of tocolytics, no single medication has been fully successful at 
halting the progress of labour, especially once labour has become established.  
This suggests redundancy in the system, which would certainly be plausible and 
desirable for such an important process as human parturition.  Suggestions have 
been made to combine tocolytic medications for the desired effect, but as yet 
no combination has been adopted in clinical obstetrics, with further work still to 
be performed. 
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1.5.6 Maternal Characteristics 
Despite the wealth of knowledge regarding the physiological processes 
underlying myometrial contractility, the maternal phenotype is capable of 
disrupting these mechanisms.  Specifically there is considerable evidence for the 
implications of maternal BMI and other maternal and pregnancy factors affecting 
parturition in-vivo62-80 295 296.  Many of these factors can be regarded as related to 
myometrial contractility function and or response to OT. These characteristic 
will be briefly discussed below. 
1.5.6.1 Body mass index (BMI) 
Maternal BMI can influence many aspects of pregnancy.  In particular to 
parturition, a low BMI<17 is associated with a higher risk of preterm labour and 
delivery19 297, while increased BMI is associated with higher rates of post date 
pregnancy62 65 298, induction of labour63-65, intrapartum emergency caesarean 
delivery for dysfunctional labour despite augmentation with oxytocin (OT) 62-64 66 
67 and post partum haemorrhage independent of mode of delivery63 65 66. 
Collectively these observational studies suggest that obesity has an inhibitory 
effect on myometrial function and response to OT.  Additionally, in-vitro 
contractility studies have suggested that organ bath environments with a high 
lipid or leptin content, representative of the circulatory maternal environment 
of those with a high BMI, can negatively affects contractile ability299-301.  Also, it 
has been suggested from rat studies that high fat diets pre-pregnancy and during 
pregnancy are associated with a lower myometrial expression of contraction 
associated proteins including connexin-43302. 
1.5.6.2 Parity 
Multiparity and previous vaginal delivery is associated with a shorter labour and 
a lower rate of caesarean delivery compared with nulliparous women303 304.  
Additionally, parity can influence the success of induction of labour, with 
women who are nulliparous undergoing elective induction of labour compared 
with spontaneous labour having an increased risk of requiring intrapartum 
caesarean delivery for dysfunctional labour.  However, this does not seem to 
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hold true for parous women49 52 305.  With increasing parity, the pressure 
generated by the uterus throughout labour which results in a normal vaginal 
delivery is less than in the nulliparous woman72.  This suggests that firstly the 
myometrium of parous women may be damaged by a previous pregnancy, labour 
and remodelling.  Alternatively, laxity of the pelvic floor after a previous 
delivery may facilitate passage of the neonate with a concomitant reduction in 
the required contractile force by the uterus. 
It is therefore uncertain as to whether parity has a direct effect on myometrial 
contractile ability or if observed clinical effects are a result of other parity 
related factors. 
1.5.6.3 Maternal age 
Maternal age is implicated in many pregnancy outcomes306.  In terms of 
contractility and labour, increasing maternal age is associated with increased 
rates of post-dates pregnancies, induction of labour and intrapartum caesarean 
delivery for dysfunctional labours68-71 307 308.  This implies that increasing 
maternal age may play a role in the negative regulation of myometrial 
contractile function. 
1.5.6.4 Previous anatomical damage or surgery 
The most common surgical scarring of the uterus is found after previous 
caesarean delivery.  Rates of caesarean delivery are increasing and currently 
account for approximately over 25% of live births in the UK 20103 4.  Therefore 
the numbers of women embarking on a subsequent pregnancy with a uterine scar 
is increasing.   
The risks following previous caesarean delivery are mainly associated with scar 
dehiscence or rupture during labour, with RCOG patient literature quoting rates 
of 0.2-0.8%74.  In terms of ability to deliver after previous CS, rates are high at 
approximately 72-76%, with further positive and negative influences from 
previous vaginal delivery, reasons for previous CS delivery, maternal BMI, age, 
induction of labour and foetal weight74-78.  However, despite clinical evidence 
suggesting a negative effect on uterine contractility, it is of interest to note that 
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progress in the first stage of labour is comparable between women with a 
previous CS and women without309. 
1.5.6.5 Birth weight and uterine wall tension 
In general, smooth muscle cells have the ability to stretch between 4-5 times in 
length whilst maintaining contractile ability.  This is thought to be due to the 
attachment of actin to the randomly scattered dense bodies (Figure 7).  In 
pregnancy, stretch and therefore uterine wall tension increases in the latter part 
of gestation as the uterus accommodates the growing foetus, placenta and 
amniotic fluid.  In situations where there is over distension of the wall as in 
multiple births and polyhydramnios, there is an increased risk of preterm labour 
3 18 23 310, however, it has been proposed that other factors not related to uterine 
wall stretch contribute to the risk of pre-term labour in these situations311.  
Additionally, increasing neonatal birthweight which may also be used as a 
surrogate marker for uterine stretch seems to be negatively associated with 
initiation of uterine contractility resulting in prolonged pregnancy79. 
In-vitro, stretch of myometrial primary culture cells (pregnant not in labour) 
resulted in an increased expression of OTR163, however, no increase was 
observed in cells derived from non-pregnant and pregnant in labour samples163.  
Additionally cells which are stretched in-vitro upregulate their expression of 
inflammatory mediators254 312 313, however, it is unclear if this is a reaction to 
cellular damage or if inflammation has the ability to stimulate contractility.  In-
vivo, where ultrasound imaging of the uterine wall has been utilised to measure 
uterine wall tension, there was no evidence of increased tension in those 
delivering preterm or those with twin gestations100.  Taken together, this would 
suggest that there is ambiguity surrounding the role of uterine wall tension or 
stretch and its role in the onset of labour in humans. 
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1.6 Summary 
Despite much evidence regarding the mechanisms of uterine contractility, the 
exact molecular pathways involved in the initiation and propagation of 
successful human labour at term is unclear.  With such a fundamental process, 
there is likely to be multiple pathways allowing for an element of redundancy in 
the situation where one pathway fails.  However in-vitro and in-vivo 
investigation of the functional and transcriptional response to prolonged 
contractions and the potential differential response to known clinical mediators 
of oxytocin, tocolysis, infection, inflammation, and maternal BMI will provide an 
invaluable insight into the workings of human pregnant myometrium.  
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1.7 Main themes of thesis 
The work presented in this thesis aims to explore the roles of many of the 
factors described above in relation to human labour.  The main themes of this 
thesis are summarised below. 
• The transcriptional changes induced in myometrium in response to long 
term (hours) exposure to oxytocin 
• The time and contraction dependent transcriptional changes induced in 
human myometrium in response to repeated contractile activity. 
• The contractile and transcriptional response of myometrium to tocolysis 
• The contractile and transcriptional response of human myometrium to a 
pro-inflammatory/infective LPS environment 
• The in-vivo changes in the maternal circulation in response to pregnancy, 
delivery by pre-labour planned caesarean section and the temporal 
changes during labour with particular reference to leukocyte numbers, 
activation status, chemokine receptor expression, circulating cytokines, 
CRP and measures of myocyte damage CK and Mb 
• The in-vitro contractile response (spontaneous and oxytocin induced) of 
myometrium and the influence of its in-vivo maternal environment 
including maternal BMI, birthweight, gestation and parity. 
  65 
Chapter 2 
Materials and methods 
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2 Methods 
Multiple experimental designs and methodologies are used throughout this thesis 
and adapted in order to address the specific research question.  Each specific 
experimental design is described in detail within the relevant chapters.  In broad 
terms two types of biological samples were collected.  Firstly myometrial 
biopsies were collected and used for the in-vitro organ bath contractility 
experiments, gene array and QPCR.  Secondly, maternal blood samples were 
taken for analysis of various in-vivo circulating parameters in relation to 
pregnancy and delivery.  The subjects and tissue handling for each biological 
sample is described below, with subsequent description of experimental 
procedures.  Details of each individual experiment and the characteristics for 
the women contributing to each of these experiments are provided at the 
beginning of each results chapter. 
2.1 Myometrial Biopsies - Subjects 
Ethical approval for sample collection was obtained from the North Glasgow 
University Hospitals Research Ethics Committee Reference 06/S0704/105 and all 
patients gave written informed consent to participate.  
Myometrial biopsies were obtained from non-laboring women with a singleton 
pregnancy, at term (≥ 37 weeks gestation) undergoing routine elective cesarean 
delivery under regional anesthesia at the Princess Royal Maternity Hospital, 
Glasgow, UK. Women were excluded if they had any clinical signs of impending 
labour (including uterine contractions or ruptured membranes), placenta 
praevia, uterine abnormalities, or pre-existing medical conditions, including pre-
existing or gestational diabetes and epilepsy or use of opiate based medications 
(including methadone), which could potentially affect contractility.  Information 
relating to the pregnancy was recorded for each woman including body mass 
index (BMI) at time of booking, maternal age, parity, gestation at the time of 
delivery, indication for planned caesarean delivery and birth weight.   
2.2 Myometrial Biopsies - Tissue handling and storage 
Following delivery of the baby and prior to delivery of the placenta, full 
thickness, myometrial biopsies were taken from the upper lip of the lower 
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uterine segment incision in the midline.  All samples were taken prior to routine 
administration of an intravenous 5IU syntocinon bolus.  Tissue samples were 
placed in a buffered Krebs solution (NaCl 133mmol/L, KCl 4.7 mmol/L, glucose 
11.1mmol/L, MgSO4 1.2 mmol/L, KH2PO4 1.2 mmol/L, CaCl2 1.2mmol/L and N-
tris(hydroxymethyl)methyl-2-amino-ethanesulfonic acid [TES] 10 mmol/L), 
stored at 4oC and used within 12 hours of collection.  
Samples taken from the lower uterine segment in this manner have 
demonstrated in-vitro functional contractile activity, comparable to samples 
from the fundus92 196.  The differential transcriptional profile of the upper and 
lower uterine segments in the human is difficult to assess firstly due to 
difficulties in accessing upper segment samples, and secondly the in-vivo 
functional difference between the two areas during labour and its inevitable 
influence on transcriptional profiles91 243 314. However, we have not found any 
regional variation in myometrial transcription throughout the length of the 
uterine horn in the mouse model315.  Additionally, the myometrial thickness of 
the lower segment in the third trimester prior to labour does not appear to be 
affected by previous caesarean section316.  In particular for this study in which 
we examine myometrial gene transcription, samples taken in this manner from 
the lower uterine segment consist almost entirely of myocytes91.  Thus down 
stream analysis is representative of the gene expression in myometrial cells.  
Tissue was snap frozen at a variety of time points after dissection as described in 
each individual chapter.  Samples which were set up in the organ bath as 
detailed below and were snap frozen once experiments were complete according 
to the pre-set time allocated to that specific contractility study.  Samples taken 
from the organ bath were loosened from tension and removed from the bath 
making sure that they were not actively contracting at the time.  The ends of 
the strips distal to the silk tie were removed to minimise any impact of tissue 
necrosis which may have occurred as a result of the ties.  The sample was then 
split transversely into 2 equal portions and excess fluid was removed from the 
sample surface by placing on blotting paper prior to weighing.  Samples were 
then immediately snap frozen in liquid nitrogen and stored at -80◦C. 
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2.3 Myometrial Biopsies - In-vitro contractility organ bath 
studies 
2.3.1 Tissue preparation 
Myometrium was dissected along the plane of the muscle fibers into longitudinal 
strips 2x2x10mm, avoiding any scar or damaged tissue and blood vessels.  Each 
tissue strip was tied at each end with silk and suspended in a separate 10ml 
organ bath filled with Krebs-Henseleit solution (NaCl 118 mmol/L, NaHCO3 25 
mmol/L, KCl 4.7 mmol/L, glucose 11.1 mmol/L, MgSO4 1.2 mmol/L, KH2PO4 1.2 
mmol/L, CaCl2 2.5 mmol/L (pH 7.4)).  The Krebs solution was made fresh daily.  
Each bath was constantly perfused with 95% O2/5% CO2, and maintained at 37
 oC.  
Myometrial strips were then placed under isometric conditions with a 20mN 
resting tension.  Contractility data were recorded via a tension transducer 
(FT03, Grass Technologies, Slough, UK) and the signal amplified and stored in a 
commercial data acquisition system (Octal ML228 Bridge Amplifier; PowerLab 
ML870/P, Chart, version 3.6, all ADInstruments).  Studies on myometrium 
performed in this manner have been shown to be suitable for examining 
spontaneous myometrial contractility and response to chemical manipulation92 
317. 
Only strips that displayed spontaneous, regular rhythmic activity between 2 and 
3 hours were used for experiments.  Basal spontaneous activity was recorded for 
up to 3 contractions before the addition of any drugs or vehicle control to the 
organ bath. 
2.3.2 Interpretation of contractility trace 
Spontaneous activity was recorded between 2 and 3 hours in all strips with 
regular activity.  Three measures of contractile activity were assessed, 
frequency, amplitude and activity integral and are illustrated in Figure 14.  
Frequency was determined as the time interval between the peaks of two 
contractions occurring at the time point of interest.  Frequency was measured in 
Hertz (Hz) with subsequent conversion to contractions/hour where appropriate.  
Contractile force was determined as the difference between baseline tension 
and maximal contraction amplitude in milli-Newtons (mN).  A summary measure 
of contractile activity was determined by the area under the tension curve for 
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one contraction and expressed as activity integral.  For both amplitude and 
activity integral, spontaneous activity was determined as an average of three 
contractions, with drug response measured as one contraction occurring at the 
time point of interest. 
 
Figure 14  Illustration of the three measures of contractile force 
(A) Amplitude measured from baseline to peak of contraction (mN).  (B) Frequency 
measured by the time difference between the peak of 2 contractions (contractions/hour).  
(C)  Activity integral determined by the area under the curve of a contraction (mN.s) 
2.3.3 Drugs used in contractility studies 
Preparation of drugs used in the contractility experiments and the methods of 
addition to the 10ml organ bath are described in the following section.  All drug 
additions were undertaken where the tissue was in a rest period as indicated by 
a return to baseline tension, in other words, drugs were not added whilst the 
tissue was undergoing a contraction. 
2.3.3.1 Oxytocin 
Oxytocin (OT) is a major endogenous uterotonin involved in human labour.  The 
hormone is a small nanopeptide produced by the posterior pituitary with 
evidence for autocrine and paracrine production in gestational tissues towards 
term91 144 145.  The immediate cellular effects of oxytocin are mediated via the 
cell surface G-coupled oxytocin receptor, which has the net result of increasing 
intracellular calcium which in turn promotes cellular contraction.  In clinical 
practice, the synthetic version Syntocinon® is widely used in the induction and 
augmentation of labour and in the promotion of contractility in the third stage 
of labour to assist delivery of the placenta and prevent atonic post-partum 
haemorrhage. 
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2.3.3.1.1 Drug preparation 
Oxytocin was purchased as oxytocin acetate salt (molecular weight 10007.19, 
Sigma UK 75968) and the 5mg vial dissolved in 4.96ml 2% acetic acid making a 
1mM OT stock solution, which was divided into aliquots, stored at -20◦C, 
defrosted and diluted in fresh Krebs solution as needed on day of experiment. 
2.3.3.1.2 Oxytocin concentration response  
Samples were collected from 25 women, with a total of 54 strips examined. 
Myometrial strips all achieved spontaneous regular activity within 2 hours.  Since 
OT acts via cell membrane receptor, it has an almost immediate effect on 
contractility.  Therefore, a traditional logarithmic cumulative addition of 
oxytocin was undertaken in the range 10pM to 10µM (10-12 to 10-6 M), with an 
interval of 20 minutes between each addition.  An example of the contractile 
pattern obtained in response to cumulative additions of OT is demonstrated in 
Figure 15.   
 
Figure 15  OT dose response contractile activity trace 
An illustrative functional trace demonstrating the contractile response to cumulative 
additions of OT. 
A Log EC50 [oxytocin] (the concentration of OT required for the tissue to 
demonstrate 50% the maximal response) was calculated based on the average % 
increase in amplitude from baseline at each bath concentration, with the overall 
Log EC50 [oxytocin] = -9.896M, (Figure 16).  
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Figure 16  OT concentration response curve 
Concentration response curve showing the effect of oxytocin (10-12 to 10-6M) on percentage 
increase in contraction amplitude from baseline measures (n subjects=25, n strips = 54).  
Values shown are mean with SEM and shown with a sigmoidal dose-response nonlinear 
regression curve.  The red dotted line indicates the LogEC50 (the concentration of oxytocin 
required to demonstrate 50% of the maximal response) 
2.3.3.1.3 Oxytocin addition to study response to a single 
concentration 
The concentration response experiments suggested that a final bath 
concentration of 1nM would be appropriate for promoting contractility in 
response to a single addition.  However, it was imperative for transcriptional 
analysis that overstimulation resulting in a prolonged tonic phase was avoided.  
Therefore, a single addition of oxytocin was undertaken giving a final bath 
concentration of 1nM, 10nM or 100nM.  An example of the effect of these 
concentrations is demonstrated in Figure 17.  These data support the use of a 
bath concentration of 1nM OT since at this concentration there is promotion of 
myometrial contractility, avoiding the tonic phase induces by the higher 
concentration of 10nM and 100nM.  Therefore, a final bath concentration of 1nM 
oxytocin was used in subsequent experiments where a single addition of the drug 
was undertaken. 
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Figure 17  Myometrial contractile response to a single addition of OT 
Example of the effect of a single concentration of 1nM, 10nM or 100nM OT on 
spontaneously contracting myometrial strips in-vitro. 
2.3.3.1.4 Oxytocin addition to study response to a single 
concentration 
The final bath concentration of 1nM oxytocin was achieved by a single addition 
of 10µl of 1mM oxytocin stock solution to the organ bath which contains a 
volume of 10ml of Krebs solution. 
2.3.3.2 ML7 
ML7 (1-(5-Iodonaphthalene-1-sulfonyl)-1H-hexahydro-1,4-diazepine 
hydrochloride, molecular weight 452.7, Sigma UK I2764) is a selective myosin 
light chain kinase inhibitor (MLCK) with the overall effect of inhibition of the 
contractile mechanisms272-275.  MLCK is an essential component of the pathway 
leading to myocyte contraction, and therefore blocking the activity of this 
enzyme will prevent phosphorylation of myosin light chain thereby preventing 
actin and myosin cross-linking and ultimately, the initiation of a contraction is 
prevented. 
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2.3.3.2.1 Drug preparation 
The 5mg vial of ML7 was dissolved in 110.5µl Dimethyl sulphoxide (DMSO) to give 
a 100mM ML7 stock.  This was stored in aliquots at -20◦C, defrosted and used as 
needed on day of experiment. 
2.3.3.2.2 ML7 concentration response 
49 myometrial strips from 9 women were assessed to determine the ideal 
concentration of ML7 required for complete inhibition of contractile activity.   
The method of action of ML7 is intracellular, and thus the effect of exposure is 
not immediately apparent.  Therefore, traditional concentration response 
experiments with cumulative additions of drugs (as described for oxytocin) could 
not be undertaken.  Thus after spontaneous activity was established in a strip, it 
was exposed to a single concentration of ML7 in the range 12.5µM to 300µM.  
Measurements of contractile activity were taken prior to addition of ML7, and at 
30, 60 and 120 minutes after addition.  After two hours of exposure, a single 
concentration of OT 1nM was added to the bath to ensure complete blockage of 
contractions had been achieved.  Measures of contraction amplitude and 
frequency were made, and percentage decrease from baseline calculated at 30, 
60 and 120 minutes after addition. 
Dose response for percentage reduction in contraction amplitude and frequency 
were compiled (Figure 18).  The inhibition of contraction amplitude observed 
using the highest concentration of ML7 (300 µM) 99.2 ± 0.5% (p<0.001).  
Furthermore, an ML7 concentration of ≥200 µM was sufficient to maintain 
complete inhibition of contractile response to oxytocin (Figure 19). 
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Figure 18  ML7 concentration response curves 
Concentration response curves showing the effects of ML7 on the magnitude and frequency 
of spontaneous contractions of strips of myometrium from pregnant women.  Values are 
means ± sem.  n subjects = 9, n strips = 49  
 
Figure 19  Myometrial contractile response to OT after pre-incubation with ML7 
An example of functional contractility trace indicating the ability of a concentration of 
200µM of ML7 to completely inhibit contractility even in the presence of OT whereas at the 
lower concentration of 100µM contractions return, albeit lower amplitude when OT is added. 
2.3.3.2.3 ML7 addition to study response to a single concentration 
A single addition of 20µl or 100mM stock ML7 was undertaken to give a final bath 
concentration of 200µM. 
2.3.3.3 Peptide 18 
Peptide 18 (molecular weight 1324.6) is a selective myosin light chain kinase 
inhibitor318.  Similar to ML7, Peptide 18 requires entry to the cell to exhibit its 
inhibitory effect on the enzyme myosin light chain kinase 
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2.3.3.3.1 Drug preparation 
The Peptide 18 (Calbiochem UK 475981) 5mg vial was dissolved in 750µl DMSO to 
give a 5mM Peptide 18 stock solution.  Aliquots were stored at -20◦C, defrosted, 
and used as needed on day of experiment. 
2.3.3.3.2 Peptide 18 concentration response 
Concentration response curve experiments for Peptide 18 were conducted in the 
same way as for ML7 using 26 strips from 3 women.  The documented IC50 for 
peptide 18 is 50nM318, therefore a drug concentration range of 0.5nM to 50µM 
was used, with contractile activity observed for 2 hours after addition when a 
single addition of 1nM OT was undertaken.  Again, measures of contraction 
amplitude and frequency were made, and percentage decrease from baseline 
calculated at 30, 60 and 120 minutes after addition. 
The inhibition of contraction amplitude observed using the highest 
concentrations of Peptide 18 (50 µM) was 8.0±1.2%, and overall Peptide 18 at the 
concentrations used appeared to ineffective at blocking contractile activity in 
myometrial biopsies.  Additionally, despite addition of Peptide 18, subsequent 
exposure to OT caused an immediate increase in contractility in all strips.  
Peptide 18 was therefore not selected as the drug of choice for inhibition of 
myometrial contractility for the future experiments. 
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Figure 20  Peptide 18 concentration response curves 
Concentration response curves showing the effects of Peptide 18 on the magnitude and 
frequency of spontaneous contractions of strips of myometrium from pregnant women.  
Values are means ± sem.  n subjects=3, n strips=26. 
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2.3.3.4 Acetic Acid vehicle 
2% acetic acid is used as the vehicle for dissolving oxytocin.  It is stored at room 
temperature, and diluted in Krebs on the day of the experiment in the same way 
as the 1mM OT stock solution with 10µl of 2% acetic acid added to the 10ml 
organ bath of Krebs solution. 
2.3.3.5 Dimethy Sulphoxide (DMSO) vehicle 
Dimethyl sulphoxide (DMSO) is used as the vehicle for dissolving both ML7 and 
Peptide 18.  100% DMSO is stored at room temperature, and added to the 10 ml 
of Krebs in the organ bath, undiluted at a volume of 20µl. 
2.3.3.6 Ritodrine 
Ritodrine acts as an agonist at the cell surface β2 adrenergic receptor which 
promotes smooth muscle relaxation and is therefore considered as a uterine 
tocolytic.  Ritodrine is used in clinical practice licensed in the UK as a tocolytic 
in the treatment of established pre-term labour239. 
2.3.3.6.1 Drug preparation 
Ritodrine (Sigma, UK) was dissolved in Normal Saline (0.9% NaCl) to give a stock 
solution of 1M and stored in aliquots at -20◦C. 
2.3.3.6.2 Ritodrine concentration response 
These were previously carried out in the department where it was demonstrated 
that a final bath concentration of 10mM was required for maximal inhibition of 
contractile activity285.  This concentration was achieved by the addition of 100µl 
of 1M stock solution to the 10ml organ bath. 
 
2.3.3.7 Nifedipine 
Nifedipine is a calcium channel antagonist and acts to reduce the entry of 
calcium to the cell via the L-type voltage gated calcium channels.  Since calcium 
is essential for the contractile machinery, reduced levels of intra-cellular 
calcium therefore lead to blockage of contractions.  Nifedipine is used in clinical 
Claire A Higgins, 2012   Chapter 2, 77  
practice as a tocolytic in the treatment of established pre-term labour 
(unlicensed in the UK)239. 
2.3.3.7.1 Drug preparation 
Nifedipine (Sigma, UK) was dissolved in ethanol to give a concentration of 0.1M.  
This was further diluted with DDW to give a working stock solution of 10mM to 
be used when single additions of Nifedipine were made.  Aliquots of stock 
solution were stored at -20◦C. 
2.3.3.7.2 Nifedipine concentration response 
These were previously carried out within the department and demonstrated the 
concentration of nifedipine required for maximal inhibition of contractile 
activity was 10µM 285.  This final bath concentration was achieved by the 
addition of 10µl of 10mM stock solution to the 10ml bath. 
2.3.3.8 Progesterone 
Progesterone is a sex steroid hormone and is produced mainly by the placenta in 
term human pregnancies.  In non-human pregnancy, withdrawal of progesterone 
is considered the initiator of labour.  Some consider progesterone to act as a 
suppressor of uterine contractility.  Traditionally progesterone compounds 
required to be reconstituted in high concentrations of ethanol.  However, these 
high concentrations of ethanol itself have a tocolytic effect on myometrium, and 
therefore the alternative water soluble progesterone was used in these 
experiments. 
2.3.3.8.1 Drug preparation 
Water-soluble progesterone (Sigma, UK) was dissolved in normal saline (0.9% 
NaCl) to give a stock solution of 10mM, with aliquots stored at -20◦C 
2.3.3.8.2 Progesterone concentration response 
These were previously performed in the laboratory and demonstrated the 
concentration of water soluble progesterone required for maximal inhibition of 
contractility was 1mM which was achieved by the addition of 1ml of 10mM stock 
to the 10ml organ bath285. 
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2.3.3.9 Levcromakalim 
Levcromakalim is an ATP-dependent potassium channel opener and works to 
hyperpolarize the cell membrane, therefore making it more difficult for the cell 
to depolarize with the net effect of promoting relaxation in smooth muscle. 
2.3.3.9.1 Drug preparation 
Levcromakalim (Sigma, UK) was dissolved in DMSO to give a stock solution of 
100mM, which was further diluted with DDW to give a working stock solution of 
10mM.  Aliquots were stored at -20◦C. 
2.3.3.9.2 Levcromakalim concentration response 
These were previously carried out in our laboratory and demonstrated that a 
final bath concentration of 10µM was required for maximal inhibition of 
contractile activity285.  This concentration was achieved by the addition of 10µl 
of 10mM stock to the 10ml organ bath. 
2.3.3.10 Lipopolysaccharide (LPS) 
Lipopolysaccharides (LPS) are a group of molecules made up from a lipid and a 
polysaccharide and are present in the cell walls of Gram-negative bacteria.  
They act via the TLR4 receptors to induce an intense pro-inflammatory response 
with release of cytokines.  They can contribute to contamination of solutions 
used for in-vitro experiments. 
2.3.3.10.1 Drug preparation 
5mg of LPS (Salmonella typhosa) (Sigma-Aldrich) was dissolved in 50ml of DDW 
to give a stock solution of 0.1mg/ml.  This was aliquoted and stored at -20◦C 
with 10µl of stock added to each 10ml bath when required to give a final bath 
concentration of 0.1µg/ml.  This final bath concentration was based on previous 
work where LPS at this level was able to induce a significant inflammatory 
response when cultured with rat aortas319. 
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2.3.3.11 Polymixin B (PMB) 
Polymixin B (PMB) is a decapeptide obtained from Bacillus polymyxa which is 
recognized as a potent antibiotic with the ability to bind and neutralize bacterial 
endotoxin (LPS) 320.  It is therefore widely used in the solutions for in-vitro 
experiments to remove any contaminating LPS. 
2.3.3.11.1 Drug preparation 
90mg of PMB (Sigma-Aldrich) was dissolved in 3ml of DDW to give a stock of 
30mg/ml.  Aliquots were stored at -20◦C.  Where the addition of PMB was 
required, 10µl of stock was added to each 10ml organ bath to give a final bath 
concentration of 30µg/ml.  This concentration of PMB was based on previous 
work in the laboratory of Professor Martin which showed this concentration of 
PMB was sufficient to suppress the inflammatory reaction of rat aorta while in 
culture319. 
2.4 Myometrial Biopsies - RNA extraction, quantification 
and quality assessment  
The frozen myometrial samples were processed in a random order, one at a 
time.  The total RNA extraction protocol has been adapted from that used by 
collaborators in Warwick, where they have experience of extracting high quality 
RNA from small myometrial samples.   
In summary, immediately on removal from the -80◦C freezer, the sample was 
homogenized in 1ml of Trizol with a hand held homogenizer with disposable tips.  
The samples then underwent an initial centrifugation at 8000xg at 4◦C allowing 
removal of any excess fibrous tissue from the homogenate.  The ‘clean’ 
homogenate was then incubated with 0.2ml of 1-Bromo-3-Chloro-Propane (Sigma 
UK, B9673) for 3 minutes at room temperature, followed by separation into the 
organic and aqueous phases while samples were centrifuged for 15 minutes at 
8000 X g at 4◦C.  Of note, 1-Bromo-3-Chloro-Propane was substituted for 
chloroform after problems with contamination of our stock of chloroform led to 
RNA degradation.   
The aqueous phase was then carefully obtained and 0.5 x aqueous phase volume 
of 100% ethanol added.  The sample was then processed according to the 
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manufacturers protocol for RNeasy MiniKit (QIAGEN) from step 10, RNeasy 
Fibrous Tissue Mini Handbook 01/2003.  The optional DNase treatment steps 
were not performed and RNA was eluted into 30µl of RNase-free water with the 
elution step repeated using the first elute in order to increase the final 
concentration of RNA. 
Total RNA was quantified on the Nanodrop ND-1000 spectrophotometer, which is 
a cuvette free method of measuring concentrations of RNA, DNA or proteins on 
microsamples (1µl).  RNA quality and integrity was assessed using the 
BioAnalyzer 2100 (Agilent RNA6000 Nano LabChips®), and performed as a service 
at the Sir Henry Welcome Functional Genomics Facility, University of Glasgow.  
Samples were considered to be of good quality if they showed clear peaks at 18S 
and 28S and produced a RNA integrity number (RIN) >7.  The RIN is a measure of 
RNA integrity developed by Agilent technologies, and aims to provide a 
standardized measure of RNA quality thereby removing individual 
interpretations.  The algorithm developed by Agilent Technologies classifies 
total RNA on a scale from 1 to 10 with 1 being the most degraded and 10 being 
most intact.  
2.5 Myometrial Biopsies - RNA amplification and Biotin 
labeling 
Once total RNA was extracted from the myometrial sample, and quality 
confirmed, the RNA underwent amplification and biotinylation prior to 
hybridization onto the Illumina gene array chips.  This was done using 
approximately 500ηg of total RNA, following the recommended method using the 
Illumina Total Prep RNA Amplification Kit (Ambion) according to manufacturers 
instructions.  This labeled cRNA was quantified on the Nanodrop ND-1000 
spectrophotometer and quality assessed on the BioAnalyser 2100.  
2.6 Myometrial Biopsies - Illumina Human Ref 6 
hybridisation and gene array 
This was outsourced and performed at The Wellcome Trust, Clinical Research 
Facility, University of Edinburgh, however, I did attend to observe the methods 
used.  The biotin labelled cRNA prepared above was diluted to give 1.5µg of 
Claire A Higgins, 2012   Chapter 2, 81  
cRNA in a final volume of 10µl which was then used for hybridisation to the gene 
array chips. 
The principle of the technique is that each Illumina chip can run 6 individual 
samples in parallel.  For each sample there are >46000 oligonucleotide probes 
which corresponds to 25440 annotated genes with the remaining probes coding 
for genes with provisional annotations, non-coding transcripts or experimentally 
confirmed mRNA sequences.  Illumina uses BeadArray™ technology where the 
chip is covered in beads held in microwells on the surface of the chip.  Each 
individual bead is covered by hundreds of thousands of identical oligonucleotide 
probes and attached to the bead via a 29 base address sequence (Figure 21) with 
each bead being present up to 30 times per array.  The address sequence is used 
to map the array prior to any hybridisation.  Each probe has been selected from 
databases including NCBI and RefSeq, and has been selected using a multistep 
algorithm to account for factors including lack of similarity to other genes, 
sequence complexity, absence of highly repeated sequence in genome and 
distance from 3prime end of the transcript, with each probe being 50 bases in 
length. 
 
Figure 21  Illustration of Illumina beads and attached probes 
An illustration of a 50 base probe linked to the bead via a short 29 base address sequence.  
Each bead is covered in hundred of thousands of identical gene specific probes and each 
bead is repeated up to 30 times per array.  The probe is hybridised to the biotin labelled 
cRNA from the study sample.  (Illustration reproduced from www.illumina.com) 
Once hybridisation of the study sample to the chip has taken place, the 
BeadChips are washed and stained.  They are then read using the BeadArray 
Reader in conjunction with the pre-determined map for that specific chip.  The 
intensity of staining is indicative of the quantity of gene present in the sample. 
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2.7 Myometrial Biopsies - Quantitative reverse 
transcription polymerase chain reaction (QPCR) 
The principle of QPCR is that it allows monitoring of the PCR reaction as it 
occurs in real time using the starter molecule complementary DNA (cDNA) which 
is made using the messenger RNA (mRNA) templates isolated from the sample of 
interest.  TaqMan technology uses a fluorescent probe which accumulates as the 
gene of interest accumulates during the PCR reaction.  Each oligonucleotide 
probe has a reporter fluorescent dye of the 5 prime end, with a quencher dye on 
the 3 prime end and while the probe is intact the quencher limits the 
fluorescent energy release.  During the PCR reaction, if the probe’s target 
sequence is present, it anneals downstream from the primer site and as the 
primer is extended the probe is cleaved at the 5 prime end by the action of the 
enzyme Taq DNA polymerase.  This cleavage of the reporter dye from the 
quencher dye allows the expression of the florescent energy which is then 
recorded.  As the PCR reaction progresses, the more target gene sequence is 
present and therefore the fluorescence emitted increases.  
2.7.1 Preparation of cDNA and quantification process 
Quantification of gene expression was carried out using sample of mRNA 
extracted above.  Batches of 40µl of cDNA was synthesised from approximately 
1.8µg of total RNA from each sample using the High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems) according to manufacturers protocol.  
Each time a batch of cDNA was made, a simultaneous control experiment was 
performed on a sample of ‘spare’ total RNA.  The master mix for the control 
sample excluded the multiscribe reverse transcriptase, and therefore acted as 
our negative control run for each 96-well TaqMan plate. 
All primer probes used for gene expression quantification were purchased as pre-
designed, inventoried Homo-Sapien TaqMan Gene Expression Assays from Applied 
Biosystems with details in Table 1.  In addition all probes used spanned exon 
junction and was therefore unlikely to and is therefore unlikely to detect 
genomic DNA contamination.  For normalisation of quantitative results, β-actin 
was used as an endogenous control/reference gene.   
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Gene 
Symbol Gene Name 
Applied Biosystems 
Assay ID 
Β-Actin Human ACTB (B-Actin) endogenous control 4310881E 
CCL2 Chemokine (C-C motif) ligand 2 Hs00234140_m1 
CCL3 Chemokine (C-C motif) ligand 3 Hs00234142_m1 
CCL8 Chemokine (C-C motif) ligand 8 Hs00271615_m1 
CCL20 Chemokine (C-C motif) ligand 20 Hs00171125_m1 
CXCL1 Chemokine (C-X-C motif) ligand 1 Hs00605382_m1 
CXCL2 Chemokine (C-X-C motif) ligand 2 Hs00601975_m1 
CXCL5 Chemokine (C-X-C motif) ligand 5 Hs00171085_m1 
CXCL8  Interleukin 8 Hs00174103_m1 
IL1B Interleukin 1 Beta Hs00174097_m1 
IL6 Interleukin 6 Hs00985641_m1 
IL10 Interleukin 10 Hs00174086_m1 
TNFα Tumor necrosis factor (TNF superfamily, member 2) Hs00174128_m1 
CHURC1 Churchill domain containing 1 Hs00540886_m1 
IFIT2 Interferon induced protein with tetratricopeptide repeats 2 Hs00533665_m1 
 
Table 1  Target assay mixes and endogenous control probes used in QPCR 
All probes were inventoried and obtained from Applied Biosystems, Cheshire, UK.  
To determine the appropriate concentration of sample to be used for each 
probe, serial dilutions were carried out with appropriate dilution determined by 
a Ct value around 28-30.  1µl of undiluted sample was used for CCL2, CCL3, 
CCL8, CXCL5, IL10 and TNFα with 1µl of a 1 in 10 dilution of sample required for 
β-actin, CXCL1, CXCL2, CXCL8, IL6, CCL20, IL1β, CHURC1 and IFIT2. 
Quantification was performed on an Applied Biosystems 7900 using a 96 well 
plate with a different probe and sample combination in each well.  Each well 
contained 12.5µl of TaqMan mastermix, 10.25µl of DEPC (Diethylpyrocarbonate) 
treated water, 1.25µl of target assay mix (probe) and 1µl of sample (either 
undiluted of diluted 1 in 10).  The thermal cycler conditions were 50◦C for 2 
minutes, 95◦C for 10 minutes followed by 40 cycles of 95◦C for 15 seconds and 
60◦C for 1 minute.  For each probe, samples were run in duplicate and control 
samples were run for every second plate using DDW and the no-RT control 
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2.7.2 Choice of endogenous control gene 
Our results were normalised to an endogenous control (reference gene), and 
therefore results are an expression of the relative quantification of the gene of 
interest in relation to the endogenous control.   A selection of potential 
endogenous control genes were chosen based on previous work investigating 
myometrial gene expression in both our department and others140.  We examined 
the expression of the endogenous control genes 18S, B-actin and GAPDH on a 
random selection of 10 myometrial RNA samples at a 1/10 dilution, with each 
probe run in triplicate for each sample.  As suggested by the application note 
from Applied Biosystems, the endogenous control should be the gene which 
shows the most stable expression in our tissue of interest (myometrium).  We 
therefore based our choice on the sample mean Ct value with the narrowest SD.  
The trial of the above probes gave the following results; 18S (mean ct=13.84, 
SD=1.15, β-actin (mean ct=22.11, SD=0.79, GAPDH (mean ct=24.65, SD=2.13) and 
therefore β-actin was chosen as our endogenous control. 
2.7.3 Analysis and determination of target gene expression 
relative to β-actin 
PCR data were captured and analysed using the automated photometric detector 
and detection software (ABI Prism 7900, Sequence Detection System v2.3).  
Threshold values for each probe were determined and used throughout for all 
PCR cycles using that probe (Table 2).  The threshold value indicates background 
level of fluorescence for that probe. 
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Gene symbol Threshold value  Gene symbol Threshold value 
Β-Actin 0.258  CXCL8  0.259 
CCL2 0.200  IL1B 0.381 
CCL3 0.249  IL6 0.315 
CCL8 0.193  IL10 0.200 
CCL20 0.190  TNFα 0.148 
CXCL1 0.130  CHURC1 0.063 
CXCL2 0.233  IFIT2 0.254 
CXCL5 0.288    
Table 2  Threshold values used for each of the probes used in QPCR 
Threshold values used for each of the probes for the determination of Ct values 
The Ct (cycle threshold) value indicates the cycle number at which the 
fluorescence passes the set threshold value (background value) and is therefore 
a way to determine the concentration of the gene of interest.  Ct values were 
then determined for each well and since samples were run in duplicate, the 
mean Ct value was used and where Ct values differed by more that 1.2 Ct 
values, they were excluded and samples repeated.  The expression was then 
determined relative to the Β-Actin value for the sample which provides a KCt (Ct 
(target gene) – Ct (endogenous control) = KCt).  In general the lower the Ct 
values, the greater the amount of gene present in the sample. 
2.8 Myometrial Biopsies - Determination of time points 
for temporal contractility studies 
Within the context of our studies, we were interested in performing temporal 
analyses of gene transcription.  We therefore aimed to establish a time-line 
description of 1) the length of time which the myometrial tissue strips would 
maintain the ability to contract following a single addition of OT1nM in the in-
vitro organ bath environment and 2) the times at which changes in gene 
expression in response to contractions are observed.   
2.8.1 Functional testing of time-points 
To assess the temporal contractile ability of the myometrial strips in our in-vitro 
organ bath, four functional experiments were carried out (n patients=4, n strips 
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from each patient=6).  Myometrium was used immediately after collection with 
each strips set up in a separate organ bath as previously described.  Each strip 
was given 2 hours to establish spontaneous activity, after which time OT was 
added to each bath to give a final bath concentration of 1nM.  One lane at a 
time was stopped at a time point of 0, 1, 2, 4 or 6 hours after addition of OT, 
and one strip left to contract overnight.   
When each lane was terminated, the myometrial strip was halved, weighed, 
snap frozen in liquid nitrogen, and then stored at -80◦C.   
In all experiments, contractions were established in response to OT, with the 
time at which contractions ceased approximately 8hours after addition of OT in 
each experiment.  It was also noted that approximately 30-60 minutes prior to 
cessation of contractile activity, the amplitude of contractions decreased.  An 
example of the functional output from these experiments is demonstrated in 
Figure 22.   
 
Figure 22  Illustration of the functional contractile data from an OT timeline experiment 
This shows establishment of spontaneous contractile activity, response to OT and the 
maximum time for which contractility is sustained being approximately 8 hours following 
OT stimulation. 
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2.8.2 Transcriptional testing of the time-line 
Samples from three of the above functional experiments were processed 
according to the total RNA extraction protocol.  They were quantified, and 
quality assessed, and good quality total RNA had been extracted.  The RNA was 
then prepared according to the Ambion total prep kit protocol and Illumina 
Human Ref 6 Beadchip arrays were performed as described above. 
Results from the transcriptional study indicated that there was a temporal 
element to gene changes with 12, 4, 37, 1036 and 655 genes differentially 
expressed compared with 0hr at the 1,2,4,6, and overnight timepoints 
respectively.   
2.8.3 Timeline determination 
Data from both the functional and transcriptional experiments suggest that the 
appropriate choice of maximal timepoint was 6 hours after drug addition.  
Additionally, the transcriptional data suggest the largest changes to occur 
between 4 and 6 hours and that earlier time points of less than one hour are not 
necessary since minimal gene changes are occurring by 1 hour. 
2.9 Myometrial Biopsies – analysis of protein products 
released by contracting samples 
To assess the inflammatory protein products which were synthesised and 
released by contracting myometrium in-vitro, analysis of the Krebs solution from 
the organ bath was undertaken 
Strips of myometrium were set up to contract spontaneously as described above.  
7 hours after initial tension was applied, experiments were terminated and 5ml 
of Krebs solution from the organ bath was frozen and stored at -80°C.  For 
comparison, a separate sample of Krebs which had never been exposed to tissue 
but had been in an organ bath, bubbled with carbogen at 37°C for 7 hours was 
also frozen and stored at -80°C. 
Samples were used neat then prepared and analysed using a Biorad Bioplex Pro 
Human Cytokine 8-Plex Panel 1 M50-000007 and analysed on the Biorad Bioplex 
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System- Luminex 100 according to manufacturers instructions.  The principles of 
multiplex analysis are described in detail below in section2.14.  The specific 
proteins assessed by this assay are IL2, IL4, IL6, IL10, CXCL8, GM-CSF, IFNγ and 
TNFα.  Inter-assay variation CV is <30% and Intra-assay CV<20%. 
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2.10 Maternal blood samples - Subjects 
Ethical approval for sample collection was obtained from the North Glasgow 
University Hospitals Research Ethics Committee Reference 08/S0704/54 and all 
patients gave written informed consent to participate.  
Women were recruited into three comparison groups as follows: 
1. Non-pregnant (NP group) women volunteers of reproductive age during 
day 2-5 of their menstrual cycle (or day 3-6 of their pill free week if 
taking combined oral contraceptive).  Women were excluded if they were 
taking a progesterone only contraceptive preparation or did not have a 
cycle.  A single sample was obtained from these women.   
2. Pregnant women at term attending for a planned caesarean delivery (CS 
group) who did not demonstrate any signs of labour including uterine 
contractions or spontaneous rupture of membranes.  A sample was 
obtained from these women in the morning of admission prior to their 
operation, with a subsequent sample obtained 1 hour following delivery of 
the placenta.  All caesarean deliveries occurred prior to 1pm and were 
uncomplicated. 
3. Pregnant women at term attending for induction of labour (IOL group) by 
artificial rupture of membranes (ARM) + syntocinon who did not 
demonstrate any current signs of labour including uterine contractions or 
spontaneous rupture of membranes.  Women were excluded if they 
required priming of the cervix with prostaglandins.  A baseline sample was 
obtained from these women immediately prior to ARM, with subsequent 
samples taken at 2 hourly intervals post ARM with the final sample 
obtained 1 hour after delivery of the placenta. 
Women in all groups were excluded if they were currently taking anti-
histamines, antibiotics (including benzylpenicillin prophylaxis during labour), 
steroids, or had received steroid injections during the current pregnancy to 
promote foetal lung maturity.  They were also excluded if they were currently 
suffering from a minor cough or cold or if they developed symptoms of sepsis 
Claire A Higgins, 2012   Chapter 2, 90  
during CS or labour including a core temperature measurement of ≥38◦C during 
labour. 
2.11 Maternal blood samples - Tissue handling and 
storage 
Blood was obtained directly into 2 standard blood sampling tubes, with 
approximately 3mls into K2EDTA tube (purple top) and 4-5mls in a lithium 
heparin tube (green top).  Blood collected in the purple tube was processed in 
the NHS accredited haematology laboratory at Glasgow Royal Infirmary which 
provided standard haematological measures including a differential white blood 
cell count.  Blood from the green tubes was used immediately for flow 
cytometry (approximately 1ml) and any remaining blood in this tube was 
centrifuged at 1200 X g for 15 minutes at 4◦C and the plasma stored at -80◦C for 
cytokine, chemokine, C-reactive protein (CRP), creatine kinase (CK) and 
myoglobin (Mb) assays. 
2.12 Maternal blood samples - processing for differential 
white cell counts 
The blood sample taken in the K2EDTA (purple topped) tube was sent directly to 
the on-site NHS haematology laboratory at Glasgow Royal Infirmary.  Samples 
were processed within 1 hour and counts were derived using Laser Flow 
Cytometry on whole blood samples adequately mixed with K2EDTA, analysed 
using the standard automatic mode (SYSMEX XE2100 Analyser, Sysmex America, 
Inc).  Counts were provided for total white blood cells (t-WBC), neutrophils, 
lymphocytes, monocytes, eosinophils and basophils. 
2.13 Maternal blood samples - Flow Cytometry analysis 
of white cell surface chemokine receptor expression 
The principle of flow cytometry is the ability to count cells which are suspended 
in fluid and differentiate between cell sub-types using characteristics including 
cell size and intracellular content.  In addition, cells can be stained with 
fluorescent antibodies and further categorised according to expression of cell 
surface markers.   
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Laser is used to detect forward and side scatter of light as it passes 
perpendicular to the line of flow of cells, with forward scatter representative of 
cell size and side scatter intracellular content.  Where cell surface markers are 
examined, when the laser hits the fluorochrome, it transfers to the excited state 
and emits fluorescence which is picked up by the automated sensors.  A diagram 
of this process is illustrated in Figure 23. 
 
Figure 23  Illustration of flow cytometry.   
Cells suspended in solution are hydrodynamically focussed to form a single cell line.  A 
laser beam passes perpendicular to the flow of the cells and light is scattered forward to the 
forward scatter detector and also sideways to the side scatter detector.  In addition where 
cell surface markers are examined, fluorescent light is released in the case of the 
experiments in this thesis, the associated fluorescences are (Fluorescein isothiocyanate 
(FITC), Phycoerythrin (PE) and Allophycocyanin (APC)). 
2.13.1 Blood processing for flow cytometry white cell expression 
of chemokine receptors 
Thirteen individual tubes were prepared with the combinations of antibodies and 
their associated fluorescence (Fluorescein isothiocyanate (FITC), Phycoerythrin 
(PE) or Allophycocyanin (APC)) for each tube listed in Table 3.  5µl of each 
antibody (undiluted) was used for each tube.  Details of each antibody used are 
listed in Table 4. 
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Tube FITC antibody PE antibody APC antibody 
1  nil Nil nil 
2 CD3 CXCR1 CD4 
3 CD3 CXCR2 CD4 
4 CD3 CXCR1 CD8 
5 CD3 CXCR2 CD8 
6 CD3 CCR2 CD4 
7 CD3 CCR6 CD4 
8 CD3 CCR2 CD8 
9 CD3 CCR6 CD8 
10 CD66b CXCR1 CD11b 
11 CD66b CXCR2 CD11b 
12 CD14 CCR2 CD11b 
13 Isotype FITC Isotype PE Isotype APC 
Table 3  Antibody combinations for flow cytometry experiments 
Combinations of FITC, PE and APC antibodies used for flow cytometry analysis of whole 
blood.  
Within 20 minutes of the blood sample being taken into the lithium heparin 
(green topped) tube, 50µl of whole blood was transferred by pipette into each 
tube and mixed with the antibodies by vortex.  The tubes were then incubated 
in the dark at room temperature for 15 minutes.  Red cell lysing buffer (1 in 10 
dilution of 10x BD Pharm LyseTM Lysing solution (BD Bioscience) with DDW) was 
brought to room temperature and 1ml was then added to each tube, with a 
further incubation in the dark at room temperature for 20 minutes.  Samples 
were then centrifuged at 1200 X g for 5 minutes at 4ºC, the supernatant was 
discarded and 2ml of wash buffer (1 in 100 dilution of FBS with PBS) was added 
to each tube, mixed by vortex, and centrifuged for 5mins at 1200 X g at 4ºC.  
This wash was repeated one further time.  The sample was prepared for analysis 
by flow cytometry by adding 0.5ml of wash buffer.  Samples were then stored on 
ice and analysed in order, with 50,000 events recorded for each tube.  Analysis 
was performed using BD FACs Calibur machine running the acquisition software 
BD CellQuestTM Pro, BD Biosciences, V1.c.6fcd. 
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Antibody 
Fluorescence & 
species 
 
Concentration 
Antibody type 
Clone name 
Supplier 
Cat no 
CD3 FITC Mouse anti-
Human CD3 
Pre diluted* Monoclonal 
HIT3a 
BD Biosciences 
555339 
CD66b FITC Mouse anti-
Human CD66b 
Pre diluted* Monoclonal 
G10F5 
BD Biosciences 
555724 
CD14 FITC Mouse anti-
Human CD14 
Pre diluted* Monoclonal 
MSE2 
BD Biosciences 
555397 
CXCR1 PE mouse anti-human 
CD181 
0.2mg/ml Monoclonal 
5A12 
BD Biosciences 
555940 
CXCR2 PE Mouse Anti-Human 
CD182 
0.2 mg/ml Monoclonal 
6C6 
BD Biosciences 
555933 
CCR2 PE Mouse Anti-Human 
CCR2 
25 µg/ml Monoclonal 
#48607 
R&D systems 
FAB151P 
CCR6 PE Mouse anti-Human 
CD196 
Pre diluted* Monoclonal 
11A9 
BD Biosciences 
551773 
CD4 APC Mouse anti-
Human CD4 
Pre diluted* Monoclonal 
RPA-T4 
BD Biosciences 
555349 
CD8 APC Mouse anti-
Human CD8 
Pre diluted* Monoclonal 
RPA-T8 
BD Biosciences 
555369 
CD11b APC Mouse anti-
Human CD11b/Mac-1 
Pre diluted* Monoclonal 
ICRF44 
BD Biosciences 
550019 
Isotype 
FITC 
FITC Mouse 
IgG2a K 
Pre diluted* Monoclonal 
G155-178 
BD Biosciences 
555573 
Isotype PE PE Mouse 
IgG1 K 
Pre diluted* Monoclonal 
MOPC-21 
BD Biosciences 
555749 
Isotype 
APC 
APC Mouse 
IgG1 K 
Pre diluted* Monoclonal 
MOPC-21 
BD Biosciences 
555751 
Table 4 Antibody types and details for flow cytometry experiments 
Details for each antibody used including clone name, species of generation and supplier.  
5µl of each antibody are used in each experimental tube with no further dilutions.  *Antibody 
reagent has been pre-diluted for use at the recommended volume per test where company 
has typically used 1 X 10e6 cells in a 100-µl experimental sample (a test). 
2.13.2 Interpretation of flow cytometry data 
Each sample was analysed individually using the analysis software on BD 
CellQuestTM Pro, BD Biosciences, V1.c.6fcd.  Cell types were gated according to 
forward scatter (the intensity of light signal attributed to cell size) and side 
scatter (intensity light signal attributable to intracellular components e.g. 
granules and cell inclusions) into granulocytes, monocytes and lymphocytes as 
shown in Figure 24.   
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Figure 24  Flow cytometry data 
An example of flow cytometry data output illustrating gating of white blood cell types into 
granulocytes, monocytes and lymphocytes based of side scatter (SSC) and forward scatter 
(FSC) of light. 
Granulocytes were further gated using the markers CD11b and CD66b, with 
neutrophils defined as CD66b+ granulocytes, and activated neutrophils defined 
as CD66b+/CD11b+ granulocytes.  Cell surface expression of the chemokine 
receptors CXCR1 and CXCR2 were then analysed firstly for the percentage of 
neutrophils (CD66b+ granulocytes) or activated neutrophils (CD66b+/CD11b+ 
granulocytes) expressing either receptor, and secondly for the cell surface 
density of that receptor as measured by the mean fluorescent intensity (MFI).  
Monocytes were defined from the population of large cells with little granularity 
which were CD14+ with activated monocytes defined as CD14+/CD11b+ 
monocytes,  The cells were then assessed for the % expressing the receptor CCR2 
and the density of cell surface expression (MFI). 
Lymphocytes were defined as smaller cells with low granularity and were further 
gated using the cell surface marker CD3 indicating T-lymphocyte cells.  
Additional gating was undertaken and defined T-helper lymphocyte cells as 
CD3+/CD4+ and T-cytotoxic lymphocyte cells and CD3+/CD8+.  Since neither 
express CCR2, this was used as a negative control to further define these 
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lymphocyte subtypes.  Analysis of the % of cells expressing the chemokine 
receptors CXCR1, CXCR2 and CCR6, and the density of expression was then 
undertaken. 
Numbers of cells of interest which express the receptor being examined are 
expressed as a % of the cells gated.  MFI (mean fluorescent intensity) expresses 
the geometric mean of light signal intensity and is an indication of the density of 
cell surface expression of the receptor of interest. 
Samples were processed and analysed immediately after collection in order to 
minimise dead cells and debris within the samples, with further exclusion on the 
basis of gating by forward and side scatter parameters. 
2.14 Maternal blood samples - Measurement of 
circulating cytokines and chemokines using multiplex 
technology 
Traditional methods for protein quantification, such as ELISA or Western 
blotting, were used to quantify one single protein at a time.  More recent 
mutiplex technologies allow the simultaneous measurement of a number of 
proteins in one single sample.  We undertook multiplex analysis of protein in the 
plasma samples using pre-designed kits from Millipore.   
An illustrative summary of the Milliplex™ MAP technology is shown in Figure 25 
and employs immunoasays on the surface of fluorescent-coded beads 
(microspheres).  Each microsphere is dyed to create a distinct colour, then 
coated with hundreds of one specific capture antibody therefore, one colour of 
bead is specific for one single capture antibody.  Any analyte present in the 
study sample will combine with the capture antibody and this is turn can 
combine with a biotinylated detection antibody.  Following a further incubation 
with a streptavidin- phycoerythrin conjugate the sample is ready for processing.  
Flow cytometry technology is used to detect the microspheres, with one laser 
able to detect with microsphere dye colour and the other the florescent dye on 
the detector molecule.   A standard curve is run on each plate for each analyte 
and is used to determine sample concentrations.   
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Figure 25  Illustration of principles behind multplex microsphere technology 
Illustration reproduced from www.millipore.com 
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2.14.1 Processing of plasma samples for cytokine 
measurement 
Circulating cytokines were measured in each individual sample using a 39-plex 
mixed human cytokine/chemokine plate and a 1-plex plate for CCL5 (RANTES) 
(Milliplex Human Cytokine/Chemokine Panel, MPXHCYTO-60K) which assessed a 
total of 40 circulating cytokines in the maternal plasma samples.  The intra-
assay coefficient of variation (CV) for the assays was 2-13%, and the inter assay 
CV 5-17%.  The specific cytokines and their corresponding minimum detection 
sensitivity using these kits with an overnight incubation are listed in Table 5.  Of 
note, the antibody used to detect GRO (growth regulated oncogene) measures 
all 3 isoforms of GRO, with the final measurement representing the sum of 
GROα(CXCL1) + GROβ(CXCL2) + GROγ(CXCL3) (personal communications from 
technicalservice@merckgroup.com, Merck Millipore). 
Cytokine Expected minimum  
detection (pg/ml) 
EGF (Epidermal Growth Factor) 2.7 
CCL11 (Eotaxin) 1.2 
FGF-2 (Basic Fibroblast Growth Factor) 1.8 
Flt-3 (CD135, fms-like tyrosine kinase receptor-3) 2.6 
CX3CL1 (Fractalkine) 6.0 
GCSF (granulocyte colony stimulating factor) 0.5 
GMCSF (granulocyte macrophage colony stimulating factor) 9.5 
CXCL1 + CXCL2 + CXCL3 (GRO (growth regulated oncogene)) 10.1 
Interferon- α2 (IFNα2) 24.5 
Interferon-γ (IFNγ) 0.1 
Interleukin-1α (IL1α) 3.5 
IL1β 0.4 
IL1ra 2.9 
IL2 0.3 
IL3 2.1 
Il4 0.6 
IL5 0.1 
IL6 0.3 
IL7 1.8 
CXCL8 (IL8) 0.2 
IL9 0.7 
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IL10 0.3 
IL12 (p40) 10.5 
IL12 (p70) 0.4 
IL13 0.4 
IL15 0.4 
IL17 0.2 
CXCL10 (Interferon-γ Inducible Protein (IP10)) 1.2 
CCL2 (Monocyte Chemotactic protein-1 (MCP1)) 0.9 
CCL7 (Monocyte Chemotactic protein-3 (MCP3)) 2.0 
CCL22 (Macrophage derived chemokine (MDC)) 3.7 
CCL3 (Macrophage inflammatory protein 1α (MIP1α)) 3.5 
CCL4 (Macrophage inflammatory protein 1β (MIP1β)) 4.5 
sCD40L (soluble CD40 ligand) 1.9 
sIL2Rα 4.4 
TGFα 0.4 
TNFα 0.1 
TNFβ 1.9 
VEGF (vascular endothelial growth factor) 5.8 
CCL5 (RANTES) 1.0 
Table 5  List of circulating cytokines/chemokines examined. 
Circulating cytokines measured using 39-plex human cytokine/chemokine panel from 
milipore.  CCL5 (RANTES) analysed on separated 1-plex (dilution of sample 1 in 100) 
All plasma samples, with the exception of those used to measure CCL5, were 
used undiluted.  A 1 in 100 dilution of sample was recommended when using the 
kit to assess CCL5 with washing buffer prior to use.  All samples were run in 
duplicate with the mean taken as the concentration value of that cytokine for 
the individual sample. 
2.15 Maternal blood samples - Measurement of 
circulating c-reactive protein (CRP) 
CRP was quantified on the stored plasma samples by ELISA (Randox hsCRP 
immunoturbidimetric assay, cat No. CP3885) as directed by the manufacturers 
instructions.  The minimum detection for this assay is 0.9mg/l, with and intra-
assay CV of <4%.  The reference range for CRP measurement in a normal 
population using this kit is 0.9-5 mg/l. 
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2.16 Maternal blood samples - Measurement of 
circulating creatine kinase (CK) 
In this study, circulating CK measurements were performed on the stored plasma 
samples within the accredited NHS Biochemistry laboratory at Glasgow Royal 
Infirmary.  Samples were processed using the ABBOTT ARCHITECT analyser and 
provided a measure of total circulating CK.  The limit of detection for this assay 
is 5.1U/L, with an intra-assay CV <2%, and inter-assay CV of <4%. 
2.17 Maternal blood samples - Measurement of 
circulating myoglobin (Mb) 
Circulating Mb concentrations were determined using commercially available 
ELISA kit (Calbiotech, Cat No. MG017C, 96 tests).  The stored plasma samples 
were diluted to 1/10 prior to analysis.  Concentrations were determined using 
Multiskan® EX using Ascent software for iEMS (Thermo Electon Corporation, 
Finland).   The lower limit of detection for this assay is 5.0ng/ml. 
2.18 Statistical Analysis 
Statistical analysis was adapted for each specific experiment and is discussed in 
full within each individual chapter. 
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Chapter 3 
Effect of oxytocin and time on myometrial 
transcriptional profile  
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3 Effect of oxytocin and time on myometrial 
transcriptional profile 
3.1 Introduction 
The hormone oxytocin (OT) plays a major role in the stimulation of uterine 
contractility.  OT is secreted by the posterior pituitary, with evidence also 
suggesting paracrine and autocrine production within the pregnant uterus 
especially towards term91 144 145.   
‘Extracts of the posterior pituitary’ were first found to promote contractility of 
the pregnant animal uterus in 1906 by Dale146 147.  In 1909, Blair Bell first began 
to use the ‘extract’ in clinical obstetric practice to control uterine bleeding 
during post partum haemorrhage and bleeding secondary to placenta praevia and 
caesarean section148.   
OT was first isolated and synthesized by Vincent du Vigneaud 1953321-324.  His 
work allowed the synthesis of Syntocinon® (Alliance Pharmaceutical), a 
synthetic oxytocin, which is widely used in modern obstetric practice to induce 
and modulate uterine contractions to facilitate labour and delivery of the infant.  
Syntocinon® also plays an important role in the prevention and treatment of 
post partum haemorrhage, and is given to women to aid delivery of the placenta 
in the third stage of labour.  Conversely blockage of oxytocin receptor (OTR) 
activity can reduce uterine contractions.  Atosiban is an OTR antagonist which 
has been shown to inhibit myometrial contractions in vitro292.  Evidence of its 
success as a tocolytic in clinical practice has been variable293, but has been 
shown to reduce the number of women  giving birth within 7 days when treated 
for pre-term labour239. 
Despite the extensive clinical use of OT and OTR antagonists the molecular and 
cellular mechanisms underlying OT-induced modulation of uterine contractility 
are not completely understood.  Elucidation of OT signalling has major clinical 
implications for patient care in obstetrics as OT has been implicated in the 
aetiology and pathogenesis of preterm delivery (7.5% of all births and 6% of all 
singleton births in Scotland 20103),  induction of labour (22.5% of live births in 
Scotland 20103) and major obstetric haemorrhage (≥2500mls or requiring 
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transfusion of ≥5units of blood affects 5.18 per 1000 live births with >50% 
attributable to uterine atony83).   
In addition to these significant clinical problems caesarean section (CS) rates 
remain high at 26.6% of live births in Scotland in 2010, with 11.3% of all 
deliveries occurring as elective CS and 15.3% as emergency CS3.  Failure to 
progress in labour has been identified as a major aetiological factor in the 
decision to perform an emergency CS, and is cited as a primary indication in up 
to 53% of intrapartum CS deliveries in singleton cephalic pregnancies58-61.  This 
occurs despite augmentation of labour with Syntocinon, as up to 81% of these 
women have received OT in the form of Syntocinon® prior to CS19 20.   
Current knowledge concerning the contractile effect of OT on myometrium is 
limited to the short term and immediate effects, with a well described pathway 
as illustrated in Figure 26. 
 
Figure 26  Intracellular events following OTR stimulation with OT 
Summary diagram of intracellular events occurring in response to OT activation of the 
oxytocin receptor (OTR) on a myometrial cell culminating in cellular contraction. 
Contractions of the myometrial myocyte have much in common with other 
contractile tissues in that contractility hinges on the interaction and cross 
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linking of myosin with actin154.  This interaction requires phosphorylation of 
myosin light chain (MLC) which is mediated by the enzyme myosin light chain 
kinase (MLCK).  MLCK becomes activated in the presence of the calcium-
calmodulin complex, which is formed in the presence of intracellular calcium.  
Thereby, increased intracellular calcium is required for this final pathway.  OT 
facilitates an increase in intracellular calcium as it binds the OTR (a seven 
transmembrane Gαq protein coupled receptor) resulting in activation of 
phospholipase C isoforms β1, β2 and β3.  This catalyses the hydrolysis of 
phosphatidylinositol 4,5-bisphosphate (PIP2) with a resultant increase in inositol-
1,4,5-triphosphate (IP3) and 1,2-diacylglycerol (DAG)
155.  IP3 acts on the 
sarcoplasmic reticulum to release its calcium stores, thereby increasing the 
availability of cytoplasmic calcium156.  The increased cytoplasmic calcium has a 
direct effect upon calcium-sensitive cationic channels which depolarise the cell, 
opening voltage gated L-type calcium channels, leading to a full action 
potential134.  The other second messenger DAG is thought to activate plasma 
membrane calcium channels in addition to mediating effects via protein kinase 
C155 157.  The subsequent influx of large quantities of calcium binds to the 
calcium binding protein calmodulin thereby facilitating activation of MLCK and 
initiation of the final common contraction pathway of actin and myosin cross-
linking.  In addition to the above contraction pathway, OT is known to increase 
the sensitivity of the contractile machinery to calcium by altering the activity 
ratio of MLCK (pro-contraction) and MLCP (pro-relaxation) as detailed in Chapter 
1, Section 1.5.1116 158. 
This knowledge of the immediate effects of OT on myometrial contractility has 
been used extensively in physiological and pharmacological studies.  However, 
there is difficulty in applying this to human labour, a process which last hours 
rather than seconds.  Additionally, the uterus is exposed to endogenous oxytocin 
throughout pregnancy as it is released in a pulsatile manner increasing towards 
term and particularly during labour167.  In primates, these oxytocin pulses have a 
diurnal variation, peaking nocturnally during periods of darkness, which 
correlates with observed increases in periods of myometrial activity during these 
hours and can be inhibited by administration of an OT antagonist172.  Gestational 
and diurnal variations in labour onset, and non-labour antenatal uterine activity 
(Braxton Hicks contractions) are also seen in human pregnancy173-178  30-35 and 
may be explained by a diurnal variation in OT release179.  The purpose of Braxton 
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Hicks contractions have not been fully elucidated, however they are popularly 
regarded as ‘practice contractions’ required by the uterus to preparing for the 
process of labour including the process of cervical ripening325 326.  To this end it 
may be postulated that long term exposure to OT during pregnancy may result in 
transcriptional changes to ‘prime’ the myometrial cells thereby enhancing the 
development of a pro-contractile phenotype which facilitates an effective and 
efficient labour. 
The mechanisms which underly these OT effects on uterine contractility are 
unclear.  At a cellular level, cultured myometrial cells which were exposed to 
OT for 1 hour showed an increase in Regulator of G Protein Signalling 2 (RGS2) 
mRNA327.  Additionally, there is evidence of an effect on the myocyte proteome 
of long term (1 hour) exposure to OT while contracting in an in-vitro organ bath 
environment.  This has shown up-regulation of the expression of 13 proteins 
associated with 5 functional classes, namely cytoskeletal function (septin-2, 
cytokeratin-19, desmin, transgelin) contractile/oxidative stress (annexin A3, 
heat shock protein 70, protein disulfide isomerise, thioredoxin), extracellular 
matrix (Osteoglycin, BIGH3), energy metabolism (EH domain protein 2, triose 
phosphate isomerise, pyruvate kinase) and protein synthesis (EF1γ)180. 
These data suggest that long-term OT exposure may promote transcriptionally 
regulated phenotypic changes in the myometrium, which are required for the 
sustained uterine activity necessary for normal labour.  An increased 
understanding of the mechanisms involved in OTR stimulation and its resultant 
cellular effects has the potential to guide the development of possible 
pharmacologic agents for the prevention, reversal or stimulation of uterine 
contractions. This knowledge may then be used to facilitate the development of 
novel and effective strategies to reduce the incidence of preterm birth, optimise 
the safe induction of labour leading to successful vaginal birth and avoidance of 
intrapatrum caesarean deliveries, in addition to minimising post-partum 
haemorrhage. 
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3.2 Hypothesis 
The overall hypothesis to be examined in this chapter regarding the role of long 
term oxytocin exposure and the effect on myometrial contractile function and 
gene transcription is summarised in Figure 27. 
 
Figure 27  Chapter 3 Overall Hypothesis 
Summary of the overall hypothesis concerning the functional and transcriptional effects of 
oxytocin exposure on in-vitro contracting human myometrium. 
Overall, we propose that in addition to the well described acute physiological 
contractile effect of OT upon the myometrial myocyte, that longer term (hours) 
exposure to OT induces a transcription led contractile phenotype in human 
myometrium.  This contractile phenotype is then able to facilitate sustained 
uterine activity and ultimately an effective and efficient labour.    
To clarify this, examination of the time-dependent transcriptional response of 
myometrium to spontaneous and OT-induced contractions in-vitro was 
undertaken with additional comparisons made where contractions were blocked 
downstream by a myosin light chain kinase (MLCK) inhibitor, ML7 (see Figure 26). 
The specific hypotheses to be tested are  
1. Oxytocin exposure will induce time dependent transcriptional changes 
over and above the transcriptional profile of spontaneously contracting 
myometrium. 
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2. Oxytocin exposure will induce time dependent transcriptional changes in 
myometrial samples even where contractions are inhibited by blocking 
MLCK function prior to oxytocin exposure. 
3. Temporal transcriptional changes occur within myometrium in response to 
contractile activity. 
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3.3 Methods  
Functional in-vitro organ bath experiments were performed with subsequent 
temporal analysis of myometrial gene expression.  A summary of the 
experimental design used in this chapter is shown in Figure 28. 
 
Figure 28  Chapter 3 Experimental Design 
Illustration of experimental design used to examine the functional and transcriptional 
effects of long term (hours) exposure of myometrium to oxytocin in-vitro.  Study groups are 
defined by drug environment (OT, ML7, OT&ML7, acetic acid (AA) and DMSO) and length of 
exposure (0, 1, 2, 4 & 6 hours) myometrial strips in each group n = 5. 
3.3.1 Patient Selection 
Myometrial strips were obtained from term pre-labour planned caesarean 
deliveries (n patients=25) as described previously in Chapter 2, Section 2.1. 
3.3.2 In vitro contractility studies 
In-vitro contractility studies were performed as previously described in Chapter 
2, Section 2.3.  Myometrial strips (n strips from each patient=5) were dissected 
and suspended in separate organ baths under physiological conditions with a 
20mN tension applied.  After establishment of spontaneous contractions (2 
hours), a single addition of ML7 (final bath concentration 200µM) was undertaken 
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into two of the baths, and a single addition of the vehicle DMSO (20µl) into one 
other bath.  Once contractile activity had been suppressed in the ML7 treated 
samples (approximately 1 hour and 30minutes after addition), OT (final bath 
concentration 1nM) was added to one of the remaining baths and one of the 
baths pre-treated with ML7.  The OT vehicle acetic acid (10µl of 2% AA) was 
added to the one remaining bath.  All drug preparations, additions and 
justification for use and of final bath concentrations are previously described in 
detail in Chapter 2.  
The experiments were terminated at either 0, 1, 2, 4 or 6 hours after the time 
at which the addition of OT was undertaken.  The myometrial strips were 
prepared for storage, weighed, snap frozen in liquid nitrogen and stored at -
80◦C. 
3.3.3 Contractile Analysis 
Spontaneous contractile activity was recorded where stable, regular rhythmic 
activity occurred at 2 hours after initial application of tension, prior to any drug 
additions and at variable time intervals during the course of the experiment 
while the tissue remained in the organ bath.  Contractile activity (amplitude, 
frequency and activity integral) are measured as previously described in Chapter 
2, Section 2.3.2. 
Contractility data are described as medians (IQR) and analysed using a Kruskal-
Wallis test or Mann-Whitney U-test comparing measures of contractility between 
study groups (defined as organ bath drug environment and time at which 
experiment was terminated) at each time point over the length of the 
experiment.   
3.3.4 RNA extraction and Illumina gene array 
RNA was extracted from each frozen sample in random order (n=125), quantified 
and RNA integrity checked as describe in Chapter 2.  The samples then 
underwent amplification and biotin labelling.  Individual Illumina (Human Ref 6) 
gene arrays were performed on each individual sample using the protocol 
described in Chapter 2.  Illumina Arrays were outsourced and performed by The 
Wellcome Trust Clinical Research Facility, University of Edinburgh. 
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3.3.5 QPCR validation 
Gene array validation was performed on the stored RNA samples above.  Genes 
used for validation were CXCL1, CXCL2, CXCL5, CXCL8, CCL2, CCL3, CCL8, 
CCL20, IL1B, IL6, IL10, TNFα, IFIT2, and CHURC1.  QPCR was carried out using 
the housekeeping gene B-actin, and performed according to the protocol 
described in Chapter 2, Section 2.7. 
3.3.6 Statistical analysis of gene array output  
Data analysis of the gene array output was performed by FIOS Genomics, 
University of Edinburgh using a combination of R programming with the Lumi and 
Limma packages from Bioconductor41-43. 
Briefly, the raw data (BeadStudio scan outputs (.txt files)) from the Illumina 
arrays was passed through a quality control step, transformed using variance 
stabilisation followed by robust spline normalisation328.  Pearson correlation 
analysis between arrays was then performed with subsequent exclusion of any 
arrays which did not pass this quality control step. 
These transformed data from arrays were then reduced to a single set of 
relevant values for each drug/time exposure (e.g. OT at 0hrs, OT at 1hr etc) 
using linear model fitting of the normalised data.  These data sets were then 
analysed using Empirical Bayes statistics t-test coupled with p value adjustment 
for multiple testing using the Benjamini & Hochberg method to test differential 
expression by drug exposure and across time as appropriate 329 330.  Fold changes 
for differential expression by drug and time were also calculated. 
3.3.7 Statistical analysis of Q-PCR data and array validation 
Validation of the array findings was performed using Q-PCR data for the probes 
CXCL1, CXCL2, CXCL5, CXCL8, CCL2, CCL3, CCL8, CCL20, IL1B, IL6, IL10, TNFα, 
IFIT2, and CHURC1.  These were chosen as they represented genes which were 
over expressed in contracting samples (those associated with inflammation) with 
the addition of IFIT2 which demonstrated a >2 fold down regulation in most 
samples in the array and CHURC1 which demonstrated up to 2 fold down 
regulation in most samples in the array. 
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Lists of fold changes were then compiled from the gene array data for each gene 
probe for each drug exposure in comparison to the baseline time 0 hours (e.g. 
fold change for CXCL1 for samples exposed to OT, 1hr vs 0hrs, 2hr vs 0hrs, 4hrs 
vs 0hrs and 6hrs vs 0hrs).  Gene array fold change was expressed as logFC (log 
base 2 fold change of the gene with a positive values indicating up regulation).   
Q-PCR data were calculated in the same manner to give the same output for 
comparison purposes.  Fold changes and ranges were calculated using the 2-∆∆Ct 
method for relative gene expression with KKCt +SD and KKCt –SD where SD is 
standard deviation for the KKCt value46 47.  The fold change value was 
subsequently log(2) transformed. 
Correlation analysis was then performed to assess the similarity between the 
array and Q-PCR data using Pearsons correlation testing since data had been 
normalised with log transformation with a p<0.05 considered significant.  
Other analyses of Q-PCR are undertaken within this chapter.  These are 
performed on the raw untransformed data using the Mann-Whitney U-test where 
comparisons are made between two groups.  No adjustments are made for 
multiple testing for these data as with our relatively small dataset adjustment 
may reduce the chance of making a type I error, but may lead to and increase in 
the chance of making a type II error and a need to increase our sample size331-
334.  A p<0.05 was considered significant. 
3.3.8 KEGG and GO enrichment analysis 
This analysis was performed on the transformed and normalised data generated 
from the Illumina Arrays and allows exploration of the underlying biological 
changes occurring within the dataset. 
Gene ontology (GO) is a database describing gene products in a consistent 
fashion335.  It categorises gene products in terms of their associated biological 
processes (BP), cellular components (CC) or molecular functions (MF).  Genes 
which had a raw significance values of p<0.001 for the differential contrast of 
interest were used regardless of the extent of fold change.  The GO categories 
relating to these differentially expressed genes were compiled as a list of 
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upregulated and downregulated categories with enrichment significance values 
supplied for each category. 
The Kyoto Encyclopaedia of Genes and Genomes (KEGG) is a similar database to 
the GO database, however some categories differ and it is useful to consider 
both databases to gain insight into the transcription driven cellular changes336.  
The stringency of matching to KEGG is higher than GO, therefore a raw 
significance value of p<0.01 for the differential expression of genes in the 
contrast of interest was used.  Again a list of upregulated and downregulated 
categories was compiled with enrichment significance values supplied for each 
category. 
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3.4 Results 
3.4.1 Patient demographics 
Samples were taken from 25 patients, with five myometrial strips dissected from 
each sample.  Data are available from 5 strips for each environment at each 
time point.  Demographic details for these patients are listed in Table 6. 
N Women 25 
N Strips  125 
Maternal BMI (kg/m2) 
Median (IQR) 
[Range] 
24 (21.9, 26.5) 
[18.5,34.6] 
Age (years) 
Median (IQR) 
[Range] 
31 (27,35) 
[21,41] 
Gestation (days) 
Median (IQR) 
[Range] 
273 (273, 275) 
[263,284] 
Baby birth weight (kg) 
Median (IQR) 
[Range] 
3.47 (3.28, 3.70) 
[2.30, 4.19] 
Indication for CS 
N (%) Previous LUSCS 
N (%) breech 
N (%) maternal request 
N (%) prev traumatic delivery 
20 (80%) 
1 (4%) 
2 (8%) 
2 (8%) 
Parity 
N (%) =0 
N (%) =1 
N (%) ≥2 
2 (8%) 
16 (64%) 
7 (28%) 
Table 6   Patient demographic details 
Demographic details of patients examining the myometrial functional and transcriptional 
effects of long term exposure to oxytocin. 
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3.4.2 Summary baseline contractility data 
An example of the contractile trace for a 6 hour experiment, which illustrates 
the timing and functional effect of each drug addition is shown in Figure 29. 
 
Figure 29  Example of contractility trace from experiments in Chapter 3 
Contraction trace from an experiment terminated 6hours following time at which addition of 
OT was undertaken.  This illustrates the timing and functional effects of each drug addition. 
OT (oxytocin), ML7 (myosin light chain kinase inhibitor), AA (acetic acid, the OT vehicle), 
DMSO (the ML7 vehicle) 
A summary of the baseline contractility (amplitude, frequency and activity 
integral) of myometrial samples at 2 hours after initial application of tension and 
prior to drug additions is shown in Figure 30 and Figure 31.  Data demonstrate 
that there was no difference in baseline contractility regardless of which drug 
was destined to be added to the organ bath, or how long the experiment was 
destined to last (amplitude, p≥0.2, frequency, p≥0.1 and activity integral, p≥0.3 
for all comparisons).
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Figure 30  Baseline measures of contractility analysed by eventual length of experiment 
Illustration of baseline measures of contractility (amplitude, frequency and activity integral) 
in myometrial strips assessed 2 hours after initial application of tension before any drug 
additions were undertaken.  Data are shown as bars indicating median and IQR, with 
Kruskal Wallis p values indicated under each graph and show no difference regardless of 
the destined length of experiment. 
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Figure 31  Baseline measure of contractility analysed by eventual type of drug exposure 
Illustration of baseline measures of contractility (amplitude, frequency and activity integral) 
in myometrial strips assessed 2 hours after initial application of tension before any drug 
additions were undertaken.  Data are shown as bars indicating median and IQR, with 
Kruskal Wallis p values indicated under each graph and show no difference regardless of 
the destined drug addition. 
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3.4.3 Array QC and normalisation 
Following transformation and normalisation of the array data, correlation plots 
indicated that although inter-array correlations were high, four arrays exhibited 
lower correlations and were subsequently removed from the data set.  
Transformation and normalisation were repeated on the remaining 121 samples 
that were subsequently used for the array analysis. 
The samples which were removed were all from different groups resulting in the 
following groups only having data from 4 myometrial strips; ML7 at 6 hours, OT 
and 4 hours, ML7 and 4 hours, and AA at 4 hours. 
3.4.4 Array validation 
Selected transcripts were identified from the array lists for verification using 
QPCR.  The gene targets chosen represented different expression profiles within 
the array in comparison to expression at time 0hrs, and included CCL2, CCL3, 
CCL8, CCL20, CXCL1, CXCL2, CXCL5, CXCL8, IL1B, IL6, IL10, TNFα, IFIT2, and 
CHURC1.  The Log2 fold change was calculated for the PCR data using the 
technique above, and Pearson correlation analysis was performed.  All gene 
targets were in good agreement with the array data (r>0.686, p<0.001) with the 
exception of CCL2 (r=0.326, p=0.161) and CHURC1 (r=0.155, p=0.515).  The 
correlation plots are demonstrated in Figure 32.  Therefore it can be assumed 
that the gene expression changes seen in the array data reflect reliable data. 
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Figure 32  Correlation analysis of array data with QPCR data. 
Fold changes were calculated for each drug environment relative to baseline time 0 hours.  
Data are shown as scatter plots with regression line and 95% confidence interval.  Pearson 
correlation analysis was performed for each gene probe, with p values demonstrated under 
each graph. 
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3.4.5 Hypothesis 1 – OT exposure will induce time dependent 
transcriptional changes over and above the transcriptional 
profile of spontaneously contracting myometrium (OT vs 
AA) 
3.4.5.1 Contractility Data 
The spontaneous activity of the myometrial strips was characterized by regular 
contractions 2 hours after initial tension applied (baseline) and also immediately 
prior to addition of either OT or AA (pre) and is illustrated in Figure 33.  There 
were no significant differences in the spontaneous activity in strips which 
received OT or acetic acid at either baseline or immediately prior to drug 
addition (AA vs OT baseline (amplitude p=0.51, frequency p=0.06, activity 
integral p=0.09) AA vs OT pre (amplitude p=0.82, frequency p=0.23, activity 
integral p=0.43). 
Addition of 1nM OT had an immediate stimulatory effect on contractile activity 
compared with vehicle (median % change (IQR) amplitude 12.5 (6.1,50.7) vs 1.4 
(0.3,6.5), p<0.001, frequency 526.7 (282.7,807.4) vs 0.0 (-12.8,10.7) p<0.001, 
activity integral 151.8 (89.3,311.0) vs -1.7 (-9.2,8.0), p<0.001).  A stimulatory 
effect of OT compared with acetic acid persisted throughout the course of each 
experiment, but differences became less significant with time (Figure 33). 
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Figure 33  The effect of OT relative to its AA vehicle on in-vitro myometrial contractility 
Illustration of the effect of OT relative to its AA vehicle on in-vitro myometrial contractility as 
measured by frequency, amplitude and activity integral throughout the time course of the 
experiment.  All measures of contractility are expressed as median and IQR with n = 25 at 
baseline, pre-drug and 0mins, n = 20 at 0.5 and 1 hour, n = 15 at 2 hours, n = 10 at 3 and 4 
hours and n = 5 at 5 and 6 hours.  Mann-Whitney U-tests were performed to assess the 
difference in contractility between OT and AA treated strips at each timepoint. *p<0.05, 
**p<0.01, ***p<0.001 
3.4.5.2 Myometrial transcription data from array 
Using an adjusted significance of p<0.05, both OT and AA vehicle treated 
myometrium demonstrated a time-dependent transcriptional wave with 
differential expression of 183 genes at 4hours and 1759 genes at 6hours in the 
OT treated group, and 804 genes at 4hours and 2262 genes at 6 hours in the AA 
vehicle treated group (Table 7).  However, using an adjusted significance of 
p<0.05, no genes were significantly altered by OT when compared to AA vehicle 
at any of the 5 time points (Table 8), and no significant difference was found 
between time dependent differentially expressed genes in the OT or vehicle 
group (Table 9).  
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n genes differentially 
expressed 
 
n genes differentially 
expressed 
Comparison 
 
 
adjusted p<0.05 
 
Comparison 
 
 
adjusted p<0.05 
 
 OT (1hr-0hr) 0  AA (1hr-0hr) 0 
 OT (2hr-0hr) 0  AA (2hr-0hr) 0 
 OT (4hr-0hr) 183  AA (4hr-0hr) 804 
 OT (6hr-0hr) 1759  AA (6hr-0hr) 2262 
Table 7  Differential gene expression in OT and AA relative to 0 hours 
The number of genes differentially expressed in myometrium relative to time 0 hours in 
response to treatment with OT or AA vehicle using an adjusted significance value of p<0.05. 
 
Comparison 
 
 
n genes differentially expressed 
adjusted p<0.05 
 
OT vs AA 0hr 0 
OT vs AA 1hr 0 
OT vs AA 2hr 0 
OT vs AA 4hr 0 
OT vs AA 6hr 0 
Table 8  Differential gene expression OT vs AA 
The number of genes differentially expressed in myometrium between exposure to OT and 
AA vehicle at each time point using an adjusted significance value of p<0.05 
 
 
Comparison 
 
 
n genes differentially expressed 
adjusted p<0.05 
 
OT(1hr-0hr) vs AA (1hr-0hr) 0 
OT (2hr-0hr)vs AA (2hr-0hr) 0 
OT (4hr-0hr) vs AA (4hr-0hr) 0 
OT (6hr-0hr) vs AA (6hr-0hr) 0 
Table 9  Differential gene expression OT vs AA relative to 0 hours 
The difference in number of genes expressed in myometrium showing no significant 
changes in expression relative to 0 hours when groups are compared using an adjusted 
significance value of p<0.05 
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3.4.5.3 Myometrial Q-PCR confirmation of array data 
QPCR examination of the probes CXCL1, CXCL2, CXCL5, CXCL8, CCL2, CCL3, 
CCL8, CCL20, IL1B, IL6, IL10, TNFα, IFIT2, and CHURC1 relative to β-actin is 
illustrated in Figure 34.  This confirmed the gene array data with no significant 
differences in gene expression between samples exposed to OT or AA vehicle, 
except at the 2 hour timepoint for CXCL8 where expression was higher in 
response to OT (p=0.03). 
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Figure 34  QPCR gene expression OT vs AA 
QPCR confirmation of no significant difference in myometrial gene transcription between 
samples exposed to OT or AA vehicle at each timepoint after first exposure.  Data are 
shown as bars indicating median and IQR with clear bars indicating AA data and shaded 
bars indicating OT data.  *p<0.5 
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3.4.6 Hypothesis 2 - OT exposure will induce time dependent 
transcriptional changes in myometrial samples even where 
contractions are inhibited by blocking MLCK function prior 
to oxytocin exposure (ML7 vs ML7 & OT) 
3.4.6.1 Contractility Data 
Addition of ML7 resulted in a diminution in contractile activity with complete 
cessation of activity within a median time of 49 minutes (IQR 34 - 61mins) for 
those exposed to ML7 only, and 40 minutes (IQR 31.5 -54mins) for those treated 
with ML7 with subsequent addition of OT.  There was no significant difference in 
the response between the two groups (p=0.4).  Additionally where OT was added 
to a strip pre-treated with ML7, there was no subsequent activity in that strip, 
with contractions remaining absent. 
3.4.6.2 Myometrial transcription data from array 
Using an adjusted significance of p<0.05 and p<0.01 both ML7 and ML7 & OT 
treated groups demonstrated a time-dependent transcriptional wave (Table 10).  
However, using an adjusted significance of p<0.05, no genes were significantly 
altered by the addition of OT in myometrial strips pre-treated with ML7 at any of 
the 5 time points (Table 11). 
 
 
n genes differentially 
expressed 
 
n genes differentially 
expressed 
Comparison 
 
adjusted 
p<0.05 
adjusted 
p<0.01 
Comparison 
 
adjusted 
p<0.05 
adjusted 
p<0.01 
ML7 (1hr-0hr) 0 0 ML7 & OT (1hr-0hr) 0 0 
 ML7 (2hr-0hr) 4 0 ML7 & OT (2hr-0hr) 2 0 
ML7 (4hr-0hr) 67 27 ML7 & OT (4hr-0hr) 279 71 
ML7 (6hr-0hr) 764 222 ML7 & OT (6hr-0hr) 2237 802 
Table 10  Differential gene expression in ML7 and ML7 & OT relative to 0 hours 
The number of genes differentially expressed in myometrium relative to time 0 hours in 
response to treatment with ML7 or ML7 & OT using an adjusted significance value of p<0.05. 
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Comparison 
 
 
n genes differentially expressed 
adjusted p<0.05 
 
ML7 vs ML7 & OT 0hr 0 
ML7 vs ML7 & OT 1hr 0 
ML7 vs ML7 & OT 2hr 0 
ML7 vs ML7 & OT 4hr 0 
ML7 vs ML7 & OT 6hr 0 
Table 11  Differential gene expression ML7 vs ML7 & OT 
The number of genes differentially expressed between myometrium treated with ML7 only or 
ML7 & OT at each time point using an adjusted significance value of p<0.05 
3.4.6.3 Myometrial Q-PCR confirmation of array data 
QPCR examination of the probes CXCL1, CXCL2, CXCL5, CXCL8, CCL2, CCL3, 
CCL8, CCL20, IL1B, IL6, IL10, TNFα, IFIT2, and CHURC1 relative to β-actin is 
illustrated in Figure 35.  This confirmed the gene array data with no significant 
difference in gene expression between samples exposed to ML7 or ML7 & OT, 
except at the 6 hour timepoint for IFIT2 and 2 hour timepoint for CHURC1 where 
expression was higher in the ML7 only group (p=0.032 and p=0.016 respectively). 
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Figure 35  QPCR gene expression ML7 vs ML7&OT 
QPCR confirmation of no significant difference in myometrial gene transcription between 
samples exposed to ML7 or ML7 & OT at each timepoint after first exposure.  Data are 
shown as bars indicating median and IQR with clear bars indicating ML7 data and shaded 
bars indicating ML7 & OT data.  *p<0.05 
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3.4.7 Hypothesis 3 - Temporal transcriptional changes occur 
within myometrium in response to contractile activity 
(DMSO vs ML7) and relative to time 0 hours (AA & DMSO & 
OT over time)  
3.4.7.1 Contractility Data  
The contractile activity of the myometrial strips used in this section is illustrated 
in Figure 36.  Addition of AA (OT vehicle) or DMSO (ML7 vehicle) to the organ 
bath did not have an effect on any aspect of contractile activity over time as 
measured using a Kruskal Wallis test, (amplitude p=0.9, p=0.8, frequency p=0.1, 
p=0.2, activity integral p=0.8, p=0.7 for AA and DMSO respectively).  Additionally 
there was no significant difference between contractile activity of strips 
exposed to AA or DMSO at any timepoint (amplitude, p>0.5, frequency, p>0.4, 
activity integral p>0.2 at each timepoint). OT had a stimulatory effect on 
contractile activity as discussed in Hypothesis 1 (Section 3.4.5) and ML7 had an 
inhibitory effect on all aspects of contractile activity as discussed in Hypothesis 
2 (Section 3.4.6). 
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Figure 36  The effect of OT, AA vehicle, ML7 or DMSO vehicle on in-vitro myometrial 
contractility 
Illustration of the effect of OT, AA vehicle, ML7 and DMSO vehicle on in-vitro myometrial 
contractility as measured by frequency, amplitude and activity integral throughout the time 
course of the experiment.  All measures of contractility are expressed as median and IQR 
with n = 25 at baseline, pre-drug and 0mins, n = 20 at 0.5 and 1 hour, n = 15 at 2 hours, n = 
10 at 3 and 4 hours and n = 5 at 5 and 6 hours.   
3.4.7.2 Myometrial transcription data from array 
3.4.7.2.1 Pattern of contraction associated transcriptional changes 
To ensure pooling of contracting samples was appropriate, comparisons were 
made between gene expression at each timepoint in the AA group with both OT 
(as illustrated earlier) and DMSO (Table 12).  Using an adjusted significance of 
p<0.05, no differences were found, therefore data from samples which 
contracted in-vitro in response to OT, AA and DMSO were pooled as one group. 
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n genes differentially 
expressed 
 
n genes differentially 
expressed 
Comparison 
 
adjusted p<0.05 
Comparison 
 
adjusted p<0.05 
OT vs AA 0hr 0 DMSO vs AA 0hr 0 
OT vs AA 1hr 0 DMSO vs AA 1hr 0 
OT vs AA 2hr 0 DMSO vs AA 2hr 0 
OT vs AA 4hr 0 DMSO vs AA 4hr 0 
OT vs AA 6hr 0 DMSO vs AA 6hr 0 
Table 12  Differential gene expression OT vs AA and DMSO vs AA 
The number of genes differentially expressed between myometrium treated with OT or AA, 
and DMSO or AA at each time point using an adjusted significance value of p<0.05 
Analysis of the contracting group (pooled OT, AA and DMSO) revealed a time-
dependent transcriptional wave with 13, 114, 2006, 4760 genes differentially 
expressed using an adjusted significance value of p<0.01 at 1, 2, 4 and 6 hours 
respectively (Table 13).   
 
n genes differentially  
expressed 
Comparison 
adjusted 
p<0.05 
adjusted  
p<0.01 
Pooled contracting samples (1hr-0hr) 101 13 
 Pooled contracting samples (2hr-0hr) 387 114 
Pooled contracting samples (4hr-0hr) 3973 2006 
Pooled contracting samples (6hr-0hr) 7034 4760 
Table 13  Differential gene expression in pooled contracting samples relative to 0 hours 
The number of genes differentially expressed relative to time 0 hours in contracting 
samples (pooled data from samples exposed to OT, AA, DMSO) using an adjusted 
significance value of p<0.05. 
The transcriptional wave for the pooled contracting samples is further illustrated 
by heatmaps in Figure 37 (all fold changes) and Figure 38 (fold changes > 2).  On 
the heatmap, the blue colour indicates down regulation and red upregulation, 
with the deeper the colour indicating a larger fold change.  A greater number of 
red and blue lines and an increase in the intensity of colour is seen at the longer 
timepoints of 4 and 6 hours consistent with a time dependent transcriptional 
wave. 
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Figure 37  Heatmap of transcriptional changes relative to O hours for pooled contracting 
samples 
Heatmap illustrating the pattern of transcriptional changes relative to time 0hr in pooled 
contracting samples (AA, DMSO and OT).  Data are shown for all fold changes where 
adjusted p<0.01.  Blue colour indicated down regulation and red upregulation, with the 
deeper the colour indicated a higher fold change.  With increasing time contracting, 
samples display an increased number and extent of gene fold changes. 
 
 
Figure 38  Heatmap of transcriptional changes relative to 0 hours for poked contracting 
samples (fold change>2) 
Heatmap illustrating the pattern of transcriptional changes relative to time 0hr in pooled 
contracting samples (AA, DMSO and OT). Data are shown for fold changes>2,  where 
adjusted p<0.01.  Blue colour indicated down regulation and red upregulation, with the 
deeper the colour indicated a higher fold change.  With increasing time contracting, 
samples display an increased number and extent of gene fold changes. 
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A further time-dependent transcriptional wave was found when samples which 
were rendered unable to contract by addition of ML7 were compared with their 
vehicle treated contracting samples (DMSO) (Table 14). 
 
n genes differentially  
expressed 
Comparison 
adjusted 
p<0.05 
adjusted  
p<0.01 
ML7 vs DMSO 0hr 2 0 
ML7 vs DMSO 1hr 4 2 
ML7 vs DMSO 2hr 25 6 
ML7 vs DMSO 4hr 487 175 
ML7 vs DMSO 6hr 3320 1548 
Table 14  Differential gene expression in ML7 vs DMSO 
The number of genes differentially expressed between ML7 and DMSO vehicle at each time 
point using an adjusted significance value of p<0.05 
 
3.4.7.2.2 Contraction associated overexpressed genes  
The top 20 genes which are upregulated at the 6 hour timepoint in contracting 
samples compared with the baseline at time 0 hours are shown in Table 15.  
There is over representation of cytokine mediated processes with 7 of the 20 
genes transcribing a cytokine, chemokine or receptor (IL11, CXCL5, IL1A, CCL20, 
IL23A, IL1B, IL13RA2).  Additionally, the genes PTGS2 and FST are also involved 
in the inflammatory response.   
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Gene Symbol Gene Name 
Log 2 Fold 
Change Adj p value 
IL11 interleukin 11 2.777602 4.03E-15 
CXCL5 chemokine (C-X-C motif) ligand 5 2.637802 9.47E-23 
IL1A interleukin 1, alpha 2.436311 1.42E-09 
MYEOV 
myeloma overexpressed gene (in 
a subset of t(11;14) positive 
multiple myelomas) 
2.326521 1.52E-11 
NA 
probeset not currently assigned 
to a gene symbol 
2.261165 3.45E-14 
CCL20 chemokine (C-C motif) ligand 20 2.14653 4.11E-07 
MMP1 
matrix metallopeptidase 1 
(interstitial collagenase) 
2.089201 3.12E-06 
SERPINB2 
serpin peptidase inhibitor, clade 
B (ovalbumin), member 2 
1.951359 3.58E-07 
FLJ27255 hypothetical LOC401281 1.930037 1.70E-14 
IL23A interleukin 23, alpha subunit p19 1.821352 3.99E-17 
KRT34 keratin 34 1.799177 4.51E-06 
GJB2 
gap junction protein, beta 2, 
26kDa 
1.797835 5.59E-11 
AKR1B1 
aldo-keto reductase family 1, 
member B1 (aldose reductase) 
1.771979 3.05E-25 
RCC1 
regulator of chromosome 
condensation 1 
1.751471 1.49E-10 
PTGS2 
prostaglandin-endoperoxide 
synthase 2 (prostaglandin G/H 
synthase and cyclooxygenase) 
1.726473 6.53E-07 
IL1B interleukin 1, beta 1.698531 0.000277 
HIST2H2AA3 histone cluster 2, H2aa3 1.684515 1.45E-07 
FST follistatin 1.676597 1.57E-07 
EVI1 ecotropic viral integration site 1 1.668135 7.32E-11 
IL13RA2 interleukin 13 receptor, alpha 2 1.658026 2.27E-13 
Table 15  Top 20 genes upregulated in contracting samples (6 hours relative to 0 hours) 
Pooled contracting samples top 20 genes with the largest fold change which are 
differentially upregulated at 6 hours compared with 0 hours.  
Furthermore, many of the same overexpressed genes are common to the data in 
Table 16 where there is again overexpression of genes involved in the 
inflammatory process in contracting myometrial samples compared with those 
which are not contracting after treatment with ML7 (DMSO vs ML7).  There is an 
overlap of 25% of the genes expressed in both comparisons, with 5 genes 
common to both lists, namely IL1B, CXCL5, IL11, IL1A and CCL20.  Additionally, 
the inflammatory associated genes FCER1G, CCL3, CD14, CCL3L3 (chemokine (C-
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C motif) ligand 3-like 3337), CCL4 L1 (chemokine (C-C motif) ligand 4-like 1338), 
FCGR2A, SLAMF1, CD163 and IL1RN also up-regulated in response to contractions 
when compared with non-contracting samples. 
Gene Symbol Gene Name 
Log 2 Fold 
Change 
Adj p value 
IL1B interleukin 1, beta 3.47154 0.054566 
CXCL5 chemokine (C-X-C motif) ligand 5 3.02576 6.66E-06 
IL11 interleukin 11 2.94093 0.010186 
IL1A interleukin 1, alpha 2.91841 0.051357 
FCER1G 
Fc fragment of IgE, high affinity I, 
receptor for; gamma polypeptide 
2.89977 0.015421 
CCL3 chemokine (C-C motif) ligand 3 2.84458 0.071062 
KYNU kynureninase (L-kynurenine hydrolase) 2.76708 0.016709 
CCL20 chemokine (C-C motif) ligand 20 2.69377 0.106052 
CD14 CD14 molecule 2.67815 0.002216 
CCL3L3 
chemokine (C-C motif) ligand 3-like 3 
(functionally different isoform of CCL3 
with differing receptor interactions.  
CCL3L3 interacts with CCR5, role 
inhibiting HIV cell entry) 
2.55156 0.118392 
MYEOV 
myeloma overexpressed gene (in a 
subset of t(11;14) positive multiple 
myelomas) 
2.52618 0.043751 
CCL4L1 
chemokine (C-C motif) ligand 4-like 1 
(functionally different isoform of CCL4 
with differing receptor interactions.  
CCL4L1  interacts with CCR5, role 
inhibiting HIV cell entry) 
2.52287 0.110971 
FCGR2A 
Fc fragment of IgG, low affinity IIa, 
receptor (CD32) 
2.51975 0.032364 
SLAMF1 
signaling lymphocytic activation 
molecule family member 1 
2.48996 0.057718 
TPSAB1 tryptase alpha/beta 1 2.44531 0.069854 
CD163 CD163 molecule 2.42854 0.042647 
KYNU kynureninase (L-kynurenine hydrolase) 2.38369 0.007839 
HCK hemopoietic cell kinase 2.35412 0.000129 
IL1RN interleukin 1 receptor antagonist 2.34052 0.115504 
SERPINB2 
serpin peptidase inhibitor, clade B 
(ovalbumin), member 2 
2.30318 0.132766 
Table 16  Top 20 genes upregulated in DMSO samples relative to ML7 samples 
Top 20 overexpressed genes as assessed by fold change in contracting sample compared 
with non-contracting samples (ML7) at 6 hour timepoint  
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3.4.7.2.3 KEGG& GO Enrichment analysis of contraction associated 
genes 
Examination of the genes expressed by myometrium in relation to contraction 
using KEGG and GO enrichment analysis showed an overall up-regulation of 
inflammatory processes and processes associated with cellular damage or death, 
with down regulation of processes concerned with cellular metabolism.   
In the pooled contracting samples (OT, AA and DMSO) compared to time 0hours, 
KEGG pathways which were upregulated in at least three of the timepoint 
comparisons were pathways 5220 ‘Chronic myeloid leukemia’, 5213 ‘Endometrial 
cancer’, 4012 ‘ErbB signalling pathway’, 4640 ‘Hematopoietic cell lineage’, 4010 
‘MAPK signalling pathway’, 4810 ‘Regulation of actin cytoskeleton’, and 5211 
‘Renal cell carcinoma’.  Down regulation was seen for pathway 650 ‘Butanoate 
metabolism’, 251 ‘Glutamate metabolism’, 563 ‘Glycosylphosphatidylinositol 
(GPI)-anchor biosynthesis’, 640 ‘Propanoate metabolism’, and 380 ‘Tryptophan 
metabolism’.  A full table of KEGG pathway analysis for contracting myometrium 
over time is provided in Appendix I. 
Additionally, contracting samples relative to time 0hrs were associated with 
upregulation in 3 or more comparison with GO associated biological processes 
(BP) of chromatin assembly (GO:0031497), chromatin assembly or disassembly 
(GO:0006333), chromosome organization and biogenesis (GO:0051276), DNA 
packaging (GO:0006323), establishment and/or maintenance of chromatin 
architecture (GO:0006325), macromolecule metabolic process (GO:0043170) , 
nucleosome assembly (GO:0006334), positive regulation of cellular process 
(GO:0048522),  protein-DNA complex assembly (GO:0065004), regulation of 
apoptosis (GO:0042981) and regulation of programmed cell death (GO:0043067).  
Upregulation in 3 or more comparisons were also seen for the molecular 
functions of binding (GO:0005488) and protein binding (GO:0005515) in addition 
to the cellular component terms of chromatin (GO:0000785) and chromosome 
(GO:0005694).  The cellular component terms of intracellular (GO:0005622), 
intracellular membrane-bound organelle (GO:0043231), intracellular organelle 
(GO:0043229), intracellular part (GO:0044424), membrane-bound organelle 
(GO:0043227), organelle (GO:0043226) are also seen to be upregulated at the 
three timepoints of 2, 4 and 6 hours, however, they also appear to be 
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downregulated at the later timepoints of 4 and 6 hours compared with the 
baseline at 0 hours.  A full table of GO pathway analysis for contracting 
myometrium over time is provided in Appendix II. 
Comparison between contracting and non-contracting myometrial samples (DMSO 
vs ML7) demonstrated that contracting myometrium was associated with an 
upregulation of the KEGG pathways 4060 ‘Cytokine-cytokine receptor 
interaction’, 4210 ‘Apoptosis’, 4640 ‘Hematopoietic cell lineage’, 4010 ‘MAPK 
signaling pathway’, and 4620 ‘Toll-like receptor signaling pathway’ at all 
timepoints from 0- 6 hours.  A full table of KEGG pathway analysis for 
contracting myometrium compared with non-contracting myometrium (ML7 Vs 
DMSO) is provided in Appendix III. 
Additionally contracting samples were associated with enrichment of 22 gene 
ontology (GO) pathways in contracting samples for 3 or more of the timepoints 
examined, with over representation of processes associated with inflammation.  
These are represented by the contraction associated upregulation of the 
biological processes of ‘acute inflammatory response’ (GO:0002526), ‘behaviour’ 
(GO:0007610), ‘chemokine activity’ (GO:0008009), ‘chemokine receptor binding’ 
(GO:0042379), ‘chemotaxis’ (GO:0006935), ‘defense response’ (GO:0006952), 
‘fever’ (GO:0001660), ‘immune response’ (GO:0006955), ‘immune system 
process’ (GO:0002376), ‘inflammatory response’ (GO:0006954), ‘locomotory 
behaviour’ (GO:0007626), ‘negative regulation of cell proliferation’ 
(GO:0008285), ‘response to chemical stimulus’ (GO:0042221), ‘response to 
external stimulus’ (GO:0009605), ‘response to stimulus’ (GO:0050896), ‘response 
to wounding’ (GO:0009611), ‘taxis’ (GO:0042330), and the molecular functions 
of ‘cytokine activity’ (GO:0005125) and ‘G-protein-coupled receptor binding’ 
(GO:0001664).  The biological processes of ‘response to protein stimulus’ 
(GO:0051789) and ‘response to unfolded protein’ (GO:0006986) are down 
regulated in contracting myometrium while ‘response to stress’ (GO:0006950) is 
both up and down regulated in response to contractions.  A full table of GO 
pathway analysis for contracting myometrium compared with non-contracting 
myometrium (ML7 Vs DMSO) is provided in Appendix IV. 
Overall this enrichment analysis using both KEGG and GO suggests that 
contractions are associated with myometrial transcriptional upregulation of 
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inflammatory processes and processes concerning cellular damage, stress or cell 
death.  In addition, the transcription of genes which are associated with cellular 
metabolic processes tend to be downregulated. 
3.4.7.3 Myometrial Q-PCR confirmation of array data 
QPCR examination of the probes CXCL1, CXCL2, CXCL5, CXCL8, CCL2, CCL3, 
CCL8, CCL20, IL1B, IL6, IL10, TNFα, IFIT2, and CHURC1 relative to β-actin was 
performed on the pooled contracting samples (AA, OT and DMSO) and is shown in 
Figure 39.  The data from this time series shows a time dependent trend for 
increased expression of these inflammatory mediators, with many showing a 
significantly higher expressed at the later timepoints of 4 and 6 hours. 
Additionally, analysis of QPCR data examining the contracting samples (DMSO) 
compared with the non-contracting ML7 treated samples is shown in Figure 40.  
This again confirmed the gene array findings suggesting a time and contraction 
dependent upregulation of inflammatory processes with significant 
overexpression of all inflammatory mediators with the exception of CCL2 at the 
6 hour timepoint in the contracting samples (Figure 40). 
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Figure 39 QPCR gene expression pooled contracting samples over time 
QPCR confirmation of array data with time dependent increase in expression of 
inflammatory related genes in contracting myometrial samples compared with a baseline of 
0 hours.  Differential expression was more likely to be significant at the longer timepoints of 
4 and 6 hours.  Data are shown as bars indicating median and IQR. Differential analysis was 
performed for each timepoint compared with 0hrs using Mann-Whitney U-test with lines 
demonstrating significance values between 2 samples under star and end of each line. 
*p<0.5, **p<0.01, ***p<0.001 
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Figure 40  QPCR gene expression ML7 vs DMSO 
QPCR confirmation of array data with significantly higher expression of inflammatory 
related genes in contracting myometrial samples (DMSO) compared with non-contracting 
samples (ML7) which is particularly apparent at the longer timepoints of 4 and 6 hours.  
Data are shown as bars indicating median and IQR with clear bars indicating ML7 data and 
shaded bars indicating DMSO data.  Analysis was performed between different drug 
exposure at each timepoint using Mann-Whitney U-test with lines demonstrating 
significance values between 2 samples under star and end of each line. *p<0.5, **p<0.01  
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3.5 Summary of Results 
3.5.1 Myometrial functional and transcriptional response to long 
term exposure to OT 
• Myometrium has a recognised increase in overall contractile activity as 
measured by amplitude, frequency and activity integral in response to 
exposure to oxytocin 
• OT exposure does not significantly alter gene transcription in contracting 
myometrial samples.  
3.5.2 Myometrial transcriptional response to long term exposure 
to OT where contractions have been blocked by inhibition of 
MLCK. 
• OT exposure does not significantly alter gene transcription in ML7 treated 
non-contracting myometrial samples. 
3.5.3 Temporal transcriptional changes in contracting 
myometrium 
• Contracting myometrium (spontaneous and OT induced) exhibits a time 
dependent alteration in gene transcription. 
• Contracting myometrium exhibits a transcriptional wave over and above 
that seen in non-contracting ML7 treated samples 
• KEGG & GO enrichment analysis demonstrates a time and contraction 
dependent up-regulation of inflammatory processes and processes 
associated with cellular damage or death, with down regulation of 
processes concerned with cell metabolism in myometrial tissue. 
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3.6 Discussion 
The data presented in this chapter demonstrate that in-vitro myometrial 
contractile activity is positively affected by exposure to oxytocin.  However, 
long term exposure to OT and its stimulatory effect does not appear to be 
modulated via transcriptional changes.  Rather our data would suggest that OT 
acts to facilitate pre-existing myometrial proteins and contractility pathways. 
Additionally, myometrial contractions in-vitro, whether OT induced or 
spontaneous, demonstrates a ‘temporal wave’ of transcriptional changes over 
and above non-contracting samples, with time related up-regulated genes 
demonstrating a preponderance of pathways concerned with inflammation and 
cellular damage or apoptosis, and down-regulation of pathways concerning 
cellular metabolism.   
The concept of human labour as an inflammatory event is well recognised, 
however the cause, timing and role is unknown.  Our data suggest uterine 
contractions during labour are associated with a myometrial derived 
inflammatory response in addition to myocyte cellular damage, death and 
reduced cellular metabolic function. 
3.6.1 Myometrial functional and transcriptional response to long 
term exposure to OT 
Our functional results concerning the stimulatory effect of OT on myometrial 
contractility are in agreement with the widely established role of OT as a 
uterotonic agent and most certainly support the physiology behind Blair Bell’s 
initial use of oxytocin in the primary prevention/treatment of atonic post 
partum haemorrhage148. 
Despite contractile stimulation by OT, our hypotheses that long term (hours) 
exposure to OT would induce transcriptional changes in addition to those seen in 
spontaneously contracting myometrium or in non-contracting myometrium 
(where MLCK function had been blocked), was not supported by our data. 
Previous evidence has suggested there may be a transcriptional role for long 
term exposure to OT which may ‘prime’ the myometrial cells and lead to an 
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efficient and effective labour 167 179 180 327.  However, despite contractile 
stimulation by OT, we were unable to demonstrate any transcriptional changes 
in addition to transcriptional changes seen in spontaneously contracting 
myometrium.  This suggests that long term OT stimulation of myometrial cells 
promotes contractile behaviour via facilitation of pre-existing proteins and 
contractility pathways. 
Despite our evidence, it must be acknowledged that since this study considered 
only a single addition of OT rather than continuous infusion therefore, firm 
conclusions about transcriptional effects of OT on myometrium may be 
hampered.  An infusion would have been more comparable to the in-vivo 
situation for both spontaneous and OT induced labours.  Additionally, with a 
single dose of OT, there may be a natural decrease in the bioavailability within 
the organ bath over time via the actions of an oxytocinase present in the 
myometrial samples.  The half life of OT in-vivo is estimated at lying anywhere 
between 3-15 minutes with evidence of pregnancy, gestation and labour specific 
variations50-54.  However, the half life of OT in our in-vitro model of labour in the 
absence of maternal serum is unknown, nevertheless, we presume it longer since 
no other routes of metabolism or excretion are present apart from the 
myometrial derived oxytocinase.  A slight drop in the OT bioavailability in the 
organ bath may explain the drop in the contractile stimulatory effect of OT in 
our samples after one hour of exposure.  However, the contractility measures of 
amplitude and activity integral did remain higher in the OT treated group than 
the control group despite a loss of significance. 
These factors were certainly considered at the study design stage of this study; 
however, we opted to have a ‘controlled’ stimulation of contractile activity by 
OT.  Thereby, we were able to avoid myometrial overstimulation or 
development of a tonic contraction as this would not be representative of 
normal labour, and a tonic contraction itself may have caused transcriptional 
changes which would hamper investigation of the OT pathway.  An additional 
factor to be considered was the presence of endogenous oxytocin within the 
myometrial samples91.  However, we assume that the comparisons back to a 
baseline measures would be sufficient to control for any stimulatory effect 
which the endogenous OT may have upon the myometrial samples. 
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Since OT itself does not have transcriptional effect on the myometrium, this 
suggests that despite OT being the agonist for Braxton Hicks contractions, the 
role of Braxton Hicks in priming or preparing the uterus for labour is through the 
action of repeated contractions rather than exposure to OT.  In this situation 
comparisons can be made with exercise training in the skeletal muscle system 
where the stimulus for contractions is neuronal rather than agonist induced.  It 
is well known that exercise training improves performance and prevents injury.  
Evidence demonstrates that even after one episode of exercise induced damage, 
there is less cellular damage following repetition of the exercise, less muscle 
soreness and recovery of muscle strength is quicker, and is referred to as the 
‘repeat bout effect’55-60.  Additionally, assessment of gene expression in trained 
and untrained muscles performing the same exercise have shown suppression of 
inflammatory pathways, blunting of the stress response, down regulation of 
glucose metabolism, mitochondrial structure, and oxidative phosphorylation, 
with enhancement of gene expression in processes involving the extracellular 
matrix and cytoskeleton development and organization61. 
3.6.2 Myometrial transcriptional response to contractions and 
time 
We have clearly demonstrated that time and contraction dependent increases in 
myometrial transcription occur in-vitro.  In particular these are associated with 
upregulation of genes associated with inflammatory processes and cellular 
damage or apoptosis, with down regulation of genes associated with cellular 
metabolism. 
This is in agreement with the widely held concept of labour as an inflammatory 
event and also the global transcriptional changes seen by others who have 
compared labouring and non-labouring myometrial samples in-vivo62-67.  
However, we are the first to demonstrate that myometrial derived inflammatory 
changes occurs in relation to contractions and time.  To assess these temporal 
changes in a controlled manner it has been necessary to use in-vitro data as in-
vivo contractility is difficult to assess and control.  However, the overlap 
between our in-vitro and in-vivo data are further assessed in Chapter 4 and 
suggests significant similarities between human labour and our in-vitro model.  
Using our in-vitro model of labour also allowed comparison between multiple 
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treatment and time groups, especially where we can examine the stimulatory 
effects of OT and the inhibitory effects of ML7. 
Interestingly, our data suggest that the transcriptional effects of myometrial 
contractions may be reversed by suppression of contractile activity via blockage 
of MLCK.  This may simply reflect the tocolytic effect of ML7; however, it may 
also reflect a direct transcriptional effect or modulation of upstream cellular 
event by ML7 in the myometrial myocyte339-341.  It may have therefore been 
beneficial to have an additional non-treated, non-contracting baseline control 
sample.  However, these concerns are partially addressed in Chapter 4, 
Hypothesis 4, which suggests that gene expression is comparable between non 
contracting samples and those where contractions are suppressed secondary to 
exposure to ML7. 
Additionally, contracting skeletal muscle has demonstrated similar pathway 
changes at the mRNA level following a single bout of endurance exercise in 
healthy, young sedentary males.  Compared to baseline measures pre-exercise, 
array analysis revealed an upregulation of inflammatory processes (in particular 
inflammatory cell recruitment) and those associated with cell stress, regulation 
of proteolysis, apoptosis, and cell growth and differentiation342.  However, 
contrary to our findings, there was a transient increase in transcription of genes 
associated with metabolism342.  Others have also shown exercise associated gene 
array changes in skeletal muscle with upregulation of processes associated with 
cell growth regulation, DNA damage response, stress response, energy 
metabolism, inflammation, extracellular matrix structure and function343.  This 
then suggests that these pathways are altered in myocytes in a non-specific 
manner in response to contractions.  
Throughout this chapter, QPCR confirmation of array data has been performed.  
We acknowledge that the samples used for validation are the same as those used 
for gene array and that validation should ideally be performed on a separate set 
of samples.  However, although not formally tested, separate in-vitro 
contracting samples are analysed in Chapter 4 which support the array findings 
of an association between contractions and inflammatory upregulation.  
Additionally, in the process of array validation there was a bias towards the use 
of QPCR probes associated with inflammation.  However this was deemed to be 
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appropriate and allowed further exploration of contraction associated 
inflammation since the pathway analysis demonstrated enhancement of 
inflammatory processes.  Despite this, further examination of transcriptional 
markers of cellular damage, stress and apoptosis would be of merit in the 
future. 
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3.7 Conclusion  
In-vitro myometrial contractions induce a transcriptional wave which is not 
significantly different to that produced under the influence of OT despite 
significant differences in functional activity. This suggests that in addition to 
contractions per se having a significant time dependent effect on the 
myometrial transcriptome that the specific actions of oxytocin are limited to the 
modification of pre-existing myometrial proteins and contractility pathways. 
Additionally, the time and contraction dependent myometrial transcriptional 
wave is associated with upregulation of pathways concerning inflammation and 
cellular damage or apoptosis, with down regulation of cellular metabolic 
pathways. 
 
Figure 41  Chapter 3 Amended Hypothesis 
Summary of the amended hypothesis regarding the effect of oxytocin on myometrial 
contractility and gene transcription.  Oxytocin has a well recognised stimulatory effect upon 
myometrial contractility, however this does not appear to be modulated via transcriptional 
changes, rather if facilitates pre-existing myometrial proteins and contractility pathways.  In 
addition, myometrial contractions (spontaneous or OT induced) appear to induce a 
transcriptional temporal wave dominated by inflammatory mediators. 
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Chapter 4 
Inflammatory changes in myometrium in response 
to time, contractions, tocolysis and infection 
Claire A Higgins, 2012   Chapter 4, 146  
4 Inflammatory changes in myometrium in 
response to time, contractions, tocolysis and 
infection 
4.1 Introduction 
In the previous chapter, our in-vitro model of labour has shown evidence that 
oxytocin (OT) per se does not appear to alter the transcriptional profile of 
myometrium.  However, the array does suggest that time and contraction 
dependent gene changes occur, with a high preponderance of inflammatory 
mediators including cytokines and chemokines.  
The concept of labour as an inflammatory event is well established209-217,  with 
8189 citations found via Pubmed using the basic search criteria ‘labour’ and 
‘inflammation’ (search performed July 2012).  Increases in numbers of immune 
cells (mainly neutrophils and macrophages) are present within gestational tissues 
including the myometrium and cervix219-221.  There is also a co-ordinated 
increase in cell adhesion molecules and cytokines within these tissues suggesting 
that the uterus can exert control over the inflammatory process in labour220-223.  
Certainly, from within our department, in-vivo gene array transcription analysis 
from the cervix and myometrium has shown labour is associated with a core 
inflammatory response, with particular increases in the chemokines CXCL3, 
CXCL5, CXCL8, CCL2 and CCL20211 
Premature activation of uterine contractile activity resulting in pre-term labour 
is associated with infection in up to 40% of cases18 235 260.  Certainly, in the mouse 
model, exposure to the TLR-4 agonist lipopolysaccharide (LPS) is a recognised 
method whereby pre-term labour is successfully induced263.  Infection is a 
classically recognised stimulus for mounting an inflammatory response264 265.  
Therefore, a pivotal role for inflammation in the initiation and propagation of 
human labour (term and pre-term) has been proposed 210 216 217 230-236.   
This obviously makes inflammation a possible target through which uterine 
contractions and human labour may be manipulated, suppressing the 
inflammatory process to prevent contractility in the case of pre-term labour or 
enhancing inflammation in an attempt to promote a contractile phenotype 
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where induction of labour is undertaken in the post-dates pregnancy233 237 238.  
However, despite this theory, dampening of the inflammatory response by 
systemic administration of inhibitors of the cyclooygenase enzyme (COX 
inhibitors) or progesterone in pregnancy has proven to be unreliable in 
preventing pre-term labour in the high risk pregnancy 239-241 287 289 290. 
Overall, labour is unquestionably an inflammatory event.  However, the cause, 
timing and role of the inflammatory changes associated with human labour are 
unknown.  We therefore sought to provide a temporal description of the 
myometrial derived inflammatory cytokines and chemokines associated with 
spontaneous myometrial contractions in-vitro and examine the overlap with 
those produced in-vivo during term human labour.  We also sought to describe 
inflammatory and functional changes to myometrium which occur in response to 
a range or tocolytic agents and subsequently in response to a pro-inflammatory, 
infective environment.  Additionally, a preliminary examination of contraction 
induced myometrial inflammatory protein products is made.  
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4.2 Hypothesis 
The hypotheses in this chapter regarding myometrial contraction and 
inflammation are summarised in Figure 42. 
 
Figure 42  Chapter 4 Overall Hypothesis 
Summary of the hypotheses to be examined regarding the association between 1) 
myometrial contractions and myometrial derived inflammatory mediators, 2) the overlap 
between myometrial response to in-vitro contractions and spontaneous human labour, 3) 
the influence of tocolysis on myometrial contractile function and transcription of 
inflammatory mediators, and 4) the influence of an infective/inflammatory environment on 
myometrial contractile function and transcription of inflammatory mediators. 
We propose that our in-vitro model of labour will reveal a contraction 
dependent increase in the myometrial gene transcription of inflammatory 
mediators, and that these changes are influenced by time.  We also propose that 
there will be an overlap of our in-vitro data with transcriptional changes in-vivo.   
Additionally, we want to examine the functional and transcriptional effects of 
various chemical methods of tocolysis, and propose that tocolytic agents 
suppress myometrial contractions and thereby lead to suppression of 
inflammatory mediator transcription. In particular, we will examine the 
transcriptional effects of ML7 in comparison to non-contracting but 
metabolically active myometrial samples to confirm the appropriateness of ML7 
as a non-contracting comparison sample in our initial gene array experiment.   
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The proposal that infection driven inflammation will enhance both contractile 
function and inflammatory transcription within the myometrium will be 
examined by assessing the in-vitro response to an infective, pro-inflammatory 
environment with specific comparisons with an endotoxin free environment. 
Lastly, we conduct a preliminary test to examine if selected inflammatory genes 
which are upregulated in contracting myometrium result in protein synthesis and 
release into their surrounding environment. 
The specific hypotheses to be tested are  
1. Myometrial transcription of inflammatory mediators is associated with 
contractions in-vitro. 
2. Myometrial transcription of inflammatory mediators is associated with 
contractions in-vitro in a time dependent manner. 
3. Myometrial transcription of inflammatory mediators in-vitro overlaps with 
those seen in-vivo. 
4. Myometrial contractility and transcription of inflammatory mediators in-
vitro is suppressed by chemical tocolysis. 
5. Myometrial contractility and transcription of inflammatory mediators in-
vitro is enhanced in response to an infective and inflammatory stimulus 
(LPS). 
6. Myometrium in-vitro can synthesise and release inflammatory protein 
product. 
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4.3 Methods  
4.3.1 Hypothesis 1 -  Myometrial transcription of inflammatory 
mediators is associated with contractions in-vitro. 
A summary of the experiment design for this hypothesis is illustrated in Figure 
43. 
 
Figure 43  Chapter 4, Hypothesis 1 Experimental Design 
Illustration of experimental design to examine the effect of in-vitro contractions on 
inflammatory gene expression as measured using Q-PCR.  Three study group environments 
and timing of sample freezing is shown. 
Samples were obtained from patients undergoing non-labouring caesarean 
delivery at term, and within 2 hours of collection the sample was cut into strips 
as previously described.  One strip was weighed and snap frozen in liquid 
nitrogen at this start point (start).  A second strip was placed without ties or 
stretch in an organ bath containing Krebs solution, bubbled with carbogen and 
maintained at 37◦C (end no contraction).  A third strip was set up to 
spontaneously contract as previously described (end spt contraction).  After 7 
hours in the organ baths, experiments were terminated and samples weighed, 
snap frozen and stored at -80◦C.  
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RNA extraction and Q-PCR were performed on each individual sample examining 
the gene expression of inflammatory mediators (CXCL1, CXCL2, CXCL5, CXCL8, 
CCL2, CCL3, CCL8, CCL20, IL1β, IL6, IL10 and TNFα). The expression of CCL20 in 
myometrial samples was low, and if both duplicates were undetected by the 
plate reader, expression of this gene was calculated as 0%.  Data are expressed 
relative to the housekeeping gene β-actin. 
Contractility data are described as medians (IQR) and analysed using a Kruskal-
Wallis test examining either amplitude, frequency of activity integral over the 
length of the experiment.  Analysis of Q-PCR results was performed on the raw 
untransformed data using the Mann-Whitney U-test.  No adjustments are made 
for multiple testing for these data as with our relatively small dataset 
adjustment may reduce the chance of making a type I error, but may lead to and 
increase in the chance of making a type II error and a need to increase our 
sample size331-334.  A p<0.05 was considered significant. 
4.3.2 Hypothesis 2 -  Myometrial transcription of inflammatory 
mediators is associated with contractions in-vitro in a time 
dependent manner 
A summary of the study design for this hypothesis is illustrated in Figure 44.  Q-
PCR was performed on the myometrial samples which were used for the gene 
array experiment in the previous chapter.  Gene expression of inflammatory 
mediators (CXCL1, CXCL2, CXCL5, CXCL8, CCL2, CCL3, CCL8, CCL20, IL1β, IL6, 
IL10 and TNFα) relative to β-actin was performed on each sample individually.  
Since the array suggested no significant difference in gene expression in 
contracting myometrium regardless of environment (OT, acetic acid or DMSO) 
results were pooled and analysed as one ‘contracting group’ with 15 individual 
samples at each of the time-points. 
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Figure 44  Chapter 4, Hypothesis 2 Experimental Design 
Illustration of experimental design to examine the effect of contractions and time on 
myometrial inflammatory gene expression measured using Q-PCR.  Three study group 
environments and timing of sample freezing is shown.  Of note despite different 
environmental exposures, previous analysis has shown no environmental effect on gene 
transcription, therefore samples are pooled for analysis with n=15 samples for each time 
point. 
Contractility data are described as medians (IQR) and analysed using a Kruskal-
Wallis test or Mann-Whitney U-test comparing measures of contractility between 
study groups (defined as time at which experiment was terminated) at each time 
point over the length of the experiment.  The raw untransformed Q-PCR data 
was analysed using Pearson’s correlations and was performed for each gene 
probe to investigate its relationship with time.  A p<0.05 was considered 
significant. 
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4.3.3 Hypothesis 3 - Myometrial transcription of inflammatory 
mediators in-vitro overlaps with those seen in-vivo 
The myometrial gene expression in samples from our in-vitro model of labour 
was compared with genes differentially expressed in contracting myometrium 
from women in term labour.  To do this we used our original array data from 
contracting samples (those exposed to oxytocin, acetic acid or DMSO) and ran an 
overlap analysis with a previously performed gene array on in-vivo myometrial 
labouring samples.  A summary of the experimental design is illustrated in Figure 
45. 
 
Figure 45  Chapter 4, Hypothesis 3 Experimental Design 
Illustration of experimental design to examine the overlap between myometrial inflammatory 
gene expression in contracting samples in-vitro (1, 2, 4 and 6hrs relative to time 0hrs) and 
in-vivo (NIL vs IL).  Of note despite different environmental exposures, in-vitro samples are 
pooled for analysis with n=15 samples for each time point. 
The in-vivo data had been collected and analysed previously211.  It is derived 
from samples of myometrium which were taken during caesarean delivery in the 
same manner as samples collected for the in-vitro experiments.  Samples were 
taken from women at term (>37 weeks gestation) either before the onset of 
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labour (NIL, n=9) or from women during spontaneous labour with a cervical 
dilatation between 4 and 10cm who were undergoing emergency caesarean 
section for presumed foetal distress (IL, n=9).  RNA was isolated from each 
sample individually.  Subsequently, 3 samples were pooled and analysed on one 
chip using the Affymetrix v2 U133 plus 2 gene arrays using the One-Cycle 
Eukaryotic Target Labelling Assay protocol (Affymetrix, Santa Clara, CA). 
The in-vitro data are derived from myometrial samples obtained at term pre-
labour caesarean deliveries (n patients = 25, n strips from each patient = 3) 
where samples then subsequently contracted in an organ bath.  The 3 samples 
from each patient were exposed to either OT, acetic acid or DMSO after 
establishment of spontaneous contractile activity.  Experiments were terminated 
at 0, 1, 2, 4 & 6hrs after drug addition. Illumina gene arrays were compiled for 
each individual sample (n=75) and were analysed together, n=15 at each time 
point (previous work shows OT alters contractions but not transcription in 
myocytes).  
Since the arrays were performed on different platforms, they were not directly 
comparable.  Therefore the Affymetrix data were reanalysed and the probesets 
that were significantly different between IL and NIL samples using an adjusted 
p<0.01 were selected (t-tests with significance correction using the Benjamini & 
Hochberg method for multiple testing).   Of these genes that were differentially 
expressed on the Affymetrix array, only those which had a gene symbol common 
to the Illumina array were included for further analysis (n=814).  The differential 
gene expression for the in-vivo data (IL vs NIL) were then compared with 
differential gene expression from the in-vitro data relative to time 0 hours (1hr 
vs 0hr, 2hr vs 0hr, 4hr vs 0hr and 6hr vs 0hr).  A list of genes common to both in-
vivo and in-vitro work was compiled for each comparison as outlined in Figure 
45.  The cellular pathways associated with the genes on this list were 
determined using the Kyoto Encyclopaedia of Genes and Genomes (KEGG).  All 
analysis of array data was performed by Fios Genomics Ltd, Edinburgh. 
Additional analysis of previously performed Q-PCR data for the chemokines 
CCL2, CCL20 and CXCL8 relative to β-actin was also undertaken.  Supplementary 
comparison with data from Hypothesis 1 in this chapter (start, end no 
contraction, end spt contraction) was also performed as baselines (NIL and start) 
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were felt to be more comparable to each other than the 0 hour timepoint where 
contractions had already been established.  As the Q-PCR on the NIL and IL 
samples had been performed using a different concentration of sample than for 
the Q-PCR performed during the other experiments in this thesis, fold changes 
and ranges were considered and calculated using the 2-∆∆Ct method for relative 
gene expression with KKCt +SD and KKCt –SD where SD is standard deviation for 
the KKCt  value344 345. 
4.3.4 Hypothesis 4 - Myometrial contractility and transcription of 
inflammatory mediators in-vitro is suppressed by chemical 
tocolysis 
A summary of the methods used to investigate the response of myometrium to 
tocolysis is illustrated in Figure 46.   
 
Figure 46  Chapter 4, Hypothesis 4 Experimental Design 
Illustration of experimental design to examine the functional and transcriptional effect of 
chemical tocolysis on in-vitro myometrial contractions and inflammatory gene expression 
as measured using Q-PCR.  Organ bath environments and timing of sample freezing is 
shown. 
Samples of myometrium were dissected into strips and set up in individual organ 
baths of Krebs solution at 37◦C, with 20mN tension applied.  Once regular 
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contractile activity was established (approximately 2 hours after initial tension 
was applied), various tocolytic agents namely ML7, nifedipine, ritodrine, 
levcromakalim and water soluble progesterone were added to the organ bath.  
Final bath concentrations were ML7 (200µM), nifedipine (10 µM), ritodrine 
(10mM), levcromakalim (10 µM) and progesterone (1mM) determined as outlined 
in Chapter 2.  Additionally, data are available for strips exposed to nifedipine 
(10 µM) throughout the experiment from time of initial tension application (0hr 
nifedipine).  Data for additional comparison is provided from 1) fresh strips 
frozen at the start of the experiment, 2) strips placed without ties or stretch in 
an organ bath containing Krebs solution, bubbled with carbogen and maintained 
at 37◦C (end no contraction) and 3) a control strip which spontaneously 
contracted in normal Krebs solution (end spt contraction) (Chapter 4, Hypothesis 
1).  Contractile activity was observed for a total of 7 hours from initial tension 
being applied after which time the experiments were terminated and samples 
stored at -80◦C.  Subsequent Q-PCR was performed on each individual sample 
examining the gene expression of inflammatory mediators (CXCL1, CXCL2, 
CXCL5, CXCL8, CCL2, CCL3, CCL8, CCL20, IL1β, IL6, IL10 and TNFα) relative to β-
actin. The expression of CCL20 in myometrial samples was low, and if both 
duplicates were undetected by the plate reader, expression of this gene was 
calculated as 0%. 
Contractility data are described as medians with IQR.  The raw untransformed Q-
PCR data were analysed using the non-parametric Kruskall-Wallis and Mann-
Whitney U-tests as appropriate.  No adjustments are made for multiple testing 
for these data as with our relatively small dataset adjustment may reduce the 
chance of making a type I error, but may lead to and increase in the chance of 
making a type II error and a need to increase our sample size331-334.  A p<0.05 
was considered significant. 
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4.3.5 Hypothesis 5 - Myometrial contractility and transcription of 
inflammatory mediators in-vitro is enhanced in response to 
an infective and inflammatory stimulus (LPS) 
A summary of the methods used to investigate the effects of a pro inflammatory 
environment of myometrium is illustrated in Figure 47.   
 
Figure 47  Chapter 4, Hypothesis 5 Experimental Design 
Illustration of experimental design to examine the functional and transcriptional effect of an 
infective, pro-inflammatory environment (Lipopolysaccharide (LPS)) on in-vitro myometrial 
spontaneous and OT induced contractions and inflammatory gene expression as measured 
using Q-PCR.  Comparisons are made with an endotoxin free environment (Polymixin-B 
(PMB)) and untreated Krebs solution.  Organ bath environments and timing of sample 
freezing is shown. 
Myometrial samples were immediately split into two part following collection at 
caesarean delivery, with one sample placed in normal Krebs solution, and the 
other in Krebs solution treated with Polymixin-B (PMB).  Myometrial strips were 
dissected and one strip from each environment was immediately snap frozen (‘n 
Krebs start’ and ‘PMB start’).  Further strips were suspended in separate organ 
baths of carbogen gassed Krebs solution under isometric conditions with a 
resting tension of 20mN.  Two baths underwent addition of PMB (30µg/ml) to 
inactivate endotoxin (‘PMB’), and the remaining two baths had an addition of 
Lipopolysaccharide (‘LPS’) (100µg/ml).  A further bath had a combination of PMB 
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and LPS (‘PMB &LPS’) and there was a sixth control bath of normal Krebs solution 
with no drug additions (‘n Krebs’).  After establishment of spontaneous 
contractions, OT (1nM) was added to one PMB bath and one LPS bath (‘PMB & 
OT’ and ‘LPS & OT’).  Contractions were then observed for a further 5 hours with 
amplitude, frequency and activity integral recorded at 0, 0.5, 1, 2, 3, 4 and 5 
hours.  At this time tissues were snap frozen with subsequent gene expression of 
inflammatory mediators (CXCL1, CXCL2, CXCL5, CXCL8, CCL2, CCL3, CCL8, 
CCL20, IL1β, IL6, IL10 and TNFα) relative to β-actin performed using Q-PCR.  
Contractility data are described as medians (IQR) and analysed using a Kruskal-
Wallis test or Mann-Whitney U-test as appropriate.  The raw untransformed Q-
PCR data were analysed using the non-parametric Kruskall-Wallis and Mann-
Whitney U-tests as appropriate.  No adjustments are made for multiple testing 
for these data as with our relatively small dataset adjustment may reduce the 
chance of making a type I error, but may lead to and increase in the chance of 
making a type II error and a need to increase our sample size331-334.  A p<0.05 
was considered significant. 
4.3.6 Hypothesis 6 – Myometrium in-vitro can synthesise and 
release inflammatory protein product 
A summary of the methods used for out preliminary examination of the synthesis 
and release of inflammatory proteins by spontaneously contracting myometrium 
in-vitro is illustrated in Figure 48 
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Figure 48  Chapter 4, Hypothesis 6 Experimental Design 
Illustration of experiment design used to provide a preliminary examination of the synthesis 
and release of inflammatory proteins by myometrium which spontaneously contracts in an 
organ bath of carbogen bubbled Krebs solution at 37◦C.   
Strips of myometrium from 6 different patients were set up to contract 
spontaneously as previously described.  7 hours after initial tension was applied, 
experiments were terminated and 5ml of Krebs solution from the organ bath was 
frozen and stored at -80°C (n=6).  A separate sample of Krebs which had never 
been exposed to tissue but had been bubbled with carbogen at 37°C for 7 hours 
was also frozen and stored at -80°C (n=1). 
Samples were prepared and analysed using a Biorad Bio-Plex Pro Human Cytokine 
8-Plex Panel 1 M50-000007 and analysed on the Biorad Bioplex System- Luminex 
100 (Chapter 2, Section 2.5 and 2.6).  Data are presented as raw fluorescence 
readings and % change from baseline, where baseline is considered expression in 
Krebs solution which has not been exposed to tissue and was calculated for each 
sample individually. 
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4.4 Results 
4.4.1 Hypothesis 1 - Myometrial transcription of inflammatory 
mediators and the association with in-vitro contractions 
4.4.1.1 Patient Demographics 
Myometrial samples were collected for 13 women.  Data were excluded if the 
sample had not been handled correctly (1 sample from ‘start group’ was not 
frozen within 2 hours, 7 samples from end not contracting group were not in an 
environment of 37◦C, 1 sample from end spontaneous contraction group did not 
contract).  The characteristics of the patients from which the samples used for 
final analysis are shown in Table 17. 
N Women 13 
N Strips 
Start 
End no contraction 
End spt contraction 
12 
6 
12 
Maternal BMI (kg/m2) 
Median (IQR) 
[Range] 
29.6 (25.0,31.2) 
[17.24,48.2] 
Age (years) 
Median (IQR) 
[Range] 
32.0 (30.0, 35.0) 
[25.0,41.0] 
Gestation (days) 
Median (IQR) 
[Range] 
274 (273,276) 
[273,280] 
Baby birth weight (kg) 
Median (IQR) 
[Range] 
3.78 (3.45, 4.02) 
[3.29,4.20] 
Indication for CS 
N (%) Previous LUSCS 
N (%) Other 
9 (69.2%) 
4 (30.8%) 
Parity 
N (%) =0 
N (%) =1 
N (%) ≥2 
2 (15.4%) 
9 (69.2%) 
2 (15.4%) 
Table 17  Hypothesis 1 - Patient demographic details  
Demographic details of patients included in experiment to examine the effect of in-vitro 
contractions on inflammatory gene expression as measured using Q-PCR (Chapter 4 
Hypothesis 1). 
4.4.1.2 Contractility data 
A total of 12 strips were used to provide contractile data (end spt contraction) 
which is summarized below in Figure 49.  Overall, Kruskal-Wallis testing showed 
no significant changes in amplitude (p=0.93), frequency (p=0.39) and activity 
integral (p=0.79) throughout the length of the experiment in the contracting 
strips. 
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Figure 49  Spontaneous contractile activity of myometrial strips 
Illustration of spontaneous contractile activity (amplitude, frequency and activity integral) in 
myometrial strips used in this experiment (n=12).  Data are shown as median (IQR) with p-
values indicated for Kruskal Wallis test of contractile activity over time showing no 
significant change. 
4.4.1.3 Myometrial transcription of inflammatory mediators 
Compared with baseline measures, all inflammatory probes tested significantly 
increased in the samples which were not contracting but still metabolically 
active in the Krebs solution at 37◦C (start vs end no contraction).  In the 
myometrial samples which contracted (end spt contraction), a further increase 
was seen in all twelve probes, with increases significantly greater than the non-
contracting counterpart for all except TNFα (Figure 50).  
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Figure 50  QPCR data contracting vs non-contracting myometrium 
Expression of inflammatory markers in myometrium at start of experiment (start) and after 
7hrs in an organ bath of normal Krebs solution at 37◦C not contracting (end no cont) or in an 
organ bath at 37◦C spontaneously contracting (end spt cont).  Raw data are shown with 
median and IQR.  Analysis performed using Mann-Whitney U test with lines demonstrating 
significance value between 2 samples under start and end of each line.  *p<0.05, ** p <0.01, 
***p<0.001 
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4.4.2 Hypothesis 2 - Myometrial transcription of inflammatory 
mediators and the temporal association with contractions 
in-vitro 
4.4.2.1 Patient Demographics 
Samples were taken from 25 patients, with three myometrial strips from each 
sample, with data from 15 strips at each time point.  Demographic details for 
these patients are listed in Table 6. 
N Women 25 
N Strips  75 
Maternal BMI (kg/m2) 
Median (IQR) 
[Range] 
24 (21.9, 26.5) 
[18.5,34.6] 
Age (years) 
Median (IQR) 
[Range] 
31 (27,35) 
[21,41] 
Gestation (days) 
Median (IQR) 
[Range] 
273 (273, 275) 
[263,284] 
Baby birth weight (kg) 
Median (IQR) 
[Range] 
3.47 (3.28, 3.70) 
[2.30, 4.19] 
Indication for CS 
N (%) Previous LUSCS 
N (%) Other 
20 (80%) 
5 (20%) 
Parity 
N (%) =0 
N (%) =1 
N (%) ≥2 
2 (8%) 
16 (64%) 
7 (28%) 
Table 18  Hypothesis 2 - Patient demographic details 
Demographic details of patients included in experiment for Chapter 4 Hypothesis 2 
examining myometrial transcription of inflammatory mediators and the temporal association 
with in-vitro contractions. 
4.4.2.2 Contractility Data 
Functional contractile data are presented in Figure 51.   
No significant difference for any measure of contractile activity at any time 
point was found between groups (defined as the time at which the sample was 
frozen) when analysed by time at which the strip was frozen (Kruskal-Wallis or 
Mann-Whitney test at each time point; amplitude, p>0.35; frequency, p>0.36; 
activity integral, p>0.37). 
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Figure 51  Contractile activity of myometrium over time 
Illustration of contractile activity (amplitude, frequency and activity integral) in myometrial 
strips, yellow = experiment terminated at 0hr, green = experiment terminated at 1hr, blue = 
experiment terminated at 2hrs, red = experiment terminated at 4hrs and black = experiment 
terminated at 6hrs (n=15 in each group).  There was no significant difference in contractile 
pattern between groups at any of the time points. Data are shown as median and IQR. 
4.4.2.3 Myometrial transcription of inflammatory mediators 
Q- PCR data for contracting myometrial strips are illustrated in Figure 52.  This 
demonstrated a clear positive correlation between duration of contraction and 
transcription of the genes CXCL1, CXCL2, CXCL5, CXCL8, CCL20, IL1β, IL6 and 
IL10 (r>0.47, p<0.001 for all).  Despite up-regulation of CCL2, CCL3, CCL8 and 
TNFα in response to contractions (Figure 50), the changes in these cytokines did 
not appear to be associated with time in these samples.  
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Figure 52  QPCR correlation of inflammatory marker with time 
Time dependent changes in myometrial transcriptional expression of selected cytokines 
with significant time and contraction dependent increases in CXCL1, CXCL2, CXCL5,CXCL 
8, CCL20, IL1B, IL6 and IL10 (n strips at each time point = 15). Raw data are shown with 
regression line and 95% confidence interval.  Analysis was performed using Spearmans 
correlation, r and p values are shown for each gene. 
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4.4.3 Hypothesis 3 - Myometrial transcription of inflammatory 
markers in-vitro overlaps with those seen in-vivo 
4.4.3.1 Patient Demographics 
Demographic details for the patients in each of the study groups are listed below 
in Table 19.  
Study group 
In-vitro 
contractility 
study 
In-vivo 
NIL 
In-vivo 
IL 
N Women 25 9 9 
N Strips/samples  75 9 9 
Maternal BMI (kg/m2) 
Median (IQR) 
[Range] 
24 (21.9, 26.5) 
[18.5,34.6] 
Not recorded Not recorded 
Age (years) 
Median (IQR) 
[Range] 
31 (27,35) 
[21,41] 
26 (21.5,32.0) 
 
24 (22.5,31.0) 
 
Gestation (days) 
Median (IQR) 
[Range] 
273 (273, 275) 
[263,284] 
273 (272, 277) 
 
283 (274, 288) 
 
Baby birth weight 
(kg) 
Median (IQR) 
[Range] 
3.47 (3.28, 3.70) 
[2.30, 4.19] 
3.26 (2.89,3.37) 
 
3.50 (3.33, 4.26) 
 
Indication for CS 
N (%) Previous CS 
N (%) Other 
20 (80%) 
5 (20%) 
5 (55.5%) 
4 (44.5%) 
0 
9 (100%) 
Parity 
N (%) =0 
N (%) =1 
N (%) ≥2 
2 (8%) 
16 (64%) 
7 (28%) 
/ 
5 (55.5%) 
/ 
/ 
1 (11.1%) 
/ 
Dilatation at CS (cm) 
Median (IQR) 
[Range] 
/ / 
6.0 (5.0,10.0) 
 
Length of labour (hr) 
Median (IQR) 
[Range] 
/ / 
11.6 (5.3,13.5) 
 
Interval from 
membrane rupture 
to delivery (hr) 
Median (IQR) 
[Range] 
/ / 
10.7 (4.5,11.7) 
 
Table 19  Hypothesis 3 - Patient demographic details 
Demographic details of patients included in experiment for Chapter 4 Hypothesis 3 
examining the overlap in myometrial transcription between the in-vitro model of labour and 
the in-vivo term human labour. 
4.4.3.2 Contractility data 
In-vitro contractility data are described previously in section 4.4.2.2 and Figure 
51.  Data describing cervical dilatation, length of labour and time from 
membrane rupture to delivery in the in-vivo labouring group are described above 
in Table 19. 
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4.4.3.3 Myometrial differential gene expression and overlap 
analysis of gene array data 
Analysis of the Affymetrix data demonstrated that using an adjusted p<0.01, 
1050 probesets were significantly different between NIL and IL samples.  Of 
these, 954 had a gene symbol with 814 having a gene symbol common to the 
Illumina arrays. 
Analysis of the overlap of these differentially expressed genes from in-vivo 
contractions with the in-vitro contractile profile at adjusted p<0.05 and 
adjusted p<0.01 is shown Table 20.  Of note a larger number of differentially 
expressed genes from the in-vivo data overlap with differentially expressed 
genes from the longer 4 and 6 hour timepoints in-vitro. 
 
Comparison 
n genes overlapping 
 
 
Adjusted p<0.05 
for in-vitro comparison 
Adjusted p<0.01 
for in-vitro comparison 
(1hr vs 0hr) cf (IL vs NIL) 
 
8 0 
(2hr vs 0hr) cf (IL vs NIL) 
 
18 4 
(4hr vs 0hr) cf (IL vs NIL) 
 
178 91 
(6hr vs 0hr) cf (IL vs NIL) 
 
292 192 
Table 20  Number of genes overlapping between in-vitro and in-vivo myometrial samples 
Overlap summary analysis of myometrial differential gene expression (adjusted p<0.01) in 
samples which have contracted in-vivo relative to samples taken prior to onset of labour (IL 
vs NIL) and samples which have contracted in-vitro for varying lengths of time relative to 
time 0hr using adjusted p<0.05 or p<0.01 (1hr vs 0hr, 2hr vs 0hr, 4hr vs 0hr and 6hr vs 0hr).   
A summary of the cellular processes represented by the overlapping genes and 
determined using KEGG is provided in Table 21.  Notably inflammatory processes 
dominated in each of the comparisons, in particular those involved with cytokine 
to cytokine receptor interactions.  The full table of KEGG determined cellular 
processes for this in-vivo and in-vitro overlap analysis can be found in Appendix 
V. 
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Comparison at adjusted p<0.01 for both in-vivo and in-vitro data 
 
(2hr v 0hr) 
cf 
(IL v NIL) 
(4hr v 0hr) 
cf  
(IL v NIL) 
(6hr v 0hr) 
cf 
(IL v NIL) 
Pathway n genes Pathway n genes Pathway n genes 
Not assigned 3 Not assigned 54 Not assigned 125 
Cytokine-
cytokine 
receptor 
interaction 
1 
Cytokine-cytokine 
receptor 
interaction 
4 
Cytokine-
cytokine 
receptor 
interaction 
8 
  
Jak-STAT signaling 
pathway 
4 
Complement and 
coagulation 
cascades 
6 
  
MAPK signaling 
pathway 
4 
Jak-STAT 
signaling 
pathway 
5 
  
Calcium signaling 
pathway 
4 
MAPK signaling 
pathway 
5 
  
GnRH signaling 
pathway 
4 
Neuroactive 
ligand-receptor 
interaction 
5 
  
Long-term 
depression 
3 
Regulation of 
actin 
cytoskeleton 
5 
  
Long-term 
potentiation 
3 
Calcium signaling 
pathway 
4 
  Melanogenesis 3 
Hematopoietic 
cell lineage 
4 
  
Complement and 
coagulation 
cascades 
2 
GnRH signaling 
pathway 
3 
  
Hematopoietic cell 
lineage 
2 
Insulin signaling 
pathway 
3 
Table 21  Top 10 cellular processes expressed in both in-vitro and in-vivo myometrial 
samples 
Top 10 cellular processes as determined by KEGG represented by overlapping differentially 
expressed genes from in-vivo (NIL vs IL) and in-vitro (1, 2, 4 and 6hours relative to 0hours) 
myometrial samples.  Significance level for differential expression was set at an adjusted 
p<0.01.  
4.4.3.4 Myometrial gene expression and comparison of fold 
changes between in-vivo and in-vitro samples 
Supplementary analysis was performed on the available QPCR data for CCL2, 
CCL20 and CXCL8 relative to β-actin and Fold change analysis is shown in Table 
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22.  Additionally, Q-PCR data from Hypothesis 1 earlier in this chapter (sample 
groups: start, end no contraction and end spt contraction) were also analysed as 
baseline measures (NIL and start) were felt to be more comparable to each other 
than the 0hr timepoint where contractions had already been established.  Fold 
change analysis showed upregulation of all three chemokines assessed, with fold 
changes smallest for the in-vitro time series, which may reflect the baseline 
‘time 0hr’ measure as previously discussed.  Using a comparable baseline 
measure (NIL and start) in-vitro differential chemokine expression was higher 
than that observed in the in-vivo data set for all three genes. 
Comparison CCL2 CCL20 CXCL8 
 
Fold Change  
(range) 
Fold Change  
(range) 
Fold Change  
(range) 
IL relative to NIL 11.5  (4.6,28.8) 
113.0 
 (13.2,966.8) 
105.2  
(13.5,819.3) 
 
   
1hr relative to 0hr 1.1  (0.5,2.3) 
1.3  
(0.6,2.9) 
1.1  
(0.5,2.5) 
2hr relative to 0hr 1.3  (0.7,2.5) 
2.6  
(1.2,5.7) 
1.6  
(0.8,3.4) 
4hr relative to 0hr 1.8  (0.4,8.8) 
6.3  
(0.9,43.2) 
2.8  
(0.4,21.4) 
6h relative to 0hr 1.3  (0.6,2.7) 
9.3  
(3.9,21.7) 
5.9  
(3.3,10.5) 
 
   
End no contraction 
relative to Start 
9.7  
(4.5,21.2) 
1570.5  
(788.3,3129.2) 
1027.8  
(612.9,1723.2) 
End contraction 
relative to Start 
27.9  
(8.3,94.1) 
12648.5 
(3465.8,46160.2) 
7600.5 
(2271.8,25427.5) 
Table 22  QPCR determined fold changes for in-vitro and in-vivo myometrial samples 
Fold changes in CCL2, CCL20 and CXCL8 measured using Q-PCR relative to B-actin and 
baseline.  The fold change and range given for each chemokine is determined using 2-∆∆Ct 
method with ∆∆Ct +SD and ∆∆Ct –SD where SD is standard deviation for the ∆∆Ct  value. 
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4.4.4 Hypothesis 4 - Myometrial contractility and transcription of 
inflammatory markers in-vitro in response to chemical 
tocolysis 
4.4.5 Patient Demographics 
Myometrial samples were collected for 13 women.  Data were excluded if the 
sample had not been handled correctly (7 samples from end not contracting 
group were not in an environment of 37◦C), or if samples did not spontaneously 
contract (1 from end spontaneous contraction group, 2 from levcromakalim 
group) or organ baths/drugs were unavailable on the day of experiment (8 
samples 0hr nifedipine, 7 samples ML7, 6 samples progesterone).  The 
characteristics of the patients from which the samples used for final analysis are 
shown previously in Table 17, with number of strips for each environment 
illustrated in Table 23. 
N women  13 
N strips End no contraction 
End spont contraction 
2hr ML7 
0hr nifedipine 
2hr nifedipine 
2hr ritodrine 
2hr levcromakalim 
2hr progesterone 
6 
12 
6 
5 
13 
13 
11 
7 
Table 23  Number of myometrial strips exposed to each environment 
Table illustrating number of myometrial strips analysed for each organ bath condition.  
Further patient demographic details are shown in Table 17. 
4.4.5.1 Contractility data 
Functional contractility analysis of the effect of tocolytic addition to the organ 
baths at 2 hours after regular spontaneous activity was achieved is illustrated in 
Figure 53. This demonstrates that at the concentrations used in this experiment, 
nifedipine and ritodrine inhibited contractions in a manner comparable with the 
effect of ML7.  Additionally, where nifedipine was present from the start of the 
experiment (0hr nifedipine) the myometrial strip was rendered unable to 
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contract at all.  Levcromakalim and water soluble progesterone did not fully 
inhibit contractile activity with contractions continuing at reduced amplitude 
following progesterone addition, and contractions returning 2 hours following 
addition of levcromakalim.   
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Figure 53  In-vitro contractile activity response to tocolytics 
The effect of tocolysis on in-vitro myometrial contractility in response to the addition of 
either ML7 (n=6), Nifedipine (n=13), Ritodrine (n=13), Levcromakalim (n=11) or Progesterone 
(n=7).  Comparison data from spontaneously contracting strips are shown in blue on each 
graph (n=12).  Data from exposure to nifedipine from start of the experiment is illustrated in 
red.  Three measures of contractility are used amplitude, frequency and activity integral 
(graphs from left to right).  Data are shown as median and IQR. Complete inhibition of 
contractile activity is achieved by ML7, nifedipine and ritodrine whereas, levcromakalim and 
progesterone are unable to fully inhibit contractions. 
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4.4.5.2 Myometrial transcription of inflammatory mediators 
Q-PCR analysis of cytokine targets was performed on all samples and 
comparisons made firstly between those exposed to effective tocolysis (ML7, 
nifedipine and ritodrine) and corresponding spontaneously contracting samples 
(Figure 54).  As expected from our initial experiments, ML7 exposure reduced 
inflammatory marker expression compared with spontaneously contracting 
samples, with the exception of CXCL2, p=0.055 (CXCL1, p=0.022; CXCL5, 
p<0.001; CXCL8 p=0.013; CCL2, p=0.006; CCL3, p=0.001; CCL8, p<0.001; CCL20, 
p<0.001; IL1β, p=0.002; IL6, p0.013; IL10, p<0.001; TNFα, p=0.003). 
However, despite abolition of contractions with nifedipine or ritodrine (Figure 
53), the expression of all inflammatory markers was comparable with expression 
in the spontaneously contracting myometrial strips with the exception of CXCL1 
which had a higher expression in the 0hr nifedipine group (p=0.040) and CCL8 
which was lower in the ritodrine group (p=0.024).  Additionally, expression levels 
of the measured inflammatory markers were significantly higher after exposure 
to nifedipine or ritodrine compared with ML7 with the exception of CXCL2 and 
IL6 which tended to be higher, but differences were not significant (Figure 54). 
Furthermore, time of nifedipine addition to the organ bath (0 hours or 2 hours) 
did not lead to any significant difference in expression of the selected 
inflammatory markers between these two groups (Figure 54). 
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Figure 54  QPCR analysis of myometrial strips exposed to successful tocolysis 
Transcriptional expression of inflammatory mediators CXCL1,2,5,8, CCL2,3,8,20, IL6, IL10, 
IL1B and TNFα  relative to β-actin in myometrial samples spontaneously contracting in 
normal Krebs solution at 37◦C (n=12) compared with samples where contractions were 
abolished by ML7 (n=6), nifedipine (addition at 0hrs (n=5) and 2hrs (n=13)) and ritodrine 
(n=13).  Raw data are shown as box and whisker plots with median, IQR and range shown.  
Analysis performed using Mann-Whitney U test with lines demonstrating significance value 
between 2 samples under start and end of each line.  *p<0.05, ** p <0.01, ***p<0.001 
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To investigate if chemically blocking the contraction with the tocolytics ML7, 
nifedipine or ritodrine resulted in a ‘non-contracting’ pattern of gene 
expression, samples were compared with a metabolically active but not 
contracting sample (end no contraction) (Figure 55).  This demonstrated that 
expression of inflammatory markers in ML7 treated strips was comparable with 
the ‘non-contracting’ pattern (end no contraction), with the exception of CCL8 
where expression is lower in the ML7 treated strips (p=0.002).  However, 
expression of inflammatory markers in the nifedipine and ritodrine tocolytic 
groups is overall higher than the non-contracting samples.  Results are 
significant for all comparisons with the exception of CXCL5 and IL1β for 
nifedipine at 0hr (p=0.052 for both), CCL3 and CCL8 for ritodrine treated strips 
(p=0.087, p=0.105 respectively) and TNFα for all (0hr nifedipine, p=0.052; 2hr 
nifedipine, p=0.236, ritodrine, p=0.087) (Figure 55).  
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Figure 55  QPCR analysis of myometrial strips exposed to successful tocolysis 
Transcriptional expression of inflammatory mediators CXCL1,2,5,8, CCL2,3,8,20, IL6, IL10, 
IL1B and TNFα relative to β-actin in myometrial samples physiologically active but not 
contracting in normal Krebs solution at 37◦C (n=12) compared with samples where 
contractions were abolished by ML7 (n=6), nifedipine (addition at 0hrs (n=5) and 2hrs 
(n=13)) and ritodrine (n=13).  Raw data are shown as box and whisker plots with median, 
IQR and range shown.  Analysis performed using Mann-Whitney U test with lines 
demonstrating significance value between 2 samples under start and end of each line.  
*p<0.05, ** p <0.01, ***p<0.001 
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To investigate if partial inhibition of contractility by levcromakalim and 
progesterone affected inflammatory gene transcription, Q-PCR data were 
compared using a Kruskal-Wallis test with data from spontaneously contracting 
strips (end spt contraction vs levcromakalim vs progesterone) (Figure 56).  No 
significant differences were found for any of the inflammatory markers 
measured.  Additionally, when compared with the tocolytics nifedipine and 
ritodrine added at 2 hours, (levcromakalim vs progesterone vs nifedipine vs 
ritodrine) no difference was found using a Kruskal-Wallis test, with the 
exception of CCL8 (p=0.005) (Figure 56).  
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Figure 56  QPCR analysis of myometrial strips exposed to all tocolysis 
Transcriptional expression of inflammatory mediators CXCL1,2,5,8, CCL2,3,8,20, IL6, IL10, 
IL1B and TNFα relative to β-actin in myometrial samples spontaneously contracting in 
normal Krebs solution compared with samples where contractions were abolished 
(nifedipine and ritodrine) and partially abolished (levcromakalim and progesterone).  Raw 
data are shown as box and whisker plots with median, IQR and range shown.  Analysis 
performed using Kruskal-Wallis test with line demonstrating significance value between the 
4 samples under the line.  ** p <0.01 
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4.4.6 Hypothesis 5 - Myometrial contractility and transcription of 
inflammatory markers in-vitro in response to an infective 
and inflammatory stimulus (LPS) 
4.4.6.1 Patient Demographics 
Myometrial samples were collected for 6 women.  Data were excluded if the 
sample did not achieve regular spontaneously contractile activity (1 from n 
Krebs group, 2 from PMB group).  The characteristics of the patients with 
number of strips for each environment are illustrated in Table 24. 
N Women 6 
N Strips 
n Krebs start 
PMB start 
n Krebs 
PMB 
PMB & LPS 
LPS 
PMB & OT 
LPS & OT 
6 
6 
5 
4 
5 
6 
6 
6 
Maternal BMI (kg/m2) 
Median (IQR) 
[Range] 
30.2 (28.0,32.1) 
[23.0,34.5] 
Age (years) 
Median (IQR) 
[Range] 
35.0 (32.8,35.0) 
[32.0,35.0] 
Gestation (days) 
Median (IQR) 
[Range] 
276.0 (273.0,277.8) 
[273.0,280.0] 
Baby birth weight (kg) 
Median (IQR) 
[Range] 
3.9 (3.5,4.1) 
[3.3,4.2] 
Indication for CS 
N (%) Previous CS 
N (%) Other 
4 (66.7%) 
2 (33.3%) 
Parity 
N (%) =0 
N (%) =1 
 1 (16.7%) 
 5 (83.3%) 
Table 24  Hypothesis 5 - Patient demographic details 
Demographic details of patients included in experiment for Chapter 4 Hypothesis 5 
examining the functional and transcriptional effect of an infective, pro-inflammatory 
environment (Lipopolysaccharide (LPS)) on myometrium in-vitro. 
4.4.6.2 Contractility data 
Functional contractile data for each environment in the absence of OT and in 
the presence of OT are presented in Figure 57.  No significant difference for any 
measure of contractile activity was found to be influenced by organ bath 
environment at any time point (Kruskal-Wallis test at each time point; 
amplitude, p>0.390; frequency, p>0.116; activity integral, p>0.304).  Notably, 
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LPS did not enhance contractile activity of response to OT (Mann-Whitney U-test 
at each time point; amplitude, p>0.093; frequency, p>0.240; activity integral, 
p>0.240). 
 
Figure 57  Contractile activity of strips exposed to LPS of PMB 
Illustration of contractility data (amplitude, frequency and activity integral (AUC)) for 
samples which contracted in an environment of LPS or PMB.  Contractions were either 
spontaneous or enhanced with a single addition of OT.  Data are shown as median and IQR 
for each time point.  Spontaneous contractility and response to OT was not enhanced by an 
LPS induced pro-inflammatory environment.  
4.4.6.3 Myometrial transcription of inflammatory mediators 
Q-PCR data demonstrated that contractions induced an upregulation of 
inflammatory mediator transcription in myometrium exposed to normal 
untreated Krebs solution (n Krebs start v n Krebs) and PMB treated, endotoxin 
free solution (PMB start vs PMB) (Figure 58).  This suggests an inflammatory 
reaction driven by contractions rather than infection.  Strips which were treated 
with both LPS & PMB expressed inflammatory mediators at a comparable level 
with PMB alone, suggesting that PMB is sufficient to eradicate endotoxins from 
the organ bath environment (Figure 58).  Additionally, strips which contracted in 
a PMB treated environment had a tendency to express lower levels of 
inflammatory mediators than strips in normal Krebs, but a significant difference 
was seen for only CCL8 (p=0.016), CCL20 (p=0.032) and IL6 (0.032) (Figure 58).     
 
Claire A Higgins, 2012   Chapter 4, 181  
 
Figure 58  QPCR analysis of myometrial strips exposed to LPS or PMB 
Transcriptional expression of inflammatory mediators CXCL1,2,5,8, CCL2,3,8,20, IL6, IL10, 
IL1B and TNFα relative to β-actin in myometrial samples  in normal Krebs or Krebs treated 
with PMB or PMB  & LPS.  Comparisons are made between transcription at start of 
experiment and strips which have spontaneously contracted.  Contractions induce 
transcription of inflammatory mediators even when environmental endotoxins are removed.  
Data shown as scatter plots with median and IQR indicated.  Analysis performed using 
Mann-Whitney U test with lines demonstrating significance value between 2 samples under 
start and end of each line.  *p<0.05, ** p <0.01 
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The presence of LPS in the organ bath leads to the induction of inflammatory 
cytokine transcription, with a significant rise for all (p<0.05) with the exception 
of CXCL5 (p=0.352) and CCL8 (p=0.067) when compared with strips in a PMB 
treated environment (Figure 59).  Additionally, the data suggest that the 
addition of LPS to the organ bath environment tends to increase the expression 
of inflammatory mediators compared with untreated Krebs, however this was 
not significant. 
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Figure 59  QPCR analysis of myometrial strips exposed to LPS, PMB or LPS&PMB 
Transcriptional expression of inflammatory mediators CXCL1, 2, 5, 8, CCL2, 3, 8, 20, IL6, 
IL10, IL1B and TNFα relative to β-actin in myometrial samples spontaneously contracting in 
1) normal Krebs solution, 2) Krebs treated with PMB for endotoxin eradication), 3) Krebs 
treated with PMB and LPS or 4) Krebs with LPS added to promote a pro-inflammatory 
environment.  LPS induces transcription of inflammatory mediators compared with PMB 
treated samples.  Data shown as scatter plots with median and IQR indicated.  Analysis 
performed using Mann-Whitney U test with lines demonstrating significance value between 
2 samples under start and end of each line.  *p<0.05, ** p <0.01 
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There was also a significant increase in the inflammatory mediators observed in 
the presence of LPS where contractions were induced by OT when compared 
with OT induced contractions in the presence of PMB (p<0.05 for all) with the 
exception of CXCL5 (p=0.3939) (Figure 60). 
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Figure 60  QPCR analysis of myometrial strips exposed to LPS&OT or PMB&OT 
Transcriptional expression of inflammatory mediators CXCL1,2,5,8, CCL2,3,8,20, IL6, IL10, 
IL1B and TNFα relative to β-actin in myometrial samples in Krebs treated with PMB or Krebs 
with LPS with contractions induced by a single addition of OT.  Environmental LPS 
promotes transcription of inflammatory mediators.  Data shown as scatter plots with median 
and IQR indicated.  Analysis performed using Mann-Whitney U test with lines demonstrating 
significance value between 2 samples under start and end of each line.  *p<0.05, ** p <0.01 
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4.4.7 Hypothesis 6 – Synthesis and release of inflammatory 
protein products from contracting myometrium in-vitro 
Expression of the inflammatory proteins Il2, IL4, IL6, Il10, CSCL8, GM-CSF, IFNγ 
and TNFα in Krebs solution is illustrated in Figure 61.  This showed an overall 
trend to increased detection of all measured proteins with the exception of IL2 
where there was a slight decrease (median decrease -13.54% (IQR -44.79, 
10.42)).  Notable increases in the median level of protein expression occurred 
for Il6 (1881% (IQR 570.3, 18200.0%)) and CXCL8 (5013% (425.8,16819%)), with 
moderate increases for TNFα (84.6% (30.8, 948.1%)) and IL10 (15.8% (2.6, 
72.1%)). 
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Figure 61  Bioplex analysis of inflammatory proteins in organ bath solution 
Expression of the inflammatory proteins IL2, IL4, IL6, IL10, CXCL8, GM-CSF, IFNγ and TNFα 
in Krebs solution which has nor been exposed to tissue (n=1) and Krebs solution which has 
been exposed to contracting myometrium for 7 hours (n=6).  Measures of expressed 
fluorescence in each environment and % change from baseline are shown.  Data are shown 
as box and whisker plots with median, IQR and range. 
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4.5 Summary of Results 
4.5.1 Myometrial inflammation and in-vitro contractions 
• Contractions induce transcription of inflammatory mediators in 
myometrial samples over and above the transcription seen in non 
contracting ex-vivo samples kept in physiological conditions. 
4.5.2 Temporal association between myometrial inflammation and 
in-vitro contractions 
• Transcription of inflammatory mediators in contracting myometrium 
occurs in a time dependent manner. 
4.5.3 Overlap of in-vitro and in-vivo myometrial transcriptional 
profile in response to contractions 
• There is an overlap of contraction associated myometrial genes between 
those derived in response to in-vivo contractions (IL vs NIL) and in-vitro 
contractions with a preponderance of genes associated with the 
inflammatory response. 
4.5.4 Myometrial contractile and inflammatory response to in-
vitro tocolysis 
• Effective tocolysis of myometrial strips is comparable between ML7, 
nifedipine and ritodrine. 
• Levcromakalim and water soluble progesterone only partially inhibit 
contractile activity of myometrial strips. 
• Transcription of inflammatory mediators is suppressed in ML7 treated 
samples compared with spontaneously contracting samples, and is 
comparable with non-contracting myometrial samples kept in 
physiological conditions. 
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• Despite abolition of contractile activity, transcription of inflammatory 
mediators in myometrium is not suppressed by exposure to nifedipine or 
ritodrine compared with spontaneously contracting samples. 
• Transcription of inflammatory mediators in myometrium is comparable 
between those which have spontaneously contracted and where 
contractions are chemically blocked or partially suppressed by nifedipine, 
ritodrine, levcromakalim or progesterone. 
4.5.5 Myometrial contractile and inflammatory response to an in-
vitro pro-inflammatory, infective environment 
• Spontaneous and OT induced myometrial contractile activity in-vitro is 
not enhanced by a pro-inflammatory, infective environment nor is it 
suppressed by an endotoxin free environment. 
• Contractions induce transcriptional up-regulation of inflammatory 
mediators in myometrial strips incubated in normal untreated Krebs 
solution and PMB (endotoxin free) Krebs solution. 
• In myometrial samples undergoing spontaneous and OT induced 
contractions, LPS induces an up-regulation of inflammatory mediator 
transcription when compared with strips contracting in a PMB treated 
(endotoxin free) environment. 
4.5.6 Synthesis and release of myometrial inflammatory proteins 
in-vitro 
• There is a non-significant trend for inflammatory protein products to be 
present in Krebs solution exposed to myometrium in an organ bath 
environment compared with Krebs solution which has not been exposed to 
myometrium. 
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4.6 Discussion 
The data presented in this chapter demonstrates that in-vitro myometrial 
contractile activity is associated with a transcriptional upregulation of 
inflammatory mediators in a time dependent manner. Additionally, there is 
overlap with the genes upregulated in response to human labour suggesting 
contractions per se are associated with the recognised inflammatory response of 
the myometrium during human labour. 
We also found that chemical manipulation of contractility has an affect on 
transcriptional expression of inflammatory mediators, with a suggestion that 
method of tocolysis, regardless of efficacy of suppressing contractile activity, 
influences the inflammatory response.  Additionally, although a pro-
inflammatory/infective environment did promote a myometrial inflammatory 
response, this did not have the expected effect of enhancing contractility, 
suggesting myometrial derived inflammatory mediators may not directly drive 
myometrial contractility. 
4.6.1 Myometrial inflammatory response and contractility 
We have provided evidence which demonstrates inflammatory up-regulation 
within non-contracting ex-vivo myometrial samples in a physiological 
environment.  This inflammatory response is significantly augmented when 
myometrial strips exhibit spontaneous contractile activity.  This suggests that 
the inflammatory up-regulation seen in our in-vitro model of labour occurs as a 
response to tissue contractions rather than ex-vivo tissue degradation.   
Further support for association between myometrial contractions and the 
inflammatory response is provided by our temporal analysis of the gene 
expression of inflammatory mediators.  This clearly demonstrates a time 
dependent relationship whereby the longer the myometrial sample contracted in 
the organ bath, the greater the inflammatory transcriptional response. 
We have demonstrated overlap between the transcription of inflammatory 
mediators by contracting myometrium in-vitro and in-vivo.  The degree of 
overlap between the array data are perhaps not as striking as we thought it may 
be.  However, this may simply reflect the fact the baseline measures (NIL and 
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0hr time point) were not truly comparable as strips at the 0hr time point had 
contracted in the organ bath and a degree of inflammatory response would have 
been already be initiated.  Therefore, it follows that fold changes at the 
subsequent time points would not be as dramatic as between the nil and labour 
samples.   
Despite this, when the QPCR data for the chemokines CCL2, CCL20 and CXCL8 
are compared between the in-vivo samples (IL vs NIL) and the in-vitro samples 
(end spt contractions vs start) the trend for upregulation of these chemokines in 
both situations is reproduced, with the extent of fold change higher for the in-
vitro samples.  This may represent the difference in an increased amount of 
cellular damage within the in-vitro myometrium sample.  Additionally it may 
suggest that labouring myometrium in-vivo does not require to wield such an 
extreme inflammatory response since there will be a leukocyte response with 
trafficking, whereas this obviously cannot occur in an organ bath.  This merits 
further investigation and further confirmation of the overlap between the 
reaction of the myometrium during labour and in the organ bath environment 
with larger numbers of inflammatory mediators and sample sizes. 
Overall, our data suggest that the inflammatory changes associated with human 
labour occur in response to uterine contractions.  Additionally, the overlap 
reassuringly suggests that our in-vitro organ bath experimental set up is a 
representative model suitable for the study of myometrial responses in human 
labour. 
4.6.2 Tocolysis and myometrial contractile and inflammatory 
response 
Our hypothesis that the chemical tocolytic agents would lead to suppression of 
both contractile activity and the myometrial inflammatory response was not 
fully supported by our data.  However, data do suggest that myometrial cells 
initiate an inflammatory reaction in response to chemically induced, non-
contractile cellular stress. 
Considering the functional contractile response of myometrium to tocolysis, we 
found variable responses which are in agreement with data from other in-vitro 
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contractility studies118 285 346.  In our hands, ML7, nifedipine and ritodrine were 
able to fully inhibit contractility while levcromakalim and progesterone were not 
as reliable with only partial inhibition.  This is also reflected in clinical practice 
where the efficacy of tocolytic agents can be variable, with only ritodrine and 
the oxytocin receptor antagonist Atosiban licensed for use in prevention of pre-
term labour in the UK, and nifedipine widely used ‘off licence’ for this 
purpose186 239.  Additionally, the inconsistency of progesterone to inhibit 
contractility in our in-vitro model has also been seen previously in-vitro and in 
the clinical situation285 287-291. 
In terms of the myometrial inflammatory response to tocolysis, results did not 
reflect our initial hypothesis, and despite complete abolition of contractions by 
nifedipine and ritodrine, transcription of inflammatory mediators was 
comparable to that of tissue which had spontaneously contracted.  Transcription 
of inflammatory mediators in response to nifedipine and ritodrine is also higher 
than in the non contracting tissue under physiological conditions.  Furthermore, 
myometrium exposed to nifedipine from the outset and therefore never 
contracted has a comparable inflammatory profile to tissue where nifedipine 
was added after contractions were established.  This suggests an alternative 
stimulus whereby the myometrium requires to initiate an inflammatory 
response, and that this may be a reflection of the method of tocolysis.   
The mechanisms whereby nifedipine and ritodrine exert their tocolytic effects 
are through manipulation of upstream cellular events; nifedipine blocks calcium 
entry into cells via L-type voltage gated calcium channels 186 187, and ritodrine 
acts via the cell surface β2 adrenergic receptor via cAMP-dependent protein 
kinase A to inactivate myosin light chain kinase (MLCK), reduce intracellular 
calcium and increase permeability to potassium 186 187.  These mechanisms 
therefore have the potential not only to affect the contractile function of the 
cell, but also other essential cellular functions.  This could be interpreted by the 
cell as ‘damage’, thereby the cell responds by mounting an inflammatory stress 
response.   
This suggested proposal is also partially supported by the response of the 
myometrial strips to ML7 whereby complete abolition of contractions is achieved 
and the inflammatory transcriptional profile is suppressed to levels comparable 
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with myometrium which is physiologically active but non-contracting.  The 
mechanism of tocolysis employed by ML7 is to specifically inhibit smooth muscle 
MLCK activity, which in terms of cellular function is a downstream event mainly 
concerned with cell contractility 272-275.  Blocking this downstream event would 
therefore not necessarily be interpreted by the cell as a threat or ‘damage’, 
with no need to initiate an inflammatory response.  However, there is some 
evidence of alternative actions of ML7 which have the potential to also influence 
some upstream transcriptional and cellular events339-341. 
The transcription of inflammatory mediators in ML7 treated samples is 
comparable with non-contracting, physiologically active samples.  Again this 
suggests that ML7 is a relatively appropriate way to block contraction without 
affecting other cellular functions.  Additionally it has been previously 
demonstrated that MLCK phosphorylation of myosin is the common final pathway 
essential in the generation of myometrial contractile force118.  It can therefore 
be concluded that ML7 as a method of inhibiting myometrial contractions in-
vitro provides a suitable contrast whereby the effects of spontaneous and 
oxytocin induced contractions can be studied, with the added advantage of 
knowing the sample has the ability to contract unlike using non-contracting 
samples only. 
Our results regarding the effect of progesterone on myometrial inflammatory 
response are not in agreement with previous suggestions where progesterone 
and progesterone related hormones have been regarded as an ‘anti-
inflammatory’ 347-349.  This may be due to differences in the timing of hormone 
exposure; pre-treating prior to any contractions compared with exposure once 
spontaneous contractile activity is already established. 
4.6.3 Infection and myometrial contractile and inflammatory 
response 
Our Q-PCR data have confirmed that an LPS rich environment induces an 
exaggerated inflammatory response in contracting myometrium compared with a 
non-inflammatory PMB environment.  However, interestingly, this inflammatory 
upregulation does not alter or enhance in-vitro myometrial spontaneous 
contractile activity or its response to OT. 
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Again, this is contrary to our initial hypothesis, and also the proposals of others 
regarding the mechanisms involved in the initiation and propagation of human 
labour, especially those associated with inflammation with or without the 
presence of infection18 199 210 216 217 230-236 260-262.  This suggests that the mechanism 
which promotes labour in the presence of infection may not be directly 
mediated by myometrial produced inflammatory mediators.  This may explain 
why studies examining the role of antibiotic therapy in the treatment or 
prevention of pre-term labour with intact membranes have been unsuccessful261 
266 267 350. However, this is an in-vitro model, and during human labour, other 
factors, for example infiltration of leukocytes into the myometrium may account 
for premature activation of contractility.   
However, our data would suggest that inflammation per se is not necessary for 
contractions to occur as is demonstrated in the PMB samples.  Additionally, 
despite the absence of an infective stimulus in the PMB treated myometrium, an 
inflammatory response still occurs as a result of myometrial contractility.  This 
suggests that in-vivo, COX-inhibitors have not been particularly effective at 
preventing pre-term birth in humans since suppression of inflammatory response 
does not necessarily suppress myometrial contractile activity. 
4.6.4 Synthesis and release of myometrial inflammatory proteins 
in-vitro 
Our data concerning levels of inflammatory proteins in the organ bath which has 
been exposed to contracting myometrium in-vitro shows a tendency towards a 
release of these proteins into the surrounding environment.  However, we must 
interpret these data with caution as this experiment was only designed to assess 
if these proteins could be measured in the Krebs solution.  However, we did not 
have the appropriate control group of Krebs which has been exposed to non-
contracting myometrial tissue, and we are therefore unable to conclude that 
myometrial contractions are responsible for the release of inflammatory 
proteins. 
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Conclusion  
We have presented novel data examining the in-vitro time and contraction 
dependent myometrial inflammatory changes and the overlap with changes 
occurring within contracting myometrium in-vivo. 
We have demonstrated that myometrial transcription of inflammatory cytokine 
and chemokines at term occurs in a co-ordinated time and contraction 
dependent manner.  Thereby, this suggests that the inflammatory response 
typical of human labour occurs as an acute reaction to myometrial contractile 
damage.  Additionally, our data suggest that the degree of inflammatory 
response mounted by the myometrium does not influence the functional 
contractility of the tissue.  Rather, the level of inflammation may be more 
appropriately interpreted as an indication of myometrial cellular stress, which is 
non-specific and can be induced not only by contractions but also exposure to 
chemical manipulation of cell function or a pro-inflammatory infective 
environment. 
Overall, the evidence tends to support much of the hypotheses proposed at the 
start of this chapter, with modifications summarised below in Figure 62.  
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Figure 62  Chapter 4 Amended Hypothesis 
Summary of the hypotheses examined regarding myometrial contractions and myometrial 
derived inflammatory mediators, the overlap between in-vitro contraction and those seen in 
human labour and the influence of tocolysis or an infective/inflammatory environment.  Red 
crosses indicate areas which were not supported by our experiments. 
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5 Circulating white blood cells, inflammatory 
cytokines and markers of myocyte damage in 
response to human labour 
5.1 Introduction 
Trafficking of leukocytes involved in the inflammatory process to areas of tissue 
damage is a basic physiological response forming part of the acute inflammatory 
reaction which should be self limiting and protective for the host264 265 351-353.  
The acute inflammatory process can occur for a number of reasons including 
defence against infection, defence and clearing of non-infective tissue damage 
and stimulation of tissue repair and healing.  Inflammatory changes are 
associated with the process of human labour both at term and pre-term, with a 
striking increase in leukocyte numbers, predominantly neutrophils and 
macrophages, throughout the uterus into the myometrium and cervix219 220 354.  
Of note, the acute inflammatory reaction of human labour occurs in a non-
infective environment in normal pregnancy, involves inflammatory cells derived 
from the maternal circulation354, is self limiting and results in uterine involution 
and return to normal function. 
Characterisation of changes to circulating leukocyte numbers during pregnancy 
have been described, with a gestation dependent increase in overall white cell 
count driven by a neutrophilia355-357.  Within the context of pregnancy, 
alterations in the levels of other white cell sub-sets are conflicting with some 
suggesting a reduction in lymphocytes and an increase in monocytes at term 
compared with non-pregnant controls, while others have observed no changes355-
361.  It is also well recognised that labour induces further changes in maternal 
circulating white cells, with increases in total white cell count and neutrophils, 
a decrease in lymphocytes, eosinophils and monocytes all of which occur in the 
absence of infective stimuli359 362-364.  These changes are consistent with those 
seen in acute inflammatory reactions in response to other stimuli including 
infection and surgical trauma264 365-371. 
Additionally, it has been proposed that maternal leukocytes may be activated or 
‘primed’ in the peripheral blood prior to labour (pre-term and term) and 
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therefore have increased responsiveness to circulating agonists and an ability to 
migrate to gestational tissues prior to the commencement of labour360 372.  
However, others have suggested no change to cellular immune function during 
pregnancy, except during delivery itself where a suppression of mitogenic 
function in circulating lymphocytes has been observed356. 
In conjunction with the changes in white cells during pregnancy, there are also 
alterations to circulating inflammatory mediators and other markers of 
inflammation.  Certainly, C-reactive protein (CRP) levels increase from an early 
gestation373 374.  Concentrations of circulating cytokines can change throughout 
pregnancy, with intrapartum increases in IL6 and IL10, however results have 
been inconsistent and many without comparison with non-pregnant 
individuals375-378. 
The actual timing and role of the changes in circulating leukocytes, cytokines 
and the leukocyte infiltration into the uterus are yet to be determined.  Current 
proposals suggest an overall inflammatory environment in gestational tissue with 
an increase in numbers and reactivity of cells within the maternal circulation are 
required for the initiation and propagation of cervical ripening, myometrial 
contractility and therefore labour210 211 216 217 219 379-382.  However, evidence from 
other contractile muscle systems, in particular exercising skeletal muscle, 
observe similar inflammatory changes in the circulation and the contracting 
tissue and suggests that inflammatory changes occur as a reaction to myocyte 
damage and play a role in clearing cellular debris with subsequent tissue repair 
and remodelling383-389.  Of note, the changes seen in both circumstances, 
especially the predominance of infiltrating neutrophils and monocytes is 
consistent with the classical changes of acute inflammation264. 
This reactionary model of acute inflammation as a response to myocyte damage 
may therefore also apply to the uterus in human labour.  There is inevitable 
damage to the myometrial tissue during labour, confirmed by myocyte cell 
structure disruption,354 and increases in circulating myocyte derived proteins 
including creatine kinase and myoglobin,390-392 in the absence of increased 
cardiac specific troponin I390.  Additionally, the gene array and transcription data 
shown in the preceding chapters has suggested that up-regulation of 
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inflammatory mediators in human myometrium is a contraction and time 
dependent event.   
Despite evidence of both myocyte damage and inflammatory changes, the acute 
time and labour dependent changes to circulatory inflammatory mediators and 
markers of muscle damage have not previously been described in a longitudinal 
manner.  Additionally, comparison with changes seen in response to delivery 
after a non-labouring caesarean section and with non-pregnant controls will 
provide a better understanding of inflammation during human labour.  
Description of these time and contraction induced inflammatory changes will aid 
our understanding of the physiology of myometrial contractility, and in addition 
could advocate the use of human labour as a model of an inflammatory process 
which is self-limiting with subsequent repair, remodelling and regeneration after 
the initial insult.  
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5.2 Hypotheses 
Based on our in-vitro transcriptional data and evidence from exercising skeletal 
muscle, the working paradigm regarding the role of inflammation can be 
summarised in Figure 63. 
 
Figure 63  Chapter 5 Overall Hypothesis 
Working paradigm concerning the role of inflammation in term human labour. 
Overall, we propose that myometrium responds to contractile damage of labour 
by releasing inflammatory signals, an event which occurs after the initiation of 
contractions.  In turn, we propose that these inflammatory mediators may play a 
pivotal role in the chemo-attraction and subsequent influx of leukocytes into the 
myometrium.   
The four main hypotheses which will be tested are  
1. Pregnancy at term induces changes to circulating inflammatory 
parameters when compared with non-pregnant controls. 
2. Term delivery by either planned, non-labour caesarean section (CS) or 
induction of labour (IOL) with syntocinon will result in a shift towards a 
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pro-inflammatory profile in the maternal circulation, with an enhanced 
response in mothers who labour. 
3. In term pregnancies, changes observed as a result of IOL occur in a time 
and contraction dependent manner in response to labour. 
4. Promotion of a pro-inflammatory phenotype in the maternal circulation in 
response to labour is associated with myometrial myocyte damage. 
The inflammatory parameters will be assessed for a time series during term 
induction of labour (IOL) with syntocinon.  IOL was used as a model of labour 
with a clear pre-labour baseline.  Additionally, we have seen in our array data 
that stimulation of contraction with exogenous oxytocin does not influence 
myometrial gene transcription.  Measures will be compared with data from two 
control groups, firstly non-pregnant females during the early follicular phase of 
the menstrual cycle, and secondly those undergoing delivery by planned non-
labouring caesarean section (CS) at term.  This second comparison group was 
included as post-partum remodelling of the myometrium would still be required, 
but likely to be less since contractile activity and therefore myometrial damage 
should be lower. 
The parameters measured within the maternal peripheral circulation will 
consider both systemic inflammation and indirect measures of myocyte damage 
and include the following; 
1) circulating leukocyte differential counts  
2) expression of leukocyte cell surface markers and chemokine receptors 
3) circulating cytokine and chemokine levels 
4) circulating c-reactive protein (CRP) levels 
5) circulating creatine kinase (CK) and myoglobin (Mb). 
A brief overview of each of the parameters analysed and the underlying 
rationale is provided below. 
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5.2.1 Differential leukocyte count 
White blood cells (WBC) or leukocytes are the immunological cells which play a 
pivotal role in the body’s defensive mechanisms.  The numbers and types of 
circulating white cells can change with recognised patterns being considered a 
typical response to a defined stimulus.  For example, an acute inflammatory 
response to a non-specific stimulus or injury is characterised by an initial sharp 
increase in circulating neutrophils driven by release of ‘new’ neutrophils from 
the bone marrow, with an accompanying later decrease in circulating monocytes 
and eosinophils264 365.   
The leukocyte parameters considered in clinical practice and within the context 
of these experiments are defined in the Table 25. 
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Leukocyte parameter Cell description 
Total white cell count 
A summative measure of the white blood cell population in the 
circulation 
Neutrophil 
A type of granulocyte containing a multilobed nucleus and 
neutrophilic granules with a major role in phagocytosis involved in 
the initial acute inflammatory/innate immune response.  
Neutrophils represent the largest population of leukocytes in the 
circulation.  
Lymphocyte 
A small dense leukocyte with 3 major types 
1) B cells (10-15% of lymphocytes) which when activated become 
plasma cells and secrete antibodies 
2) T cells (CD3+ lymphocytes, 75% of lymphocytes) further 
subdivided into 
- CD4+ T-cell (T-helper/Th cells) activate other cells e.g. B-cells 
and macrophages.  4 further sub-classes of T-helper cells are 
recognised Th1 (pro-inflammatory), Th2 (anti-inflammatory), Th17 
and Treg (suppressor). Memory Th cell can develop after 
activation. 
- CD8+ T-cell (T-cytotoxic/Tc cells) role in direct destruction of 
damaged or infected cells. Memory Tc cells can develop after 
activation. 
3) Natural killer cells (NK cells) have the ability to kill ‘non-self’ 
cells and are considered part of the innate immune response 
Monocyte 
A circulating leukocyte which matures and differentiates into a 
macrophage within tissue where its primary role is phagocytosis 
Eosinophil 
A type of granulocyte involved in defence against parasite 
infection, and allergy, also role in acute inflammatory/innate 
immune response393 
Basophil 
A type of granulocyte representing <1% of total white cell count 
with possible role in Th2 response (anti-inflammatory) and B cell 
activation394 
Table 25  White blood cell (leukocyte) parameters 
Summary table of white blood cell (leukocyte) parameters measured within the context of 
this experiment. 
5.2.2 Leukocyte cell surface markers and chemokine receptors 
The specific trafficking of leukocytes to areas where they are required can be 
driven by local release of chemokines, which via the appropriate chemokine 
receptor on the cell surface will mediate the influx of the particular subset of 
cells required.  Chemokine receptors exist as mainly transmembrane, G-protein 
coupled receptors, with activation stimulating downstream cellular functional 
responses which include adhesion molecule expression, chemokine/cytokine 
release and of course chemotaxis and migration of the leukocyte to the area of 
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chemokine release395 396.  The leukocytes which typically increase in number 
within uterus (myometrium and cervix) in response to labour are predominantly 
neutrophils and macrophages, with T-lymphocytes increasing in the myometrium 
of the lower segment only219 354.  These cell types were therefore studied in the 
maternal circulation. 
As described in Chapter 2, Section 2.13, flow cytometry allows cell types and 
properties to be analysed.  Dependent on the characteristics assessed, cells 
were defined as neutrophils (CD66b+ granulocytes), activated neutrophils 
(CD66b+/CD11b+ granulocytes), monocytes (CD14+ monocytes), activated 
monocytes (CD14+/CD11b+ monocytes), T-helper lymphocytes (CD3+/CD4+ 
lymphocytes) or T-cytotoxic lymphocytes (CD3+/ CD8+ lymphocytes).  A study 
was then made of the chemokine receptors expressed by each white cell subset, 
with the particular chemokine receptors examined being CXCR1, CXCR2, CCR2 
and CCR6.  
CD11b (Mac-1, αMβ2) is a cell surface molecule which is constitutively expressed 
in low levels on the surface of neutrophils and monocytes, and is also found in a 
preformed state within cytoplasmic granules.  Activation of these leukocytes by 
CXCL8 via CXCR1 and CXCR2 causes rapid mobilisation (minutes) of cytoplasmic 
CD11b with an enhanced cell surface expression397 398, and is a typical innate 
immunity response to sepsis.  CD11b plays a crucial role in leukocyte 
chemotaxis, adhesion and sequestration from circulation to the area of tissue 
damage by increasing the cells adhesive capacity to the endothelium via 
facilitating binding to the cell adhesion molecule ICAM-1.  A high density of cell 
surface expression of CD11b is therefore consistent with neutrophils and 
monocytes being in an ‘activated state’. 
CXCR1 and CXCR2 are the main chemokine receptors present on the cell surface 
of granulocytes, with evidence suggesting expression on T-lymphocytes, but to a 
much lesser extent399.  The main ligand for both receptors is CXCL8 which is 
bound with a high affinity400 401.  In addition, CXCR2 is a more promiscuous 
receptor and additional ligands include CXCL1, 2, 3 and CXCL5402.  Activation of 
the receptors plays a significant role in activation of the neutrophils and 
promotes chemoattraction and migration to the site of chemokine release. 
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CCR2 (CD192) is primarily expressed by monocytes and subsequently 
macrophages once migration into the tissue has occurred402.  CCR2 is the 
predominant receptor for the ligand CCL2 which is involved in the chemotaxsis 
of monocytes to areas of inflammation402 403.   CCR2 can also interact with the 
CC-ligands CCL7404, CCL8405, CCL13402 406. 
CCR6 is expressed by lymphocytes (CD4+ve T-helper cells, CD8+ve T-cytotoxic 
cells, and B-cells) but not by granulocyte, NK-cells or monocytes.  The 
corresponding chemotactic ligand for CCR6 is CCL20402 407. 
5.2.3 Circulating cytokines and chemokines 
Cytokines are small signalling molecules which are released by cells (mostly 
activated leukocytes, fibroblasts and endothelial cells) and have a key role in 
the mediation of inflammation and immunity in response to tissue damage.  
They can act in an autocrine, paracrine or endocrine manner.  Additionally, 
chemokines (chemotactic cytokines) are a type of cytokine which act via 
leukocyte chemokine cell surface receptors and stimulate chemotaxis and 
trafficking of white blood cells in both health and disease. 
The cytokines and chemokines assessed in the circulation of women in this 
experiment and a description of their main functional roles is outlined below in 
Table 26. 
Cytokine Function 
EGF (Epidermal Growth Factor) 
Stimulates cell proliferation , differentiation 
and survival 
CCL11 (Eotaxin) Chemotactic for eosinophils via CCR3 
FGF-2 (Basic Fibroblast Growth Factor) 
Growth factor involved in angiogenesis during 
wound healing and tumour development 
Flt-3 (CD135, fms-like tyrosine kinase 
receptor-3) 
Growth factor that increases number of immune 
cells by activating haematopoietic progenitors 
CX3CL1 (Fractalkine) 
Chemotactic for monocytes and Tcells via 
CX3CR1 
GCSF (granulocyte colony stimulating factor) Growth factor which stimulates bone marrow 
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production, maturation and release of 
granulocytes 
GMCSF (granulocyte macrophage colony 
stimulating factor) 
Growth factor stimulating bone marrow 
production and release of granulocytes and 
monocytes 
CXCL1, 2, and 3 (GRO (growth regulated 
oncogene)) 
Primarily involved in the chemotaxsis of 
neutrophils via CXCR2.  The assay used 
measures GRO as a whole and does not separate 
into isoforms. 
Interferon- α2 (IFNα2) Involved in response to viral infection 
Interferon-γ (IFNγ) 
Main cytokine involved in the Th1 pro-
inflammatory response 
Interleukin-1α (IL1α) 
Produced by macrophages and epithelial cells, 
promotes leukocyte adhesion, T-cell and 
macrophage activation, stimulates release of 
acute phase proteins from liver, considered an 
endogenous pyrogen 
Interleukin-1β (IL1β) See IL1α 
IL1ra IL1 receptor antagonist 
IL2 (T-cell growth factor) 
Produced by T cells, promotes T cell 
proliferation, activates B cells and NK cell 
IL3 (multicolony CSF) 
Produced by T cells, plays a role in 
haematopoiesis 
IL4 
Produced by Tcells and mast cells, IgE synthesis 
and Th2 response 
IL5 
Eosinophil growth and differentiation, B cell 
activation 
IL6 
Role in final differentiation of B cell and 
generation of Th17 cells. Induces acute phase 
response proteins (including CRP) from liver, 
endogenous pyrogen, mainly released by 
monocytes/macrophages and also contracting 
muscle (a ‘myokine’). Involved in resolution of 
inflammation via shift from innate to adaptive 
response. 
IL7 
Released by bone marrow, stimulates growth 
and differentiation of T cells and B cells 
CXCL8 (IL8) Chemotaxis of neutrophils, and weak attraction 
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of basophils and T cells via CXCR1 and CXCR2 
IL9 Enhances mast cell activity 
IL10 
Produced by T cells and macrophages, ‘anti-
inflammatory cytokine’, potent suppressor of 
macrophage function, can block NF-кβ, inhibits 
synthesis of pro-inflammatory cytokines 
including IFNγ, IL2, IL3, TNFα, GMCSF 
IL12 (p40) (IL12β subunit) 
Produced by macrophages, involved in the 
stimulation of T-cells and NK cells and 
production of IFNγ and TNFα 
IL12 (p70) (IL12) 
Produced by macrophages, involved in the 
stimulation of T-cells and NK cells and 
production of IFNγ and TNFα 
IL13 Produced by Th2, involved in allergen response 
IL15 Stimulates growth of T cells and NK cells 
IL17 
Produced by CD4+ T cells, stimulates IL6, IL8, 
GCSF and PGE2 release from epithelial, 
endothelial and fibroblastic cells 
CXCL10 (Interferon-γ Inducible Protein (IP10)) 
Chemoattractant for monocytes and T cells via 
CXCR3. produced in response to IFNγ, 
antiangiogenic. 
CCL2 (Monocyte Chemotactic protein-1 
(MCP1)) 
Chemoattractant for monocytes and basophils 
via CCR2 
CCL7 (Monocyte Chemotactic protein-3 
(MCP3)) 
Chemoattractant for macrophages via CCR1, 
CCR2, CCR3 
CCL22 (Macrophage derived chemokine (MDC)) 
Chemoattractant for NK cells, activated Tcells, 
monocytes and dendritic cells via CCR4 
CCL3 (Macrophage inflammatory protein 1α 
(MIP1α)) 
Chemoattractant for lymphocytes via CCR1 and 
CCR5, inhibits proliferation of haematopoietic 
stem cells 
CCL4 (Macrophage inflammatory protein 1β 
(MIP1β)) 
Chemoattractant for lymphocytes, especially T-
helper cells via CCR1 and CCR5 
sCD40L (soluble CD40 ligand) Induces B cell activation via Th cells 
sIL2Rα (sCD25) 
Produced by activated macrophage, involved in 
regulation of IL2 activity 
TGFα (transforming growth factor α) 
Produced by macrophages, involved in 
epithelial development, related to EGF 
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TNFα (tumour necrosis factor α) 
Produced by macrophages and T cells 
endogenous pyrogen, activates neutrophils, 
endothelial cells and acute phase reactants, 
role in wound healing 
TNFβ (tumour necrosis factor β) 
Produced by activated T lymphocytes similar 
activity as TNFα but less potent 
VEGF (vascular endothelial growth factor) 
Growth factor which promotes angiogenesis, 
also chemoattractant for monocytes 
CCL5 (RANTES) 
Chemoattractant for monocytes, Th cells and 
eosinophils via CCR3, CCR5 and CCR1. Involved 
in histamine release from basophils and 
activation of eosinophils. 
Table 26  Circulating cytokine/chemokine parameters 
Summary of the circulating cytokines/chemokines measured within the context of this 
experiment and a brief summary of their functions.  
5.2.4 C-reactive protein (CRP) 
C-reactive protein (CRP) is an acute phase response protein which is 
manufactured by hepatocytes as part of the systemic response to acute 
inflammation, infection or tissue damage.  Its production is predominantly under 
the control of circulating IL6, and its appearance in the circulation occurs 
approximately 6 hours following stimulation, peaking at approximately 48hours.  
The half life of CRP in the circulation is 19hours, and importantly remains 
constant regardless of the health of the individual.  It is therefore widely used in 
clinical practice as a marker of systemic response to treatment as return to 
baseline measures is taken to be indicative of resoloution408. 
In response to pathogen induced inflammation, CRP mimics the actions of 
antibodies and can opsonise the pathogen and activate the complement cascade.  
CRP does not display specificity and therefore recognises a broad range of 
pathogens.  However, the production of CRP is not specific to bacterial 
infections and levels rise in response to any trigger which increases circulating 
IL6. 
Claire A Higgins, 2012   Chapter 5, 210  
5.2.5 Creatine kinase (CK) 
Creatine kinase (CK) is an enzyme responsible for the catalysing the reaction of 
creatine to creatine phosphate (a high energy compound found in high 
concentrations within muscle cells and provides the energy required during 
myocyte contractions).  It is found as 2 iso-enzymes CK-MM or CK-BB, and the 
majority of the total CK in the body is present within muscle cells.  During 
muscle damage or degradation, CK is released into the circulation and is 
therefore used as a biomarker of muscle damage.  Circulating CK was 
traditionally used in the diagnosis of myocardial infarction, however, CK is non-
specific and rises are also seen following surgical procedures, including 
abdominal surgery, reaching a peak on the second post-operative day409. In 
pregnancy the concentration of CK within uterine cells has been shown to 
increase with gestation410 and thus can be considered a suitable marker of 
uterine myocyte damage.  Its half life in the circulation is approximately 
15.5hrs. 
5.2.6 Myoglobin (Mb) 
Myoglobin (Mb) is the primary oxygen binding protein found in myocytes.  It 
contains iron and therefore gives muscle its red colour; haemoglobin is the 
equivalent molecule found in red blood cells.  The protein is a single chain 
apoprotein of 153 or 154 amino acids surrounding a central haem molecule.  
Previously believed to be absent from smooth muscle, more recent data have 
demonstrated its presence at both gene and protein levels within the 
myometrium411 and it is certainly found to be present at a transcription level 
within our gene array data.  Mb is an intracellular protein and enters the 
circulation at times of muscle damage, and in a similar manner to CK rises are 
associated with myocardial infarction and surgery involving muscle disruption409 
412  In addition, release of myoglobin from the myocyte appears to occur up to 24 
hours prior to the peak in circulating CK409, its half life in the circulation is 
approximately 10 minutes and is cleared by the renal system. 
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5.3 Materials and methods 
An illustration of the overall study design for this chapter is shown in Figure 64.  
Patients were recruited into three study groups (non-pregnant (NP), pregnant 
undergoing a planned, non-labour caesarean section (CS) and pregnant 
undergoing induction of labour (IOL)) as described in the methods chapter.  
Blood samples were taken from women as previously described at the time-
points ascribed to their particular study group, with approximately 3mls into 
K2EDTA tube (purple top) and 4-5mls in a lithium heparin tube (green top). 
 
Figure 64 Chapter 5 Experimental Design 
Illustration of overall study design to examine circulating inflammatory parameters 
associated with pregnancy and labour showing 3 study groups, timing of samples and the 4 
main parameters measured. 
Blood samples were then processed as described in the Methods section with 
measures being made for differential white cell counts, flow cytometry for 
leukocyte cell surface markers and chemokine receptors CD11b, CCR2, CCR6, 
CXCR1 and CXCR2.  Plasma from the blood samples was stored at -80◦C and 
subsequently used to measure circulating cytokines, chemokines, C-reactive 
protein (CRP), creatine kinase (CK) and myoglobin (Mb) as described in the 
methods section. 
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5.3.1 Data analysis 
Demographic data are presented as medians, IQR, range with non-parametric 
Kruskal-Wallis, Mann-Whitney and Chi-squared test as appropriate.  Demographic 
data were analysed using Minitab® 15.1.30.0.  For biochemical data, a one way 
ANOVA was used to compare baseline data between the three groups, with 
unpaired and paired t-tests to compare between 2 groups as appropriate.  Where 
comparison between non-pregnant (NP) and pregnant at term (PT) groups are 
made the PT group is the pooled pre-CS and pre-IOL data (n=16). To improve 
analysis in relation to the assumption of normal distribution, data for white cell 
differential counts, cytokines, CRP, CK and Mb were analysed on a log-
transformed scale.  Where results for cytokine quantification were outwith the 
pre-determined sensitivity of the multiplex kit, a minimum of 50% of expected 
readings was considered the minimum required for analysis (i.e. 4 readings in 
each comparison group, 8 readings for pooled pregnant at term data or 21 
readings where correlation analysis was performed).  No adjustments are made 
for multiple testing for these data as with our relatively small dataset 
adjustment may reduce the chance of making a type I error, but may lead to and 
increase in the chance of making a type II error and a need to increase our 
sample size331-334.  A p<0.05 was considered significant. 
Where temporal changes as a result of labour were examined, data were 
analysed by calculating the % time of total duration of labour (time of ARM=0%, 
and 1 hour post delivery of placenta = 100%) at which the sample was obtained 
and performing a time correlation analysis using a Pearson correlation.  
Statistical analysis of biochemical data were performed using GraphPad Prism® 
V5.00. 
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5.4 Results 
5.4.1 Patient Demographics 
The characteristics of each patient group are outlined in Table 27.  No 
significant differences between all three groups for age or BMI were detected.  
Parity differed between the groups, with only one woman in the non-pregnant 
group and 3 women in the IOL group having had a previous pregnancy compared 
with those in the CS group where all women had at least one previous full term 
pregnancy (p=0.002).  Previous mode of delivery also differed between groups 
with only women in the CS group having had a previous caesarean delivery 
(p<0.001), however whether or not women had a previous SVD was not 
significantly different between groups (p=0.446). No significant differences were 
found between the 2 pregnant groups in terms of maternal BMI, gestation at 
time of starting the study or baby’s birthweight.  As expected, the estimated 
blood loss during caesarean section was higher compared with that during 
induction of labour (p=0.018). 
Indications for caesarean delivery in the index pregnancy in the CS group were, 
breech presentation (n=1), previous traumatic vaginal delivery (n=1) and 
previous caesarean delivery (previous indications were 5 intrapartum caesareans 
for presumed foetal distress and 1 planned delivery for malposition).  Indications 
for IOL were post dates (n=4), reduced maternal reporting of foetal movement 
(n=3) and elevated blood pressure in the absence of other symptoms of pre-
eclampsia (n=1).  
In the NP group 4 women were using a combined oral contraceptive preparation 
with 2 women on their 4th pill free day and 2 women on their 6th pill free day.  
One woman was using the Mirena intrauterine system and blood was taken on 
day 5 of her cycle.  The remaining 3 women were not using any hormonal 
contraceptive preparations with 2 women on day 2 of their cycle and 1 on day 3. 
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Study Group 
3 group 
comparison 
2 group 
comparison 
 NP CS IOL p-value p-value 
 N women 8 8 8 / / 
Age  
(years) 
Median  
(IQR)  
[range] 
29.0 
(27.0,30.8) 
[23.0,32.0] 
30.5 
(25.5,36.0)     
[22.0,38.0] 
27.0                      
(21.0,31.5)     
[21.0,37.0] 
P=0.295 / 
Parity 
N (%) =0 
N (%) =1 
N (%) ≥2 
7 (87.5%) 
1 (12.5%) 
0 (0.0%) 
0.(0.0%) 
7 (87.5%) 
1 (12.5%) 
5 (62.5%) 
1 (12.5%) 
2 (25.0%) 
0.002 / 
Previous SVD† 
 
N (%) =0 
N (%) =1 
N (%) ≥2 
7 (87.5%) 
1 (12.5%) 
0 (0.0%) 
5 (62.5%) 
3 (37.5%) 
0(0.0%) 
5 (62.5%) 
1 (12.5%) 
2 (25.0%) 
0.446 / 
Previous 
LUSCS 
 
N (%) =0 
N (%) =1 
N (%) ≥2 
8 (100%) 
0 (0%) 
0(0%) 
2 (25.0%) 
6 (75.0%) 
0 (0.0%) 
8 (100%) 
0 (0%) 
0(0%) 
<0.001 / 
Gestation at 
first sample 
(days) 
Median 
(IQR)  
[range] 
n/a 
274.5 
(273.3,275.0) 
[272.0,281.0] 
286.5 
(271.5,292.8) 
[269.0,293.0] 
n/a 0.345 
Baby wt (kg) 
 
Median  
(IQR)  
[range] 
n/a 
3.49 
(3.31,3.74)    
[3.26,3.94] 
3.60 
(3.34,3.84)     
[3.03,4.00] 
n/a P=0.462 
Maternal BMI Median  
(IQR)  
[range] 
23.4 
(21.5,24.9) 
[20.1,26.0] 
24.5 
(23.2,28.5)     
[20.0,32.0] 
24.5 
(23.6,32.8)     
[18.5,36.0] 
P=0.411 / 
EBL (mls) Median 
(IQR) 
[range] 
n/a 
400 
(400,500) 
[300,700] 
300 
(263,375) 
[150,400] 
/ P=0.018 
Labour 
length(mins) 
Median  
(IQR)  
[range] 
n/a n/a 
433 
(308,533)  
[255,775] 
/ / 
Table 27  Patient demographic details 
Patient characteristics for each study group, non-pregnant (NP), those attending for non-
labouring planned caesarean delivery (CS) and those attending at term for induction of 
labour by artificial rupture of membrane and syntocinon (IOL).  †Chi-squared test performed 
on pooled SVD data ie previous SVD ‘yes’ or previous SVD ‘no’. 
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5.4.2 Hypothesis 1 – Pregnancy at term induces a difference in 
circulating inflammatory parameters.  
5.4.2.1 White Blood Cells 
Baseline measure of differential white blood cell counts for the three study 
groups (NP, pre-CS and pre-IOL) are illustrated in Figure 65 with direct 
comparisons between non-pregnant (NP) and pregnant at term (PT (pre-CS + pre-
IOL)) groups annotated below each graph.   
There were significant differences between the NP and PT groups for baseline 
measures of overall WBC (NP vs PT, p<0.001) with differences observed between 
all 3 comparison groups (NP vs CS-pre vs IOL-pre, p<0.001, NP vs CS-pre, 
p=0.027, NP vs IOL-pre, p=0.001, CS-pre vs IOL pre, p=0.011).  This increase in 
overall white cell count appears to be driven by a neutrophilia (NP vs PT, 
p<0.001) and again varies between the three groups (NP vs CS-pre vs IOL-pre, 
p<0.001, NP vs CS-pre, p=0.001, NP vs IOL-pre, p=0.01, CS-pre vs IOL-pre, 
p<0.001).  There was an overall lower lymphocyte count in pregnancy (NP vs PT, 
p=0.09), however this was only significant between NP and pre-CS groups (NP vs 
CS-pre (p=0.008)).  Eosinophils also differed in response to pregnancy (NP vs PT, 
p=0.008), which with further testing was significant between the non-pregnant 
group and women prior to induction of labour (NP vs IOL-pre (p=0.005)).  
Basophils counts were lower in pregnancy (NP vs PT, p=0.034), however analysis 
between all 3 groups did not show any significant differences (NP vs CS-pre vs 
IOL-pre, p=0.109, NP vs CS-pre, p=0.065, NP vs IOL-pre, p=0.125, CS-pre vs IOL-
pre, p=0.766).  Pregnancy did not appear to induce any significant changes to 
the circulating number of monocytes (NP vs PT, p=0.162).  
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Figure 65  Baseline measure of WBC subtypes 
Baseline concentrations of circulating white blood cells for each study group with p values 
for the comparison between non-pregnant and pooled pregnant at term groups (NP vs PT).  
Raw data are shown as scatter plots with median and IQR.  Data were log transformed prior 
to analysis.  Unpaired t-tests were performed with lines demonstrating significance value 
between 2 samples under start and end of each line *p<0.05, **p≤0.01, ***p≤0.001  
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5.4.2.2 Leukocyte cell surface markers and chemokine receptors 
5.4.2.2.1 Granulocytes 
An example of the flow cytometry profile used to assess the granulocyte 
parameters is shown in Figure 66.  Data were initially gated using forward and 
side scatter parameters with granulocytes defined as large cells with high 
granularity (Region 3 (R3) on diagram).  These selected cells were then gated 
based on there positive expression of CD66b and CD11b and defined as activated 
granulocytes (R5 on diagram).  Cells defined by R5 were then further gated 
based on their cell surface expression of the chemokine receptor CXCR1 or 
CXCR2. 
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Figure 66  Representative flow cytometry profile used for granulocyte analysis 
Initial gating based on forward and side scatter (R3).  Subsequent gating was based on 
expression of the cell surface marker CD66b and CD11b, with further analysis for cell 
surface expression of the chemokine receptors CXCR1 and CXCR2. 
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Granulocyte cell surface marker data are illustrated in Figure 67.  The 
percentage of CD66b+ granulocytes expressing CD11b did not differ significantly 
with pregnancy (NP vs PT, p=0.62) or between the 3 groups (p=0.34).  The 
density of CD11b did not differ with pregnancy (NP vs PT, p=0.60) however, it 
was higher in the CS-pre group than the IOL-pre group (CS-pre vs IOL-pre, 
p=0.009), with no significant difference found between non-pregnant women 
and those prior to CS (NP vs CS-pre, p=0.11) or between non-pregnant and 
women and those prior to IOL (NP vs IOL-pre, p=0.36). 
The percentage of CD11b+/CD66b+ granulocytes (activated neutrophils) 
expressing CXCR1 and the density of cell surface expression was not significantly 
different with pregnancy (NP vs PT, p=0.64, p=0.5271 respectively) or between 
the 3 groups (p=0.81, p=0.81 respectively).  The percentage of activated 
neutrophils expressing CXCR2 was higher in pregnancy (NP vs PT, p=0.009) and in 
women pre-IOL compared with the non-pregnant group (NP vs IOL-pre, p=0.022), 
however this difference was not found between non-pregnant women and those 
prior to CS (NP vs CS-pre, p=0.069) or between the 2 pregnant groups (CS-pre vs 
IOL-pre, p=0.69).  Conversely, the density of CXCR2 cell surface expression was 
lower in the IOL group compared with the non-pregnant group (NP vs IOL-pre, 
p=0.008), and again no significant difference was found between the non-
pregnant group and those prior to CS (NP vs CS-pre, p=0.34) or between the 2 
pregnant groups (CS-pre vs IOL-pre, p=0.40) and additionally no significant 
difference was found with respect to pregnancy (NP vs PT, p=0.08) (Figure 67).  
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Figure 67  Baseline measure of granulocytes 
Baseline measurements for granulocytes for each study group with p values for the 
comparison between non-pregnant and pooled pregnant at term groups (NP vs PT).  
Parameters examined are 1)  the % of CD66b+ granulocytes expressing CD11b and the cell 
surface density of CD11b, 2) the % of CD11b+/CD66b+ granulocytes expressing CXCR1  and 
the cell surface density of CXCR1 and 3) the % of CD11b/CD66b+ granulocytes expressing 
CXCR2 and the cell surface density of CXCR2.  The cell surface density is indicated by the 
mean fluorescence intensity (MFI).  Raw data are shown with median and IQR.  Data were 
log transformed prior to analysis, Unpaired t-tests were performed with lines demonstrating 
significance value between 2 samples under start and end of each line *p<0.05,**p≤0.01 
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5.4.2.2.2 Monocytes 
An example of the flow cytometry profile used to assess the monocyte 
parameters is shown in Figure 68.  Data were initially gated using forward and 
side scatter parameters with monocytes defined as large cells with lower 
granularity than granulocytes (Region 2 (R2) on diagram).  These selected cells 
were then gated based on there positive expression of CD14 and CD11b and 
defined as activated monocytes (R5 on diagram).  Cells defined by R5 were then 
further gated based on their cell surface expression of the chemokine receptor 
CCR2.
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Figure 68  Representative flow cytometry profile used for monocyte analysis 
Initial gating based on forward and side scatter to define monocyte population (R2).  
Subsequent gating was based on expression of the cell surface marker CD14 and CD11b, 
with further analysis for cell surface expression of the chemokine receptor CCR2. 
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Monocyte data are illustrated in Figure 69.  No difference was seen with 
pregnancy in the % of CD14+ monocytes expressing CD11b or the density of 
CD11b expression (np vs PT, p=0.61, p=0.24 respectively).  On further analysis 
the density of CD11b was higher in those prior to CS (NP vs CS-pre, p=0.034, CS-
pre vs IOL-pre, p=0.013), with no difference between non-pregnant and those 
prior to IOL (NP vs IOL-pre, p=0.77). 
The % of CD14+/CD11b+ monocytes expressing CCR2 reduced slightly with 
pregnancy which was significant (NP vs PT, p=0.022), however was not found to 
differ significantly between the 3 groups (NP vs CS-pre vs IOL-pre, p=0.070).  
The density of CCR2 expression did not differ over all with pregnancy (NP vs PT, 
p=0.079) however density appeared to be lower in the pre-IOL group compared 
with the non-pregnant group (NP vs IOL-pre, p<0.005), with no significant 
differences between non-pregnant women and those prior to CS (NP vs CS-pre, 
p=0.498) or between the 2 pregnant groups (CS-pre vs IOL-pre, p=0.077). 
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Figure 69  Baseline measure of monocytes 
Baseline measurements for monocytes for each study group with p values for the 
comparison between non-pregnant and pooled pregnant at term groups (NP vs PT).  
Parameters examined are 1)  the % of CD14+ monocytes expressing CD11b and the cell 
surface density of expression of CD11b and 2) the % of CD14+/CD11b+ monocytes 
expressing CCR2 and the cell surface density of expression of CCR2.  The cell surface 
density is indicated by the mean fluorescence intensity (MFI).  Raw data are shown with 
median and IQR.  Data were log transformed prior to analysis,  Unpaired t-tests were 
performed with lines demonstrating significance value between 2 samples under start and 
end of each line *p<0.05,**p≤0.01 
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5.4.2.2.3 Lymphocytes 
An example of the flow cytometry profile used to assess the lymphocyte 
parameters is shown in Figure 70.  Data were initially gated using forward and 
side scatter parameters with lymphocytes defined as small cells with low 
granularity (Region 1 (R1) on diagram).  These selected cells were then gated 
based on there positive expression of CD3 and defined as T-lymphocytes (R4).  
APC fluorescence of R4 gated indicated expression of CD4 (or CD8 dependent on 
tube combination) and R5 gated cells defined T-cell population as either CD4+ 
(Th cells) or CD8+ (Tc cells).  Cells defined by R5 were then further gated based 
on their cell surface expression of the chemokine receptors CXCR1, CXCR2 or 
CCR6.
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Figure 70  Representative flow cytometry profile used for lymphocyte analysis 
Initial gating based on forward and side scatter to define lymphocyte population (R1).  
Subsequent gating was based on expression of the cell surface marker CD3 to define T-
lymphocytes.  Analysis was then undertaken to examine the proportion of T-lymphocytes 
which were CD4+ or CD8+ (R5), with further analysis for cell surface expression of the 
chemokine receptor CXCR1, CXCR2 and CCR6. 
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The percentage of CD3+ lymphocytes (T cells) expressing CD4 (T helper cell (Th-
cell)) or CD8 (T cytotoxic (Tc-cell)) did not differ with pregnancy (NP vs PT, 
p=0.21, p=0.51 respectively) or between the 3 study groups (p=0.41, p=0.69 
respectively) (Figure 71). 
 
Figure 71  Baseline measures for CD3+/CD4+ and CD3+/CD8+ lymphocytes 
Baseline measurements of the % of circulating CD3+/CD4+ (T helper lymphocytes) and the 
% of CD3+/CD8+ (T cytotoxic lymphocytes) for each study group with p values for the 
comparison between non-pregnant and pooled pregnant at term groups (NP vs PT).  Raw 
data are shown with median and IQR.  Data were log transformed prior to analysis. 
Data for Th-cells (CD3/CD4+ lymphocytes) are presented in Figure 72.  The 
percentage of Th-cells expressing CXCR1, CXCR2 or CCR6 did not differ with 
pregnancy (NP vs PT, p=0.96, p=0.87, p=0.613 respectively) or between groups 
(p=0.98, p=0.95, p=0.86 respectively).  The density of cell surface expression of 
CXCR1 and CXCR2 on Th-cells was lower in pregnancy (NP vs PT, p=0.011, 
p=0.002 respectively).  CXCR1 MFI was higher in the NP group compared to those 
prior to CS (NP vs CS-pre, p=0.030), however no difference in CXCR1 density 
were found for the remaining comparisons (NP vs IOL-pre, p=0.06, CS-pre vs IOL-
pre, p=0.91).  The density of CXCR2 on Th-cells was higher in the NP group 
compared with both pregnant groups (NP vs CS-pre, p=0.021, NP vs IOL-pre, 
p=0.026), no difference existed between the pregnant groups (CS-pre vs IOL-pre, 
p=0.92).  Density of CCR6 expression on Th-cells did not significantly change 
with pregnancy (NP vs PT, p=0.15), however further analysis suggested 
expression was lower in those prior to IOL (NP vs IOL-pre, p=0.038, CS-pre vs 
IOL-pre, p=0.046), with no significant difference between NP and CS-pre groups 
(NP vs CS-pre, p=0.66). 
Claire A Higgins, 2012   Chapter 5, 228  
 
Figure 72  Baseline measures of CD3+/CD4+ lymphocytes 
Baseline measurements for CD3+/CD4+ lymphocytes (T-helper cells) for each study group 
with p values for the comparison between non-pregnant and pooled pregnant at term 
groups (NP vs PT).  Parameters examined are 1)  the % of T-helper lymphocytes expressing 
CXCR1 and cell surface density of CXCR1, 2) the % or T-helper lymphocytes expressing 
CXCR2 and the cell surface density of CXCR2, and 3) the % of T-helper lymphocytes 
expressing CCR6 and the cell surface density of CCR6. The cell surface density is indicated 
by the mean fluorescence intensity (MFI).  Raw data are shown with median and IQR.   Data 
were log transformed prior to analysis, Unpaired t-tests were performed with lines 
demonstrating significance value between 2 samples under start and end of each line 
*p<0.05, **p<0.01. 
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Data for Tc-cells (C3/CD8+ lymphocytes) is illustrated in Figure 73.  Similarly, 
the % of Tc-cells expressing CXCR1, CXCR2 or CCR6 did not differ with pregnancy 
(NP vs PT, p=0.79, p=0.427, p=0.43 respectively) or between groups (p=0.79, 
p=0.59, p=0.74 respectively).   Similarly, the density of CXCR1 and CXCR2 
expression fell with pregnancy (NP vs PT p<0.001, p=0.006 respectively).  
Further analysis confirmed CXCR1 MFI was lower with pregnancy (NP vs CS-pre, 
p=0.006, NP vs IOL-pre, p=0.003), but did not differ between pregnant groups 
(CS-pre vs IOL-pre, p=0.73).  The density of CXCR2 expression was higher in the 
NP groups compared with CS-pre (NP vs CS-pre, p=0.04), however no significant 
difference was found for CXCR2 between the other groups (NP vs IOL-pre, 
p=0.055, CS-pre vs IOL-pre, p=0.62).  CCR6 density of expression did not 
significantly differ with pregnancy (NP vs PT, p=0.38) or between the three 
groups (p=0.16). 
Claire A Higgins, 2012   Chapter 5, 230  
 
Figure 73  Baseline measures of CD3+/CD8+ lymphocytes 
Baseline measurements for CD3+/CD8 lymphocytes (T-cytotoxic) for each study group with 
p values for the comparison between non-pregnant and pooled pregnant at term groups (NP 
vs PT).  Parameters examined are 1)  the % of T-cytotoxic lymphocytes expressing CXCR1 
and cell surface density of CXCR1, 2) the % or T-cytotoxic lymphocytes expressing CXCR2 
and the cell surface density of CXCR2, and 3) the % of T-cytotoxic lymphocytes expressing 
CCR6 and the cell surface density of CCR6. The cell surface density is indicated by the 
mean fluorescence intensity (MFI).  Raw data are shown with median and IQR.   Data were 
log transformed prior to analysis, Unpaired t-tests were performed with lines demonstrating 
significance value between 2 samples under start and end of each line *p<0.05, **p<0.01. 
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5.4.2.3 Circulating cytokines and chemokines 
Due to limitations of the range of sensitivities for cytokines in human plasma, a 
full complement of results is available for CCL11 (eotaxin), FGF2, GCSF, GMCSF, 
GRO (CXCL1, 2, 3), IL6, CXCL8 (IL8), IL10, CXCL10 (IP10), CCL2 (MCP-2), CCL22 
(MDC), CCL4 (MIP1b) and TNFα.  In cases where more than 50% of values for an 
individual analyte were missing in each group (n<4), they were excluded from 
analysis.  Missing values for these analytes were below the threshold of 
sensitivity.  Data for each of the analytes is shown in Table 28. 
Significant differences between the three groups were noted for 3 of the 
cytokines tested, namely FGF2 (p=0.003), GCSF (p=0.008), and CXCL1, 2, 3 
(GRO)(p=0.002).  Measures of FGF2 were lower in those pre-IOL compared with 
both their non-pregnant and pre-CS counterparts (NP vs CS-pre (p=0.1379), NP vs 
IOL-pre (p=0.033), CS-pre vs IOL-pre (p=0.002)), however, when pregnancy data 
were pooled, no significant difference was found between NP and PT individuals 
(NP vs PT (p=0.552)).  Measures of CXCL1,2,3 (GRO) were higher in the pre-CS 
group with no significant difference between non-pregnant and pre-IOL groups 
(NP vs CS-pre (p=0.035), NP vs IOL-pre (p=0.65), CS-pre vs IOL-pre (p=0.002)), 
however, again no significant difference was found between NP and PT 
individuals when pregnancy data were pooled (NP vs PT (p=0.955)).  In terms of 
GCSF a higher circulating concentration was seen in both pregnant groups 
compared with non-pregnant values (NP vs PT (p=0.003)), however, the only 
significant difference was between the non-pregnant and pre-IOL group (NP vs 
CS-pre (p=0.06), NP vs IOL-pre (p=0.006)) but did not differ between the 2 
pregnant groups (CS-pre vs IOL-pre (p=0.18)). 
Cytokine/ 
Chemokine (pg/ml) 
Study Group 
p value 
unpaired t-test 
 NP CS-pre IOL-pre NP v PT NP v CS NP v IOL CS v IOL 
EGF  Median  
(IQR)  
[range] 
N 
28.93 
(22.82,152.2) 
[12.18,488.4] 
6 
31.42 
(3.97,60.42) 
[6.12,64.06] 
6 
10.84 
/ 
[7.840,13.83] 
2 
0.199 0.370 / / 
CCL11  Median  
(IQR)  
[range] 
N 
294.6 
(171.4,432.4) 
[63.9,647.8] 
8 
103.3 
(92.74,231.8) 
[75.69,429.2] 
8 
187.2 
(119.9,221.2) 
[66.66,263.0] 
8 
0.044* 0.081 0.142 0.569 
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Cytokine/ 
Chemokine (pg/ml) 
Study Group 
p value 
unpaired t-test 
 NP CS-pre IOL-pre NP v PT NP v CS NP v IOL CS v IOL 
FGF-2  Median  
(IQR)  
[range] 
N 
75.1 
(63.3,90.1) 
[46.1,112.4] 
8 
93.33 
(87.92,103.3) 
[55.85,119.4] 
8 
56.75 
(40.79,68.85) 
[21.92,71.68] 
8 
0.552 0.138 0.033* 0.002** 
Flt-3  Median  
(IQR)  
[range] 
N 
5.62 
(2.195,35.11) 
[1.30,44.69] 
4 
38.25 
/ 
/ 
1 
5.335 
/ 
[1.3,9.37] 
2 
/ / / / 
CX3CL1  Median  
(IQR)  
[range] 
N 
27.04 
(9.83,73.21) 
[4.25,173.0] 
7 
21.27 
(8.520,27.04) 
[4.830,66.83] 
7 
60.07 
(36.93,734.6) 
[27.04,1370] 
5 
0.592 0.530 0.117 0.031* 
GCSF  Median  
(IQR)  
[range] 
N 
19.24 
(10.69,36.17) 
[2.61,102.3] 
8 
43.22 
(23.97,78.88) 
[17.02,129.6] 
8 
74.74 
(43.28,99.61) 
[33.22,154.3] 
8 
0.003** 0.061 0.006** 0.179 
GMCSF  Median  
(IQR)  
[range] 
N 
56.80 
(34.43,140.9) 
[5.63,1815.0] 
8 
76.97 
(31.43,190.9) 
[8.450,306.3] 
8 
46.89 
(24.38,110.6) 
[10.29,139.7] 
8 
0.704 0.964 0.571 0.504 
CXCL1,2,3,  Median  
(IQR)  
[range] 
N 
1169 
(801.7,1493) 
[604.1,1589] 
8 
1687 
(1207,2140) 
[940.6,3038] 
8 
804.0 
(481.2,992.2) 
[238.1,1218] 
8 
0.955 0.035* 0.065 0.002** 
IFNα2 Median  
(IQR)  
[range] 
N 
13.70 
(4.935,65.61) 
[0.79,79.87] 
5 
115.4 
/ 
[42.18,188.6] 
2 
15.24 
(12.92,58.17) 
[12.15,72.48] 
4 
/ / 0.645 / 
IFNγ Median  
(IQR)  
[range] 
N 
24.37 
(5.508,82.55) 
[1.89,140.7] 
8 
8.800 
(2.140,14.23) 
[2.070,91.04] 
7 
6.510 
(2.688, 55.49) 
[2.340,67.31] 
8 
0.225 0.256 0.385 0.757 
IL1α Median  
(IQR)  
[range] 
N 
128.8 
(90.24,375.6) 
[86.50,1555] 
7 
166.8 
(78.90, 375.7) 
[59.58, 938.0]  
8 
192.2 
(111.8, 271.5) 
[67.67, 274.3] 
6 
0.714 0.818 0.701 0.878 
IL1β Median  
(IQR)  
[range] 
N 
7.15 
/ 
[1.91,12.39] 
2 
1.34 
/ 
/ 
1 
1.34 
/ 
/ 
1 
/ / / / 
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Cytokine/ 
Chemokine (pg/ml) 
Study Group 
p value 
unpaired t-test 
 NP CS-pre IOL-pre NP v PT NP v CS NP v IOL CS v IOL 
IL1ra Median  
(IQR)  
[range] 
N 
2.64 
/ 
/ 
1 
6.96 
/ 
/ 
1 
2.64 
/ 
/ 
1 
/ / / / 
IL2 Median  
(IQR)  
[range] 
N 
5.30 
/ 
[1.50,154.1] 
3 
2.640 
(0.8550, 3.390) 
[0.7800, 4.000] 
5 
1.160 
(0.995,3.850) 
[0.930,4.550] 
5 
/ / / 0.912 
IL3 Median  
(IQR)  
[range] 
N 
9.49 
/ 
[0.75,66.12] 
3 
5.24 
/ 
/ 
1 
29.27 
/ 
/ 
1 
/ / / / 
Il4 Median  
(IQR)  
[range] 
N 
/ 
/ 
/ 
0 
/ 
/ 
/ 
0 
75.88 
/ 
/ 
1 
/ / / / 
IL5 Median  
(IQR)  
[range] 
N 
1.51 
/ 
[0.62,2.4] 
2 
0.38 
/ 
[0.23,0.53] 
2 
/ 
/ 
/ 
0 
/ / / / 
IL6 Median  
(IQR)  
[range] 
N 
63.93 
(31.49,272.1) 
[15.06,669.7] 
6 
8.820 
(4.335, 63.76) 
[3.360, 185.2] 
6 
11.79 
(3.025, 283.6) 
[2.690, 549.3] 
5 
0.054 0.051 0.167 0.857 
IL7 Median  
(IQR)  
[range] 
N 
49.21 
(12.88,103.9) 
[4.630,118.2] 
4 
5.660 
(3.665, 38.72) 
[2.000, 41.44] 
5 
7.405 
(3.600, 11.21) 
[3.600, 11.21] 
2 
/ 0.219 / / 
CXCL8  Median  
(IQR)  
[range] 
N 
27.35 
(19.62,47.23) 
[12.38,71.94] 
8 
17.57 
(6.930, 30.19) 
[3.010, 63.20] 
8 
16.03 
(6.675, 42.35) 
[4.740, 65.12] 
8 
0.112 0.111 0.204 0.767 
IL9 Median  
(IQR)  
[range] 
N 
19.98 
(9.563,25.31) 
[6.46,26.72] 
4 
2.89 
/ 
/ 
1 
4.940 
(1.985, 44.09) 
[1.640, 78.71] 
5 
/ / 0.324 / 
IL10 Median  
(IQR)  
[range] 
N 
2.575 
(1.76,4.99) 
[0.82,23.90] 
8 
2.200 
(1.605, 5.960) 
[1.260, 21.52] 
8 
1.815 
(1.535, 3.040) 
[1.490, 3.130] 
6 
0.734 0.891 0.374 0.279 
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Cytokine/ 
Chemokine (pg/ml) 
Study Group 
p value 
unpaired t-test 
 NP CS-pre IOL-pre NP v PT NP v CS NP v IOL CS v IOL 
IL12 (p40) Median  
(IQR)  
[range] 
N 
62.75 
(8.120,1.87.1) 
[8.120,187.1] 
3 
207.4 
/ 
/ 
1 
179.8 
(170.6,192.5) 
[170.6,192.5] 
3 
/ / / / 
IL12 (p70) Median  
(IQR)  
[range] 
N 
8.36 
(1.95,197.6) 
[1.36,704.2] 
7 
2.940 
(1.360, 372.5) 
[1.360, 372.5] 
3 
2.340 
(1.855, 202.8) 
[1.490, 402.1] 
5 
0.573 / 0.511 / 
IL13 Median  
(IQR)  
[range] 
N 
37.82 
(5.64,331.6) 
[2.94,382.8] 
5 
1.150 
/ 
/ 
1 
/ 
/ 
/ 
0 
/ / / / 
IL15 Median  
(IQR)  
[range] 
N 
0.81 
(0.525,1.815) 
[0.48,1.92] 
5 
0.92 
(0.68,3.30 ) 
[0.68, 3.30] 
3 
1.330 
(0.765, 3.31) 
[0.480, 4.57] 
5 
0.374 / 0.383 / 
IL17 Median  
(IQR)  
[range] 
N 
47.46 
(13.41,81.63) 
[9.8,149.8] 
8 
18.97 
(5.990, 66.67) 
[3.980, 140.6] 
6 
12.29 
(3.140, 57.51) 
[1.720, 116.2] 
8 
0.125 0.294 0.117 0.589 
CXCL10  Median  
(IQR)  
[range] 
N 
512.2 
(318.7,569.2) 
[298.7,642.9] 
8 
823.8 
(537.7, 1464) 
[272.0, 4959] 
8 
565.5 
(425.5, 718.7) 
[225.0, 903.2] 
8 
0.126 0.050 0.424 0.136 
CCL2  Median  
(IQR)  
[range] 
N 
327.1 
(219.7,423.0) 
[194.3,536.3] 
8 
235.4 
(210.3, 305.0) 
 [157.6, 503.3] 
8 
229.9 
(172.2, 282.4) 
[95.36, 469.1] 
8 
0.111 0.262 0.112 0.489 
CCL7  Median  
(IQR)  
[range] 
N 
7.075 
(3.045,36.66) 
[2.11,143.9] 
8 
7.700 
(2.313, 26.20) 
[2.110, 51.04] 
6 
6.290 
(1.830, 10.28) 
[1.550, 12.18] 
5 
0.465 0.806 0.339 0.431 
CCL22  Median  
(IQR)  
[range] 
N 
1192 
(878.0,1314) 
[498.9,1614] 
8 
547.2 
(406.4, 1035) 
[259.6, 1291] 
8 
566.1 
(349.8, 1369) 
[321.4, 1978]  
8 
0.031* 0.022* 0.106 0.703 
CCL3  Median  
(IQR)  
[range] 
N 
47.82 
(39.07,82.01) 
[37.17,162.0] 
7 
41.21 
(28.08, 97.76) 
[25.20, 124.2] 
5 
38.60 
(22.71, 177.5) 
[21.12, 178.3] 
7 
0.7001 0.529 0.863 0.772 
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Cytokine/ 
Chemokine (pg/ml) 
Study Group 
p value 
unpaired t-test 
 NP CS-pre IOL-pre NP v PT NP v CS NP v IOL CS v IOL 
CCL4  Median  
(IQR)  
[range] 
N 
80.85 
(36.75,176.5) 
[16.38,403.5] 
8 
57.55 
(24.02, 95.48) 
[20.47, 323.2] 
8 
42.98 
(18.55, 176.9) 
[6.170, 217.6] 
8 
0.375 0.506 0.401 0.787 
sCD40L  Median  
(IQR)  
[range] 
N 
3849 
(2056,4946) 
[1726,5044] 
4 
4130 
/ 
/ 
1 
3447 
(1551, 7070) 
[738.3, 8610] 
8 
0.928 / 0.880 / 
sIL2Rα Median  
(IQR)  
[range] 
N 
25.72 
(23.25,28.19) 
[23.25,28.19] 
2 
8.570 
(5.770, 51.51) 
[4.560, 65.05] 
5 
1.180 
/ 
/ 
1 
/ / / / 
TGFα Median  
(IQR)  
[range] 
N 
6.280 
(3.67,10.14) 
[3.46,49.27] 
7 
8.010 
(3.490, 8.440) 
[3.220, 12.99] 
7 
2.750 
(0.483, 9.143) 
[0.340, 21.06] 
6 
0.266 0.816 0.113 0.103 
TNFα Median  
(IQR)  
[range] 
N 
2.27 
(1.698,7.125) 
[1.320,15.89] 
8 
4.830 
(3.198, 9.235) 
[1.740, 15.44] 
8 
3.865 
(1.183, 7.113) 
[0.810, 8.380] 
8 
0.580 0.246 0.886 0.205 
TNFβ Median  
(IQR)  
[range] 
N 
0.78 
(0.74,1.60) 
[0.74,1.60] 
3 
1.0 
(0.78,1.88) 
[0.78,1.88] 
3 
1.12 
/ 
/ 
1 
/ / / / 
VEGF  Median  
(IQR)  
[range] 
N 
108.2 
(51.83,525.9) 
[34.78,669.0] 
8 
146.5 
(70.67, 161.9) 
[16.60, 352.8] 
7 
113.5 
(14.46, 305.9) 
[4.000, 347.5] 
4 
0.404 0.626 0.331 0.483 
CCL5  Median  
(IQR)  
[range] 
N 
35173 
(5116,56938) 
166.0,130414 
7 
12464 
(6870, 19638) 
[362.4, 23230] 
8 
1466 
(422.3, 12007) 
[422.3, 12007] 
3 
0.303 0.575 / / 
Table 28  Baseline measures of circulating cytokines/chemokines 
Table showing baseline levels of circulating cytokines for each study group.  Raw data are 
presented with analysis performed on normalised log transformed data.  Where boxes are 
marked with / this indicates that less than 50% of expected values were present (n expected 
in each group n=8 or N=16 in pooled pregnant at term group (PT)), therefore analysis not 
performed. *p<0.05, **p≤0.01, ***p≤0.001 
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5.4.2.4 Circulating CRP 
Baseline measures of CRP were higher with pregnancy (NP vs PT, P=0.002) which 
was confirmed by further analysis showing no significant difference between the 
two pregnant groups (CS-pre vs IOL-pre, p=0.25), with levels in pregnancy 
significantly higher (NP vs CS-pre (p=0.039), NP vs IOL-pre (p=0.002)) (Figure 74). 
 
Figure 74  Baseline measures of circulating CRP 
Baseline measure of circulating CRP for each study group with p values for the comparison 
between non-pregnant and pooled pregnant at term groups (NP vs PT).  Raw data are shown 
as scatter plots with median and IQR.  Data were log transformed prior to analysis. Unpaired 
t-tests were performed with lines demonstrating significance value between 2 samples 
under start and end of each line*p<0.05,**p≤0.01,
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5.4.3 Hypothesis 2 – Term delivery by either planned, non-labour 
CS or IOL with syntocinon will result in a shift towards a 
pro-inflammatory profile in the maternal circulation, with 
and enhanced response in mothers who labour 
5.4.3.1 White Blood Cells 
Pre and post delivery values for each white cell subset were firstly compared 
within groups (Figure 75).  Changes induced as a result of delivery by either CS 
or IOL showed significant increases in circulating t-WBC (CS-pre vs CS-post 
(p=0.03), IOL-pre vs IOL-post (p<0.001)) and neutrophils (CS-pre vs CS-post 
(p=0.005), IOL-pre vs IOL-post (p<0.001)), with decreases in lymphocytes (CS-pre 
vs CS-post p=0.02, IOL-pre vs IOL-post (p=0.001)) and eosinophils (CS-pre vs CS-
post (p=0.015), IOL-pre vs IOL-post (p=0.015)).  Additionally, circulating 
monocytes increase pre to post IOL (p=0.006).  
The extent of changes in white cell concentrations in response to delivery was 
significantly larger in response to IOL than to CS for t-WBC (p<0.001), 
neutrophils (p<0.001), lymphocytes (p=0.006), monocytes (p=0.002) and 
eosinophils (p=0.02).  These differences are illustrated in Figure 76. 
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Figure 75  WBC subtypes pre and post delivery 
Concentration of circulating white blood cell sub-sets pre and post delivery by planned 
caesarean delivery (CS) or vaginal delivery after induction of labour with syntocinon only 
(IOL).  Raw data are shown as scatter plots with median and interquartile ranges indicated.  
Data were log transformed prior to analysis.  Paired t-tests were performed with lines 
demonstrating significance value between 2 samples under start and end of each line  
*p<0.05, **p≤0.01, ***p≤0.001 
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Figure 76  ∆WBC subtypes (post-pre) delivery 
Change in circulating white blood cells post to pre delivery for CS and IOL.  Raw data are 
shown with scatter plots with median and interquartile range indicated.  Analysis was 
performed on log transformed data where log ∆ CS = (log CS post)- (log CS pre) and log ∆ 
IOL = (log IOL post) – (log IOL pre).  Unpaired t-tests were performed with lines 
demonstrating significance value between 2 samples under start and end of each line. 
*p<0.05, **p≤0.01, ***p≤0.001 
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5.4.3.2 Leukocyte cell surface markers and chemokine receptors  
5.4.3.2.1 Granulocytes 
The percentage of CD66+ granulocytes expressing CD11b did not change in 
response to delivery by either CS or IOL (p=0.21, p=0.59 respectively).  There 
was a trend for a fall in the density of expression of CD11b in response to 
delivery, with the fall being significant in the CS group (CS-pre vs CS-post 
p=0.047, IOL-pre vs IOL-post p=0.69) (Figure 77). 
The % of CD11b/CD66b+ granulocytes expressing CXCR1 increased with IOL but 
not CS (CS-pre vs CS-post (p=0.14), IOL-pre vs IOL-post, p=0.02), with the same 
pattern for CXCR2 (CS-pre vs CS-post (p=0.39), IOL-pre vs IOL-post (p=0.005)).  
Additionally the density of expression of CXCR1 fell in response to both CS and 
IOL (CS-pre vs CS-post (p=0.007), IOL-pre vs IOL-post (p=0.001)).  CXCR2 MFI also 
fell in response to delivery (CS-pre vs CS-post (p=0.043), IOL-pre vs IOL-post, 
(p<0.0001)) (Figure 77). 
The extent of changes to any of the measured granulocyte parameters did not 
differ significantly by mode of delivery (Figure 78). 
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Figure 77  Granulocytes pre and post delivery 
Assessment of granulocytes in the maternal circulation in response to delivery by either 
planned caesarean delivery (CS) or vaginal delivery after induction of labour (IOL).  
Parameters examined are 1)  the % of CD66b+ granulocytes expressing CD11b and the cell 
surface density of CD11b, 2) the % of CD11b+/CD66b+ granulocytes expressing CXCR1  and 
the cell surface density of CXCR1 and 3) the % of CD11b/CD66b+ granulocytes expressing 
CXCR2 and the cell surface density of CXCR2.  The cell surface density is indicated by the 
mean fluorescence intensity (MFI).  Raw data are shown with median and IQR.  Data were 
log transformed prior to analysis, Paired t-tests were performed with lines demonstrating 
significance value between 2 samples under start and end of each line.  *p<0.05,**p≤0.01, 
***p≤0.001. 
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Figure 78  ∆granulocytes (post-pre) delivery 
Change in the % of circulating granulocytes expressing CD11b, CXCR1 and CXCR2 and the 
density of expression (MFI) post to pre delivery for CS and IOL.  Transformed data are 
shown with scatter plots with median and interquartile range indicated.  Analysis was also 
performed on log transformed data where log ∆ CS = (log CS post)- (log CS pre) and log ∆ 
IOL = (log IOL post) – (log IOL pre) and p values are shown for each graph. 
 
Claire A Higgins, 2012   Chapter 5, 243  
5.4.3.2.2 Monocytes 
Monocyte data in response to delivery are illustrated in Figure 79.  The 
percentage of monocytes expressing CD11b did not change significantly in 
response to CS (p=0.89), however the density of expression fell (p=0.04).  In 
response to IOL, the % of monocytes expressing CD11b increased (p=0.014), but 
density of expression did not alter significantly (p=0.09). 
CCR2 MFI decreased in response to CS (CS-pre vs CS-post (p=0.028)), however no 
other measured monocyte parameters changed significantly in response to 
delivery (Figure 79). 
 
Figure 79  Monocytes pre and post delivery 
Assessment of monocytes in the maternal circulation in response to delivery by either 
planned caesarean delivery (CS) or vaginal delivery after induction of labour (IOL).  
Parameters examined are 1)  the % of CD14+ monocytes expressing CD11b and the cell 
surface density of CD11b, and 2) the % of CD14/CD11b+ monocytes expressing CCR2  and 
the cell surface density of CCR.  The cell surface density is indicated by the mean 
fluorescence intensity (MFI).  Raw data are shown with median and IQR.  Data were log 
transformed prior to analysis, Paired t-tests were performed with lines demonstrating 
significance value between 2 samples under start and end of each line. *p<0.05,**p≤0.01, 
***p≤0.001. 
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The extent of changes to any of the measured monocyte parameters did not 
differ significantly by mode of delivery (Figure 80). 
 
 
Figure 80  ∆monocytes (post-pre) delivery 
Change in the % of circulating monocytes expressing CD11b and CCR2 and the density of 
expression (MFI) post to pre delivery for CS and IOL.  Transformed data are shown with 
scatter plots with median and interquartile range indicated.  Analysis was also performed on 
log transformed data where log ∆ CS = (log CS post)- (log CS pre) and log ∆ IOL = (log IOL 
post) – (log IOL pre) and p values are shown for each graph. 
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5.4.3.2.3 Lymphocytes 
The percentage of T-cells (CD3+ lymphocytes) expressing either CD4 (T-h cells) 
or CD8 (T-c cells) did not change significantly in response to delivery by either 
CS (CD3+/CD4+ CS-pre vs CS-post (p=0.22), CD3+/CD8+ CS-pre vs CS-post 
(p=0.12)) or IOL(CD3+/CD4+ IOL-pre vs IOL-post (p=0.70), CD3+/CD8+ IOL-pre vs 
IOL-post (p=0.69)) (Figure 81).  No significant difference according to mode of 
delivery was confirmed by further analysis illustrated in Figure 82.  
 
Figure 81  CD3+/CD4+ and CD3+/CD8+ lymphocytes pre and post delivery 
Measurements of the % of circulating CD3+/CD4+ (T helper lymphocytes) and the % of 
CD3+/CD8+ (T cytotoxic lymphocytes) in the maternal circulation in response to delivery by 
either planned caesarean delivery (CS) or vaginal delivery after induction of labour (IOL).  
Raw data are shown with median and IQR.  Data were log transformed prior to analysis. 
 
Figure 82  ∆ CD3+/CD4+ and CD3+/CD8+ lymphocytes (post-pre) delivery 
Change in the % of circulating CD3+ lymphocytes expressing either CD4 (T-helper cells) or 
CD8 (T-cytotoxic cells) post to pre delivery for CS and IOL.  Transformed data are shown 
with scatter plots with median and interquartile range indicated.  Analysis was also 
performed on log transformed data where log ∆ CS = (log CS post)- (log CS pre) and log ∆ 
IOL = (log IOL post) – (log IOL pre) and p values and shown for each graph. 
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All measures of chemokine receptor expression on T-h cells (CD3/CD4+ 
lymphocytes) were unchanged by delivery with the exception of the density of 
CXCR2 and CCR6 which decreased in response to CS (CS-pre vs CS-post p=0.037, 
p=0.027 respectively), however this was not observed in response to IOL (IOL-pre 
vs IOL-post p=0.17, p=0.50 respectively) (Figure 83).  The extent of changes to 
any of the measured T-h lymphocyte parameters did not differ significantly by 
mode of delivery (Figure 84). 
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Figure 83  CD3+/CD4+ lymphocytes pre and post delivery 
Assessment of CD3+/CD4+ lymphocytes (T-helper cells) in the maternal circulation in 
response to delivery by either planned caesarean delivery (CS) or vaginal delivery after 
induction of labour (IOL).  Parameters examined are 1)  the % of T-helper lymphocytes 
expressing CXCR1 and cell surface density of CXCR1, 2) the % or T-helper lymphocytes 
expressing CXCR2 and the cell surface density of CXCR2, and 3) the % of T-helper 
lymphocytes expressing CCR6 and the cell surface density of CCR6. The cell surface 
density is indicated by the mean fluorescence intensity (MFI).  Raw data are shown with 
median and IQR.   Data were log transformed prior to analysis,  Paired t-tests were 
performed with lines demonstrating significance value between 2 samples under start and 
end of each line. *p<0.05, **p<0.01. 
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Figure 84  ∆ CD3+/CD4+ lymphocytes (post-pre) delivery 
Change in % of circulating CD3/CD4+ lymphocytes (T-helper cells) expressing CXCR1, 
CXCR2 and CCR6 post to pre delivery for CS and IOL.  Transformed data are shown with 
scatter plots with median and interquartile range indicated.  Analysis was also performed on 
log transformed data where log ∆ CS = (log CS post)- (log CS pre) and log ∆ IOL = (log IOL 
post) – (log IOL pre) and p values are shown for each graph. 
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Analysis of T-c cell chemokine receptor expression of CXCR1 and CXCR2 showed 
no significant response to either type of delivery.  In response to IOL, the % of T-
cytotoxic cells expressing CCR6 decreased (p=0.048), however density of 
expression remained stable (p=0.98).  In response to CS, the % of T-cytotoxic 
cells expressing CCR6 did not alter significantly (p=0.048), while the density of 
expression fell (p=0.045) (Figure 85).  The extent of changes to any of the 
measured T-c lymphocyte parameters did not differ significantly by mode of 
delivery (Figure 86).
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Figure 85  CD3+/CD8+ lymphocytes pre and post delivery 
Assessment of CD3+/CD8 lymphocytes (T-cytotoxic) in the maternal circulation in response 
to delivery by either planned caesarean delivery (CS) or vaginal delivery after induction of 
labour (IOL).  Parameters examined are 1)  the % of T-cytotoxic lymphocytes expressing 
CXCR1 and cell surface density of CXCR1, 2) the % or T-cytotoxic lymphocytes expressing 
CXCR2 and the cell surface density of CXCR2, and 3) the % of T-cytotoxic lymphocytes 
expressing CCR6 and the cell surface density of CCR6. The cell surface density is indicated 
by the mean fluorescence intensity (MFI).  Raw data are shown with median and IQR.   Data 
were log transformed prior to analysis,  Paired t-tests were performed with lines 
demonstrating significance value between 2 samples under start and end of each line. 
*p<0.05, **p<0.01. 
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Figure 86  ∆CD3+/CD8+ lymphocytes (post-pre) delivery 
Change in % of circulating CD3/CD8+ lymphocytes (T-cytotoxic cells) expressing CXCR1, 
CXCR2 and CCR6 post to pre delivery for CS and IOL.  Transformed data are shown with 
scatter plots with median and interquartile range indicated.  Analysis was also performed on 
log transformed data where log ∆ CS = (log CS post)- (log CS pre) and log ∆ IOL = (log IOL 
post) – (log IOL pre) and p values are shown for each graph. 
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5.4.3.3 Circulating cytokines and chemokines 
Cytokine data are described in Table 29.  Data for the cytokines FLT3, IL1β, 
IL1RA, IL3, IL4, IL5, IL12p40, IL13 and TNF β was not analysed for any 
comparison since more than four values were missing as measures for these 
analytes were below the threshold of sensitivity. 
Four cytokines were found to change in response to CS but not IOL; FGF2 and 
TGFα decreased (CS-pre vs CS-post p= 0.004, and p=0.006 respectively), while 
IL2 and IL6 increased, (CS-pre vs CS-post p=0.003 and p=0.04 respectively).   
There were changes to a further 8 cytokines in response to IOL but changes were 
not significant in response to CS.  CCL11, IFNγ and CXCL10 decreased (IOL-pre vs 
IOL-post, p=0.007, p=0.034, p=<0.001 respectively).  There were significant 
increases in GCSF, CXCL1,2,3, IL10, CCL2 and CCL7 (IOL-pre vs IOL-post, 
p=0.021, p=0.008, p=0.002. p=0.001, p=0.048 respectively). 
Cytokine/ 
Chemokine (pg/ml) 
Study Group 
Paired  
t-test 
Study Group 
Paired 
t-test 
log K CS 
vs 
log K IOl 
 
CS-pre CS-post 
p-value 
n pairs 
IOL-pre IOL-post 
p-value 
n pairs 
p-value 
EGF  Median  
(IQR)  
[range] 
N 
31.42 
(3.97,60.42) 
[6.12,64.06] 
6 
6.205 
(3.190,62.58) 
[3.918,81.33] 
4 
0.087 
4 
10.84 
 
[7.840,13.83] 
2 
13.94 
(6.115,19.31) 
[3.970,22.35] 
6 
/ / 
CCL11  Median  
(IQR)  
[range] 
N 
103.3 
(92.74,231.8) 
[75.69,429.2] 
8 
98.56 
(87.26,209.9) 
[78.23,293.1] 
8 
0.056 
8 
187.2 
(119.9,221.2) 
[66.66,263.0] 
8 
137.8 
(104.3,173.3) 
[54.46,200.3] 
8 
0.007** 
8 
0.142 
FGF-2  Median  
(IQR)  
[range] 
N 
93.33 
(87.92,103.3) 
[55.85,119.4] 
8 
56.04 
(40.66,75.31) 
[34.20,88.27] 
8 
0.004** 
8 
56.75 
(40.79,68.85) 
[21.92,71.68] 
8 
55.47 
(39.41,70.02) 
[16.68,73.67] 
8 
0.751 
8 
0.022* 
Flt-3  Median  
[range] 
N 
38.25 
 
1 
34.79 
 
1 
/ 
5.34 
[1.30,9.37] 
2 
12.30 
[4.65,19.94] 
2 
/ / 
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Cytokine/ 
Chemokine (pg/ml) 
Study Group 
Paired  
t-test 
Study Group 
Paired 
t-test 
log K CS 
vs 
log K IOl 
 
CS-pre CS-post 
p-value 
n pairs 
IOL-pre IOL-post 
p-value 
n pairs 
p-value 
CX3CL1  Median  
(IQR)  
[range] 
N 
21.27 
(8.520,27.04) 
[4.830,66.83] 
7 
33.58 
(7.455,56.05) 
[4.250,66.83] 
5 
0.0513 
5 
60.07 
(36.93,734.6) 
[27.04,1370] 
5 
50.14 
(31.21,418.9) 
[4.250,1379] 
6 
0.726 
5 
0.778 
GCSF  Median  
(IQR)  
[range] 
N 
43.22 
(23.97,78.88) 
[17.02,129.6] 
8 
76.38 
(34.85,96.95) 
[18.26,158.5] 
8 
0.198 
8 
74.74 
(43.28,99.61) 
[33.22,154.3] 
8 
141.5 
(86.13,413.1) 
[68.91,496.4] 
8 
0.021* 
8 
0.133 
GMCSF  Median  
(IQR)  
[range] 
N 
76.97 
(31.43,190.9) 
[8.450,306.3] 
8 
41.95 
(22.06,160.6) 
[15.24,311.0] 
8 
0.131 
8 
46.89 
(24.38,110.6) 
[10.29,139.7] 
8 
70.69 
(23.06,145.3) 
[12.22,190.1] 
8 
0.221 
8 
0.047* 
CXCL1,2,3,  Median  
(IQR)  
[range] 
N 
1687 
(1207,2140) 
[940.6,3038] 
8 
1239 
(917.1,1590) 
[883.3,3025] 
8 
0.070 
8 
804.0 
(481.2,992.2) 
[238.1,1218] 
8 
1160 
(792.1,1621) 
[641.6,3273] 
8 
0.008** 
8 
0.001*** 
IFNα2 Median  
(IQR)  
[range] 
N 
115.4 
 
[42.18,188.6] 
2 
103.0 
 
[42.90,163.1] 
2 
/ 
15.24 
(12.92,58.17) 
[12.15,72.48] 
4 
15.24 
(4.940,58.52) 
[0.7900,95.64] 
5 
0.712 
4 
/ 
IFNγ Median  
(IQR)  
[range] 
N 
8.800 
(2.140,14.23) 
[2.070,91.04] 
7 
10.08 
(5.135,50.74) 
[3.330,89.72] 
5 
0.813 
5 
6.510 
(2.688, 55.49) 
[2.340,67.31] 
8 
4.140 
(2.850,28.26) 
[2.040,57.72] 
8 
0.034* 
8 
0.175 
IL1α Median  
(IQR)  
[range] 
N 
166.8 
(78.90, 375.7) 
[59.58, 938.0]  
8 
139.7 
(85.96, 298.4) 
[54.86, 844.1] 
7 
0.178 
7 
192.2 
(111.8, 271.5) 
[67.67, 274.3] 
6 
185.1 
(101.7, 198.1) 
[89.78, 204.2] 
5 
0.225 
5 
0.760 
IL1β Median 
N 
1.34 
1 
1.64 
1 
/ 
1.34 
1 
1.34 
1 
/ / 
IL1ra Median 
[range] 
N 
6.46 
 
1 
5.38 
 
1 
/ 
2.64 
 
1 
4.21 
[3.93,5.68] 
3 
/ / 
IL2 Median  
(IQR)  
[range] 
N 
2.640 
(0.8550, 3.390) 
[0.7800, 4.000] 
5 
3.295 
(1.505, 4.673) 
[0.9300,5.110] 
4 
0.003** 
4 
1.160 
(0.995,3.850) 
[0.930,4.550] 
5 
1.410 
(0.830, 11.10) 
[0.810, 18.16] 
5 
0.274 
4 
0.504 
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Cytokine/ 
Chemokine (pg/ml) 
Study Group 
Paired  
t-test 
Study Group 
Paired 
t-test 
log K CS 
vs 
log K IOl 
 
CS-pre CS-post 
p-value 
n pairs 
IOL-pre IOL-post 
p-value 
n pairs 
p-value 
IL3 Median 
N 
5.24 
1 
4.62 
1 
/ 
29.57 
1 
32.13 
1 
/ / 
Il4 Median 
N 
 
0 
 
0 
/ 
75.88 
1 
 
0 
/ / 
IL5 Median 
[range] 
N 
0.38 
[0.23,0.53] 
2 
0.74 
 
1 
/ 0 0 / / 
IL6 Median  
(IQR)  
[range] 
N 
8.820 
(4.335, 63.76) 
[3.360, 185.2] 
6 
23.80 
(16.34, 50.40) 
[12.11, 133.8] 
7 
0.040* 
6 
11.79 
(3.025, 283.6) 
[2.690, 549.3] 
5 
63.68 
(34.01, 158.8) 
[19.97, 248.5] 
8 
0.093 
5 
0.350 
IL7 Median  
(IQR)  
[range] 
N 
5.660 
(3.665, 38.72) 
[2.000, 41.44] 
5 
18.51 
(2.873 , 32.36) 
[2.210, 32.42] 
4 
0.182 
4 
7.405 
 
[3.600, 11.21] 
2 
4.825 
 
[2.90, 6.75 ] 
2 
/ / 
CXCL8  Median  
(IQR)  
[range] 
N 
17.57 
(6.930, 30.19) 
[3.010, 63.20] 
8 
7.76 
(4.593, 17.95) 
[2.720, 64.48] 
8 
0.060 
8 
16.03 
(6.675, 42.35) 
[4.740, 65.12] 
8 
24.74 
(12.81, 43.79) 
[9.130, 64.91] 
8 
0.330 
8 
0.057 
IL9 Median  
(IQR)  
[range] 
N 
2.89 
 
1 
2.84 
 
1 
/ 
4.940 
(1.985, 44.09) 
[1.640, 78.71] 
5 
4.990 
(3.110, 17.91) 
[2.080, 29.43] 
5 
0.762 
5 
/ 
IL10 Median  
(IQR)  
[range] 
N 
2.200 
(1.605, 5.960) 
[1.260, 21.52] 
8 
3.150 
(2.210, 5.890) 
[1.610, 19.67] 
8 
0.191 
8 
1.815 
(1.535, 3.040) 
[1.490, 3.130] 
6 
16.29 
(6.478, 29.59) 
[2.030, 101.6] 
8 
0.002** 
6 
<0.001*** 
IL12 (p40) Median 
[range] 
N 
207.4 
 
1 
174.1 
 
1 
/ 
179.8 
[170.6,192.5] 
3 
209.6 
[193.5,220.5] 
3 
/ / 
IL12 (p70) Median  
(IQR)  
[range] 
N 
2.940 
 
[1.360, 372.5] 
3 
226.8 
 
[3.090, 450.6]  
2 
/ 
2.340 
(1.855, 202.8) 
[1.490, 402.1] 
5 
6.945 
(2.473, 101.0) 
[2.270, 131.1] 
4 
0.888 / 
IL13 Median 
[range] 
N 
1.15 
 
1 
0 / 0 
2.245 
[0.87,3.72] 
2 
/ / 
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Cytokine/ 
Chemokine (pg/ml) 
Study Group 
Paired  
t-test 
Study Group 
Paired 
t-test 
log K CS 
vs 
log K IOl 
 
CS-pre CS-post 
p-value 
n pairs 
IOL-pre IOL-post 
p-value 
n pairs 
p-value 
IL15 Median  
(IQR)  
[range] 
N 
0.92 
 
[0.68, 3.30] 
3 
1.965 
 
[0.840, 3.090] 
2 
/ 
1.330 
(0.765, 3.31) 
[0.480, 4.57] 
5 
1.905 
(1.440, 2.958) 
[0.780, 4.990] 
6 
0.712 / 
IL17 Median  
(IQR)  
[range] 
N 
18.97 
(5.990, 66.67) 
[3.980, 140.6] 
6 
9.995 
(4.365, 65.85) 
[3.720, 143.8] 
6 
/ 
12.29 
(3.140, 57.51) 
[1.720, 116.2] 
8 
4.925 
(3.763, 24.30) 
[2.120, 82.66] 
8 
0.095 / 
CXCL10  Median  
(IQR)  
[range] 
N 
823.8 
(537.7, 1464) 
[272.0, 4959] 
8 
660.1 
(474.7, 1357) 
[288.4, 3676] 
8 
0.061 
8 
565.5 
(425.5, 718.7) 
[225.0, 903.2] 
8 
399.8 
(313.1, 429.5) 
[158.5, 460.2] 
8 
<0.001*** 
8 
0.013* 
CCL2  Median  
(IQR)  
[range] 
N 
235.4 
(210.3, 305.0) 
 [157.6, 503.3] 
8 
282.6 
(232.7, 449.2) 
[146.3, 553.5] 
8 
0.211 
8 
229.9 
(172.2, 282.4) 
[95.36, 469.1] 
8 
397.4 
(241.4, 592.0) 
[146.4, 1093] 
8 
0.001** 
8 
0.027* 
CCL7  Median  
(IQR)  
[range] 
N 
7.700 
(2.313, 26.20) 
[2.110, 51.04] 
6 
4.260 
(2.650, 14.49) 
[2.110, 42.43] 
7 
0.138 
6 
6.290 
(1.830, 10.28) 
[1.550, 12.18] 
5 
8.290 
(5.440, 12.67) 
[4.190, 17.14] 
7 
0.048* 
4 
0.003** 
CCL22  Median  
(IQR)  
[range] 
N 
547.2 
(406.4, 1035) 
[259.6, 1291] 
8 
539.2 
(373.2, 879.6) 
[227.0, 1228] 
8 
0.270 
8 
566.1 
(349.8, 1369) 
[321.4, 1978]  
8 
484.2 
(312.1, 1201) 
[230.4, 1514] 
8 
0.154 
8 
0.492 
CCL3  Median  
(IQR)  
[range] 
N 
41.21 
(28.08, 97.76) 
[25.20, 124.2] 
5 
34.34 
(19.08, 103.1) 
 [9.660, 148.2] 
5 
0.357 
5 
38.60 
(22.71, 177.5) 
[21.12, 178.3] 
7 
30.35 
(24.52, 114.4) 
[23.40, 152.2] 
7 
0.216 
7 
0.708 
CCL4  Median  
(IQR)  
[range] 
N 
57.55 
(24.02, 95.48) 
[20.47, 323.2] 
8 
36.55 
(25.53, 70.74) 
[24.16, 310.9] 
8 
0.1977 
8 
42.98 
(18.55, 176.9) 
[6.170, 217.6] 
8 
30.77 
(15.68, 117.5) 
[5.580, 141.5] 
8 
0.259 
8 
0.545 
sCD40L  Median  
(IQR)  
[range] 
N 
4130 
 
 
1 
2649 
(1783, 5586) 
[1563, 10393] 
7 
/ 
3447 
(1551, 7070) 
[738.3, 8610] 
8 
3861 
(1507, 4600) 
[727.8, 5633] 
8 
0.777 
8 
/ 
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Cytokine/ 
Chemokine (pg/ml) 
Study Group 
Paired  
t-test 
Study Group 
Paired 
t-test 
log K CS 
vs 
log K IOl 
 
CS-pre CS-post 
p-value 
n pairs 
IOL-pre IOL-post 
p-value 
n pairs 
p-value 
sIL2Rα Median  
(IQR)  
[range] 
N 
8.570 
(5.770, 51.51) 
[4.560, 65.05] 
5 
8.300 
(4.525, 41.88) 
[1.810, 56.22] 
5 
0.2357 
4 
1.180 
 
 
1 
9.835 
 
[3.200, 16.47] 
2 
/ / 
TGFα Median  
(IQR)  
[range] 
N 
8.010 
(3.490, 8.440) 
[3.220, 12.99] 
7 
2.200 
(1.250, 5.940) 
[1.150, 12.51] 
7 
0.006** 
7 
2.750 
(0.483, 9.143) 
[0.340, 21.06] 
6 
4.860 
(3.590, 8.245) 
[3.340, 9.140] 
5 
0.213 
5 
0.011* 
TNFα Median  
(IQR)  
[range] 
N 
4.830 
(3.198, 9.235) 
[1.740, 15.44] 
8 
4.185 
(1.893, 6.803) 
 [1.320, 14.29] 
8 
0.054 
8 
3.865 
(1.183, 7.113) 
[0.810, 8.380] 
8 
3.245 
(1.433, 7.108) 
[0.580, 8.120] 
8 
0.454 
8 
0.359 
TNFβ Median 
[range] 
N 
1.0 
[0.78,1.88] 
3 
0.85 
[0.74,2.18] 
3 
/ 
1.12 
 
1 
1.0 
 
1 
/ / 
VEGF  Median  
(IQR)  
[range] 
N 
146.5 
(70.67, 161.9) 
[16.60, 352.8] 
7 
103.7 
(29.10, 137.4) 
[24.98, 245.3] 
7 
0.0801 
7 
113.5 
(14.46, 305.9) 
[4.000, 347.5] 
4 
26.79 
(1.600, 168.4) 
[1.600, 201.6] 
5 
0.101 
4 
0.474 
CCL5  Median  
(IQR)  
[range] 
N 
12464 
(6870, 19638) 
[362.4, 23230] 
8 
12098 
 
[1907, 22939] 
3 
/ 
1466 
 
[422.3, 12007] 
3 
6211 
 
[3493, 8929] 
2 
/ / 
 
Table 29  Circulating cytokine/chemokine levels pre and post delivery 
Cytokine levels pre and post delivery.  Raw data are presented with analysis performed on 
normalised log transformed data.  Where changes in levels are examined, log ∆ CS = (log 
CS post)- (log CS pre) and log ∆ IOL = (log IOL post) – (log IOL pre).  Where boxes are 
marked with / this indicates that less than 4 values were present (n expected in each group 
n=8), therefore analysis was not performed.  
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5.4.3.4 Circulating CRP 
CRP did not change significantly in response to delivery by either CS or IOL, (CS-
pre vs CS-post p=0.05, IOL-pre vs IOL-post, p=0.18).  However the extent of 
change in CRP levels was significantly more in response to delivery following IOL 
compared with CS (log K CS vs log K IOL, p=0.024).  Data are shown in Figure 87. 
 
 
Figure 87  Circulating CRP pre and post delivery and ∆CRP (post-pre) delivery 
Maternal circulating CRP in response to delivery by CS or IOL at term.  No significant 
changes were induced, however the extent of change in CRP levels was significantly higher 
in response to IOL.  Raw data and log transformed data are shown.  Analysis was performed 
on log transformed data where log ∆ CS = (log CS post)- (log CS pre) and log ∆ IOL = (log 
IOL post) – (log IOL pre).  Paired and unpaired t-tests were performed as appropriate with 
lines demonstrating significance value between 2 samples under start and end of each line. 
*p<0.05 
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5.4.4 Hypothesis 3 – In term pregnancies, circulatory changes 
observed pre and post IOL occur in a time dependent 
manner. 
5.4.4.1 Differential white blood cell count 
Correlation plots and regression lines are shown for the normalised, log 
transformed values for each white cell sub-set in Figure 88.  Levels of circulating 
white cells were correlated with the time sample was taken during labour, with 
time 0% equivalent to IOL –pre sample and time 100% equivalent to IOL-post 
sample.  Changes in circulating leukocyte numbers occurred in a time dependent 
manner for WBC (r=0.68, p<0.0001), neutrophils (r=0.68, p<0.0001), lymphocytes 
(r=-0.35, p=0.022), monocytes (r=0.45, p=0.002) and eosinophils (r=-0.60, 
p<0.0001). 
Claire A Higgins, 2012   Chapter 5, 259  
 
Figure 88  Correlation of WBC subtype with time in labour 
Correlation plots and regression lines for each white blood cell sub-type and % length of 
labour (ARM-1hr post delivery of placenta).  Log transformed data are shown.  Pearson 
correlation r values and p values are shown for each graph. 
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5.4.4.2 Leukocyte cell surface markers and chemokine receptors  
5.4.4.2.1 Granulocytes 
The association between granulocyte cell surface markers and receptors is 
illustrated in Figure 89, with significant changes occurring for CXCR1 and CXCR2 
expression on neutrophils The percentage of neutrophils expressing CXCR1 and 
CXCR2 both were positively associated with the time in labour (CXCR1 r=0.44, 
p=0.003, CXCR2 r=0.48, p=0.001), with the density of cell surface expression of 
both of these receptors falling with time in labour (CXCR1 r=-0.56, p<0.001, 
CXCR2 r=-0.48, p=0.001).  
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Figure 89  Correlation of granulocytes with time in labour 
Correlation plots and regression lines with 95% confidence intervals for % of circulating 
granulocytes expressing CD11b, CXCR1 and CXCR2, and the cell surface density of 
expression (MFI) plotted against the length of time in labour (ARM-1hr post delivery of 
placenta).  Data shown and used for analysis was log transformed, Pearson correlation r 
values and significance p values and shown for each graph. 
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5.4.4.2.2 Monocytes 
No changes in monocytes receptor expression occurred in association with length 
of time in labour (Figure 90). 
 
Figure 90  Correlation of monocytes with time in labour 
Correlation plots and regression lines with 95% confidence intervals for % of circulating 
monocytes expressing CD11b, CCR2, and the cell surface density of expression (MFI) 
plotted against the length of time in labour (ARM-1hr post delivery of placenta).  Data shown 
and used for analysis was log transformed, Pearson correlation r values and significance p 
values and shown for each graph. 
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5.4.4.2.3 Lymphocytes 
Changes in lymphocytes are illustrated in Figure 91, Figure 92 and Figure 93.  
Despite no significant difference between pre and post IOL sample, a negative 
correlation was found between time in labour and the MFI of CXCR1 on T-helper 
cells (r=-0.324, p=0.042). 
 
Figure 91  Correlation of CD3+/CD4+ and CD3+/CD8+ lymphocytes with time in labour 
Correlation plots and regression lines with 95% confidence intervals for % of circulating 
CD3+ lymphocytes expressing CD4 (T-helper cells) of CD8 (T-cytotoxic cells) plotted against 
the length of time in labour (ARM-1hr post delivery of placenta).  Data shown and used for 
analysis was log transformed, Pearson correlation r values and significance p values and 
shown for each graph. 
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Figure 92  Correlation of CD3+/CD4+ lymphocytes with time in labour 
Correlation plots and regression lines with 95% confidence intervals for % of circulating 
CD3/CD4+ lymphocytes (T-helper cells) expressing CXCR1, CXCR2 and CCR6 and the cell 
surface density of expression (MFI) plotted against the length of time in labour (ARM-1hr 
post delivery of placenta).  Data shown and used for analysis were log transformed, 
Pearson correlation r values and significance p values and shown for each graph. 
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Figure 93  Correlation of CD3+/CD8+ lymphocytes with time in labour 
Correlation plots and regression lines with 95% confidence intervals for % of circulating 
CD3/CD8+ lymphocytes (T-cytotoxic cells) expressing CXCR1, CXCR2 and CCR6 and the 
cell surface density of expression (MFI) plotted against the length of time in labour (ARM-
1hr post delivery of placenta).  Data shown and used for analysis were log transformed, 
Pearson correlation r values and significance p values and shown for each graph. 
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5.4.4.3 Circulating cytokines and chemokines 
All circulating cytokines were examined for the relationship between expression 
levels at the time in labour at which the sample was taken (Table 30).  The 
cytokines FLT3, IL1β, ILRA, IL3, IL4, IL5, IL7, IL12p40, IL13, sIL2Rα, TNFβ and 
CCL5 were excluded as there were <50% of expected readings.   
Cytokines which showed a significant positive correlation with time of labour 
were GCSF (r=0.50, p<0.001), CXCL1, 2, 3 (r=0.30, p=0.047), IL6 (r=0.48, 
p=0.002), CXCL8 (r=0.35, p=0.023), IL10 (r=0.58, p<0.001), CCL2 (r=0.34, 
p=0.025), CCL7 (r=0.35, p=0.042).  CXCL10 showed a negative association with 
time in labour (r=-0.32, p=0.036). 
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Cytokine/Chemokine Correlation with % time  Cytokine/Chemokine Correlation with % time 
 n pairs r-value p-value   n pairs r-value p-value 
EGF  25 0.643 0.760  IL9 24 -0.036 0.869 
CCL11  43 -0.161 0.303  IL10 38 0.577 <0.001*** 
FGF-2  43 -0.055 0.725  IL12 (p40) 19 / / 
Flt-3  11 / /  IL12 (p70) 22 0.108 0.631 
CX3CL1  35 0.031 0.859  IL13 3 / / 
GCSF  43 0.504 <0.001***  IL15 30 0.198 0.294 
GMCSF  43 0.135 0.388  IL17 41 0.026 0.869 
CXCL1,2,3 43 0.305 0.047*  CXCL10 43 -0.320 0.036* 
IFNα2 26 -0.219 0.282  CCL2 43 0.342 0.025* 
IFNγ 42 0.015 0.925  CCL7 34 0.351 0.042* 
IL1α 31 -0.142 0.446  CCL22 43 0.007 0.963 
IL1β 3 / /  CCL3 38 0.050 0.767 
IL1ra 11 / /  CCL4 43 -0.028 0.858 
IL2 26 0.118 0.567  sCD40L 40 -0.107 0.513 
IL3 5 / /  sIL2Rα 8 / / 
Il4 4 / /  TGFα 32 0.331 0.065 
IL5 0 / /  TNFα 43 0.013 0.936 
IL6 40 0.481 0.002**  TNFβ 3 / / 
IL7 10 / /  VEGF  24 -0.146 0.497 
CXCL8  43 0.346 0.023*  CCL5  16 / / 
Table 30  Correlation of circulating cytokines/chemokines with time in labour 
Table illustrating correlation of measured cytokines with % time during IOL (ARM-1hr post 
delivery of placenta).   Analysis was performed using Pearson’s correlation using log 
transformed data.  Where <50% of expected cytokine readings were obtained (n<22) the 
cytokine was excluded from analysis. *p<0.05, **p≤0.01, ***p≤0.001 
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5.4.4.4 Circulating CRP 
Circulating maternal CRP was not correlated with % length of labour (r=0.10, 
p=0.51) (Figure 94 A).  However, as described above, IL6 levels increase in 
response to labour (Table 30), and since IL6 stimulation of hepatocyte CRP 
production can take 6 hours, a further analysis was undertaken to examine 
changes in CRP which occur over time as measured in hours.  Additionally, since 
each patient had a different labour length, changes were explored for each 
patient individually.  This analysis suggests that circulating CRP levels initially 
remains static and increases or there is a tendency for CRP to increase acutely in 
those where labour is longer and thus IL6 has had time to increase and exert an 
effect on CRP production by the liver (Figure 94 B) 
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Figure 94  Correlation of maternal circulating CRP with time in labour 
(A) Correlation plot and regression line with 95% confidence interval for CRP according to 
% length of labour (ARM-1hr post delivery of placenta).  Pearson correlation r and p values 
are shown.  (B) Point and line plots for raw CRP levels demonstrating values for each 
individual patient across time in minutes.   
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5.4.5 Hypothesis 4 - Promotion of a pro-inflammatory phenotype 
in the maternal circulation is associated with myometrial 
myocyte damage resulting from repeated contractions 
during labour. 
5.4.5.1 CK and Mb in response to pregnancy and delivery 
Baseline measures of for creatine kinase (CK) and myoglobin (Mb) are illustrated 
in Figure 95.  Circulating CK did not differ significantly between the 3 groups (NP 
vs CS-pre vs IOL-pre, p=0.19) or between pregnant and non-pregnant women (NP 
vs PT p=0.07).  Baseline measures of Mb were found to differ between the 3 
groups (NP vs CS-pre vs IOL-pre, p=0.037) with lower levels found in women pre-
IOL (np vs CS-pre p=0.56, np vs IOL-pre p=0.020, CS-pre vs IOL-pre p=0.047), 
however, no difference was found between non=pregnant and the pooled 
pregnancy values (NP vs PT p=0.08). 
 
Figure 95  Baseline measures of CK and Mb 
Baseline measures of circulating CK and Mb in non-pregnant, pregnant at term pre-CS and 
pregnant and term pre-IOL.  Raw data are shown as scatter plots with median and 
interquartile ranges indicated.  Data were log transformed prior to analysis.  Unpaired t-tests 
were performed with lines demonstrating significance value between 2 samples under start 
and end of each line *p<0.05 
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Delivery by both CS and IOL induced a significant increase in both circulating CK 
and Mb (CK: CS-pre vs CS-post, p=0.003, IOL-pre vs IOL post, p=0.005, Mb: CS-pre 
vs CS-post, p<0.001, IOL-pre vs IOL post, p<0.001) (Figure 96).   
 
Figure 96  Circulating CK and Mb pre and post delivery 
Concentration of circulating CK and Mb pre and post delivery by planned caesarean 
delivery (CS) or vaginal delivery after induction of labour with syntocinon only (IOL).  Raw 
data are shown as scatter plots with median and interquartile ranges indicated.  Data were 
log transformed prior to analysis.  Paired t-tests were performed with lines demonstrating 
significance value between 2 samples under start and end of each line.  *p<0.05, **p≤0.01, 
***p≤0.001  
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The difference in both CK and Mb was greater in response to IOL, however the 
difference was only significant for the change in circulation Mb (CK: log K CS vs 
log K IOL, p=0.13, Mb: log K CS vs log K IOL, p=0.012) (Figure 97).   
 
Figure 97  ∆CK and ∆Mb (post-pre) delivery 
Change in circulating levels of CK and Mb post to pre delivery for CS and IOL.  Raw data are 
shown as scatter plots with median and interquartile range indicated.  Analysis was 
performed on log transformed data where log ∆ CS = (log CS post)- (log CS pre) and log ∆ 
IOL = (log IOL post) – (log IOL pre). Unpaired t-tests were performed with lines 
demonstrating significance value between 2 samples under start and end of each line.  
*p<0.05 
Additionally the change in circulating CK and Mb levels occurred in a time 
dependent manner during labour (CK r=0.48, p=0.001, Mb r=0.60, p<0.001) 
(Figure 98). 
 
Figure 98  Correlation of CK and Mb with time in labour 
Correlation plot and regression lines with 95% confidence intervals for circulating CK  and 
Mb levels during labour (ARM-1hr post delivery of placenta). Log transformed data are 
shown and Pearson correlation r and p values are shown. 
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5.4.5.2 CK and Mb and correlation with markers of inflammation 
To evaluate the association between inflammation in labour and contraction 
induced myometrial cell damage, the correlation between CK levels, Mb, white 
blood cell subsets and circulating inflammatory markers was examined.  
All white blood cell subsets demonstrated a significant correlation with both 
circulating CK and Mb levels; WBCs (CK; r=0.56, p=0.0001, Mb; r=0.67, 
p<0.0001), neutrophils (CK; r=0.53, p=0.0003, Mb; r=0.68, p<0.0001), 
lymphocytes (CK; r=-0.32, p=0.036, Mb; r=-0.51, p=0.0005), monocytes (CK; 
r=0.50, p=0.0006, Mb; r=0.50, p=0.0007), eosinophils (CK; r=-0.48, p=0.002, Mb; 
r=-0.51, p=0.001) and basophils (CK; r=0.33, p=0.044, Mb; r=0.89, p=0.014) 
(Figure 99 and Figure 100). 
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Figure 99  Correlation of WBC subtype with CK 
Correlation plots, regression lines with 95% confidence intervals for circulating CK levels 
and white cell sub-sets.  Log transformed data are shown with Pearson correlation r and p-
values shown. 
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Figure 100  Correlation of WBC subtype with Mb 
Correlation plots, regression lines with 95% confidence intervals for circulating Mb levels 
and white cell sub-sets.  Log transformed data are shown with Pearson correlation r and p-
values shown. 
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Additionally, circulating CK and Mb levels have a significant positive correlation 
with levels of GCSF, IL10 and CCL2, and a negative correlation with  IFNγ, IL17, 
CCL3, CCL4 and VEGF.  IL2 has a negative correlation with CK and IL6 is 
positively correlated with Mb (Table 31). 
Cytokine/Chemokine Correlation with  CK  Correlation with MB 
 n pairs r-value p-value  r-value p-value 
EGF  25 -0.045 0.831  -0.077 0.714 
CCL11  43 0.225 0.146  0.092 0.555 
FGF-2  43 0.043 0.787  -0.054 0.731 
Flt-3  11 / /  / / 
CX3CL1  35 -0.302 0.078  -0.215 0.216 
GCSF  43 0.511 0.0005***  0.588 <0.0001*** 
GMCSF  43 -0.212 0.172  -0.085 0.588 
CXCL1,2,3,  43 0.160 0.307  0.202 0.193 
IFNα2 26 0.205 0.316  0.084 0.684 
IFNγ 42 -0.492 0.0009***  -0.413 0.007** 
IL1α 31 -0.248 0.179  -0.194 0.295 
IL1β 0 / /  / / 
IL1ra 11 / /  / / 
IL2 26 -0.414 0.036*  -0.363 0.069 
IL3 5 / /  / / 
Il4 4 / /  / / 
IL5 0 / /  / / 
IL6 40 0.276 0.085  0.364 0.021* 
IL7 10 / /  / / 
CXCL8  43 -0.037 0.814  0.104 0.509 
IL9 24 0.176 0.411  0.148 0.491 
IL10 38 0.472 0.003**  0.659 <0.0001*** 
IL12 (p40) 19 / /  / / 
IL12 (p70) 22 0.075 0.740  0.017 0.941 
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Cytokine/Chemokine Correlation with  CK  Correlation with MB 
 n pairs r-value p-value  r-value p-value 
IL13 0 / /  / / 
IL15 30 0.055 0.774  0.134 0.479 
IL17 41 -0.473 0.002**  -0.390 0.012* 
CXCL10 43 0.071 0.651  0.041 0.795 
CCL2 43 0.325 0.034*  0.397 0.008** 
CCL7 34 -0.013 0.943  0.022 0.901 
CCL22 43 -0.294 0.056  -0.163 0.296 
CCL3 38 -0.485 0.002**  -0.402 0.012* 
CCL4 43 -0.524 0.0003***  -0.487 0.0009*** 
sCD40L 40 0.031 0.851  0.006 0.970 
sIL2Rα 8 / /  / / 
TGFα 32 -0.163 0.373  -0.072 0.695 
TNFα 43 0.219 0.158  0.205 0.188 
TNFβ 0 / /  / / 
VEGF  24 -0.478 0.018*  -0.512 0.011* 
CCL5  16 / /  / / 
Table 31  Correlation of circulating cytokines/chemokines with CK and Mb 
Table illustrating correlation of measured cytokines with circulating CK and Mb during IOL 
(ARM-1hr post delivery of placenta).   Analysis was performed using Pearson’s correlation 
using log transformed data.  Where <50% of expected cytokine readings were obtained 
(n<22) the cytokine was excluded from analysis.  *p<0.05, **p≤0.01, ***p≤0.001 
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5.5 Summary of Results 
5.5.1 Pregnancy and maternal peripheral inflammation 
• Pregnancy at term is associated with a state of low grade inflammation in 
the maternal circulation at term with a tendency for a higher CRP and a 
neutrophil driven leucocytosis as compared with non-pregnant women. 
• Our flow cytometry data do not show evidence of priming of maternal 
circulating leukocytes at term as compared with non-pregnant women.   
• Pregnancy at term is associated with minimal alteration in circulating 
cytokine concentrations with only GCSF increasing and CCL11 and CCL22 
decreasing. 
5.5.2 Labour and maternal peripheral inflammation 
• Labour induces a time dependent increase in total leukocytes, neutrophils 
and monocytes with a decrease in lymphocytes and eosinophils.  The 
extent of change is greater in response to labour than to delivery by non-
labouring CS. 
• Labour induces a time dependent increase in the % of granulocytes 
expressing CXCR1 and CXCR2 with a fall in the cell surface density of the 
receptor. 
• Labour induces a time dependent increase in circulating GCSF, GRO 
(CXCL1,2,3), IL6, IL10, CXCL8, CCL2 and CCL3. 
• Labour induces a time dependent decrease in circulating CXCL10. 
• Labour tends to increase the level of circulating CRP in a time dependent 
manner.  
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5.5.3 Muscle damage, labour and maternal peripheral 
inflammation  
• Circulating markers of muscle damage (CK and Mb) at term are not 
altered from non-pregnant levels. 
• Labour induces a time dependent increase in muscle damage (as 
measured by circulating CK and Mb) which is greater than in response to 
delivery by non-labouring CS. 
• Peripheral total white cell counts, neutrophils, monocytes and basophils 
are positively associated with the extent of muscle damage during labour. 
• Peripheral lymphocytes and eosinophils are negatively associated with 
extent of muscle damage during labour. 
• Muscle damage during labour as measured by CK is positively correlated 
with GCSF, IL10 and CCL2, and negatively correlated with IFN γ, IL2, IL17, 
CCL3 and CCL4. 
• Muscle damage during labour as measured by Mb is positively correlated 
with GCSF, IL6, IL10 and CCL2, and negatively correlated with IFN γ, IL17, 
CCL3 and CCL4. 
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5.6 Discussion 
The data presented in this chapter demonstrate that peripheral inflammatory 
changes in the maternal circulation seen in response to pregnancy at term 
appear to be limited to increased total white cell counts driven by a 
neutrophilia, with no suggestion of leukocyte priming prior to labour.  
Additionally, term pregnancy is associated with an increase in CRP, an increase 
in GCSF corresponding with the neutrophilia and a suppression of the cytokines 
CCL11 and CCL22. 
Subsequently, we found that term labour induces dramatic changes in 
inflammatory cells and mediators in the maternal circulation.  Importantly, 
these changes occur in a co-ordinated time and contraction dependent manner, 
with the degree of inflammation associated with the time in labour and the 
degree of myocyte damage as measured by circulating CK and Mb. 
5.6.1 Pregnancy and maternal peripheral inflammation 
Our data confirm the well known changes to circulating leukocyte numbers in 
pregnancy with an overall increase in total white cell count, driven by increased 
neutrophills355 356 358.  We also found a decrease in circulating lymphocytes, 
eosinophils and basophil counts, with no significant change in monocytes induced 
by pregnancy at term, which may reflect a dilutional effect of pregnancy. 
Specific analysis of leukocyte cell surface markers and chemokine receptors do 
not suggest priming of circulating maternal leukocytes in term pregnancy.  In 
particular, there is no change in the expression of CD11b on the neutrophil or 
monocyte cell population, suggesting activation status of these cells is 
comparable with the non-pregnant controls.  In addition the percentage of CD3+ 
lymphocytes (T-cells) that were either CD4+ or CD8+ did not alter with 
pregnancy, however we were unable to comment on the CD4+ cell sub-types 
(Th1, Th2, Th17 or Treg) in this study which may have given further information 
as to the type of Th cell response to be expected in pregnancy.  Concerning 
chemokine receptor expression, again results do not suggest that term 
pregnancy promotes priming of leukocytes since only the percentage neutrophils 
expressing CXCR2 increases in pregnancy with a non significant trend to a 
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reduction in the density of CXCR2 expression.  Contrary to leukocyte priming, 
our data suggest that pregnancy actually decreases chemokine receptor 
expression on monocytes, Th and Tc cells with a reduced number on monocytes 
expressing CCR2, and a decreased density of CXCR1 and CXCR2 expression on Th 
and Tc cells. 
Compared with non-pregnant women, pregnancy was only associated with 
alterations in the circulating cytokines GCSF, CCL11 and CCL22.  The increase in 
GCSF is consistent with previous results378 and also its proposed production by 
gestational tissues413.  This increase would also explain the typical neutrophilia 
of pregnancy since it promotes release of neutrophils from the bone marrow, 
and has been suggested to represent a compensatory increase in innate 
immunity, while there is some suppression of the adaptive immune response in 
pregnancy378.  The cause for the decrease in circulating CCL11 in pregnancy is 
unclear, however it has been reported by others378 and certainly fits with the 
reduced numbers of circulating eosinophils.  The role of decreased CCL22 is 
similarly uncertain, however, a reduction in pregnant cervico-vaginal fluid has 
been reported and it was postulated that it may have a suppressive effect upon 
the maternal innate immune response414.  Additionally, comparisons across the 
three groups suggested FGF-2 levels were higher pre-CS compared with pre-IOL, 
and lower pre-IOL compared with NP levels with a similar pattern for CXCL1,2&3 
levels.  However, when pregnant data were pooled giving n=16, no significant 
differences were found when compared with the NP controls, and therefore 
differences in data may simply reflect patient variability, but would necessitate 
further investigation with larger numbers. 
Our observation of a significantly higher plasma CRP in pregnant women is in 
agreement with previous descriptions of an early gestational and persistent rise 
in CRP373 374.  Certainly, it has been suggested that a CRP>10mg/L (upper range 
of normal in non-pregnant individuals408) may be normal for pregnancy373, with a 
suggested upper limit of 15mg/L374.  Reassuringly, markers of muscle damage, 
namely CK and Mb did not differ with pregnancy in the groups examined implying 
no effect of pregnancy upon muscular damage or remodelling. 
Overall, our data suggest that pregnancy does induce a shift to a state of low 
grade inflammation as indicated by the recognised changes of neutrophilia, 
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raised CRP and GCSF, but there is no suggestion of leukocyte priming or acute 
inflammatory changes in preparation for labour at term. 
5.6.2 Labour and maternal peripheral inflammation 
The overall response to delivery by either CS or IOL produces a pattern of acute 
inflammatory changes.   Given that the extent of change was more pronounced 
in response to IOL this suggests that the observed inflammatory changes may be 
contraction dependent.  Furthermore many of the inflammatory changes seen 
with delivery by IOL occur in a time dependent manner, as suggested by the 
correlations with time in labour. 
5.6.2.1 Leukocytes 
In terms of circulating leukocyte numbers, there is agreement with previous 
studies in labour with an increase total white cell count, increased neutrophils, 
and decreases in lymphocyte and eosinophil numbers 359 362-364, with a greater 
change in response to labour when compared with a non-labouring caesarean 
delivery360.  Specifically, we observed the total white cell count to reach a 
maximum level of 22.09x109/L, with a neutrophil count of 20.6x109/L in the 
absence of infective stimuli.  The accompanying reduction in the density of cell 
surface expression of CXCR1 and CXCR2 on circulating activated neutrophils post 
delivery suggests that the majority of circulating neutrophils tend to be 
immature.  This tendency toward immature neutrophils, typical of an acute 
inflammatory response264, is most probably driven by two factors; trafficking of 
mature activated neutrophils into the myometrium and other inflammatory and 
immune tissues219 in conjunction with release of neutrophils stores from the 
bone marrow under the influence of increased circulating GCSF. 
The reduction in circulating lymphocytes and eosinophils is consistent with 
previous findings in labour362 363, and suggests that there may be a degree of 
cellular recruitment from the circulation to the contracting uterus.  In response 
to delivery, there is a decrease in the density of expression of CCR6 on 
circulating T-lymphocytes with no change in the % of Th or Tc cells expressing 
this receptor.  This suggests that the type of T-cell sequestered into the 
inflammatory tissue is likely to express CCR6.  Of note, CCR6 is the only 
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chemokine receptor which is attracted via CCL20, which although not included 
on the serum cytokine panel used in this experiment, transcription of CCL20 was 
significantly upregulated in contracting myometrium (Chapter 3 and Chapter 4). 
Our monocyte data suggest there is an increase in circulating monocytes in 
response to labour, with no significant change found pre to post delivery by CS.  
Previous studies examining monocyte changes with labour have described either 
numbers increasing, falling and remaining static362 363.  However, our study has 
the advantages of using repeated measures rather than one single measure 
during an arbitrary timepoint in labour in addition to our comparison back to 
baseline measures taken directly before delivery. 
5.6.2.2 Cytokines 
In response to delivery, we found that a limited number of circulating cytokine 
concentrations changed.  In particular, significant changes were seen in response 
to IOL rather than CS with increases in GCSF, GRO (CXCL1,2,3), IL10, CCL2 and 
CCL7.  Of note all these cytokines were also positively associated with time in 
labour suggesting that an increased inflammatory response occurs in advancing 
labour.  Additionally, despite no significant change pre to post delivery by IOL, 
there were positive associations found between time in labour and the cytokines 
IL6 and CXCL8.  Three cytokines were found to fall in response to IOL, namely 
CCL11, IFN-γ and CXCL10 with CXCL10 being negatively associated with time in 
labour.   
The changes in circulating inflammatory proteins suggests an association with 
and therefore perhaps an effect of labour, especially since we have controlled 
for delivery with the CS comparison group.  Certainly, the specific cytokine 
changes which we have observed are consistent with recognised labour 
associated inflammatory changes to circulating white cells359 362-364 and leukocyte 
infiltration to gestational tissues219 220 354.  Specifically, GCSF is consistent with 
peripheral neutrophilia, GRO and CXCL8 with neutrophil chemotaxis, CCL2 and 
CCL7 with monocyte chemotaxsis, and IL6 with muscle damage and an overall 
upregulation of the acute inflammatory response.  The cytokines IL10, CXCL10 
and IFNγ may be associated with a suppression of the initial inflammatory 
response with a tendency toward repair and resolution.  These changes may 
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occur via suppression of macrophage function and NFkB activity by IL10 and 
reduced chemotaxis of CD4+ T-lymphocytes by a reduced level of CXCL10 and 
suppression of an overall pro-inflammatory environment with a reduction in IFNγ 
levels. 
Additionally, the levels of circulating chemokines may also be regulated by 
interaction with atypical chemokine receptors (ACRs)415-418.  These are 
structurally similar to other chemokine receptors, however they do not have the 
ability to stimulate intracellular signalling pathways, and thus interaction of 
chemokines with ACRs does not stimulate migration and sequestration of 
peripheral leukocytes as is seen with ‘traditional’ chemokine receptor 
interactions.  Recognised ACRs or ‘decoy receptors’ include D6 and the Duffy 
antigen receptor for chemokines (DARC)415-419.  They are thought to play a role in 
‘scavenging’ chemokines by interacting with high affinity and internalising a 
number of chemokines without activation cellular activity419 420.  There has also 
been proposal that ARCs may facilitate leukocytes acting as a ‘sink’ and 
‘resevoir’ for circulating chemokines and thus exerting a further element of 
control over the inflammatory response and leukocyte trafficking, releasing 
chemokines when required419 421.  Concerning muscle damage, evidence from the 
myocardium post infarction has also suggested that D6 may play a role in 
preventing excessive inflammation and muscle remodelling422.  This then raises 
the possibility of a further comparable role for D6 and possibly other ACRs in the 
labouring myometrium, especially considering the high density of D6 expression 
within the placenta and gestational tissues during pregnancy420 423. 
5.6.2.3 CRP 
Despite increases in other inflammatory indices in response to delivery, there 
was only a non significant trend for CRP to increase, however the extent of 
increase was significantly greater in response to labour rather than CS.  This may 
reflect the timing of the serum sampling in that CRP rises in the circulation may 
not be as acute as other mediators since the time delay between IL6 mediated 
stimulation of hepatic CRP production and its appearance in the circulation is 
approximately 6hours.  Despite this, in the patients with later serum sampling 
there is evidence of an acute rise in CRP to levels surpassing the clinically 
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accepted maximum of 10mg/L.  Again this suggests inflammation occurs as a 
reaction to labour rather than being necessary for it progression. 
5.6.3 Muscle damage, labour and maternal peripheral 
Inflammation 
5.6.3.1 Myometrial contractile damage 
Overall, the rise in circulating CK and Mb is consistent with the finding of others 
for human labour391 392, response to OT induced tonic contraction of the pregnant 
and non-pregnant uterus424 and also surgical trauma in the non obstetric 
patient409.  When the type of delivery is taken into account IOL enhances the 
extent of change in the level of circulating Mb, however, the change in 
circulating CK is comparable between IOL and CS.  This is in keeping with the 
findings of peak rises in Mb on the first post-operative day and maximal CK on 
the second post-operative day409.   
Although CK and Mb are not specific to myometrial myocytes411, the contracting 
uterus is the most likely source of these proteins since no subject displayed 
evidence of alternative muscle damage; no complaints of chest pain consistent 
with myocardial infarction and no skeletal muscle injury or exercise since all 
were confined to a labour room bed for the duration of the labour.  This is in 
accordance with previous data where no rise in troponin I is observed390 
suggesting a non-cardiac cause for muscle damage. 
The causative link between the repeated contractions typical of human labour 
and increased myometrial cellular damage is suggested by the temporal 
association with both CK and Mb in the IOL group.  This link with repeated 
contractions is further supported by the higher levels of CK and Mb in response 
to IOL compared with CS.  This occurs despite the skeletal muscle disruption and 
sustained tonic contraction following the standard 5iu bolus and infusion of 
syntocinon which occurs during caesarean section.   
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5.6.3.2 Contractile damage and leukocytes 
As with time in labour, contraction induced damage as measured by CK and Mb 
are both correlated with the changes in peripheral circulating leukocytes.  This 
suggests that changes in circulating maternal leukocytes in labour can be 
considered a time and contraction dependent event, and the pattern of changes 
may reflect the reactive inflammatory process with bone marrow release of the 
neutrophils required and reduction in other leukocyte types most probably 
reflecting trafficking into damaged myometrium and gestational tissues in 
addition to sequestration into other inflammatory related tissues. 
5.6.3.3 Contractile damage and cytokines 
In addition to temporal changes to inflammatory cytokines during labour, there 
were also correlations with the extent of muscle damage as measured by 
circulating CK and Mb.  In particular, GCSF, IL6, IL10, and CCL2 were all 
positively associated with these markers of muscle damage.  There were 
additional negative associations between CK and Mb with IFNγ, IL17, CCL3 and 
CCL4, and CK with IL2.  The combination of these correlations would suggest 
that a high level of uterine muscle damage can stimulate and also suppresses the 
release of certain cytokines, thereby exerting control over the acute 
inflammatory reaction in addition to possible modulation of circulating 
chemokines by atypical chemokine receptors (ARCs).  This may in turn limit the 
cellular damage by infiltrating leukocytes and perhaps promote a repair and 
remodelling phenotype. 
5.6.4 Exercising skeletal muscle and inflammation 
The observed contraction dependent inflammation of human labour has marked 
similarities to that reported for exercising skeletal muscle.   In this parallel 
situation, it is suggested that contractions of skeletal muscle cause myocyte 
damage, which in turn drives myocyte release of inflammatory mediators and 
promotion of the ensuing circulating inflammatory changes and leukocyte influx 
into the damaged muscle 383 386 389 425-429.   
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In response to contractions of exercising skeletal muscle, damage has been 
measured by both direct changes (MRI and disruption to cell ultrastructure) and 
indirect measures (increases in circulating CK, Mb and slow twitch skeletal 
myosin heavy chain fragments)386 387.  These changes occur in the absence of 
increased cardiac troponin T387 390 thereby suggesting release from the exercising 
muscle rather than cardiac muscle.   
The subsequent myocyte release of inflammatory cytokines shows that some are 
common to our labour data, in particular increases in IL6, IL10, CXCL8 and 
CCL4384 385 428.   The inflammatory reaction which ensues in the skeletal muscle 
shows a cellular influx of predominantly neutrophils and macrophages383 386 429 
which is comparable to the pattern seen in the uterus during labour219.  Of note, 
there is also a similar peripheral leukocyte response383 426 430 with increased 
neutrophils and decreased lymphocytes.  Additionally, there is a similarity in the 
systemic inflammatory response to surgery, trauma, and sepsis366-370 409 with a 
similar CK and Mb response409 suggesting this is a non-specific acute reaction to 
muscle damage. 
Clinically, the inflammation associated with skeletal muscle exercise presents as 
muscle soreness in the following hours and days, a phenomenon which is well 
recognised and referred to as delayed onset muscle soreness (DOMS), with the 
degree of soreness dependent on the type of exercise and amount of damage 
induced386.  The proposed timing and sequence of events involved in DOMS was 
proposed by Smith over 20 years ago and illustrated in Figure 101389.  
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Figure 101  Inflammation and cellular damage in exercising skeletal muscle 
The sequence of inflammatory events in response to contraction induced myocyte damage 
in exercising skeletal muscle.  Taken from Acute inflammation: the underlying mechanism 
in delayed onset muscle soreness?, L Smith,1991389 
In this model, leukocytes (mainly neutrophils and macrophages) are thought to 
play a pivotal role in clearing damaged tissue with subsequent muscle repair and 
remodelling.  Certainly in CCR2 null mice the repair of exercise damaged muscle 
is impaired and is thought to be an effect of reduced monocyte/macrophage 
recruitment despite a sparing of the neutrophil response431.  In addition, some 
CC chemokines (CCL2, CCL3 and CCL4) produced at the site of injury are thought 
to have a direct effect upon healing and repair of the damaged myocytes432 433. 
5.6.5 The role of inflammation in labour 
Overall, our data would suggest an association between contraction induced 
myocyte damage and the recognised inflammatory changes typical of term 
labour in humans.  This does not provide direct evidence of the initiating event, 
however, the concept of labour associated inflammation as a reaction to muscle 
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damage is somewhat supported by the inflammatory time course in the skeletal 
muscle model.   
The role of the inflammatory response in human labour is not addressed in this 
work.  However, there is a suggestion that rather than being involved in the 
initiation and propagation of labour, inflammation is required for tissue repair 
and remodelling.  Certainly, an inflammatory response appears to aid uterine 
involution in humans which is delayed in women who underwent a non-labouring 
caesarean section compared with normal labour, regardless of breast-feeding434 
435.  Additionally, monocyte infiltration to the uterus is not necessary for normal 
labour to occur in the CCR2 knock out mouse315, but appears to be required for 
skeletal muscle repair431.  There is also preliminary observational evidence from 
our lab which suggests that CCR2 deficient mice are more prone than their wild-
type counterparts to birthing difficulties in their second and third pregnancies. 
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5.7 Conclusion 
This is the first study to examine the maternal cellular and humoral 
inflammatory response to term pregnancy and labour and relate this to the 
degree of myocyte damage. 
Collectively our data suggest that the previously described inflammatory changes 
observed in human labour at term occur in response to contractile myometrial 
damage and may play a principal role in tissue repair and remodelling rather 
than the initiation of labour.  Overall, the evidence tends to support the 
hypothesis proposed at the start of this chapter and is summarised in Figure 102. 
 
 
Figure 102  Overall Hypothesis Chapter 5 
Proposed hypothesis summarising the inflammatory events of human labour. 
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6 Maternal and pregnancy characteristics and 
myometrial contractility in-vitro 
6.1 Introduction 
Obesity is a major health problem across the world.  In the UK, obesity affects 
one-fifth of the female population, with 18.8% of all females in the reproductive 
age group (16-44 years) classed as obese436-438.  Similar rises have been observed 
in the pregnant population in the UK and Ireland with up to one in five women 
booking for antenatal care being clinically obese with a BMI ≥30kg/m2 295 439 440.  
To date prospective cohort studies have demonstrated a wide variety of 
perinatal complications associated with maternal obesity which have been 
suggested to be independent of glucose tolerance status63 295 296 441, including a 
reduction in spontaneous term labour62, with a concomitant increase in necessity 
for post-dates induction of labour63-65, and an increased risk of emergency 
caesarean delivery (CS) for dysfunctional labour63 64 66 67, despite induction and 
augmentation of labour by oxytocin (OT) analogues62 66.  Furthermore the 
incidence of post-partum haemorrhage is increased with maternal obesity which 
is independent of mode of delivery and use of OT63 65 66.  Collectively these 
observational studies suggest that obesity has an inhibitory effect on myometrial 
function and response to OT. 
Traditionally the ineffectual progress in labour associated with maternal obesity 
has been attributed to either foetal macrosomia, narrowing of the pelvic outlet 
by adipose tissue deposition or inadequate active second stage of labour.  
However, caesarean delivery is required in a significant proportion of women 
even in the absence of  macrosomia442, furthermore magnetic resonance imaging 
(MRI) studies of pelvis do not support a role for adiposity obstructing labour443, 
and lastly intrauterine pressures exerted during active second stage are 
comparable in obese and lean women444.  
Given that myometrial function may be the common link between intrapartum 
and postpartum complications, myocyte specific explanations have been 
proposed, with the increases in myocyte cell membrane lipid content in obese 
women thought to be responsible299 445. Certainly pregnancy in obese women is 
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associated with exaggeration of the normal metabolic response and development 
of a dyslipidaemic environment, characterized by hypertriglyceridaemia and low 
high density lipoproteins446, which could potentially facilitate alterations to the 
membrane lipid composition.  Acute lipid loading of myocyte cellular membranes 
in-vitro with cholesterol or low-density lipoproteins has also been associated 
with a reduction in both spontaneous and OT induced contractility, with 
improvement in myocyte activity with lipid reduction299 300.  Alternatively, or in 
addition, obese pregnant women are hyperleptinaemic446, with leptin being an 
adipocyte derived hormone whose circulating levels are directly proportional to 
the amount of adipose tissue in the body.  In terms of uterine function, leptin 
has been shown to have a direct inhibitory effect on myometrial contractile 
activity in-vitro301.  Studies in rats have also suggested that high fat diets pre-
pregnancy and during pregnancy are associated with a lower myometrial 
expression of contraction associated proteins including connexin-43 which may 
influence contractile ability302. 
Additionally, other maternal characteristics including maternal age68-71, parity72 
73, previous mode of delivery74-78, gestation79 80 and birthweight79 have shown 
associations with clinical outcomes which can be regarded as related to 
myometrial contractility function and or response to OT. 
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6.2 Hypothesis 
The overall hypothesis to be examined in this chapter is summarised below in 
Figure 103. 
 
Figure 103  Overall Hypothesis Chapter 6 
Summary of the overall hypothesis concerning the effect of maternal characteristics on 
myometrial spontaneous contractility and myometrial contractile response to oxytocin (OT). 
Overall we hypothesised that where myometrium has a chronic exposure during 
pregnancy to a hyperlipidaemic and hyperleptinaemic environment (implied by a 
high early pregnancy body mass index (BMI)) that both spontaneous and OT 
induced contractility would be impaired and that this would underlie the clinical 
association with impaired myometrial function and apparent resistance to 
intervention with OT.  Additionally, high maternal age, increasing gestation, 
high birthweight, previous delivery by CS and low parity would be associated 
with reduced myometrial contractility and response to OT as suggested by the 
increased need for induction of labour and intrapartum caesarean section. 
The specific hypotheses to be tested are  
1. Spontaneous in-vitro myometrial contractility is impaired by maternal 
obesity in a body mass index (BMI) dependent manner. 
2. Myometrial contractile response in-vitro to OT is impaired by maternal 
obesity in a body mass index (BMI) dependent manner. 
Claire A Higgins, 2012   Chapter 6, 295  
3. Spontaneous in-vitro myometrial contractility is influenced by other 
maternal characteristics including age, parity, gestation and birthweight. 
4. Myometrial contractile response in-vitro to OT is influenced by other 
maternal characteristics including age, parity, gestation and birthweight. 
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6.3 Methods 
6.3.1 Patient Selection 
Myometrial biopsies were obtained as described previously in Chapter 2.  
Samples were collected on consecutive days; one sample per day was obtained 
from the first patient of the day providing inclusion criteria were met.  
Indications for planned caesarean delivery were, previous caesarean delivery (n 
= 65), breech presentation (n = 8), maternal request (n = 6), previous traumatic 
vaginal delivery (n = 5) and foetal reasons (n = 1). 
Early pregnancy demographic data were recorded for each woman including 
body mass index, maternal age and parity.  At the time of delivery the 
gestation, indication for elective caesarean delivery and birth weight were also 
recorded.   
6.3.2 In-vitro contractility and response to oxytocin (OT) 
Myometrial strips were dissected and placed under a 20mN tension in separate 
organ baths and left to develop spontaneous contractility as previously described 
in Chapter 2.  Where OT response was studied, a single addition of the drug was 
undertaken after the establishment of regular contractile activity, resulting in a 
bath concentration of 1nM with the contractile response observed for 60 
minutes.  OT concentration response curves were performed on separate sample 
strips by using cumulative additions of OT in the range 10-12 to 10-6 M, with an 
interval of 20 minutes between each addition.  
6.3.3 Contractile analysis 
Spontaneous activity was recorded where stable, regular, rhythmic activity was 
established within 4 hours after application of the 20mN resting tension.  A 
record of samples achieving spontaneous activity within 2 hours and between 2-4 
hours was made.  Three measures of contractile activity were assessed: 
frequency, amplitude and activity integral as described in Chapter 2.  Frequency 
was determined from the time interval between the peaks of two contractions 
occurring at the time point of interest, and was expressed as contractions/hour.  
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Contractile force was determined as the difference between baseline tension 
and maximal contraction amplitude in milli-Newtons (mN).  A summary measure 
of contractile activity was determined by the area under the tension curve and 
expressed as activity integral in mN.s.  For both amplitude and activity integral, 
spontaneous activity was determined by the average of three contractions when 
activity was regular, with response to a single concentration of OT measured as 
one contraction occurring at the time point of interest, either 0, 30 or 60 
minutes after addition of OT to the bath.  Contractile measurements of 
amplitude were recorded for OT concentration-response curves, with values 
recorded immediately prior to the next drug addition.  Concentration-response 
curves were constructed for each patient using percentage increase in amplitude 
from baseline activity.  A log EC50 [OT] was calculated for each strip.   
6.3.4 Statistical analysis  
For all strips achieving spontaneous contractions within 4 hours, contractile 
activity was analyzed using linear mixed effects regression models447 with 
random patient effects for each outcome, to account for the natural correlation 
in each measurement between strips taken from the same woman.  To improve 
the fit of each model in relation to the assumption of normally distributed 
residuals, contractile frequency was analyzed on a log transformed scale, whilst 
amplitude and activity integral were analyzed on a square root scale. The 
patient level estimates of the average contractile activity measures were 
extracted from each model and correlated amongst themselves and with other 
patient characteristics. Since the patient level average activity measures were 
estimated quantities, robust confidence intervals and p-values were derived by 
applying a bootstrap method448 estimating the required correlations from 10,000 
replicated datasets. 
For each woman, the number of strips that developed spontaneous contractions 
within 2 hours was analyzed using logistic regression, in relation to pregnancy 
characteristics, to assess factors associated with the rate with which 
spontaneous contractions were achieved. The effect of each characteristic was 
assessed individually, and multivariate models were used to assess which 
characteristics were independently associated with the rate of achieving 
spontaneous contractions. 
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Data from the single concentration OT experiments were analyzed  with similar 
linear mixed effects models; contractile activity measures at all four time points 
(pre-OT and 0, 30 or 60 minutes post-OT exposure) were included, with 
hierarchical random effects for women and strips within women, allowing for a 
general symmetric correlation structure between measurements at the four time 
points. The time response of each measure was modeled using fixed effects for 
time. Patient characteristics were then added to each regression model as fixed 
effects to assess whether they were associated with response to OT, either at all 
time points or at specific time points, through the inclusion of covariate-by-time 
interaction terms. 
Finally, linear mixed effects regression models were used to model log EC50 as 
estimated in the OT concentration experiment. Patient level predicted values 
were extracted and correlated with patient characteristics, with robust 
confidence intervals and p-values derived by bootstrapping with 10,000 
replicated datasets.  Estimated correlations and model effects are reported as 
estimate [95% confidence interval], p-value. No adjustments are made for 
multiple statistical testing.   
Statistical analysis of data in this chapter was outsourced and performed by The 
Robertson Centre for Biostatistics, University of Glasgow. 
6.3.5 Study Power 
Since the primary aim of the study was to estimate the association between 
contractile measurements and BMI, the sample size of 85 women had 80% power 
to detect a correlation of 0.300 between maternal BMI and the model predicted 
patient level average for each measurement.  With an average of 7.2 strips 
analyzed for each patient, this is equivalent to a correlation of 0.112 between 
maternal BMI and contractile measurements from a single strip. 
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6.4 Results 
6.4.1 Demographic data 
Myometrial biopsies were obtained from 85 women with maternal BMI ranging 
from 18.0 – 42.2kg/m2.  World Health Organisation (WHO) definitions of BMI 
revealed that in our study group 2 women (2.3%) were underweight (BMI < 18.5), 
38 women (44.7%) were in the normal range (BMI = 18.5-24.99), 23 (27.1%) were 
overweight (BMI = 25.0-29.99), 13 (15.3%) were obese class I (BMI = 30.0-34.99), 
6 (7.1%) were obese class II (BMI = 35.0-39.99) and 3 (3.5%) obese class III (BMI ≥ 
40).  Strips were analyzed where spontaneous contractions were observed within 
4 hours (609 strips) and in two experimental subsets, namely a single 
concentration OT response group (56 strips from 39 women) and an OT 
concentration-response group (40 strips from 21 women, of whom 15 were 
included in the analysis of the response to a single concentration of OT).  Patient 
characteristics are shown for each group in Table 32; no significant differences 
were observed between those women included or excluded from each subgroup.   
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Single Oxytocin 1nM Response Oxytocin Concentration Response 
  
Spontaneous 
Contractions  Included Excluded p-value 
 
Included Excluded p-value 
N Women 85  39 46   21 64  
N Strips 609  56    40   
BMI (kg/m2) 
Median (IQR) 
[Range] 
25.0 (22.9, 30.0) 
[18.0, 42.2] 
 
24.3 (22.3, 28.0) 
[18.5, 42.2] 
26.1 (23.0, 31.8) 
[18.0, 40.0] 
p=0.202  
27.3 (23.6, 34.2) 
[18.0, 42.2] 
24.9 (22.4, 28.6) 
[18.0, 40.0] 
p=0.141 
Age (years) 
Median (IQR) 
[Range] 
31.0 (27.0, 35.0) 
[19.0, 42.0] 
 
31.0 (27.0, 34.5) 
[21.0, 41.0] 
32.0 (27.0, 35.0) 
[19.0, 42.0] 
p=0.418  
32.0 (28.0, 35.0) 
[19.0, 42.0] 
31.0 (27.0, 34.2) 
[21.0, 41.0] 
p=0.556 
Gestation (days) 
Median (IQR) 
[Range] 
273 (273, 275) 
[259, 284] 
 
273 (273, 274) 
[259, 284] 
273 (273, 275) 
[263, 282] 
p=0.874  
274 (273, 275) 
[269, 276] 
273 (273, 275) 
[259, 284] 
p=0.378 
Birth Weight (kg) 
Median (IQR) 
[Range] 
3.55 (3.18, 3.78) 
[2.18, 4.72] 
 
3.50 (3.20, 3.73) 
[2.18, 4.72] 
3.62 (3.21, 3.83) 
[2.48, 4.57] 
p=0.449  
3.66 (3.31, 3.97) 
[2.30, 4.72] 
3.54 (3.17, 3.70) 
[2.18, 4.57] 
p=0.418 
Ethnicity 
N (%) Caucasian 
N (%) Non-Caucasian 
79 (92.9%) 
6 (7.1%) 
 
35 (89.7%) 
4 (10.3%) 
44 (95.7%) 
2 (4.3%) 
p=0.406  
20 (95.2%) 
1 (4.8%) 
59 (92.2%) 
5 (7.8%) 
p=1.000 
Indication 
for Caesarean 
N (%) Previous Caesarean 
N (%) Other 
63 (74.1%) 
22 (25.9%) 
 
30 (76.9%) 
9 (23.1%) 
33 (71.7%) 
13 (28.3%) 
p=0.627  
16 (76.2%) 
5 (23.8%) 
47 (73.4%) 
17 (26.6%) 
p=1.000 
Parity 
N (%) =0 
N (%) =1 
N (%) ≥2 
11 (12.9%) 
53 (62.4%) 
21 (24.7%) 
 
5 (12.8%) 
23 (59.0%) 
11 (28.2%) 
6 (13.0%) 
30 (65.2%) 
10 (21.7%) 
p=0.551  
2 (9.5%) 
12 (57.1%) 
7 (33.3%) 
9 (14.1%) 
41 (64.1%) 
14 (21.9%) 
p=0.282 
Table 32  Patient demographic details 
Characteristics of women included in the main study group ('Spontaneous Contractions'), and each substudy group ('Single Oxytocin 1nM Response' and 
'Oxytocin Concentration Response'). 
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Spontaneous contractile activity 
Variations in spontaneous activity of myometrial strips between women and 
between strips were accounted for with linear mixed effects models, giving an 
average frequency across the 85 women of 7.22 (range 4.39, 11.89) 
contractions/hour, with an average amplitude of 55.57 (range 24.74, 98.72) mN 
and activity integral of 3383 (range 1335, 6365) mN.s.  No correlation was found 
between maternal BMI and any indices of spontaneous myometrial contractile 
activity: frequency (r=-0.03 [-0.26, 0.30], p=0.780), amplitude (r=0.12 [-0.07, 
0.30], p=0.228), activity integral (r=-0.13, [-0.32, 0.08], p=0.231).  As expected, 
there was a correlation between increasing maternal BMI and increasing infant 
birth weight (r=0.54, [0.38, 0.68], p<0.001).  However, in terms of myometrial 
activity, birth weight, maternal age, parity, previous caesarean delivery and 
gestational age were unrelated to spontaneous contractility (Table 33). 
  Frequency Amplitude 
Activity 
Integral 
BMI 
BMI 
Correlation 
(95% CI) 
p-value 
-0.03 
(-0.26, 0.30) 
p=0.780 
0.12 
(-0.07, 0.30) 
p=0.228 
-0.13 
(-0.32, 0.08) 
p=0.231 
 
Age 
Correlation 
(95% CI) 
p-value 
-0.13 
(-0.33, 0.08) 
p=0.205 
-0.02 
(-0.23, 0.26) 
p=0.815 
-0.02 
(-0.23, 0.19) 
p=0.874 
0.15 
(-0.07, 0.34) 
p=0.171 
Gestational 
age 
Correlation 
(95% CI) 
p-value 
-0.13 
(-0.34, 0.09) 
p=0.274 
0.00 
(-0.23, 0.24) 
p=0.950 
0.05 
(-0.15, 0.22) 
p=0.580 
-0.03 
(-0.21, 0.13) 
p=0.684 
Birth 
weight 
Correlation 
(95% CI) 
p-value 
0.01 
(-0.19, 0.20) 
p=0.927 
0.10 
(-0.12, 0.35) 
p=0.436 
-0.12 
(-0.31, 0.04) 
p=0.195 
0.54 
(0.38, 0.68) 
p<0.001 
Previous 
caesarean 
delivery 
Correlation 
(95% CI) 
p-value 
0.16 
(-0.07, 0.35) 
p=0.166 
-0.13 
(-0.31, 0.07) 
p=0.196 
0.07 
(-0.14, 0.28) 
p=0.497 
0.20 
(-0.04, 0.44) 
p=0.092 
Parity 
Correlation 
(95% CI) 
p-value 
0.10 
(-0.12, 0.31) 
p=0.382 
-0.10 
(-0.37, 0.13) 
p=0.451 
0.07 
(-0.11, 0.25) 
p=0.397 
0.21 
(-0.02, 0.40) 
p=0.061 
Table 33  Correlation between maternal characteristics and contractile activity 
Correlations between patient average frequency, amplitude and activity integral of 
spontaneous contractions, based on linear mixed effects models of transformed variables, 
and maternal BMI, age, gestational age, birth weight, number of previous caesarean 
deliveries and parity. 
The association between maternal characteristics and the proportion of strips 
contracting spontaneously within 2 hours is shown in Table 34.  Univariate 
analysis demonstrated that maternal BMI, ethnicity and gestational age at birth 
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did not appear to affect time to development of spontaneous activity.  However, 
strips were more likely to develop regular spontaneous activity within 2 hours in 
older mothers, those with increased parity relative to nulliparous women or if 
they had a previous caesarean delivery.  Greater infant birth weight appeared to 
be associated with a reduced probability of spontaneous contraction within 2 
hours.  Subsequent multivariate logistic regression of the proportion of strips 
spontaneously contracting within 2 hours found that the previously observed 
association with parity was explained by the association with maternal age.  
Nevertheless, independent associations were found for maternal age, birth 
weight and previous caesarean delivery, with the latter independent of the 
indication for previous caesarean section.  Therefore, despite contractile 
strength being unaffected by maternal characteristics,  strips taken from 
mothers over 35 years, with a previous caesarean delivery or with smaller babies 
tended to spontaneously contract sooner than those from other women. 
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Univariate Association Multivariate Association 
Factor Level N strips/Total (%) 
Odds Ratio (95% CI) p-value 
 
Odds Ratio (95% CI) p-value 
BMI 
(kg/m2) 
<25 
25-30 
>30 
272/299 (91.0%) 
131/143 (91.6%) 
150/167 (89.8%) 
1.00  
1.08 (0.53, 2.20) 
0.88 (0.46, 1.65) 
0.856  -  
Age 
(years) 
< 30 
30-34 
35+ 
220/249 (88.4%) 
174/198 (87.9%) 
159/162 (98.1%) 
1.00  
0.96 (0.54, 1.70) 
6.98 (2.12, 22.99) 
<0.001  
1.00 
0.86 (0.44, 1.68) 
5.21 (1.50, 18.10) 
p=0.002 
Gestation 
(days) 
≤ 39 wks 
> 39 wks 
304/333 (91.3%) 
249/276 (90.2%) 
1.00  
0.88 (0.51, 1.52) 
0.648  -  
Birth Weight 
(kg) 
< 3.5 kg 
≥ 3.5 kg 
250/262 (95.4%) 
274/313 (87.5%) 
1.00  
0.34 (0.17, 0.66) 
0.001  
1.00 
0.31 (0.15, 0.61) 
p<0.001 
Ethnicity 
Caucasian 
Non-Caucasian 
511/560 (91.2%) 
42/49 (85.7%) 
1.00  
0.58 (0.25, 1.35) 
0.227  -  
Previous 
caesarean delivery 
No 
Yes 
127/149 (85.2%) 
416/450 (92.4%) 
1.00  
2.12 (1.20, 3.75) 
0.012  
1.00 
2.36 (1.21, 4.58) 
p=0.013 
Parity 
0 
1 
≥ 2 
75/87 (86.2%) 
339/377 (89.9%) 
139/145 (95.9%) 
1.00  
1.43 (0.71, 2.86) 
3.71 (1.34, 10.26) 
0.021  -  
Table 34  Association between maternal characteristics and time to developing contractile activity 
Associations between patient characteristics and probability of spontaneous contraction within 2 hours, from univariate logistic regression models for each 
characteristic, and from multiple logistic regression model found by forward stepwise regression approach. 
Claire A Higgins, 2012   Chapter 6, 304  
6.4.2 Contractile response to a single addition of oxytocin (OT) 
Exposure to a concentration of 1nM OT produced an immediate increase in 
contractile activity in the strips, with model predictions of the average response 
for each time point for frequency, amplitude and activity integral shown in 
Figure 104.  Maternal BMI was unrelated to all measures of contractile response 
to 1nM OT. The estimated changes in each contractile measure for every 5kg/m2 
increase in BMI were: for log frequency, +0.03 [-0.04, 0.09], p=0.454; for the 
square root of amplitude, -0.29 [-0.89, 0.31], p=0.352; for the square root of 
activity integral, -4.9 [-10.6, 0.8], p=0.098.  Additionally, there was no evidence 
that contractile response to OT was affected by any other patient characteristic 
including maternal age, gestation, birth weight, ethnicity, parity or previous 
caesarean delivery (Table 35). 
 
Figure 104  Contractile response to OT 
Model predictions of average myometrial contractile activity (with 95% confidence interval) 
as measured by frequency, amplitude and activity integral following exposure to a single 
concentration (1nM) oxytocin. 
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Measure Factor Estimate 95% CI p-value 
Frequency 
 
BMI 
Maternal Age 
Gestational Age 
Birth weight 
Ethnicity 
Indication for LUSCS 
Parity 
 
0.03 
-0.08 
0.09 
0.21 
0.34 
-0.07 
0.02 
 
(-0.04, 0.09) 
(-0.29, 0.13) 
(-0.04, 0.22) 
(-0.08, 0.51) 
(0.00, 0.68) 
(-0.27, 0.13) 
(-0.09, 0.14) 
 
0.454 
0.469 
0.175 
0.162 
0.058 
0.489 
0.664 
Amplitude 
 
BMI 
Maternal Age 
Gestational Age 
Birth weight 
Ethnicity 
Indication for LUSCS 
Parity 
 
 
-0.29 
-0.63 
-0.65 
0.06 
1.36 
-0.20 
0.44 
 
(-0.89, 0.31) 
(-2.06, 0.81) 
(-1.51, 0.21) 
(-2.66, 2.77) 
(-0.95, 3.67) 
(-1.81, 1.40) 
(-0.41, 1.29) 
 
0.352 
0.398 
0.145 
0.966 
0.256 
0.805 
0.317 
Activity Integral 
 
BMI 
Maternal Age 
Gestational Age 
Birth weight 
Ethnicity 
Indication for LUSCS 
Parity 
 
 
-4.9 
3.5 
-7.5 
4.4 
12.8 
1.7 
7.9 
 
(-10.6, 0.8) 
(-10.7, 17.7) 
(-15.8, 0.8) 
(-23.0, 31.8) 
(-10.0, 35.6) 
(-14.1, 17.4) 
(-0.2, 15.9) 
 
0.098 
0.628 
0.084 
0.756 
0.277 
0.838 
0.063 
Table 35  Effects of maternal characteristics on contractile response to OT 
Estimated effects of BMI (per 5 kg/m2 increase), maternal age (per 10 year increase), 
gestational age (per 5 day increase), birth weight (per 500 g increase), ethnicity (Caucasian 
vs. Other), indication for caesarean delivery (LUSCS) (Previous LUSCS vs. Other) and parity 
(per additional pregnancy) on the contractile response to a single concentration of 1nM OT 
6.4.3 Oxytocin (OT) concentration response curves 
Cumulative additions of OT in the range 10-12 to 10-6 M resulted in a gradual 
increase in amplitude from baseline median 53.9 mN (35.0 - 81.5) to maximal 
amplitude at 10-7M of 101.7 mN (81.6-117.2) with a slight fall in amplitude after 
maximal activity. Based on the model, the expected mean log EC50 [OT] was -9.7 
(5-95% range -10.7, -8.7), and was unrelated to maternal BMI (r=0.03 [-0.36, 
0.35], p=0.977) (Figure 105).  Parity, maternal age, gestational age, birth weight 
and previous caesarean delivery were similarly unrelated to log EC50 [OT] (Table 
36).  
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Figure 105  Correlation of maternal BMI and log EC50 [OT] 
Scatter plot of model predicted log EC50 [OT] relative to maternal BMI, with line showing 
average log EC50 [OT] 
  log EC50 
BMI 
Correlation 
(95% CI) 
p-value 
0.00 
(-0.36, 0.35) 
p=0.977 
Age 
Correlation 
(95% CI) 
p-value 
0.02 
(-0.49, 0.38) 
p=0.846 
Gestational 
Age 
Correlation 
(95% CI) 
p-value 
-0.06 
(-0.44, 0.26) 
p=0.713 
Birth 
Weight 
Correlation 
(95% CI) 
p-value 
0.15 
(-0.30, 0.55) 
p=0.513 
Previous 
LUSCS 
Correlation 
(95% CI) 
p-value 
0.12 
(-0.30, 0.49) 
p=0.509 
Parity 
Correlation 
(95% CI) 
p-value 
0.15 
(-0.32, 0.57) 
p=0.438 
 
Table 36  Correlation between maternal characteristics and log EC50 [OT] 
Correlations between patient average log EC50 for the response of amplitude to OT, based 
on a linear mixed effects model, and maternal BMI, age, gestational age, birth weight, 
number of previous LUSCS and parity. 
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6.5 Summary of Results 
6.5.1 Maternal BMI and spontaneous contractile activity  
• Maternal BMI does not influence myometrial spontaneous contractile 
activity in-vitro  
6.5.2 Maternal BMI and contractile response to oxytocin (OT) 
• Maternal BMI does not influence myometrial contractile response to OT in-
vitro 
6.5.3 Maternal and pregnancy characteristics and spontaneous 
contractile activity 
• Maternal and pregnancy characteristics of age, ethnicity, parity, previous 
caesarean delivery, gestation and birth weight do not influence 
myometrial spontaneous contractile activity (amplitude, frequency and 
activity integral) in-vitro. 
• There is a tendency for the maternal characteristics of older age (>35 
years), previous caesarean delivery or smaller baby to shorten the time 
required for myometrium in-vitro to establish spontaneous activity 
despite no influence on contractile strength. 
6.5.4 Maternal and pregnancy characteristics and contractile 
response to oxytocin (OT) 
• Maternal and pregnancy characteristics of age, ethnicity, parity, previous 
caesarean delivery, gestation and birth weight do not influence 
myometrial contractile response to OT in-vitro. 
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6.6 Discussion 
6.6.1 Myometrial contractility and maternal BMI 
In this study we clearly demonstrate that maternal obesity is not associated with 
an alteration in in-vitro myometrial function. Specifically maternal obesity does 
not impair the ability of the myometrium to generate spontaneous contractile 
activity as measured by contraction amplitude, frequency of contractions and 
activity integral.  Furthermore, we demonstrate that increasing maternal BMI 
does not alter the myometrial response to either a single concentration of OT or 
cumulative additions of OT (concentration response).  These findings are 
applicable to the obstetric population since the maternal BMI distribution in our 
sample set is comparable with that in both the general and obstetric female 
population436 439.  
The dyslipidaemic environment of obese mothers446 449 has the potential to 
modulate cellular membrane lipid content445 450 451.  In particular the areas with 
a high cholesterol content may be affected, namely lipid rafts or caveolae, 
which are associated with and can alter efficacy of calcium channels451 and OT 
receptors450 – key systems in regulating myometrial contractile responses. The 
increasing hyperlipidaemic state of pregnancy across gestation452 may therefore 
facilitate an increase in cellular membrane activity in preparation for labour. In 
support of this, OT receptors450 and caveolae453 are noted to increase in number 
with increasing gestation. Furthermore cholesterol deposition within the cell 
membrane allows stabilization of the OT receptor with enhanced agonist 
affinity450.  These lipid dependent effects on OT receptors may ensure an 
adequate response to OT in obese women.  
The findings related to maternal BMI and contractility are in agreement with 
other data which found no relationship between BMI and in-vitro spontaneous 
contractile activity in addition to no relationship with response to the tocolytics 
nifedipine and indomethacin454.  However, there is a contrast with other 
previous smaller studies examining in-vitro myometrial spontaneous contractile 
activity.  This potentially reflects technical differences with respect to the organ 
bath work in terms of organ bath solutions, temperature and the degree of 
tension applied to the strip.  It may also reflect the number of women in the 
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study or the previous lack of accounting for inter-strip variability, with the 
current study including at least 3, and an average of 7.2 strips per patient, 
ultimately increasing the robustness of our findings66 300 301.  Additionally, in 
previous studies examining the alteration of the membrane composition, 
differences in maternal BMI were not considered300 301.  These studies may 
therefore only reflect the effect of acute changes in membrane composition in 
comparison to this study where samples were exposed to the hyperlipidaemic 
and hyperleptinaemic environment for the prolonged period of pregnancy where 
myometrium may adapt to maintain a pro-contractile state.   
The observed response to a single concentration of OT is of interest; initial high 
frequency contractions with subsequent return to baseline frequency, and 
maintenance of an increased amplitude and activity integral over 1 hour.  This 
reflects the ideal pattern of contractions required for the safe delivery of an 
infant, with a balance between frequency and force providing sufficient energy 
to encourage passage through the pelvic outlet, but still allowing time for 
recovery of uterine and placental blood flow between contractions. 
6.6.2 Contractility and other maternal characteristics 
Similar to the relationship with maternal BMI, increased maternal age is known 
to be associated with increased rates of dysfunctional labour, augmentation of 
labour with OT, and an increase in the need for intrapartum caesarean delivery68 
69.  Data presented show no relationship between maternal age and the ability of 
the myometrium to produce a contractile force in-vitro, and in fact myometrium 
from older mothers achieves stable contractile activity quicker than younger 
mothers.  This suggests that myometrium per se is not affected by age, lending 
support to the alternative hypothesis that contractility is modulated by age 
related changes in the uterine blood supply (see section 6.6.3.1 for further 
discussion)69.   
Our data also confirm other large observational studies where increasing 
maternal BMI is correlated with increased birth weight63 296, and although 
birthweight may be surrogate for uterine stretch our data do not suggest a 
relationship with myometrial contractile activity, either spontaneous or OT 
induced.   
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This study similarly does not demonstrate a relationship between previous 
caesarean delivery and myometrial activity. This is consistent with our sampling 
techniques avoiding scar tissue, the high incidence of successful vaginal birth77 
and no difference in progress in the first stage of labour after a previous 
caesarean delivery309.  It would also suggest that the increased risk of scar 
rupture during induction of labour is not related to a problem with the 
contractile mechanisms per se, but reflects the weakness of the uterine scar. 
6.6.3 Alternative mechanisms of poor contractility in-vivo 
Given the lack of an impact of maternal obesity on the relationship of 
myometrial function and OT, we would suggest that alternative mechanisms are 
responsible for the observed high rates of dysfunctional labour in obese mothers.   
6.6.3.1 Alteration in microvascular function and accumulation of 
lactic acid 
Microvascular function is impaired in conjunction with maternal obesity at all 
stages of pregnancy455 456 and this impairment in circulation may result in the 
local accumulation of metabolic waste products including lactic acidic – a known 
inhibitor of myocyte contractile function457.  Notably we have also observed a 
time dependent decrease in myometrial function in-vitro consistent with a 
detrimental effect of metabolite accumulation on myocyte function.  Consistent 
with this blood from myometrial capillaries of women experiencing dysfunctional 
labour has a significantly lower pH, higher lactate and lower oxygen saturation 
than samples from women not in labour, and those labouring normally with or 
without syntocinon458.    Increases in maternal age also affect microvascular 
function459 and in addition, evidence also suggests age related changes to the 
walls of the larger uterine arteries69, which may explain the increased rate of 
dysfunctional labour in this group of women68 69. Interestingly, women with pre-
eclampsia have also been shown to have microvascular dysfunction460, and 
although little evidence exists to the length of labour in this group of women, 
available data suggest either no difference461 or a prolonged induction to 
delivery time compared to case matched unaffected women462.   
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6.6.3.2 Asynchrony of uterine contractions and cervical ripening 
The rate of cervical dilatation in obese women is also significantly slower than 
normal weight women62 and despite OT augmentation and significant 
improvement in myometrial contractility, caesarean delivery may still be 
required for failure to progress463.  Changes in cervical structure occur across 
gestation including remodelling of cervical smooth muscle97 with longer cervical 
length in the second trimester predictive of caesarean at term and  cervical 
length positively associated with maternal obesity464.  These gradual changes in 
cervical structure occur in conjunction with gestation related changes in the 
myometrium and indeed mathematical modelling of the acute changes in 
association with labour suggest that asynchrony of uterine and cervical 
structural changes result in slow progress, which is difficult to overcome despite 
normal or high contractile pressures465.  The increased risk of caesarean delivery 
may therefore be in part iatrogenic as if in the obese mother, the cervix does lag 
behind the uterus in its ability to prepare for labour, cervical priming may be 
more difficult, and syntocinon commenced prior to sufficient change in 
composition or effacement of the cervix.  This may lead to a situation where 
smooth muscle cells are still within the tubular structure of the cervix, and when 
stimulated with exogenous OT they contract, thereby providing resistance to the 
myometrial force and ultimately the cervix in unable to dilate466.  This is in part 
supported by the finding that over 50% of women who in their first pregnancy 
had a caesarean delivery performed for dysfunctional labour, managed to have a 
vaginal delivery in the subsequent pregnancy77, and suggests that consideration 
for alternative cervical priming regimes should be given to women with higher 
BMI.  
These changes in cervical dilatation do not, however, explain the observed 
increase in postpartum haemorrhage in conjunction with vaginal deliveries.  
Instead this association may simply reflect the increased birth weight of 
offspring of obese mothers63 296 with a concomitant increase in placental size and 
thereby placental bed size the main source of atonic bleeding. 
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6.7 Conclusion 
The data presented within this chapter demonstrate through the use of in-vitro 
contractility studies that maternal obesity does not impair spontaneous or OT 
induced myometrial contractions in-vitro, suggesting that the observed 
implication of obesity on parturition in vivo (high rates of induction of labour, 
high rates of intrapartum caesarean delivery and post partum haemorrhage) 
cannot be explained by an effect on myometrial contraction per se.  Suggestions 
for alternative mechanisms which may be responsible for the observed increased 
risk in myometrial related complications have been proposed, which may include 
impaired microvascular function or asynchrony in preparation of the cervix for 
labour.  Both mechanisms merit further investigation as targets to ultimately 
promote labour, decrease rates of intrapartum caesarean delivery for 
dysfunctional labour and reduce post partum haemorrhage in obese mothers. 
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7 Discussion and Future Research 
The process of parturition resulting in the delivery of a newborn is a 
fundamental event ensuring survival of the species.  In humans, the main clinical 
problems of parturition include activation of the process too early or too late 
resulting in the delivery of pre-term and post-term infants, both with their own 
implications for future health of the mother and baby8 14 37 44 45 467-470.  
Additionally, where parturition systems are not activated correctly, 
dysfunctional labour with the resulting need for caesarean delivery may occur58-
61 471, with further complications still feasible after the delivery namely atonic 
post-partum haemorrhage4 81-83.  Overall, in the UK approximately 40% of 
pregnancies are affected by one of these problems 3 4 58-61 83.  However, the exact 
processes involved in the initiation and maintenance of parturition in the human 
are not fully understood.  With such an important event, influences are most 
likely to be multi-factorial, with hormonal, mechanical, inflammatory, 
biochemical and maternal environmental factors playing a part.  
In this thesis I have explored a range of factors associated with human 
parturition.  The advantages of using a temporal analysis approach in 
combination with in-vitro and in-vivo data are revealed, all of which I believe to 
add strength to our findings and conclusions. 
7.1 Oxytocin 
The hormone oxytocin (OT) plays a major role in the stimulation of uterine 
contractility and can help facilitate human parturition, both when labour onset 
is spontaneous or induced.  In this section we focussed on the long term (hours) 
cellular effects of OT on the contracting myometrium as it has been suggested 
that OT may prepare the myocytes for efficient and effective labour by 
transcriptional changes influencing a pro-contractile phenotype180 327. 
We confirmed Blair Bell’s century old observation of the uterotonic effects of OT 
on our in-vitro samples with immediate increases in contractile activity 
following addition to the organ bath148.  However, despite evidence suggesting 
‘priming of the uterus’ by long term exposure to OT, our in-vitro time and 
contraction series analysis did not reveal any transcriptional changes over and 
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above those seen in spontaneously contracting samples.  Possible reasons for our 
observation are discussed within the chapter, and overall our results may 
suggest that the uterotonic effects of OT occur by actions facilitating or 
modulating pre-existing intracellular pro-contractile proteins rather that de-
novo transcriptional changes. 
7.2 The myometrial temporal transcriptional wave and 
inflammation 
To our knowledge, we are the first to examine the time dependent 
transcriptional changes which take place within human myometrium in response 
to repeated contractile activity.  The most striking finding was the temporal 
transcriptional wave which was dominated by genes associated with the cellular 
processes of inflammation, cellular damage and apoptosis with a concomitant 
down regulation of genes associated with cellular metabolism.  Previous data 
from our department suggest similar changes to myometrial transcription are 
seen in-vivo in response to labour211.  Despite limitations of in-vivo data with 
only 2 timepoints (‘not in labour’ or ‘in labour’), we found an overlap of 
contraction associated genes with a preponderance of genes associated with the 
inflammatory response. 
Confirmation that the inflammatory response was contraction induced was 
suggested by comparison with metabolically active but non-contracting samples.  
Here we found that despite evidence of an inflammatory response in the non-
contracting, metabolically active samples, the response was greatly enhanced 
over and above these levels where the myometrium contracted.  These data 
suggest that it is the repeated physical contractile activity of the myometrium 
which is the driving force behind the pro-inflammatory shift associated with 
human labour.   
We also examined the paradigm of infection causing inflammation which in turn 
activates contractile activity.  However, this proposal was not confirmed by our 
data.  In contracting myometrium exposed to an infective LPS environment, the 
transcription of genes associated with inflammation was certainly greatly 
upregulated compared to contracting myometrium in a non-infective/non-
inflammatory environment.  However, despite enhancement of these pro-
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inflammatory changes, we observed no impact on any measure of contractile 
activity.  This is contrary to other proposals which have suggested inflammation 
is necessary to promote contractility in the myometrium 210 216 217 230-236.  This 
discordance may underlie why trials of anti-inflammatory medication and 
antibiotics in the prevention and treatment of preterm labour have 
demonstrated non-consistent results239-241 261 271 287 289 290 350 472. 
Additionally, the link between cellular damage and a non-specific inflammatory 
response was suggested by the use of various tocolytic agents.  We found the 
results to be initially surprising, with myometrium treated with the tocolytic 
agents nifedipine, ritodrine, levcromakalim and progesterone mounting an 
inflammatory response comparable with that seen in contracting samples.  
However, the tocolytic ML7 showed suppression of inflammation.  This suggests 
that inflammatory upregulation is influenced by the method of tocolysis.  In this 
case, the difference may be explained by the level of the contractile pathway 
which is altered.  Where ‘down-stream’ processes are blocked (e.g. MLCK 
blockage by ML7) the inflammatory response is inhibited, whereas when ‘up-
stream’ events are modulated (e.g. calcium entry inhibition via nifedipine) this 
effects many other cellular activities which are not contraction related.  The 
abnormal regulation of these cellular processes may be perceived by the cell as 
cellular damage, thereby leading to the tissue upregulating inflammatory 
processes.  However, our data do not prove this theory and further investigation 
of myometrial reactions to chemical tocolytics including prostaglandin inhibitors,  
would be of interest. 
Overall, data suggest that the myometrium is able to mount a non-specific 
inflammatory response to cellular damage whether this is induced by 
contractions, infection or chemical means.  Additionally, with an extended 
exposure to cellular damage, for example contraction time, the more intense 
the degree of inflammatory response mounted by the myometrium. 
7.3 Maternal peripheral inflammatory changes in 
pregnancy and during labour 
Compared to non-pregnant controls, we found only minor changes to circulating 
markers of inflammation, with an overall picture of low grade inflammation 
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associated with term pregnancy.  These changes included the well described 
neutrophil driven leukocytosis355-357, concomitant increased GCSF and lower 
CCL11 and CCL22, with CRP levels increased despite remaining within the 
accepted ‘normal range’373 374.  In terms of leukocyte cell surface marker 
expression, we found no difference between groups and no evidence of 
leukocyte priming in the circulation of women at term.  This is contrary to 
suggestions of others372, however, in contrast to other studies, our data can be 
considered more representative of both term pregnancy induced and parturition 
induced changes since we used repeated measures on the same patients with a 
non-labouring baseline measurement in addition to having data from two 
comparison groups; a non-pregnant population and those pre and post a non-
labouring caesarean delivery.  Ideally, it would also be advantageous to examine 
gestation dependent changes to leukocyte cell surface chemokine receptor 
expression, and data collection for this is currently being undertaken within our 
department. 
In terms of a temporal wave of inflammatory changes in response to labour, we 
have been able to demonstrate that this also occurs within the maternal 
circulation.  Additionally by using the comparison group of women undergoing 
non-labouring caesarean delivery (CS), we were able to control for delivery of an 
infant.  Therefore, given that the extent of change was more pronounced in 
response to labour this suggests that the observed inflammatory changes may be 
contraction dependent.  Overall, the inflammatory changes within the maternal 
circulation during labour tend to represent those observed during an acute 
inflammatory response which is commonly associated with other stimuli 
including infection and surgical trauma264 365-371.  We also found that alterations 
to circulating leukocyte numbers and cytokine concentrations were consistent 
with the chemotaxis of leukocytes into labouring myometrium which has been 
noted by other studies219 220.  Additionally we also found an overlap with the in-
vitro myometrial transcription data with similar responses for CXCL1, CXCL2, 
IL10, IL6, CXCL8 and CCL2 which suggest the circulating cytokines may originate 
from the contracting myometrium.   
CRP levels showed a tendency to increase the longer the labour progressed.  
However, differential levels for CRP pre-labour to post-labour were not 
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significant, though this is most probably a reflection of the delay between initial 
inflammatory response and hepatic manufacture of CRP. 
Overall, we suggest that pregnancy per se results in a recognised low grade 
inflammatory response.  However the labour associated inflammatory changes 
seem to be restricted to a non-specific acute inflammatory response during the 
period where the uterus is undergoing repeated contractions.  Additionally we 
found no evidence to suggest circulating leukocytes undergo priming or 
preparation for the event of parturition. 
7.4 Myometrial and systemic inflammatory responses 
and the association with cellular damage 
The association between the inflammatory response of labour, and contraction 
induced myometrial cell damage is proposed by the combination of data using 
both in our in-vitro and in-vivo models of labour. 
Using the in-vitro model, the observed myometrial transcriptional changes were 
time and contraction dependent, and were dominated by the concomitant 
upregulation of genes involved in the cellular processes of inflammation and 
cellular damage/apoptosis.  Additionally, as discussed earlier, a similar non-
specific inflammatory transcriptional response can also occur as a result of non-
contractile myocyte damage i.e. infection or chemical mediated damage. 
This relationship between myocyte damage and inflammation was further 
confirmed by the in-vivo data showing a strong association between maternal 
circulatory inflammatory response and the release of the muscle damage 
specific proteins creatine kinase (CK) and myoglobin (Mb). 
Overall, these data supports our earlier proposal of inflammation in labour as a 
non-specific response to cellular damage, including contraction induced damage, 
with additional support suggested by the similarities with exercising skeletal 
muscle models383 386 389 425-429.   
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7.5 The uterus as an exercising muscle  
Overall the evidence supplied within the context of this thesis tends to support 
the concept of the labouring uterus as an exercising muscle, with significant 
similarities between labour and the cellular and humoral responses by skeletal 
muscle to exercise.  Research on exercising skeletal muscle suggests that 
contractions cause myocyte damage, which in turn drives myocyte release of 
inflammatory mediators and promotion of the ensuing circulating inflammatory 
changes including leukocyte influx into the damaged muscle 383 386 389 425-429 
The inflammatory response seen in the exercising skeletal muscle model has 
been suggested to be involved with the repair and remodelling of damaged 
muscle tissue with leukocytes (mainly neutrophils and macrophages) playing a 
pivotal role in clearing damaged tissue with subsequent muscle repair, 
remodelling and restoration of function389 429.  Certainly in CCR2 null mice the 
repair of exercise damaged muscle is impaired and is thought to be an effect of 
reduced monocyte/macrophage recruitment despite a sparing of the neutrophil 
response431.  In addition, some CC chemokines (CCL2, CCL3 and CCL4) and IL6 
produced at the site of injury are thought to have a direct effect upon healing 
and repair of the damaged myocytes432 433 473. 
The role of the inflammatory response in human labour is not addressed in this 
work.  However, there is a suggestion that rather than being involved in the 
initiation and propagation of labour, inflammation is required for tissue repair 
and remodelling.  Certainly, an inflammatory response appears to aid uterine 
involution in humans which is delayed in women who underwent a non-labouring 
caesarean section compared with normal labour, regardless of breast-feeding434 
435.  Additionally, monocyte infiltration to the uterus is not necessary for normal 
labour to occur in the CCR2 knock out mouse315, but appears to be required for 
skeletal muscle repair431.  There is also preliminary observational evidence from 
our lab which suggests that CCR2 deficient mice are more prone than their wild-
type counterparts to birthing difficulties in their second and third pregnancies. 
If our proposal regarding the role of inflammation in labour is correct, it would 
suggest that the inflammatory process may be necessary for sufficient involution 
of the postpartum uterus, and may also be required for adequate repair of 
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damaged tissues in order that they may be used again in the future for 
pregnancy and parturition.  Furthermore, our data suggest that inflammation 
may not be a suitable target in the manipulation of labour, either in the pre-
term situation or where labour induction is undertaken since its pivotal role may 
be in limiting damage, repairing tissue and ultimately restoring tissue function. 
7.6 The contracting uterus and the influence of maternal 
and pregnancy factors 
Despite the robustness of the physiological processes underlying human 
parturition, the maternal phenotype is capable of disrupting these mechanisms.  
Specifically there is considerable evidence for the implications of maternal BMI 
and other maternal and pregnancy factors affecting parturition in-vivo62-80 295 296.  
In terms of parturition and maternal BMI, complications associated with 
myometrial contractility include high rates of post dates induction of labour63-65, 
high numbers of intrapartum caesarean deliveries for dysfunctional labour63 64 66 
67 and high rates of post partum haemorrhage independent of mode of delivery 
and use of OT63 65 66. 
Despite these clinical population based observations, our in-vitro model of 
labour showed no association between myometrial contractile ability including 
response to OT and maternal characteristics, in particular maternal BMI.  These 
data therefore suggest an alternative mechanism for the observed clinical 
outcomes associated with maternal factors, particularly BMI, and myometrial 
contractile function.  Suggestions for an alternative include altered 
microvascular function with accumulation of lactic acid, or asynchrony of 
uterine contractions and cervical ripening. 
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7.7 Future research  
From the work presented in this thesis, many novel concepts have been 
suggested.  Inevitably, confirmation and further exploration of our findings will 
be required; therefore areas and suggestions for possible future works are 
outlined below. 
In Chapter 3 we have attempted to address the transcriptional role of long term 
(hours) exposure of myometrium to OT.  Our data would suggest no additional 
transcriptional role for OT with effects mainly concerned with facilitation and 
modulation of pre-existing proteins.  However, we were unable to address the 
possible confounding factor of inherent oxytocinase activity within the samples 
themselves.  Therefore, to strengthen our findings, it would be important to 
repeat the organ bath experiment and perhaps use a continuous infusion of OT 
rather than the one single addition.  This would also have the added advantage 
of being more comparable to the clinical situation of induction of labour. 
However, it may also bring difficulties as differential myometrial contractile 
responses may be obtained and a decision regarding consistency between 
experiments would need to be determined, e.g. rate of infusion or a measure of 
contractility. 
In Chapter 4 we have suggested a temporal aspect to the inflammatory response 
seen in human labour.  In addition, a possible mechanism of contraction induced 
cellular damage has been proposed as the causative factor with a great deal of 
overlap with data from contracting skeletal muscle.  In view of this proposed 
causative link, it would be pertinent to examine further the gene array data 
with complementary QPCR, with particular reference to correlations between 
inflammatory upregulation and transcription of genes related to stress proteins.  
There has been particular interest in the role of myometrial Heat Shock Proteins 
in human labour474-477, and certainly in view of our data, a relationship with 
inflammation would seem logical. 
The difficulties concerning the overlap analysis of in-vitro and in-vivo gene array 
data was discussed within Chapter 4.  These issues were somewhat addressed by 
the QPCR analysis with never contracted and contracting samples from our 
studies.  However, the probes used were limited and it is pertinent that these 
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QPCR inflammatory data are completed for additional comparison and 
confirmation that the in-vitro model emulates the in-vivo occurrences during 
human parturition.  Since completion of this thesis, samples are currently being 
processed and it is anticipated data will be available later in the year. 
In Chapter 5, our in-vivo data concerning measurable factors in the maternal 
circulation of women during pregnancy at term and in response to delivery have 
shown results comparable with our transcriptional data.  However, we must 
acknowledge that numbers are small, although it does represent essential initial 
pilot data.  Therefore, to confirm our results, these experiments would require 
to be repeated on larger numbers.  This would have the additional benefit of 
providing essential intrapartum clinical ‘normal’ values for the measured 
parameters.  This has the potential to affect clinical management during labour 
including selective use of intrapartum antibiotic therapy, administration of 
antibiotics to the newborn and choice of analgesia, especially regional epidural 
anaesthesia.  Additionally, these parameters may be able to guide the obstetric 
clinician to decision making for determination of those who are progressing in 
labour and have a good chance of achieving a vaginal delivery and those who are 
not.  Markers of muscle cell damage may also have the potential to be used as a 
marker of pre-term labour and importantly determining those who are at risk of 
pre-term birth therefore helping guide clinical decision making for tocolytic 
therapy, antenatal steroid administration and in-utero hospital transfer. 
Our in-vivo maternal circulation data included those undergoing non-labouring 
caesarean delivery and those undergoing induction of labour.  Since labour was 
being induced, we have inevitably been unable to study circulatory changes 
induced prior to and during spontaneous labour.  These may be identical to 
those seen in our study, but perhaps occur over a longer time period.  However, 
repeated measures data from women as they approach term and the relationship 
with delivery outcome does require to be studied in order to address fully the 
relationship between uterine contractility, cellular damage and inflammation, in 
particular leukocyte priming prior to labour onset.   
Additionally, any changes in maternal circulating inflammatory measures 
throughout pregnancy would also be of interest.  Since the completion of this 
thesis we have been involved in ongoing sampling of women throughout 
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pregnancy, with samples taken in each gestation.  These have been processed 
for FACS with data analysis to take place this summer.  These stored samples 
will also be analysed for a number of inflammatory cytokines and delivery 
outcome data for these women are also available.  It is hoped this would add 
further evidence for the pattern and role of inflammation throughout the length 
of pregnancy. 
A potentially wide reaching aspect of the findings within this thesis is the use of 
human labour in the study of systemic inflammatory conditions where it is 
essential to promote tissue repair and restoration of function to the affected 
organs.  Human labour could provide an excellent model since we propose that 
contraction induced muscle damage leads to a local and systemic inflammatory 
response with subsequent repair and remodelling of the uterus with restoration 
of function.  Therefore, further exploration of the mechanisms and role of 
inflammation in human parturition is certainly merited by those working both 
within the field of obstetrics and in other clinical specialities.  Within our 
department further in-vivo studies examining the role of inflammation in 
parturition are being undertaken.  Specifically, local and humoral inflammatory 
changes over the course of pregnancy and also within the post-partum period are 
being assessed in the mouse model478.  In addition, a comparison between wild-
type and CCR2 knock-out mice is being undertaken which we hope will provide 
data regarding post-partum uterine remodelling and the importance of the 
myometrial inflammatory infiltrate in facilitating repair and return to function 
after delivery.  This is of particular interest as we have preliminary 
observational evidence from our lab which suggests that CCR2 deficient mice are 
more prone than their wild-type counterparts to birthing difficulties in their 
second and third pregnancies. 
Lastly, in Chapter 6, we have provided strong evidence of a lack of association 
between maternal BMI and the inherent ability of the myometrium to contract 
and respond appropriately to OT stimulation.  Alternative mechanisms for the 
observed contractile functional problems were discussed.  These would merit 
investigation as reducing rates of induction of labour, caesarean delivery and 
post partum haemorrhage among this group of women would obviously be 
advantageous.  One option may be to attempt to reduce the build up of lactic 
acid within the contracting uterine system.  There is a potential that lactic acid 
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build up and therefore contractile efficiency could be lessened by promoting 
aerobic metabolism of the uterine muscle during labour.  In the skeletal and 
cardiac muscle system this is achieved via improving cardio-respiratory fitness 
through physical activity and aerobic exercise, which also hold true within 
pregnancy479-482.  The effects of maternal fitness on the resultant parturition 
related outcomes could be assessed using ongoing cohort studies, for example 
the UK Pregnancies Better Eating and Activity Trial (UPBEAT)483, which may then 
provide more evidence for the advantages of promoting physical exercise during 
pregnancy.  
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7.8 Summary and Final Conclusions 
In this thesis I have explored a selection of factors associated with human 
parturition.  Overall I have provided further evidence that human labour is an 
inflammatory process and that contrary to the current paradigm of inflammation 
driving contractions, our data suggest labour associated inflammation is a non-
specific response to contraction induced cellular damage.  Additionally, based 
on comparison with complimentary data from the exercising skeletal muscle 
model, we have suggested that the peripheral and local inflammatory response 
of labour may play a role in tissue repair and remodelling post delivery. 
The functional and cellular influences of the uterotonic OT, various tocolytics, 
an inflammatory environment and maternal pregnancy characteristics were 
investigated with details of findings relating to inflammation in parturition 
illustrated in Figure 106 and an overall summary of the main findings of this 
thesis illustrated below in Figure 107. 
Overall, understanding of these pathways aids the understanding of myometrial 
and inflammatory physiology involved in human pregnancy and labour.  
Ultimately increasing our knowledge surrounding these aspects will aid the safe 
and effective delivery of maternity care and delivery of the newborn infant in 
the future. 
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Figure 106  Main experimental findings 
Illustration summarising the main findings relating specifically to inflammation and 
parturition from the research presented in this thesis. 
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Figure 107  Summary overall hypothesis 
Illustration summarising the main findings from the research presented in this thesis, and 
proposal of how the findings relate to one another.  These are shown against the time 
course of the normal process of human pregnancy and parturition. 
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Appendix I 
Tabular description of cellular pathways represented by enrichment pathway analysis using 
the Kyoto Encyclopedia of Genes and Genomes (KEGG) performed on genes differentially 
expressed between contracting and non-contracting myometrium (DMSO vs ML7) 
Timepoint 
of 
comparison 
KEGG 
path ID 
Direction of change Pathway description P value 
1 530 Up Aminosugars metabolism 0.014436 
 4320 Up Dorso-ventral axis formation 0.014436 
 51 Up Fructose and mannose metabolism 0.042081 
 31 Up Inositol metabolism 0.036786 
 5130 Up 
Pathogenic Escherichia coli 
infection - EHEC 0.002134 
 5131 Up 
Pathogenic Escherichia coli 
infection - EPEC 0.002134 
 3320 Up PPAR signaling pathway 0.038261 
 521 Up Streptomycin biosynthesis 0.013899 
 410 Down beta-Alanine metabolism 0.01657 
 650 Down Butanoate metabolism 0.000386 
 4020 Down Calcium signaling pathway 0.035786 
 5213 Down Endometrial cancer 0.026338 
 5214 Down Glioma 0.011754 
 251 Down Glutamate metabolism 0.027044 
 4730 Down Long-term depression 0.024759 
 4070 Down 
Phosphatidylinositol signaling 
system 0.026033 
 640 Down Propanoate metabolism 0.006078 
 5216 Down Thyroid cancer 0.024724 
 380 Down Tryptophan metabolism 0.009613 
 220 Down 
Urea cycle and metabolism of 
amino groups 0.027044 
 280 Down 
Valine, leucine and isoleucine 
degradation 3.84E-05 
2 5220 Up Chronic myeloid leukemia 0.021641 
 5213 Up Endometrial cancer 0.044284 
 4012 Up ErbB signaling pathway 0.004599 
 4640 Up Hematopoietic cell lineage 0.015721 
 4010 Up MAPK signaling pathway 0.032488 
 1510 Up Neurodegenerative Diseases 0.014454 
 5215 Up Prostate cancer 0.016757 
 4810 Up Regulation of actin cytoskeleton 0.028046 
 5211 Up Renal cell carcinoma 0.003974 
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Timepoint 
of 
comparison 
KEGG 
path ID 
Direction of change Pathway description P value 
 5216 Up Thyroid cancer 0.021965 
 4940 Up Type I diabetes mellitus 0.023474 
 4310 Up Wnt signaling pathway 0.02244 
 1430 Down Cell Communication 0.047093 
 4110 Down Cell cycle 0.042796 
 4512 Down ECM-receptor interaction 0.002597 
 4510 Down Focal adhesion 0.018488 
 563 Down 
Glycosylphosphatidylinositol(GPI)-
anchor biosynthesis 0.035083 
 626 Down 
Naphthalene and anthracene 
degradation 0.026887 
 860 Down 
Porphyrin and chlorophyll 
metabolism 0.011957 
4 4520 Up Adherens junction 0.002895 
 4662 Up B cell receptor signaling pathway 0.029954 
 4110 Up Cell cycle 0.028058 
 5110 Up Cholera - Infection 0.030657 
 5220 Up Chronic myeloid leukemia 0.017961 
 4710 Up Circadian rhythm 0.025869 
 5213 Up Endometrial cancer 0.045391 
 5120 Up 
Epithelial cell signaling in 
Helicobacter pylori infection 0.01974 
 4012 Up ErbB signaling pathway 0.001778 
 4640 Up Hematopoietic cell lineage 0.026284 
 4630 Up Jak-STAT signaling pathway 0.011826 
 4010 Up MAPK signaling pathway 0.002139 
 4330 Up Notch signaling pathway 0.006577 
 5020 Up Parkinson's disease 0.007434 
 4810 Up Regulation of actin cytoskeleton 0.019129 
 5211 Up Renal cell carcinoma 0.000115 
 5222 Up Small cell lung cancer 0.012028 
 4120 Up Ubiquitin mediated proteolysis 0.046959 
 252 Down Alanine and aspartate metabolism 0.005555 
 970 Down Aminoacyl-tRNA biosynthesis 0.000185 
 330 Down Arginine and proline metabolism 0.008413 
 120 Down Bile acid biosynthesis 0.040353 
 650 Down Butanoate metabolism 0.001764 
 710 Down Carbon fixation 0.007408 
 4110 Down Cell cycle 0.012775 
 62 Down 
Fatty acid elongation in 
mitochondria 0.002018 
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Timepoint 
of 
comparison 
KEGG 
path ID 
Direction of change Pathway description P value 
 251 Down Glutamate metabolism 0.002742 
 561 Down Glycerolipid metabolism 0.012818 
 563 Down 
Glycosylphosphatidylinositol(GPI)-
anchor biosynthesis 0.00423 
 340 Down Histidine metabolism 0.003174 
 785 Down Lipoic acid metabolism 0.030769 
 310 Down Lysine degradation 0.000558 
 401 Down Novobiocin biosynthesis 0.030769 
 670 Down One carbon pool by folate 0.020531 
 30 Down Pentose phosphate pathway 0.04851 
 640 Down Propanoate metabolism 0.0019 
 230 Down Purine metabolism 0.008051 
 240 Down Pyrimidine metabolism 0.038987 
 620 Down Pyruvate metabolism 0.009903 
 72 Down 
Synthesis and degradation of 
ketone bodies 0.009862 
 380 Down Tryptophan metabolism 0.001015 
 220 Down 
Urea cycle and metabolism of 
amino groups 0.032333 
 290 Down 
Valine, leucine and isoleucine 
biosynthesis 6.69E-05 
 280 Down 
Valine, leucine and isoleucine 
degradation 2.05E-08 
6 5221 Up Acute myeloid leukemia 0.000523 
 4520 Up Adherens junction 0.003332 
 4210 Up Apoptosis 0.02304 
 4662 Up B cell receptor signaling pathway 0.002492 
 5219 Up Bladder cancer 0.007922 
 4110 Up Cell cycle 0.018868 
 5110 Up Cholera - Infection 0.016786 
 5220 Up Chronic myeloid leukemia 2.36E-05 
 4060 Up 
Cytokine-cytokine receptor 
interaction 0.01071 
 5050 Up 
Dentatorubropallidoluysian atrophy 
(DRPLA) 0.018439 
 4320 Up Dorso-ventral axis formation 0.001782 
 5213 Up Endometrial cancer 0.009171 
 5120 Up 
Epithelial cell signaling in 
Helicobacter pylori infection 0.005253 
 4012 Up ErbB signaling pathway 1.48E-05 
 4664 Up Fc epsilon RI signaling pathway 0.015789 
 5214 Up Glioma 0.024981 
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 4640 Up Hematopoietic cell lineage 0.004815 
 5040 Up Huntington's disease 0.004539 
 4910 Up Insulin signaling pathway 0.006982 
 4630 Up Jak-STAT signaling pathway 0.004352 
 4010 Up MAPK signaling pathway 0.000217 
 1510 Up Neurodegenerative Diseases 0.011112 
 5223 Up Non-small cell lung cancer 0.013185 
 4330 Up Notch signaling pathway 0.00064 
 4115 Up p53 signaling pathway 0.048119 
 5215 Up Prostate cancer 0.001128 
 3050 Up Proteasome 0.012732 
 4810 Up Regulation of actin cytoskeleton 0.00013 
 5211 Up Renal cell carcinoma 1.12E-06 
 3010 Up Ribosome 0.047831 
 5222 Up Small cell lung cancer 0.004815 
 4660 Up T cell receptor signaling pathway 0.005601 
 252 Down Alanine and aspartate metabolism 0.016712 
 970 Down Aminoacyl-tRNA biosynthesis 7.55E-05 
 440 Down Aminophosphonate metabolism 0.028894 
 530 Down Aminosugars metabolism 0.015349 
 330 Down Arginine and proline metabolism 0.025237 
 120 Down Bile acid biosynthesis 0.006358 
 780 Down Biotin metabolism 0.011277 
 363 Down Bisphenol A degradation 0.043088 
 650 Down Butanoate metabolism 0.010411 
 62 Down 
Fatty acid elongation in 
mitochondria 0.008981 
 71 Down Fatty acid metabolism 0.00212 
 790 Down Folate biosynthesis 0.030531 
 51 Down Fructose and mannose metabolism 0.014888 
 52 Down Galactose metabolism 0.013354 
 5214 Down Glioma 0.03614 
 251 Down Glutamate metabolism 0.024264 
 563 Down 
Glycosylphosphatidylinositol(GPI)-
anchor biosynthesis 0.025707 
 340 Down Histidine metabolism 0.001863 
 310 Down Lysine degradation 0.001086 
 626 Down 
Naphthalene and anthracene 
degradation 0.003519 
 520 Down Nucleotide sugars metabolism 0.005428 
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 860 Down 
Porphyrin and chlorophyll 
metabolism 0.009929 
 640 Down Propanoate metabolism 0.000622 
 230 Down Purine metabolism 0.017488 
 240 Down Pyrimidine metabolism 0.003291 
 620 Down Pyruvate metabolism 0.005539 
 4130 Down 
SNARE interactions in vesicular 
transport 0.006358 
 380 Down Tryptophan metabolism 0.000211 
 130 Down Ubiquinone biosynthesis 0.019822 
 290 Down 
Valine, leucine and isoleucine 
biosynthesis 0.004133 
 280 Down 
Valine, leucine and isoleucine 
degradation 4.40E-06 
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Appendix II 
Tabular description of cellular pathways represented by enrichment pathway analysis using 
the Gene Ontology (GO) performed on genes differentially expressed in contracting 
myometrial samples (AA, DMSO, OT) at timepoints 1hr, 2hr, 4hr and 6 hours relative to 
baseline 0 hours.   
Timepoint 
of 
comparison 
Direction 
of 
change 
Ontology 
group 
GO path ID Pathway description 
Enrichment 
P value 
1 Up MF GO:0003706 ligand-regulated transcription factor 
activity 
0.0006221
73 
 Up BP GO:0048522 positive regulation of cellular process 0.000691733 
 Up MF GO:0005515 protein binding 0.00023372 
 Up MF GO:0003704 specific RNA polymerase II transcription factor activity 
0.0007882
04 
 Down MF GO:0005487 nucleocytoplasmic transporter activity 0.000848817 
2 Up MF GO:0005488 binding 2.57E-05 
 Up CC GO:0000785 chromatin 9.67E-06 
 Up BP GO:0031497 chromatin assembly 3.72E-06 
 Up BP GO:0006333 chromatin assembly or disassembly 1.15E-05 
 Up CC GO:0044427 chromosomal part 0.000417698 
 Up CC GO:0005694 chromosome 0.000166287 
 Up BP GO:0051276 chromosome organization and biogenesis 
0.0003923
57 
 Up MF GO:0003677 DNA binding 0.000506751 
 Up BP GO:0006323 DNA packaging 5.38E-07 
 Up BP GO:0006325 establishment and/or maintenance of 
chromatin architecture 
0.0001510
35 
 Up MF GO:0008201 heparin binding 0.000340187 
 Up CC GO:0005622 intracellular 0.000130194 
 Up CC GO:0043231 intracellular membrane-bound organelle 0.000203262 
 Up CC GO:0043229 intracellular organelle 0.000157989 
 Up CC GO:0044424 intracellular part 0.000141089 
 Up BP GO:0043170 macromolecule metabolic process 0.000105493 
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 Up CC GO:0043227 membrane-bound organelle 0.000206202 
 Up MF GO:0003676 nucleic acid binding 0.000680035 
 Up CC GO:0000786 nucleosome 1.51E-06 
 Up BP GO:0006334 nucleosome assembly 1.27E-06 
 Up CC GO:0005634 nucleus 2.03E-05 
 Up CC GO:0043226 organelle 0.000161434 
 Up BP GO:0006996 organelle organization and biogenesis 0.000625805 
 Up MF GO:0005515 protein binding 3.66E-05 
 Up BP GO:0006611 protein export from nucleus 0.000948706 
 Up BP GO:0065004 protein-DNA complex assembly 9.71E-05 
 Up BP GO:0042981 regulation of apoptosis 0.000404679 
 Up BP GO:0043067 regulation of programmed cell death 0.000473937 
 Down MF GO:0003689 DNA clamp loader activity 0.000987566 
 Down MF GO:0033170 DNA-protein loading ATPase activity 0.000987566 
4 Up MF GO:0050681 androgen receptor binding 0.000545202 
 Up BP GO:0030521 androgen receptor signaling pathway 0.000967225 
 Up BP GO:0006915 apoptosis 5.16E-05 
 Up MF GO:0005488 binding 2.01E-05 
 Up BP GO:0065007 biological regulation 1.01E-05 
 Up BP GO:0043283 biopolymer metabolic process 1.63E-06 
 Up BP GO:0043412 biopolymer modification 0.000217054 
 Up BP GO:0007049 cell cycle 0.000585277 
 Up BP GO:0008219 cell death 9.40E-05 
 Up BP GO:0048468 cell development 0.000335693 
 Up BP GO:0008283 cell proliferation 8.65E-05 
 Up BP GO:0044237 cellular metabolic process 0.000484337 
 Up CC GO:0000785 chromatin 3.64E-06 
 Up BP GO:0031497 chromatin assembly 2.86E-05 
 Up BP GO:0006333 chromatin assembly or disassembly 1.30E-06 
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 Up CC GO:0044427 chromosomal part 0.000359826 
 Up CC GO:0005694 chromosome 0.000127255 
 Up BP GO:0051276 chromosome organization and biogenesis 1.32E-05 
 Up BP GO:0016265 death 9.40E-05 
 Up BP GO:0006323 DNA packaging 1.36E-05 
 Up BP GO:0006325 establishment and/or maintenance of 
chromatin architecture 1.06E-05 
 Up BP GO:0000082 G1/S transition of mitotic cell cycle 0.000158293 
 Up CC GO:0005622 intracellular 2.06E-05 
 Up CC GO:0043231 intracellular membrane-bound organelle 2.98E-05 
 Up CC GO:0043229 intracellular organelle 0.000208213 
 Up CC GO:0044424 intracellular part 1.01E-05 
 Up BP GO:0043170 macromolecule metabolic process 1.00E-06 
 Up CC GO:0043227 membrane-bound organelle 3.08E-05 
 Up BP GO:0008152 metabolic process 4.58E-05 
 Up BP GO:0043066 negative regulation of apoptosis 0.000385525 
 Up BP GO:0048519 negative regulation of biological process 3.54E-05 
 Up BP GO:0048523 negative regulation of cellular process 5.56E-05 
 Up BP GO:0043069 negative regulation of programmed cell death 
0.0004671
71 
 Up CC GO:0000786 nucleosome 7.66E-06 
 Up BP GO:0006334 nucleosome assembly 5.79E-06 
 Up CC GO:0005634 nucleus 5.89E-08 
 Up CC GO:0043226 organelle 0.000217066 
 Up MF GO:0016773 phosphotransferase activity, alcohol group as acceptor 
0.0005102
85 
 Up BP GO:0048518 positive regulation of biological process 4.73E-06 
 Up BP GO:0048522 positive regulation of cellular process 4.83E-06 
 Up BP GO:0045935 
positive regulation of nucleobase, 
nucleoside, nucleotide and nucleic acid 
metabolic process 
0.0002030
91 
 Up BP GO:0045941 positive regulation of transcription 0.000234308 
 Up BP GO:0043687 post-translational protein modification 3.20E-05 
 Up BP GO:0044238 primary metabolic process 3.53E-05 
 Up BP GO:0012501 programmed cell death 6.99E-05 
 Up MF GO:0005515 protein binding 1.23E-07 
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 Up BP GO:0006464 protein modification process 9.60E-05 
 Up BP GO:0065004 protein-DNA complex assembly 2.41E-06 
 Up BP GO:0042981 regulation of apoptosis 7.95E-06 
 Up BP GO:0050789 regulation of biological process 2.48E-06 
 Up BP GO:0051726 regulation of cell cycle 0.00042839 
 Up BP GO:0050794 regulation of cellular process 4.97E-06 
 Up BP GO:0000079 regulation of cyclin-dependent protein kinase activity 
0.0006238
79 
 Up BP GO:0050793 regulation of developmental process 0.000364192 
 Up BP GO:0045682 regulation of epidermis development 0.000866689 
 Up BP GO:0019222 regulation of metabolic process 0.000304849 
 Up BP GO:0043067 regulation of programmed cell death 1.15E-05 
 Up BP GO:0006950 response to stress 0.000368938 
 Up MF GO:0015081 sodium ion transmembrane transporter 
activity 
0.0009724
21 
 Down MF GO:0030554 adenyl nucleotide binding 2.17E-05 
 Down MF GO:0032559 adenyl ribonucleotide binding 0.000114652 
 Down BP GO:0009308 amine metabolic process 9.02E-05 
 Down BP GO:0006519 amino acid and derivative metabolic process 
0.0002632
05 
 Down BP GO:0006520 amino acid metabolic process 5.70E-05 
 Down MF GO:0005524 ATP binding 6.52E-05 
 Down BP GO:0009058 biosynthetic process 2.40E-05 
 Down BP GO:0019752 carboxylic acid metabolic process 4.60E-07 
 Down MF GO:0003824 catalytic activity 1.50E-11 
 Down CC GO:0005623 cell 3.06E-05 
 Down BP GO:0051301 cell division 0.000304009 
 Down CC GO:0044464 cell part 2.98E-05 
 Down BP GO:0044249 cellular biosynthetic process 1.27E-05 
 Down BP GO:0044237 cellular metabolic process 7.83E-05 
 Down MF GO:0050897 cobalt ion binding 0.000569987 
 Down BP GO:0051188 cofactor biosynthetic process 4.69E-05 
 Down BP GO:0051186 cofactor metabolic process 2.12E-05 
 Down CC GO:0000777 condensed chromosome kinetochore 0.000381024 
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 Down CC GO:0000779 condensed chromosome, pericentric 
region 
0.0006585
13 
 Down CC GO:0005737 cytoplasm 1.94E-11 
 Down CC GO:0044444 cytoplasmic part 5.78E-12 
 Down BP GO:0006259 DNA metabolic process 6.31E-05 
 Down BP GO:0006281 DNA repair 0.000372685 
 Down BP GO:0006260 DNA replication 0.000112245 
 Down BP GO:0051656 establishment of organelle localization 0.000985606 
 Down BP GO:0046483 heterocycle metabolic process 6.43E-05 
 Down CC GO:0005622 intracellular 7.24E-15 
 Down CC GO:0043231 intracellular membrane-bound organelle 7.88E-14 
 Down CC GO:0043229 intracellular organelle 1.08E-10 
 Down CC GO:0044446 intracellular organelle part 3.46E-09 
 Down CC GO:0044424 intracellular part 4.84E-14 
 Down CC GO:0000776 kinetochore 0.000112545 
 Down MF GO:0016874 ligase activity 0.000197695 
 Down CC GO:0043227 membrane-bound organelle 8.35E-14 
 Down CC GO:0031974 membrane-enclosed lumen 5.24E-07 
 Down BP GO:0008152 metabolic process 9.37E-06 
 Down BP GO:0051310 metaphase plate congression 0.000562598 
 Down MF GO:0008168 methyltransferase activity 0.000653603 
 Down CC GO:0042579 microbody 0.000121067 
 Down CC GO:0031980 mitochondrial lumen 4.52E-05 
 Down CC GO:0005759 mitochondrial matrix 4.52E-05 
 Down CC GO:0044429 mitochondrial part 2.52E-06 
 Down CC GO:0005739 mitochondrion 5.52E-13 
 Down BP GO:0032787 monocarboxylic acid metabolic process 0.000552538 
 Down BP GO:0006807 nitrogen compound metabolic process 0.000461512 
 Down MF GO:0004518 nuclease activity 0.000355999 
 Down MF GO:0000166 nucleotide binding 0.00055534 
 Down CC GO:0043226 organelle 1.16E-10 
 Down CC GO:0043233 organelle lumen 5.24E-07 
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 Down CC GO:0031090 organelle membrane 7.45E-05 
 Down CC GO:0044422 organelle part 4.59E-09 
 Down BP GO:0006082 organic acid metabolic process 5.60E-07 
 Down CC GO:0000940 outer kinetochore of condensed 
chromosome 
0.0001276
27 
 Down MF GO:0016491 oxidoreductase activity 0.000184099 
 Down CC GO:0005777 peroxisome 0.000121067 
 Down BP GO:0043507 positive regulation of JNK activity 0.000985606 
 Down BP GO:0044238 primary metabolic process 0.000262287 
 Down BP GO:0045426 quinone cofactor biosynthetic process 4.26E-05 
 Down BP GO:0042375 quinone cofactor metabolic process 4.26E-05 
 Down BP GO:0006974 response to DNA damage stimulus 0.00019872 
 Down MF GO:0004540 ribonuclease activity 0.000288313 
 Down MF GO:0008641 small protein activating enzyme activity 2.09E-05 
 Down CC GO:0005819 spindle 0.000900018 
 Down MF GO:0016740 transferase activity 0.000448862 
 Down MF GO:0016765 transferase activity, transferring alkyl or 
aryl (other than methyl) groups 2.76E-05 
 Down MF GO:0016741 transferase activity, transferring one-
carbon groups 
0.0001054
35 
 Down BP GO:0006399 tRNA metabolic process 0.000909314 
 Down BP GO:0006744 ubiquinone biosynthetic process 4.26E-05 
 Down BP GO:0006743 ubiquinone metabolic process 4.26E-05 
6 Up MF GO:0030554 adenyl nucleotide binding 0.000569117 
 Up MF GO:0032559 adenyl ribonucleotide binding 0.000118964 
 Up BP GO:0006916 anti-apoptosis 0.000142591 
 Up BP GO:0006915 apoptosis 9.33E-09 
 Up MF GO:0005524 ATP binding 8.08E-05 
 Up MF GO:0005488 binding 7.77E-10 
 Up BP GO:0065007 biological regulation 4.19E-11 
 Up BP GO:0043285 biopolymer catabolic process 0.000658938 
 Up BP GO:0043283 biopolymer metabolic process 1.40E-13 
Claire A Higgins, 2012   Appendix II, 340  
Timepoint 
of 
comparison 
Direction 
of 
change 
Ontology 
group 
GO path ID Pathway description 
Enrichment 
P value 
 Up BP GO:0043412 biopolymer modification 2.34E-14 
 Up BP GO:0007596 blood coagulation 0.000257161 
 Up BP GO:0007049 cell cycle 8.74E-05 
 Up BP GO:0008219 cell death 3.18E-08 
 Up BP GO:0048468 cell development 2.74E-06 
 Up BP GO:0030154 cell differentiation 5.12E-05 
 Up BP GO:0016049 cell growth 0.000445274 
 Up BP GO:0008283 cell proliferation 1.00E-06 
 Up BP GO:0048869 cellular developmental process 5.12E-05 
 Up BP GO:0044265 cellular macromolecule catabolic process 
0.0003860
38 
 Up BP GO:0044260 cellular macromolecule metabolic process 2.77E-11 
 Up BP GO:0044237 cellular metabolic process 1.76E-09 
 Up BP GO:0009987 cellular process 6.09E-05 
 Up BP GO:0044257 cellular protein catabolic process 0.000279914 
 Up BP GO:0044267 cellular protein metabolic process 1.23E-11 
 Up CC GO:0000785 chromatin 2.21E-05 
 Up BP GO:0031497 chromatin assembly 0.000121759 
 Up BP GO:0006333 chromatin assembly or disassembly 2.09E-07 
 Up BP GO:0016568 chromatin modification 7.09E-06 
 Up CC GO:0016585 chromatin remodeling complex 0.000923263 
 Up CC GO:0005694 chromosome 0.000252343 
 Up BP GO:0051276 chromosome organization and biogenesis 2.04E-08 
 Up BP GO:0050817 coagulation 0.000300563 
 Up MF GO:0005125 cytokine activity 0.000599409 
 Up CC GO:0005737 cytoplasm 0.000192793 
 Up BP GO:0016265 death 3.18E-08 
 Up BP GO:0006323 DNA packaging 5.22E-06 
 Up BP GO:0006325 establishment and/or maintenance of 
chromatin architecture 1.87E-08 
 Up BP GO:0000082 G1/S transition of mitotic cell cycle 4.05E-05 
 Up BP GO:0010467 gene expression 1.68E-05 
Claire A Higgins, 2012   Appendix II, 341  
Timepoint 
of 
comparison 
Direction 
of 
change 
Ontology 
group 
GO path ID Pathway description 
Enrichment 
P value 
 Up MF GO:0008083 growth factor activity 0.000464648 
 Up BP GO:0007599 hemostasis 0.000544573 
 Up BP GO:0051329 interphase of mitotic cell cycle 0.000700009 
 Up CC GO:0005622 intracellular 8.81E-09 
 Up CC GO:0043231 intracellular membrane-bound organelle 1.73E-06 
 Up CC GO:0043229 intracellular organelle 6.66E-06 
 Up CC GO:0044424 intracellular part 3.07E-08 
 Up BP GO:0007242 intracellular signaling cascade 1.72E-06 
 Up MF GO:0016301 kinase activity 1.90E-08 
 Up BP GO:0043170 macromolecule metabolic process 6.88E-14 
 Up BP GO:0000165 MAPKKK cascade 0.000771931 
 Up CC GO:0043227 membrane-bound organelle 1.82E-06 
 Up BP GO:0008152 metabolic process 3.47E-09 
 Up BP GO:0043632 modification-dependent macromolecule 
catabolic process 
0.0002010
07 
 Up BP GO:0019941 modification-dependent protein catabolic process 
0.0002010
07 
 Up BP GO:0043066 negative regulation of apoptosis 5.37E-05 
 Up BP GO:0048519 negative regulation of biological process 1.98E-06 
 Up BP GO:0048523 negative regulation of cellular process 7.59E-06 
 Up BP GO:0043069 negative regulation of programmed cell death 7.32E-05 
 Up BP GO:0007219 Notch signaling pathway 0.000977857 
 Up CC GO:0031981 nuclear lumen 2.84E-05 
 Up CC GO:0044428 nuclear part 3.41E-05 
 Up CC GO:0005654 nucleoplasm 1.62E-05 
 Up CC GO:0044451 nucleoplasm part 1.51E-05 
 Up BP GO:0006334 nucleosome assembly 0.000172674 
 Up MF GO:0000166 nucleotide binding 0.000119412 
 Up CC GO:0005634 nucleus 5.12E-11 
 Up CC GO:0043226 organelle 5.51E-06 
 Up BP GO:0006996 organelle organization and biogenesis 7.74E-06 
 Up BP GO:0006796 phosphate metabolic process 7.33E-09 
 Up MF GO:0004721 phosphoprotein phosphatase activity 0.000520766 
 Up BP GO:0006793 phosphorus metabolic process 7.33E-09 
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 Up BP GO:0016310 phosphorylation 2.15E-07 
 Up MF GO:0016773 phosphotransferase activity, alcohol group as acceptor 5.88E-09 
 Up BP GO:0043065 positive regulation of apoptosis 0.000912617 
 Up BP GO:0048518 positive regulation of biological process 3.92E-10 
 Up BP GO:0031325 positive regulation of cellular metabolic process 
0.0004088
31 
 Up BP GO:0048522 positive regulation of cellular process 8.14E-10 
 Up BP GO:0051094 positive regulation of developmental process 
0.0007156
91 
 Up BP GO:0009893 positive regulation of metabolic process 0.000297795 
 Up BP GO:0045933 positive regulation of muscle contraction 0.000381614 
 Up BP GO:0045935 
positive regulation of nucleobase, 
nucleoside, nucleotide and nucleic acid 
metabolic process 
2.19E-05 
 Up BP GO:0051254 positive regulation of RNA metabolic process 1.57E-05 
 Up BP GO:0045987 positive regulation of smooth muscle 
contraction 8.26E-05 
 Up BP GO:0045941 positive regulation of transcription 3.04E-05 
 Up BP GO:0045893 positive regulation of transcription, DNA-dependent 1.26E-05 
 Up BP GO:0043687 post-translational protein modification 1.61E-15 
 Up BP GO:0044238 primary metabolic process 1.08E-10 
 Up BP GO:0012501 programmed cell death 1.74E-08 
 Up BP GO:0006470 protein amino acid dephosphorylation 0.000273465 
 Up BP GO:0006468 protein amino acid phosphorylation 2.17E-08 
 Up MF GO:0005515 protein binding 7.03E-26 
 Up BP GO:0030163 protein catabolic process 0.000597574 
 Up MF GO:0004672 protein kinase activity 2.46E-07 
 Up BP GO:0007243 protein kinase cascade 1.05E-05 
 Up BP GO:0019538 protein metabolic process 1.15E-10 
 Up BP GO:0006464 protein modification process 6.55E-15 
 Up MF GO:0004674 protein serine/threonine kinase activity 1.18E-05 
 Up BP GO:0065004 protein-DNA complex assembly 0.000551818 
 Up MF GO:0004713 protein-tyrosine kinase activity 5.99E-05 
 Up BP GO:0051603 proteolysis involved in cellular protein 
catabolic process 
0.0002247
64 
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 Up MF GO:0032555 purine ribonucleotide binding 0.000384687 
 Up MF GO:0005102 receptor binding 0.000522273 
 Up BP GO:0042981 regulation of apoptosis 1.90E-07 
 Up BP GO:0050789 regulation of biological process 1.73E-11 
 Up BP GO:0065008 regulation of biological quality 0.000558859 
 Up BP GO:0051726 regulation of cell cycle 0.000637963 
 Up BP GO:0001558 regulation of cell growth 0.000359988 
 Up BP GO:0008361 regulation of cell size 0.000155778 
 Up BP GO:0031323 regulation of cellular metabolic process 0.000105878 
 Up BP GO:0050794 regulation of cellular process 2.50E-10 
 Up BP GO:0050793 regulation of developmental process 1.32E-05 
 Up BP GO:0010468 regulation of gene expression 9.29E-05 
 Up BP GO:0040008 regulation of growth 0.000173336 
 Up BP GO:0043549 regulation of kinase activity 0.000712491 
 Up BP GO:0019222 regulation of metabolic process 8.48E-06 
 Up BP GO:0019219 
regulation of nucleobase, nucleoside, 
nucleotide and nucleic acid metabolic 
process 
0.0001375
82 
 Up BP GO:0043067 regulation of programmed cell death 3.49E-07 
 Up BP GO:0045859 regulation of protein kinase activity 0.00046392 
 Up BP GO:0051252 regulation of RNA metabolic process 0.000142124 
 Up BP GO:0045449 regulation of transcription 0.000244709 
 Up BP GO:0006357 regulation of transcription from RNA polymerase II promoter 1.31E-08 
 Up BP GO:0006355 regulation of transcription, DNA-dependent 
0.0001620
74 
 Up BP GO:0006950 response to stress 5.48E-05 
 Up BP GO:0009611 response to wounding 0.000147318 
 Up MF GO:0032553 ribonucleotide binding 0.000384687 
 Up BP GO:0032774 RNA biosynthetic process 9.26E-05 
 Up BP GO:0016070 RNA metabolic process 0.000326724 
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 Up MF GO:0003702 RNA polymerase II transcription factor 
activity 
0.0009890
57 
 Up BP GO:0006350 transcription 9.96E-05 
 Up MF GO:0003713 transcription coactivator activity 0.000870098 
 Up MF GO:0003712 transcription cofactor activity 1.94E-05 
 Up MF GO:0008134 transcription factor binding 5.86E-05 
 Up BP GO:0006366 transcription from RNA polymerase II promoter 1.71E-07 
 Up MF GO:0030528 transcription regulator activity 6.33E-05 
 Up MF GO:0016564 transcription repressor activity 8.28E-05 
 Up BP GO:0006351 transcription, DNA-dependent 8.16E-05 
 Up MF GO:0016772 transferase activity, transferring phosphorus-containing groups 7.79E-07 
 Up BP GO:0006512 ubiquitin cycle 2.59E-06 
 Up BP GO:0006511 ubiquitin-dependent protein catabolic process 
0.0001795
17 
 Up BP GO:0042060 wound healing 0.000315407 
 Down BP GO:0009308 amine metabolic process 0.00086876 
 Down BP GO:0009058 biosynthetic process 0.000178283 
 Down MF GO:0016884 carbon-nitrogen ligase activity, with glutamine as amido-N-donor 
0.0007730
59 
 Down BP GO:0019752 carboxylic acid metabolic process 5.26E-05 
 Down MF GO:0003824 catalytic activity 3.37E-10 
 Down CC GO:0005623 cell 9.59E-07 
 Down CC GO:0044464 cell part 9.18E-07 
 Down BP GO:0044249 cellular biosynthetic process 0.000596365 
 Down BP GO:0044237 cellular metabolic process 1.85E-07 
 Down BP GO:0051188 cofactor biosynthetic process 5.47E-05 
 Down BP GO:0051186 cofactor metabolic process 5.33E-06 
 Down CC GO:0005737 cytoplasm 2.84E-11 
 Down CC GO:0044444 cytoplasmic part 1.67E-12 
 Down BP GO:0006259 DNA metabolic process 4.31E-05 
 Down BP GO:0006281 DNA repair 4.31E-05 
 Down MF GO:0004519 endonuclease activity 0.000997769 
 Down MF GO:0004521 endoribonuclease activity 0.000111669 
 Down MF GO:0004527 exonuclease activity 0.000911533 
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 Down MF GO:0016796 
exonuclease activity, active with either 
ribo- or deoxyribonucleic acids and 
producing 5'-phosphomonoesters 
0.0003353
86 
 Down MF GO:0004532 exoribonuclease activity 0.000780098 
 Down MF GO:0016896 exoribonuclease activity, producing 5'-phosphomonoesters 
0.0007800
98 
 Down BP GO:0009296 flagellum biogenesis 0.00089663 
 Down BP GO:0043064 flagellum organization and biogenesis 0.00089663 
 Down BP GO:0006783 heme biosynthetic process 0.000753702 
 Down BP GO:0042168 heme metabolic process 0.000624421 
 Down MF GO:0016788 hydrolase activity, acting on ester bonds 0.000456605 
 Down CC GO:0005622 intracellular 1.50E-16 
 Down CC GO:0043231 intracellular membrane-bound organelle 1.10E-21 
 Down CC GO:0043229 intracellular organelle 1.84E-13 
 Down CC GO:0044446 intracellular organelle part 3.64E-05 
 Down CC GO:0044424 intracellular part 2.29E-16 
 Down CC GO:0005764 lysosome 0.00011404 
 Down CC GO:0000323 lytic vacuole 0.00011404 
 Down CC GO:0043227 membrane-bound organelle 1.22E-21 
 Down CC GO:0031974 membrane-enclosed lumen 6.19E-08 
 Down BP GO:0008152 metabolic process 6.54E-10 
 Down MF GO:0008168 methyltransferase activity 7.35E-07 
 Down CC GO:0005740 mitochondrial envelope 0.000994704 
 Down CC GO:0031980 mitochondrial lumen 5.12E-09 
 Down CC GO:0005759 mitochondrial matrix 5.12E-09 
 Down CC GO:0044429 mitochondrial part 1.57E-09 
 Down CC GO:0005761 mitochondrial ribosome 1.79E-08 
 Down CC GO:0005763 mitochondrial small ribosomal subunit 0.000862723 
 Down CC GO:0005739 mitochondrion 1.16E-21 
 Down BP GO:0006379 mRNA cleavage 0.000750444 
 Down BP GO:0016071 mRNA metabolic process 0.000501094 
 Down BP GO:0006397 mRNA processing 0.000329943 
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of 
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group 
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Enrichment 
P value 
 Down MF GO:0004518 nuclease activity 5.77E-06 
 Down BP GO:0006139 nucleobase, nucleoside, nucleotide and 
nucleic acid metabolic process 6.65E-05 
 Down CC GO:0005730 nucleolus 0.000774181 
 Down CC GO:0000313 organellar ribosome 1.79E-08 
 Down CC GO:0000314 organellar small ribosomal subunit 0.000862723 
 Down CC GO:0043226 organelle 2.07E-13 
 Down CC GO:0043233 organelle lumen 6.19E-08 
 Down CC GO:0031090 organelle membrane 0.000884751 
 Down CC GO:0044422 organelle part 4.80E-05 
 Down BP GO:0006082 organic acid metabolic process 6.49E-05 
 Down MF GO:0016491 oxidoreductase activity 0.000913126 
 Down BP GO:0006733 oxidoreduction coenzyme metabolic process 
0.0005996
05 
 Down BP GO:0044238 primary metabolic process 3.05E-07 
 Down BP GO:0008104 protein localization 0.000952195 
 Down BP GO:0015031 protein transport 0.000658299 
 Down BP GO:0045426 quinone cofactor biosynthetic process 5.19E-05 
 Down BP GO:0042375 quinone cofactor metabolic process 5.19E-05 
 Down MF GO:0016854 racemase and epimerase activity 4.09E-05 
 Down MF GO:0016857 racemase and epimerase activity, acting 
on carbohydrates and derivatives 
0.0001522
77 
 Down BP GO:0006974 response to DNA damage stimulus 6.06E-06 
 Down BP GO:0009719 response to endogenous stimulus 5.85E-05 
 Down MF GO:0004540 ribonuclease activity 9.04E-08 
 Down MF GO:0003723 RNA binding 6.20E-07 
 Down BP GO:0006396 RNA processing 2.23E-08 
 Down MF GO:0016741 transferase activity, transferring one-
carbon groups 1.32E-07 
 Down BP GO:0006399 tRNA metabolic process 0.00023904 
 Down BP GO:0006744 ubiquinone biosynthetic process 5.19E-05 
 Down BP GO:0006743 ubiquinone metabolic process 5.19E-05 
 Down CC GO:0005773 vacuole 0.000170295 
Claire A Higgins, 2012   Appendix III, 347  
Appendix III 
Tabular description of cellular pathways represented by enrichment pathway analysis using 
the Kyoto Encyclopedia of Genes and Genomes (KEGG) performed on genes differentially 
expressed between contracting and non-contracting myometrium (DMSO vs ML7) 
Timepoint 
of 
comparison 
KEGG 
path ID 
Direction of change Pathway description P value 
0hr 5010 Up Alzheimer's disease 0.000904 
 4210 Up Apoptosis 0.000255 
 4060 Up Cytokine-cytokine receptor interaction 0.006752 
 4640 Up Hematopoietic cell lineage 7.35E-08 
 4010 Up MAPK signaling pathway 0.006978 
 5060 Up Prion disease 0.021749 
 4620 Up Toll-like receptor signaling pathway 0.011167 
 4940 Up Type I diabetes mellitus 3.79E-05 
 592 Down alpha-Linolenic acid metabolism 0.010812 
 590 Down Arachidonic acid metabolism 0.038558 
 565 Down Ether lipid metabolism 0.022259 
 564 Down Glycerophospholipid metabolism 0.04839 
 591 Down Linoleic acid metabolism 0.022259 
 4010 Down MAPK signaling pathway 0.011172 
 4370 Down VEGF signaling pathway 0.049789 
1hr 5010 Up Alzheimer's disease 0.003804 
 4210 Up Apoptosis 0.002398 
 4060 Up Cytokine-cytokine receptor interaction 0.001087 
 4640 Up Hematopoietic cell lineage 0.002745 
 4010 Up MAPK signaling pathway 0.009029 
 5060 Up Prion disease 0.04306 
 4350 Up TGF-beta signaling pathway 0.034319 
 4620 Up Toll-like receptor signaling pathway 0.004079 
 4940 Up Type I diabetes mellitus 0.000374 
 440 Down Aminophosphonate metabolism 0.006429 
 650 Down Butanoate metabolism 0.041306 
 71 Down Fatty acid metabolism 0.044705 
 281 Down Geraniol degradation 0.03566 
 563 Down Glycosylphosphatidylinositol(GPI)-
anchor biosynthesis 0.009751 
 340 Down Histidine metabolism 0.036406 
 310 Down Lysine degradation 0.00017 
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KEGG 
path ID 
Direction of change Pathway description P value 
 626 Down Naphthalene and anthracene degradation 0.008012 
 190 Down Oxidative phosphorylation 0.008805 
 620 Down Pyruvate metabolism 0.036406 
 450 Down Selenoamino acid metabolism 0.019402 
 380 Down Tryptophan metabolism 0.000819 
 280 Down Valine, leucine and isoleucine degradation 0.039646 
2hr 4920 Up Adipocytokine signaling pathway 0.027409 
 5010 Up Alzheimer's disease 0.001984 
 4612 Up Antigen processing and presentation 0.046953 
 4210 Up Apoptosis 0.000849 
 4060 Up Cytokine-cytokine receptor interaction 0.007604 
 4664 Up Fc epsilon RI signaling pathway 0.030458 
 4640 Up Hematopoietic cell lineage 0.000115 
 4010 Up MAPK signaling pathway 0.008094 
 4620 Up Toll-like receptor signaling pathway 0.001966 
 4940 Up Type I diabetes mellitus 0.007253 
 624 Down 1- and 2-Methylnaphthalene degradation 0.006828 
 632 Down Benzoate degradation via CoA ligation 0.008525 
 5120 Down Epithelial cell signaling in Helicobacter pylori infection 0.045513 
 564 Down Glycerophospholipid metabolism 0.045513 
 903 Down Limonene and pinene degradation 0.009129 
 4010 Down MAPK signaling pathway 0.008121 
 400 Down Phenylalanine, tyrosine and tryptophan biosynthesis 0.039824 
4hr 5010 Up Alzheimer's disease 0.002605 
 4612 Up Antigen processing and presentation 0.039482 
 4210 Up Apoptosis 0.003343 
 4662 Up B cell receptor signaling pathway 0.046014 
 4514 Up Cell adhesion molecules (CAMs) 0.039431 
 4610 Up Complement and coagulation 
cascades 0.008568 
 4060 Up Cytokine-cytokine receptor interaction 1.85E-07 
 5120 Up Epithelial cell signaling in Helicobacter pylori infection 0.007791 
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KEGG 
path ID 
Direction of change Pathway description P value 
 4664 Up Fc epsilon RI signaling pathway 0.004858 
 4640 Up Hematopoietic cell lineage 8.85E-09 
 533 Up Keratan sulfate biosynthesis 0.046649 
 4010 Up MAPK signaling pathway 0.025465 
 4650 Up Natural killer cell mediated 
cytotoxicity 0.000357 
 4620 Up Toll-like receptor signaling pathway 1.07E-05 
 4940 Up Type I diabetes mellitus 0.006772 
 252 Down Alanine and aspartate metabolism 0.017707 
 650 Down Butanoate metabolism 0.002328 
 710 Down Carbon fixation 0.032387 
 20 Down Citrate cycle (TCA cycle) 0.009972 
 790 Down Folate biosynthesis 0.001422 
 51 Down Fructose and mannose metabolism 0.001617 
 480 Down Glutathione metabolism 0.006418 
 630 Down Glyoxylate and dicarboxylate 
metabolism 0.006544 
 190 Down Oxidative phosphorylation 0.008509 
 400 Down Phenylalanine, tyrosine and tryptophan biosynthesis 0.02342 
 640 Down Propanoate metabolism 0.000507 
 620 Down Pyruvate metabolism 0.000248 
 720 Down Reductive carboxylate cycle (CO2 fixation) 0.00395 
 500 Down Starch and sucrose metabolism 0.041838 
 72 Down Synthesis and degradation of ketone bodies 0.02951 
 280 Down Valine, leucine and isoleucine degradation 4.60E-05 
6hr 5221 Up Acute myeloid leukemia 0.003155 
 4520 Up Adherens junction 0.00736 
 4210 Up Apoptosis 0.038984 
 4360 Up Axon guidance 0.0404 
 4110 Up Cell cycle 0.012101 
 5220 Up Chronic myeloid leukemia 0.001144 
 4710 Up Circadian rhythm 0.048279 
 5210 Up Colorectal cancer 0.010021 
 4060 Up Cytokine-cytokine receptor interaction 7.37E-06 
 5120 Up Epithelial cell signaling in Helicobacter pylori infection 0.035117 
 4664 Up Fc epsilon RI signaling pathway 0.00736 
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KEGG 
path ID 
Direction of change Pathway description P value 
 4640 Up Hematopoietic cell lineage 4.96E-05 
 5040 Up Huntington's disease 0.017556 
 4630 Up Jak-STAT signaling pathway 0.001254 
 533 Up Keratan sulfate biosynthesis 0.026056 
 4010 Up MAPK signaling pathway 0.000714 
 4650 Up Natural killer cell mediated 
cytotoxicity 0.000998 
 4330 Up Notch signaling pathway 0.008837 
 5212 Up Pancreatic cancer 0.013166 
 770 Up Pantothenate and CoA biosynthesis 0.026056 
 5130 Up Pathogenic Escherichia coli infection - EHEC 0.019503 
 5131 Up Pathogenic Escherichia coli infection - EPEC 0.019503 
 5215 Up Prostate cancer 0.032029 
 4810 Up Regulation of actin cytoskeleton 0.00051 
 5211 Up Renal cell carcinoma 3.69E-05 
 4660 Up T cell receptor signaling pathway 0.006004 
 4620 Up Toll-like receptor signaling pathway 0.013185 
 4120 Up Ubiquitin mediated proteolysis 0.046777 
 624 Down 1- and 2-Methylnaphthalene degradation 0.00334 
 252 Down Alanine and aspartate metabolism 0.000226 
 960 Down Alkaloid biosynthesis II 0.025849 
 970 Down Aminoacyl-tRNA biosynthesis 0.000101 
 330 Down Arginine and proline metabolism 0.022743 
 632 Down Benzoate degradation via CoA ligation 4.68E-05 
 100 Down Biosynthesis of steroids 0.01176 
 363 Down Bisphenol A degradation 0.024077 
 650 Down Butanoate metabolism 0.000209 
 930 Down Caprolactam degradation 0.005768 
 710 Down Carbon fixation 0.037292 
 272 Down Cysteine metabolism 0.046992 
 62 Down Fatty acid elongation in 
mitochondria 0.006592 
 71 Down Fatty acid metabolism 0.004423 
 790 Down Folate biosynthesis 0.017674 
 51 Down Fructose and mannose metabolism 0.000455 
 251 Down Glutamate metabolism 0.034037 
 903 Down Limonene and pinene degradation 6.62E-05 
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 310 Down Lysine degradation 0.015297 
 626 Down Naphthalene and anthracene degradation 0.016942 
 401 Down Novobiocin biosynthesis 0.019556 
 190 Down Oxidative phosphorylation 6.57E-09 
 360 Down Phenylalanine metabolism 0.034037 
 400 Down Phenylalanine, tyrosine and tryptophan biosynthesis 0.000176 
 860 Down Porphyrin and chlorophyll 
metabolism 1.10E-05 
 640 Down Propanoate metabolism 0.005595 
 230 Down Purine metabolism 0.003756 
 240 Down Pyrimidine metabolism 0.000249 
 620 Down Pyruvate metabolism 0.020305 
 3020 Down RNA polymerase 0.037292 
 643 Down Styrene degradation 0.019556 
 380 Down Tryptophan metabolism 0.009394 
 350 Down Tyrosine metabolism 0.009394 
 4120 Down Ubiquitin mediated proteolysis 0.019251 
 220 Down Urea cycle and metabolism of 
amino groups 0.034037 
 280 Down Valine, leucine and isoleucine degradation 0.000701 
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Appendix IV 
Tabular description of cellular pathways represented by enrichment pathway analysis using 
the Gene Ontology (GO) performed on genes differentially expressed between contracting 
and non-contracting myometrium (DMSO vs ML7) 
Timepoint 
of 
comparison 
Direction 
of change 
Ontology 
group 
GO path ID Pathway description 
Enrichment 
P value 
0hr Up BP GO:0032288 myelin formation 0.000302 
 Up BP GO:0030913 paranodal junction assembly 0.000302 
 Down BP GO:0051353 
positive regulation of oxidoreductase 
activity 
0.000906 
 Down CC GO:0005662 DNA replication factor A complex 0.000818 
 Down MF GO:0035014 
phosphoinositide 3-kinase regulator 
activity 
0.000833 
1hr Up BP GO:0001525 angiogenesis 0.000924 
 Up BP GO:0001660 fever 0.000755 
 Up BP GO:0032755 
positive regulation of interleukin-6 
production 
0.000755 
 Down BP GO:0042158 lipoprotein biosynthetic process 0.000666 
 Down BP GO:0006497 protein amino acid lipidation 0.000547 
2hr Up BP GO:0002526 acute inflammatory response 0.000381 
 Up BP GO:0007610 behavior 1.63E-05 
 Up BP GO:0051641 cellular localization 0.000757 
 Up BP GO:0006935 chemotaxis 2.53E-07 
 Up BP GO:0006952 defense response 6.16E-06 
 Up BP GO:0051649 establishment of cellular localization 0.000638 
 Up BP GO:0006887 exocytosis 2.22E-05 
 Up BP GO:0001660 fever 3.71E-06 
 Up BP GO:0031649 heat generation 2.22E-05 
 Up BP GO:0006955 immune response 0.00011 
 Up BP GO:0002376 immune system process 9.93E-06 
 Up BP GO:0006954 inflammatory response 5.32E-08 
 Up BP GO:0007626 locomotory behavior 9.65E-07 
 Up BP GO:0008285 
negative regulation of cell 
proliferation 
0.000889 
 Up BP GO:0017157 regulation of exocytosis 0.000332 
 Up BP GO:0042221 response to chemical stimulus 6.92E-05 
 Up BP GO:0009605 response to external stimulus 1.32E-06 
 Up BP GO:0050896 response to stimulus 5.88E-05 
 Up BP GO:0006950 response to stress 9.22E-06 
 Up BP GO:0009611 response to wounding 7.27E-07 
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 Up BP GO:0046903 secretion 0.000387 
 Up BP GO:0032940 secretion by cell 8.51E-05 
 Up BP GO:0045045 secretory pathway 0.0003 
 Up BP GO:0042330 taxis 2.53E-07 
 Up BP GO:0001659 thermoregulation 7.74E-05 
 Up BP GO:0016192 vesicle-mediated transport 0.000243 
 Up CC GO:0044421 extracellular region part 0.000275 
 Up CC GO:0005615 extracellular space 2.00E-05 
 Up MF GO:0008009 chemokine activity 1.80E-06 
 Up MF GO:0042379 chemokine receptor binding 1.96E-06 
 Up MF GO:0005125 cytokine activity 3.66E-06 
 Up MF GO:0001664 G-protein-coupled receptor binding 1.03E-05 
 Up MF GO:0005149 interleukin-1 receptor binding 0.000261 
 Up MF GO:0001871 pattern binding 5.12E-05 
 Up MF GO:0042834 peptidoglycan binding 0.000121 
 Up MF GO:0005102 receptor binding 0.000278 
 Down BP GO:0008633 
activation of pro-apoptotic gene 
products 
0.000831 
 Down BP GO:0051789 response to protein stimulus 1.35E-05 
 Down BP GO:0006950 response to stress 0.000732 
 Down BP GO:0006986 response to unfolded protein 1.35E-05 
4hr Up BP GO:0002253 activation of immune response 0.000583 
 Up BP GO:0002526 acute inflammatory response 2.90E-05 
 Up BP GO:0002250 adaptive immune response 4.78E-06 
 Up BP GO:0002460 
adaptive immune response based on 
somatic recombination of immune 
receptors built from immunoglobulin 
superfamily domains 
4.78E-06 
 Up BP GO:0006915 apoptosis 6.83E-10 
 Up BP GO:0019724 B cell mediated immunity 0.000222 
 Up BP GO:0007610 behavior 4.02E-07 
 Up BP GO:0007154 cell communication 0.000144 
 Up BP GO:0008219 cell death 1.16E-09 
 Up BP GO:0048468 cell development 1.01E-05 
 Up BP GO:0030154 cell differentiation 6.69E-06 
 Up BP GO:0008283 cell proliferation 0.000519 
 Up BP GO:0048869 cellular developmental process 6.69E-06 
 Up BP GO:0006935 chemotaxis 1.99E-10 
 Up BP GO:0051181 cofactor transport 0.000914 
 Up BP GO:0001816 cytokine production 2.73E-06 
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 Up BP GO:0050663 cytokine secretion 0.000627 
 Up BP GO:0016265 death 1.16E-09 
 Up BP GO:0006952 defense response 2.62E-11 
 Up BP GO:0032502 developmental process 0.000367 
 Up BP GO:0001660 fever 0.00028 
 Up BP GO:0030097 hemopoiesis 2.90E-06 
 Up BP GO:0048534 
hemopoietic or lymphoid organ 
development 
6.45E-06 
 Up BP GO:0048872 homeostasis of number of cells 9.78E-05 
 Up BP GO:0006959 humoral immune response 0.000955 
 Up BP GO:0002252 immune effector process 0.000552 
 Up BP GO:0006955 immune response 3.98E-17 
 Up BP GO:0002520 immune system development 2.45E-06 
 Up BP GO:0002376 immune system process 7.81E-23 
 Up BP GO:0016064 
immunoglobulin mediated immune 
response 
0.000199 
 Up BP GO:0048305 immunoglobulin secretion 0.00028 
 Up BP GO:0006917 induction of apoptosis 6.92E-06 
 Up BP GO:0008624 
induction of apoptosis by extracellular 
signals 
0.000237 
 Up BP GO:0012502 induction of programmed cell death 7.33E-06 
 Up BP GO:0006954 inflammatory response 7.92E-15 
 Up BP GO:0032635 interleukin-6 production 0.000154 
 Up BP GO:0007242 intracellular signaling cascade 0.000327 
 Up BP GO:0030595 leukocyte chemotaxis 2.64E-05 
 Up BP GO:0002521 leukocyte differentiation 0.000727 
 Up BP GO:0050900 leukocyte migration 8.79E-06 
 Up BP GO:0007626 locomotory behavior 9.67E-10 
 Up BP GO:0030099 myeloid cell differentiation 5.94E-06 
 Up BP GO:0043066 negative regulation of apoptosis 9.07E-05 
 Up BP GO:0048519 
negative regulation of biological 
process 
7.94E-05 
 Up BP GO:0008285 
negative regulation of cell 
proliferation 
0.000104 
 Up BP GO:0048523 negative regulation of cellular process 0.000147 
 Up BP GO:0051093 
negative regulation of developmental 
process 
0.000329 
 Up BP GO:0043069 
negative regulation of programmed 
cell death 
0.000104 
 Up BP GO:0051048 negative regulation of secretion 0.000627 
 Up BP GO:0030593 neutrophil chemotaxis 0.000914 
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 Up BP GO:0018212 peptidyl-tyrosine modification 0.000125 
 Up BP GO:0018108 peptidyl-tyrosine phosphorylation 9.78E-05 
 Up BP GO:0016310 phosphorylation 0.000894 
 Up BP GO:0002821 
positive regulation of adaptive 
immune response 
0.000511 
 Up BP GO:0002824 
positive regulation of adaptive 
immune response based on somatic 
recombination of immune receptors 
built from immunoglobulin 
superfamily domains 
0.000511 
 Up BP GO:0043065 positive regulation of apoptosis 1.05E-05 
 Up BP GO:0048518 
positive regulation of biological 
process 
1.22E-07 
 Up BP GO:0050867 positive regulation of cell activation 0.000334 
 Up BP GO:0048522 positive regulation of cellular process 2.38E-06 
 Up BP GO:0032270 
positive regulation of cellular protein 
metabolic process 
0.000459 
 Up BP GO:0001819 
positive regulation of cytokine 
production 
5.11E-05 
 Up BP GO:0051094 
positive regulation of developmental 
process 
1.74E-07 
 Up BP GO:0050778 
positive regulation of immune 
response 
4.70E-05 
 Up BP GO:0002684 
positive regulation of immune system 
process 
8.58E-07 
 Up BP GO:0032755 
positive regulation of interleukin-6 
production 
0.00028 
 Up BP GO:0002696 
positive regulation of leukocyte 
activation 
0.000334 
 Up BP GO:0043410 positive regulation of MAPKKK cascade 0.000627 
 Up BP GO:0051240 
positive regulation of multicellular 
organismal process 
1.71E-07 
 Up BP GO:0050731 
positive regulation of peptidyl-
tyrosine phosphorylation 
1.60E-05 
 Up BP GO:0045937 
positive regulation of phosphate 
metabolic process 
4.68E-06 
 Up BP GO:0042327 positive regulation of phosphorylation 3.30E-06 
 Up BP GO:0043068 
positive regulation of programmed 
cell death 
1.22E-05 
 Up BP GO:0001934 
positive regulation of protein amino 
acid phosphorylation 
9.97E-07 
 Up BP GO:0051247 
positive regulation of protein 
metabolic process 
0.000586 
 Up BP GO:0031401 
positive regulation of protein 
modification process 
6.53E-06 
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 Up BP GO:0048584 
positive regulation of response to 
stimulus 
0.000333 
 Up BP GO:0009967 
positive regulation of signal 
transduction 
0.000422 
 Up BP GO:0032760 
positive regulation of tumor necrosis 
factor production 
0.00083 
 Up BP GO:0012501 programmed cell death 9.22E-10 
 Up BP GO:0006468 protein amino acid phosphorylation 0.00043 
 Up BP GO:0007243 protein kinase cascade 0.000191 
 Up BP GO:0009306 protein secretion 0.000141 
 Up BP GO:0042981 regulation of apoptosis 5.56E-09 
 Up BP GO:0050865 regulation of cell activation 0.000592 
 Up BP GO:0045595 regulation of cell differentiation 7.54E-05 
 Up BP GO:0042127 regulation of cell proliferation 9.79E-05 
 Up BP GO:0001817 regulation of cytokine production 0.000649 
 Up BP GO:0050793 regulation of developmental process 8.24E-10 
 Up BP GO:0050776 regulation of immune response 0.000165 
 Up BP GO:0002682 regulation of immune system process 1.23E-05 
 Up BP GO:0032675 regulation of interleukin-6 production 8.95E-05 
 Up BP GO:0002694 regulation of leukocyte activation 0.000592 
 Up BP GO:0051239 
regulation of multicellular organismal 
process 
1.80E-05 
 Up BP GO:0045637 
regulation of myeloid cell 
differentiation 
0.000273 
 Up BP GO:0050730 
regulation of peptidyl-tyrosine 
phosphorylation 
1.08E-05 
 Up BP GO:0019220 
regulation of phosphate metabolic 
process 
7.34E-06 
 Up BP GO:0051174 
regulation of phosphorus metabolic 
process 
7.34E-06 
 Up BP GO:0042325 regulation of phosphorylation 4.27E-06 
 Up BP GO:0043067 regulation of programmed cell death 7.59E-09 
 Up BP GO:0001932 
regulation of protein amino acid 
phosphorylation 
1.88E-06 
 Up BP GO:0031399 
regulation of protein modification 
process 
1.53E-05 
 Up BP GO:0042221 response to chemical stimulus 1.64E-07 
 Up BP GO:0009605 response to external stimulus 2.74E-15 
 Up BP GO:0050896 response to stimulus 7.76E-11 
 Up BP GO:0006950 response to stress 1.36E-11 
 Up BP GO:0009611 response to wounding 1.19E-15 
 Up BP GO:0033363 
secretory granule organization and 
biogenesis 
0.00028 
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 Up BP GO:0007165 signal transduction 0.000401 
 Up BP GO:0042330 taxis 1.99E-10 
 Up CC GO:0005602 complement component C1 complex 0.000271 
 Up CC GO:0005576 extracellular region 3.48E-05 
 Up CC GO:0044421 extracellular region part 6.12E-05 
 Up CC GO:0005615 extracellular space 2.62E-07 
 Up CC GO:0005887 integral to plasma membrane 0.000145 
 Up CC GO:0031226 intrinsic to plasma membrane 0.000189 
 Up CC GO:0016020 membrane 4.38E-05 
 Up CC GO:0005886 plasma membrane 4.64E-05 
 Up CC GO:0044459 plasma membrane part 0.000697 
 Up MF GO:0015665 
alcohol transmembrane transporter 
activity 
0.000722 
 Up MF GO:0008009 chemokine activity 8.86E-06 
 Up MF GO:0042379 chemokine receptor binding 1.02E-05 
 Up MF GO:0005125 cytokine activity 2.46E-08 
 Up MF GO:0001664 G-protein-coupled receptor binding 0.000153 
 Up MF GO:0005149 interleukin-1 receptor binding 3.72E-05 
 Up MF GO:0060089 molecular transducer activity 6.27E-09 
 Up MF GO:0042834 peptidoglycan binding 0.000295 
 Up MF GO:0015166 
polyol transmembrane transporter 
activity 
0.000722 
 Up MF GO:0005515 protein binding 0.000154 
 Up MF GO:0004872 receptor activity 1.42E-05 
 Up MF GO:0005102 receptor binding 7.72E-06 
 Up MF GO:0005057 receptor signaling protein activity 0.000392 
 Up MF GO:0004871 signal transducer activity 6.27E-09 
 Down BP GO:0044260 
cellular macromolecule metabolic 
process 
0.000393 
 Down BP GO:0044267 cellular protein metabolic process 0.000595 
 Down BP GO:0051789 response to protein stimulus 9.02E-06 
 Down BP GO:0006950 response to stress 0.00017 
 Down BP GO:0006986 response to unfolded protein 9.02E-06 
 Down CC GO:0005737 cytoplasm 3.29E-05 
 Down CC GO:0005622 intracellular 5.07E-07 
 Down CC GO:0043231 
intracellular membrane-bound 
organelle 
0.000115 
 Down CC GO:0043229 intracellular organelle 0.000536 
 Down CC GO:0044424 intracellular part 6.87E-07 
 Down CC GO:0043227 membrane-bound organelle 0.000116 
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 Down CC GO:0043226 organelle 0.000545 
 Down MF GO:0030554 adenyl nucleotide binding 0.000397 
 Down MF GO:0032559 adenyl ribonucleotide binding 0.000178 
 Down MF GO:0005524 ATP binding 0.000142 
6hr Up BP GO:0002526 acute inflammatory response 0.000427 
 Up BP GO:0001525 angiogenesis 0.000756 
 Up BP GO:0006915 apoptosis 5.31E-11 
 Up BP GO:0007610 behavior 1.03E-06 
 Up BP GO:0065007 biological regulation 1.14E-06 
 Up BP GO:0043412 biopolymer modification 1.49E-05 
 Up BP GO:0001568 blood vessel development 0.000475 
 Up BP GO:0055080 cation homeostasis 0.000547 
 Up BP GO:0007154 cell communication 2.58E-05 
 Up BP GO:0008219 cell death 4.18E-10 
 Up BP GO:0048468 cell development 3.46E-08 
 Up BP GO:0030154 cell differentiation 8.87E-09 
 Up BP GO:0016477 cell migration 0.000531 
 Up BP GO:0006928 cell motility 0.000179 
 Up BP GO:0008283 cell proliferation 1.14E-07 
 Up BP GO:0048869 cellular developmental process 8.87E-09 
 Up BP GO:0044260 
cellular macromolecule metabolic 
process 
0.000388 
 Up BP GO:0044267 cellular protein metabolic process 0.000252 
 Up BP GO:0006935 chemotaxis 8.61E-10 
 Up BP GO:0019221 
cytokine and chemokine mediated 
signaling pathway 
1.72E-05 
 Up BP GO:0001816 cytokine production 0.000161 
 Up BP GO:0016265 death 4.18E-10 
 Up BP GO:0006952 defense response 4.53E-08 
 Up BP GO:0032502 developmental process 5.19E-05 
 Up BP GO:0030218 erythrocyte differentiation 0.000588 
 Up BP GO:0034101 erythrocyte homeostasis 0.000588 
 Up BP GO:0030097 hemopoiesis 3.34E-06 
 Up BP GO:0048534 
hemopoietic or lymphoid organ 
development 
3.26E-06 
 Up BP GO:0048872 homeostasis of number of cells 0.000845 
 Up BP GO:0006955 immune response 6.51E-08 
 Up BP GO:0002520 immune system development 8.20E-07 
 Up BP GO:0002376 immune system process 3.05E-12 
 Up BP GO:0006954 inflammatory response 8.31E-11 
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 Up BP GO:0032635 interleukin-6 production 5.05E-06 
 Up BP GO:0007242 intracellular signaling cascade 8.77E-06 
 Up BP GO:0030595 leukocyte chemotaxis 3.16E-06 
 Up BP GO:0050900 leukocyte migration 4.73E-06 
 Up BP GO:0051674 localization of cell 0.000179 
 Up BP GO:0007626 locomotory behavior 2.93E-08 
 Up BP GO:0033002 muscle cell proliferation 0.000344 
 Up BP GO:0030099 myeloid cell differentiation 9.57E-06 
 Up BP GO:0043066 negative regulation of apoptosis 0.000184 
 Up BP GO:0048519 
negative regulation of biological 
process 
2.77E-09 
 Up BP GO:0008285 
negative regulation of cell 
proliferation 
8.51E-05 
 Up BP GO:0048523 negative regulation of cellular process 2.20E-09 
 Up BP GO:0051093 
negative regulation of developmental 
process 
2.41E-05 
 Up BP GO:0042347 
negative regulation of NF-kappaB 
import into nucleus 
0.000872 
 Up BP GO:0045934 
negative regulation of nucleobase, 
nucleoside, nucleotide and nucleic 
acid metabolic process 
0.000363 
 Up BP GO:0043069 
negative regulation of programmed 
cell death 
0.000224 
 Up BP GO:0051253 
negative regulation of RNA metabolic 
process 
0.000695 
 Up BP GO:0051048 negative regulation of secretion 0.000574 
 Up BP GO:0016481 negative regulation of transcription 0.000168 
 Up BP GO:0048513 organ development 0.000654 
 Up BP GO:0006796 phosphate metabolic process 0.000167 
 Up BP GO:0006793 phosphorus metabolic process 0.000167 
 Up BP GO:0016310 phosphorylation 0.000109 
 Up BP GO:0043065 positive regulation of apoptosis 0.000191 
 Up BP GO:0048518 
positive regulation of biological 
process 
3.88E-09 
 Up BP GO:0048522 positive regulation of cellular process 8.21E-09 
 Up BP GO:0001819 
positive regulation of cytokine 
production 
0.000726 
 Up BP GO:0051094 
positive regulation of developmental 
process 
0.000253 
 Up BP GO:0043068 
positive regulation of programmed 
cell death 
0.000231 
 Up BP GO:0051254 
positive regulation of RNA metabolic 
process 
0.000903 
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Timepoint 
of 
comparison 
Direction 
of change 
Ontology 
group 
GO path ID Pathway description 
Enrichment 
P value 
 Up BP GO:0009967 
positive regulation of signal 
transduction 
0.000441 
 Up BP GO:0045893 
positive regulation of transcription, 
DNA-dependent 
0.000805 
 Up BP GO:0043687 
post-translational protein 
modification 
3.57E-06 
 Up BP GO:0012501 programmed cell death 8.79E-11 
 Up BP GO:0006468 protein amino acid phosphorylation 6.49E-06 
 Up BP GO:0007243 protein kinase cascade 1.54E-07 
 Up BP GO:0019538 protein metabolic process 0.000237 
 Up BP GO:0006464 protein modification process 1.65E-05 
 Up BP GO:0042981 regulation of apoptosis 1.40E-07 
 Up BP GO:0050789 regulation of biological process 6.03E-07 
 Up BP GO:0065008 regulation of biological quality 8.63E-06 
 Up BP GO:0045595 regulation of cell differentiation 0.00011 
 Up BP GO:0042127 regulation of cell proliferation 1.06E-06 
 Up BP GO:0050794 regulation of cellular process 3.68E-06 
 Up BP GO:0001817 regulation of cytokine production 9.04E-05 
 Up BP GO:0050793 regulation of developmental process 1.50E-08 
 Up BP GO:0045682 regulation of epidermis development 3.98E-05 
 Up BP GO:0032675 regulation of interleukin-6 production 5.89E-05 
 Up BP GO:0045637 
regulation of myeloid cell 
differentiation 
0.000856 
 Up BP GO:0043067 regulation of programmed cell death 2.14E-07 
 Up BP GO:0006357 
regulation of transcription from RNA 
polymerase II promoter 
0.000132 
 Up BP GO:0042221 response to chemical stimulus 4.52E-07 
 Up BP GO:0009605 response to external stimulus 3.74E-12 
 Up BP GO:0050896 response to stimulus 0.000541 
 Up BP GO:0006950 response to stress 1.31E-07 
 Up BP GO:0009611 response to wounding 3.77E-12 
 Up BP GO:0007165 signal transduction 3.66E-05 
 Up BP GO:0048731 system development 0.000598 
 Up BP GO:0042330 taxis 8.61E-10 
 Up BP GO:0001944 vasculature development 0.000591 
 Up CC GO:0005887 integral to plasma membrane 1.49E-05 
 Up CC GO:0031226 intrinsic to plasma membrane 2.42E-05 
 Up CC GO:0044459 plasma membrane part 8.53E-05 
 Up MF GO:0005488 binding 4.48E-05 
 Up MF GO:0008009 chemokine activity 3.52E-05 
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 Up MF GO:0042379 chemokine receptor binding 4.25E-05 
 Up MF GO:0005125 cytokine activity 3.61E-06 
 Up MF GO:0001664 G-protein-coupled receptor binding 0.000355 
 Up MF GO:0060089 molecular transducer activity 0.000952 
 Up MF GO:0015205 
nucleobase transmembrane 
transporter activity 
0.000784 
 Up MF GO:0005515 protein binding 3.64E-13 
 Up MF GO:0004672 protein kinase activity 0.000536 
 Up MF GO:0005057 receptor signaling protein activity 0.000159 
 Up MF GO:0004871 signal transducer activity 0.000952 
 Down BP GO:0042773 
ATP synthesis coupled electron 
transport 
2.44E-07 
 Down BP GO:0009058 biosynthetic process 2.86E-09 
 Down BP GO:0044249 cellular biosynthetic process 6.71E-11 
 Down BP GO:0044237 cellular metabolic process 7.11E-14 
 Down BP GO:0042769 
DNA damage response, detection of 
DNA damage 
0.000517 
 Down BP GO:0006118 electron transport 4.14E-07 
 Down BP GO:0010467 gene expression 3.87E-07 
 Down BP GO:0006091 
generation of precursor metabolites 
and energy 
8.29E-07 
 Down BP GO:0042168 heme metabolic process 0.000331 
 Down BP GO:0006886 intracellular protein transport 0.000532 
 Down BP GO:0065002 
intracellular protein transport across 
a membrane 
0.000233 
 Down BP GO:0046907 intracellular transport 0.000777 
 Down BP GO:0009059 macromolecule biosynthetic process 8.29E-08 
 Down BP GO:0043170 macromolecule metabolic process 2.37E-07 
 Down BP GO:0008152 metabolic process 1.92E-15 
 Down BP GO:0006120 
mitochondrial electron transport, 
NADH to ubiquinone 
4.54E-07 
 Down BP GO:0006139 
nucleobase, nucleoside, nucleotide 
and nucleic acid metabolic process 
4.04E-07 
 Down BP GO:0042775 
organelle ATP synthesis coupled 
electron transport 
2.44E-07 
 Down BP GO:0006119 oxidative phosphorylation 2.30E-08 
 Down BP GO:0043043 peptide biosynthetic process 0.000517 
 Down BP GO:0006778 porphyrin metabolic process 0.000959 
 Down BP GO:0044238 primary metabolic process 6.85E-11 
 Down BP GO:0006457 protein folding 1.17E-05 
 Down BP GO:0015031 protein transport 0.000396 
Claire A Higgins, 2012   Appendix IV, 362  
Timepoint 
of 
comparison 
Direction 
of change 
Ontology 
group 
GO path ID Pathway description 
Enrichment 
P value 
 Down BP GO:0051789 response to protein stimulus 0.000359 
 Down BP GO:0006986 response to unfolded protein 0.000359 
 Down BP GO:0006396 RNA processing 1.65E-06 
 Down BP GO:0016072 rRNA metabolic process 0.000233 
 Down BP GO:0006364 rRNA processing 0.000747 
 Down BP GO:0019748 secondary metabolic process 0.000353 
 Down BP GO:0033013 tetrapyrrole metabolic process 0.000959 
 Down BP GO:0006412 translation 1.44E-09 
 Down BP GO:0006399 tRNA metabolic process 6.81E-06 
 Down BP GO:0008033 tRNA processing 7.92E-05 
 Down CC GO:0005623 cell 0.000754 
 Down CC GO:0044464 cell part 0.00074 
 Down CC GO:0005737 cytoplasm 2.24E-10 
 Down CC GO:0044444 cytoplasmic part 2.05E-12 
 Down CC GO:0031975 envelope 6.13E-08 
 Down CC GO:0005622 intracellular 3.15E-21 
 Down CC GO:0043231 
intracellular membrane-bound 
organelle 
1.46E-21 
 Down CC GO:0043232 
intracellular non-membrane-bound 
organelle 
0.000957 
 Down CC GO:0043229 intracellular organelle 9.34E-18 
 Down CC GO:0044446 intracellular organelle part 3.20E-10 
 Down CC GO:0044424 intracellular part 1.20E-20 
 Down CC GO:0015934 large ribosomal subunit 0.000386 
 Down CC GO:0032991 macromolecular complex 1.61E-09 
 Down CC GO:0043227 membrane-bound organelle 1.56E-21 
 Down CC GO:0031974 membrane-enclosed lumen 7.82E-14 
 Down CC GO:0005740 mitochondrial envelope 4.24E-10 
 Down CC GO:0005743 mitochondrial inner membrane 9.76E-12 
 Down CC GO:0005762 mitochondrial large ribosomal subunit 3.22E-07 
 Down CC GO:0031980 mitochondrial lumen 5.95E-14 
 Down CC GO:0005759 mitochondrial matrix 5.95E-14 
 Down CC GO:0031966 mitochondrial membrane 1.56E-09 
 Down CC GO:0044455 mitochondrial membrane part 1.27E-10 
 Down CC GO:0044429 mitochondrial part 1.22E-19 
 Down CC GO:0005746 mitochondrial respiratory chain 4.16E-07 
 Down CC GO:0005747 
mitochondrial respiratory chain 
complex I 
6.10E-08 
 Down CC GO:0005761 mitochondrial ribosome 1.30E-16 
 Down CC GO:0005763 mitochondrial small ribosomal subunit 2.61E-06 
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 Down CC GO:0005739 mitochondrion 2.91E-25 
 Down CC GO:0030964 NADH dehydrogenase complex 6.10E-08 
 Down CC GO:0043228 non-membrane-bound organelle 0.000957 
 Down CC GO:0031981 nuclear lumen 0.000296 
 Down CC GO:0044428 nuclear part 0.000314 
 Down CC GO:0044452 nucleolar part 0.000734 
 Down CC GO:0005730 nucleolus 0.000193 
 Down CC GO:0005634 nucleus 9.53E-06 
 Down CC GO:0000315 organellar large ribosomal subunit 3.22E-07 
 Down CC GO:0000313 organellar ribosome 1.30E-16 
 Down CC GO:0000314 organellar small ribosomal subunit 2.61E-06 
 Down CC GO:0043226 organelle 1.02E-17 
 Down CC GO:0031967 organelle envelope 6.13E-08 
 Down CC GO:0019866 organelle inner membrane 8.09E-11 
 Down CC GO:0043233 organelle lumen 7.82E-14 
 Down CC GO:0031090 organelle membrane 0.000275 
 Down CC GO:0044422 organelle part 4.16E-10 
 Down CC GO:0043234 protein complex 2.54E-05 
 Down CC GO:0045271 respiratory chain complex I 6.10E-08 
 Down CC GO:0030529 ribonucleoprotein complex 7.35E-09 
 Down CC GO:0033279 ribosomal subunit 2.85E-07 
 Down CC GO:0005840 ribosome 5.16E-08 
 Down CC GO:0015935 small ribosomal subunit 0.000258 
 Down MF GO:0003824 catalytic activity 1.67E-06 
 Down MF GO:0050662 coenzyme binding 0.000352 
 Down MF GO:0003688 DNA replication origin binding 0.000573 
 Down MF GO:0009055 electron carrier activity 4.66E-08 
 Down MF GO:0008168 methyltransferase activity 0.000175 
 Down MF GO:0050136 
NADH dehydrogenase (quinone) 
activity 
1.10E-06 
 Down MF GO:0008137 
NADH dehydrogenase (ubiquinone) 
activity 
1.10E-06 
 Down MF GO:0003954 NADH dehydrogenase activity 1.10E-06 
 Down MF GO:0003676 nucleic acid binding 2.87E-05 
 Down MF GO:0016491 oxidoreductase activity 2.28E-06 
 Down MF GO:0016651 
oxidoreductase activity, acting on 
NADH or NADPH 
3.69E-06 
 Down MF GO:0016655 
oxidoreductase activity, acting on 
NADH or NADPH, quinone or similar 
compound as acceptor 
3.08E-06 
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 Down MF GO:0003723 RNA binding 7.88E-05 
 Down MF GO:0003735 structural constituent of ribosome 3.90E-07 
 Down MF GO:0016741 
transferase activity, transferring one-
carbon groups 
0.000223 
 Down MF GO:0004549 tRNA-specific ribonuclease activity 0.000915 
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Appendix V 
Tabular description of cellular pathways represented by enrichment pathway analysis using 
the Kyoto Encyclopedia of Genes and Genomes (KEGG) performed on overlapping 
differentially expressed genes from in-vivo (NIL vs IL) and in-vitro (1, 2, 4 and 6hours 
relative to 0hours) myometrial samples.  Significance level for differential expression was 
set at an adjusted p<0.01.  
 
N gene overlapping for their differential expression 
between in-vivo and in-vitro data adjusted p<0.01 
Process 
(2hr vs 0hr) 
cf 
(IL vs NIL) 
(4hr vs 0hr) 
cf 
(IL vs NIL) 
(6hr vs 0hr) 
cf 
(IL vs NIL) 
Not assigned 3 54 124 
Cytokine-cytokine receptor 
interaction 
1 4 8 
Complement and coagulation 
cascades 
 2 6 
Jak-STAT signaling pathway  4 5 
MAPK signaling pathway  4 5 
Neuroactive ligand-receptor 
interaction 
 1 5 
Regulation of actin cytoskeleton  1 5 
Calcium signaling pathway  4 4 
Hematopoietic cell lineage  2 4 
GnRH signaling pathway  4 3 
Insulin signaling pathway  2 3 
    
Glycolysis / Gluconeogenesis  1 3 
Lysine degradation  0 3 
Valine, leucine and isoleucine 
degradation 
 0 3 
Long-term depression  3 2 
Long-term potentiation  3 2 
Melanogenesis  3 2 
Focal adhesion  2 2 
Glycan structures - biosynthesis 2  2 2 
Small cell lung cancer  2 2 
Apoptosis  1 2 
    
Arachidonic acid metabolism  1 2 
Axon guidance  1 2 
Cell adhesion molecules (CAMs)  1 2 
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Fructose and mannose metabolism  1 2 
mTOR signaling pathway  1 2 
Natural killer cell mediated 
cytotoxicity 
 1 2 
Purine metabolism  1 2 
Systemic lupus erythematosus  1 2 
Vibrio cholerae infection  1 2 
p53 signaling pathway  0 2 
    
Propanoate metabolism  0 2 
Toll-like receptor signaling pathway  0 2 
Ubiquitin mediated proteolysis  0 2 
Cell junctions  2 1 
ErbB signaling pathway  2 1 
Glycosphingolipid biosynthesis - 
ganglio series 
 2 1 
Glycosphingolipid biosynthesis - 
globo series 
 2 1 
Wnt signaling pathway  2 1 
ABC transporters - General  1 1 
Acute myeloid leukemia  1 1 
Allograft rejection  1 1 
Aminosugars metabolism  1 1 
Arginine and proline metabolism  1 1 
Asthma  1 1 
Autoimmune thyroid disease  1 1 
Biosynthesis of steroids  1 1 
Cell cycle  1 1 
Chronic myeloid leukemia  1 1 
Drug metabolism - other enzymes  1 1 
ECM-receptor interaction  1 1 
Endometrial cancer  1 1 
Epithelial cell signaling in 
Helicobacter pylori infection 
 1 1 
Galactose metabolism  1 1 
Gap junction  1 1 
Glycan structures - biosynthesis 1  1 1 
Keratan sulfate biosynthesis  1 1 
O-Glycan biosynthesis  1 1 
Oxidative phosphorylation  1 1 
PPAR signaling pathway  1 1 
Pyrimidine metabolism  1 1 
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Renin-angiotensin system  1 1 
Starch and sucrose metabolism  1 1 
Streptomycin biosynthesis  1 1 
T cell receptor signaling pathway  1 1 
Thyroid cancer  1 1 
VEGF signaling pathway  1 1 
3-Chloroacrylic acid degradation  0 1 
Ascorbate and aldarate metabolism  0 1 
beta-Alanine metabolism  0 1 
Bile acid biosynthesis  0 1 
Butanoate metabolism  0 1 
Carbon fixation in photosynthetic 
organisms 
 0 1 
Fatty acid metabolism  0 1 
Folate biosynthesis  0 1 
Glycerolipid metabolism  0 1 
Glycosylphosphatidylinositol(GPI)-
anchor biosynthesis 
 0 1 
Graft-versus-host disease  0 1 
Histidine metabolism  0 1 
Inositol metabolism  0 1 
Limonene and pinene degradation  0 1 
Nicotinate and nicotinamide 
metabolism 
 0 1 
Pancreatic cancer  0 1 
Prion disease  0 1 
Pyruvate metabolism  0 1 
Renal cell carcinoma  0 1 
SNARE interactions in vesicular 
transport 
 0 1 
Tight junction  0 1 
Tryptophan metabolism  0 1 
Urea cycle and metabolism of amino 
groups 
 0 1 
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Menzies FM, Oldham R, Higgins CA, Nibbs RJB, Nelson SM. Temporal Analysis 
of Chemokine Production and Immune Cell Influx into the Uterus in Mice and 
Humans. Reproductive Sciences 2011;18(3):243A-43A. 
Menzies FM, Oldham R, Higgins CA, Nibbs RJ, Nelson SM. Temporal analysis of 
chemokine production and immune cell influx into the uterus in mice and 
humans. Immunology 2010;131:61-61. 
Labour is a co-ordinated process and mechanisms required for its initiation in humans are not 
fully understood.  Studies suggest that immune cells play an important role in stimulating 
myometrial contractions through creation of an inflammatory environment.  Inflammation is a 
necessary component of implantation and pregnancy, however excessive inflammation can also 
be detrimental and has been associated with miscarriage.  To further understand the role of 
immune cells and their influx into the uterus during labour, we sought to characterise the 
chemokine profile of the pregnant, labouring and post partum uterus within a mouse model.  In 
order to achieve this, we obtained uterine horn tissue from C57BL/6 female mice at term 
pregnancy (day 18), during labour or during the post partum period (n=5-6 mice per group).  
Quantitative real-time PCR (qRT-PCR) analysis revealed that term pregnancy in mice is 
associated with an increase in expression of chemokines involved in monocyte, macrophage and 
neutrophil chemotaxis, some of which were further upregulated during labour and the post 
partum period.  Macrophages, neutrophils and T cells within these tissues were also enumerated 
by qRT-PCR and immunohistochemistry.  Furthermore, analysis of circulating chemokine levels in 
humans throughout labour demonstrated that this process is associated with a temporal increase 
in chemokines involved in monocyte and neutrophil trafficking.  These studies show that an 
inflammatory type response is evident within the uterus throughout labour, however immune 
cells and the chemokine which attract them, continue to increase beyond labour initiation in 
order to aid in the post partum remodelling of the uterus. 
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Higgins CA, McConnachie A, Nibbs RJB, Nelson SM. Temporal Changes to 
Leukocyte Subpopulations, Chemokine Receptor Expression and Circulating 
Cytokines during Human Parturition. Reproductive Sciences 
2010;17(3):179A-79A.  
Background:  Human labour is associated with significant induction of chemokine mediated 
leukocyte trafficking into myometrium and cervix. We sought to characterise the temporal 
changes to the peripheral inflammatory response in term pregnancy during induction of 
labour(IOL) & non-labour planned caesarean delivery(CS).  
 
Methods:  Blood samples were obtained from non-pregnant females (day 2-5 of cycle)(NP=8), pre 
CS (n=8), post CS (n=8), and pre, post&2hrly during induction of labour (n=8). Analyses were 
made for 1)counts of peripheral blood leukocytes (PBL), 2)PBL chemokine receptor (PBLCR) 
profile (CXCR1, CXCR2, CCR2, CCR6) characterised by flow cytometry and 3)plasma cytokine 
concentrations measured using 39 multiplex ELISA. Data was analysed by ANOVA, paired and 2-
sample t-tests. 
 
Results:  Total white cell count (tWCC) was increased during pregnancy (p<0.001) reflecting 
increased neutrophils (p<0.001). CS & IOL both induced acute increases in tWCC, neutrophils & 
monocytes (p<0.001 for all), while lymphocytes and esoinophils decreased (p<0.05 for both). The 
extent of change was greater with IOL for tWCC, neutrophils, lymphocytes and monocytes 
(p<0.001 for all). The changes in tWCC and leukocyte subpopulations strongly correlated with % 
length of labour (r>0.39, p<0.01 for all). PBL chemokine expression did not differ with 
pregnancy, however with IOL the number of CXCR1&2 neutrophils increased, with a 
corresponding decrease in density of expression (p<0.05 for both). No differences were observed 
for CCR2+ or CCR6+ leukocytes. Only GCSF increased in pregnancy (p=0.01), with further 
increases in response to IOL, in addition GRO, IL6, IL10, CCL2 and CCL7 increased with labour 
(P<0.01 for all). No differences in circulating cytokines in response to CS were observed. 
 
Conclusions:  Induction of labour is associated with a systemic acute inflammatory response 
characterised by changes in the circulating leukocyte profile and inflammatory cytokines and 
chemokine production. Notably this is associated with the % length of labour, and neutrophils 
characteristics typical of those newly recruited from bone marrow. Changes during pregnancy 
appear to be limited to increased neutrophil count and corresponding GCSF with no suggestion of 
leukocyte priming prior to labour. 
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Higgins CA, Martin W, Blanks AM, Catalano R, Thornton S, Nelson SM. 
Myometrial Cytokines and Chemokines during Human Labour: A Co-Ordinated 
Time and Contraction Dependent Event. Reproductive Sciences 
2010;17(3):179A-79A. 
Introduction:  The cause of the inflammatory changes associated with human labour are 
unknown. We sought to provide a temporal and functional description of the myometrial derived 
inflammatory cytokines and chemokines associated with myometrial contractions in-vitro and the 
overlap with human labour. 
Methods:  Myometrial strips from term pre-labour caesarean deliveries (patients=25, strips from 
each patient=3) were suspended in an organ bath. After establishment of spontaneous 
contractions, oxytocin (OT) was added to 1 strip/patient, the remaining strips continued 
spontaneous contractions, and were terminated at 0, 1, 2, 4 & 6hrs after drug addition. Illumina 
gene arrays were compiled for each individual sample (n=75) and were analysed together, n=15 
at each time point (previous work shows OT alters contractions but not transcription in myoctes). 
Differential gene expression analysis was undertaken with subsequent validation by qPCR and 
functional enrichment analysis by GO&KEGG. Overlap comparison of significant genes was made 
with previously undertaken affymetrix gene arrays from myometrium at term not-in-labour 
(NIL=9) and in labour (IL=9). 
Results:  In-vitro studies revealed a time-dependent transcriptional wave with 13, 114, 2006 & 
4760 genes differentially expressed at 1, 2, 4 & 6hrs respectively (adjusted p<0.01). GO & KEGG 
enrichment analysis showed up-regulation of inflammatory processes, with predominance of 
cytokines and chemokines. qPCR validation confirmed increased CXCL1, 2,5,8, CCL20, IL6,IL8 & 
IL1B expression, with all positively associated with the duration of contractions (r>0.36, p<0.001 
for all). Analysis of the overlap of this in-vitro contractile profile with genes differentially 
expressed in myometrium of spontaneous labouring women (p<0.01) demonstrated an overlap 
with 126,163, 323, 417 genes at 1, 2, 4 & 6hrs. Notably again inflammatory processes dominated. 
Conclusions:  Inflammatory cytokine and chemokine release from myometrium at term occurs in 
a co-ordinated time and contraction dependent manner, implying inflammation in labour may 
occur as an acute response to myometrial contractions. 
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Higgins CA, Martin W, Blanks AM, Nelson SM. Lipopolysaccharide induces and 
intense inflammatory response to myometrium, but is not associated with a 
functional contractile response in-vitro. Bjog-an International Journal of 
Obstetrics and Gynaecology 2010;117(5):631-32. 
Background:  The TLR-4 agonist Lipopolysaccharide(LPS) has been implicated in the initiation of 
pre-term and term labour.  We have examined whether LPS induces an inflammatory response in 
myometrium and whether this was associated with stimulation of contractile activity in-vitro. 
Methods:  Myometrial strips were exposed to LPS(100µg/ml) or Polymixin-B (30µg/ml ) to 
inactivate endotoxin + exposure to a single concentration of oxytocin(OT,1nM).  Contractions 
were observed for 5hours after stable activity or addition of OT and tissue frozen for Q-PCR. 
Results:  LPS induced a significantly higher expression of the inflammatory mediators; 
CXCL2,CXCL8,CCL2,CCL3,CCL8,CCL20,IL6 and IL1β(p<0.05 for all).  However, contractile 
amplitude, frequency or activity integral was not affected.  Additionally, the contractile 
stimulatory effect of OT was not enhanced by LPS, despite further significant enhancement of 
the inflammatory response. 
Conclusions:  Activation of TLR-4 by LPS stimulates a significant up-regulation of myometrial 
chemokine production.  However, this does not alter inherent in-vitro myometrial contractility, 
or response to OT. 
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Higgins CA, Martin W, Blanks A, Thornton S, Nelson SM. Investigation of 
Myometrial Gene Expression in Response to Sustained Spontaneous and 
Oxytocin Induced Contraction In-vitro. Reproductive Sciences 
2009;16(3):292A-93A. 
Introduction: Oxytocin (OT) is a major endogenous uterotonin which induces myometrial 
contractions by stimulating intracellular calcium release and voltage gated calcium entry. At 
present it is unclear whether oxytocin receptor signalling may have longer term actions on gene 
expression in addition to an acute physiological effect. To clarify this, we examined the time-
dependent transcriptional response of myometrium to spontaneous and OT-induced contractions 
in-vitro. 
Methods: Myometrial strips from term pre-labor planned caesarean deliveries (n patients=25, n 
strips from each patient=2) were suspended in an organ bath under physiological conditions.  
After establishment of spontaneous contractions, a single addition of either OT (1nM) or acetic 
acid vehicle (2µM) was undertaken and frequency, amplitude and activity integral of contractile 
activity was recorded. Contractions were terminated at either 0,1,2,4 or 6 hours after drug 
addition and individual Illumina gene arrays were performed on each sample (n=50), with array 
validation using qRT-PCR. Data from arrays were analysed using t-test coupled with p value 
adjustment for multiple testing using the Benjamini & Hochberg method. 
Results: Addition of 1nM OT had an immediate stimulatory effect on contractile activity 
compared with vehicle (median % change (IQR) frequency 526.7 (524.8) vs 0.0 (23.5) p<0.001, 
amplitude 12.5 (44.6) vs 1.4 (6.1), p<0.001, activity integral 151.8 (222.0) vs -1.7 (17.2), 
p<0.001). OT and vehicle treated myometrium demonstrated a time-dependent transcriptional 
wave with differential expression of 804 genes at 4h and 2262 genes at 6 h. Using an adjusted 
significance of p<0.05, no genes were significantly altered by OT when compared to vehicle 
alone at any of the 5 time points.   
Conclusion: In-vitro myometrial contractions induce a transcriptional wave identical to that 
produced under the influence of OT despite significant differences in functional activity. This 
suggests that contractions per se have a significant time dependent effect on the myometrial 
transcriptome and the specific actions of oxytocin are limited to the modification of pre-existing 
myometrial proteins. 
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Higgins CA, Martin W, Blanks A, Thornton S, Norman JE, Nelson SM. Maternal 
obesity does not impair spontaneous or oxytocin-induced contractility of 
human myometrium in vitro. Reproductive Sciences 2008;15(2):113A-14A. 
Introduction: Maternal obesity is associated with an increased need for operative delivery due to 
ineffectual progress in labour despite oxytocin (OT) augmentation. It is unclear whether this 
reflects impaired myometrial contractility, spontaneous or OT-induced, or alternative 
mechanisms. To clarify this we have examined myometrial activity in-vitro and related this to 
maternal body mass index. 
 
Methods: Lower uterine segment myometrial samples were obtained at term pre-labour elective 
caesarean section (n=43). Maternal BMI was calculated using early pregnancy weight (12-14 
weeks). Myometrial strips were placed in an organ bath of Carbogen gassed Krebs solution and 
suspended under isometric conditions with a resting tension of 20mN. After establishment of 
spontaneous contractions, strips were exposed to a single concentration of OT (1nM), with 
contractions observed for 60 min. OT concentration-response curves, 10-12 M-10-7 M, were also 
undertaken (n=21). Amplitude and frequency of contractile activity was recorded using a 
PowerLab with Chart v3.6 software. Data were analysed using one-way ANOVA, paired t-test and 
Pearson correlation.  
 
Results: Mean BMI was 26.25 5.19 kg/m2. Increasing BMI was not associated with a difference in 
spontaneous myometrial activity; mean amplitude=61.84mN, r=-0.10, p=0.51, mean 
frequency=7.68 contractions/hr, r=0.25, p=0.10. Exposure to a concentration of 1nM OT 
produced an immediate increase in activity in all samples (amplitude mean increase=19.74mN, 
p=<0.01, frequency mean increase=50.56 contractions/hr p<0.01). % increase in both amplitude 
and frequency respectively were not related to BMI at immediate (108.7% r=-0.08, p=0.59; 
880.8% r=-0.03 p= 0.85), 30min (171.3% r=-0.06, p=0.72; 59.28% r=0.12 p=0.48) or 60min (173.8% 
r=-0.06, p=0.73; 47.58% r=0.10 p=0.56) timepoints. Analysis of OT concentration-response curves 
did not show a BMI dependent effect (mean BMI 28.44 6.05 kg/m2, mean Log EC50=-9.73M, 
r=0.25, p=0.27). 
 
Conclusion: The association between maternal obesity and operative delivery is not due to 
impaired spontaneous myometrial activity or responsiveness to OT, and may reflect pelvic 
adiposity, or a decrease in bioavailabilty of OT with increasing BMI.
 377 
 
List of References 
 
1. United States Census Bureau, International Data Base, International Programs. 
http://www.census.gov/population/international/data/idb/information
Gateway.php, May 2012. 
2. March of Dimes, PMNCH, Save the Children, WHO.  Born Too soon: The Global 
Action Report on Preterm Birth. Geneva: World Health Organization, 
2012. 
3. Births in Scottish Hospitals, year ending 31 March 2010. Edinburgh: 
Information Services Division (ISD), NHS National Services, Scotland, 2011. 
4. NHS Maternity Data, England: 2010-11, 
http://www.hesonline.nhs.uk/Ease/servlet/ContentServer?siteID=1937&c
ategoryID=1815: Hospital Episode Statistics, HES online, 2012. 
5. Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller A-B, Narwal R, et al. 
National, regional, and worldwide estimates of preterm birth rates in the 
year 2010 with time trends since 1990 for selected countries: a systematic 
analysis and implications. The Lancet 2012;379(9832):2162-72. 
6. Nosarti C, Reichenberg A, Murray RM, Cnattingius S, Lambe MP, Yin L, et al. 
Preterm Birth and Psychiatric Disorders in Young Adult LifePreterm Birth 
and Psychiatric Disorders. Archives of General Psychiatry 2012;69(6):610-
17. 
7. Moster D, Lie RT, Markestad T. Long-term medical and social consequences of 
preterm birth. New England Journal of Medicine 2008;359(3):262-73. 
8. Saigal S, Doyle LW. An overview of mortality and sequelae of preterm birth 
from infancy to adulthood. The Lancet 2008;371(9608):261-69. 
9. Mwaniki MK, Atieno M, Lawn JE, Newton CRJC. Long-term 
neurodevelopmental outcomes after intrauterine and neonatal insults: a 
systematic review. The Lancet 2012;379:445-52. 
10. Gilbert WM. The cost of preterm birth: the low cost versus high value of 
tocolysis. Bjog 2006;3:4-9. 
11. Gilbert WM, Nesbitt TS, Danielsen B. The cost of prematurity: quantification 
by gestational age and birth weight. Obstet Gynecol 2003;102(3):488-92. 
12. Saigal S, Pinelli J, Streiner DL, Boyle M, Stoskopf B. Impact of extreme 
prematurity on family functioning and maternal health 20 years later. 
Pediatrics 2010;126(1):7. 
13. Singer LT, Fulton S, Kirchner HL, Eisengart S, Lewis B, Short E, et al. 
Parenting very low birth weight children at school age: maternal stress 
and coping. J Pediatr 2007;151(5):463-9. 
14. Saigal S, Burrows E, Stoskopf BL, Rosenbaum PL, Streiner D. Impact of 
extreme prematurity on families of adolescent children. J Pediatr 
2000;137(5):701-6. 
15. Keller M, Felderhoff-Mueser U, Lagercrantz H, Dammann O, Marlow N, Huppi 
P, et al. Policy benchmarking report on neonatal health and social policies 
in 13 European countries. Acta Paediatr. 2010;99(11):1624-29. 
16. Phibbs CS, Schmitt SK. Estimates of the cost and length of stay changes that 
can be attributed to one-week increases in gestational age for premature 
infants. Early Hum. Dev. 2006;82(2):85-95. 
17. Petrou S. The economic consequences of preterm birth duringthe first 10 
years of life. BJOG: An International Journal of Obstetrics & Gynaecology 
2005;112:10-15. 
 378 
18. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of 
preterm birth. The Lancet 2008;371(9606):75-84. 
19. Steer P. The epidemiology of preterm labour. BJOG: An International 
Journal of Obstetrics & Gynaecology 2005;112:1-3. 
20. Gracie S, Lyon A, Kehler H, Pennell C, Dolan S, McNeil D, et al. All Our 
Babies Cohort Study: recruitment of a cohort to predict women at risk of 
preterm birth through the examination of gene expression profiles and the 
environment. BMC Pregnancy and Childbirth 2010;10(1):87. 
21. Copper RL, Goldenberg RL, Das A, Elder N, Swain M, Norman G, et al. The 
preterm prediction study: maternal stress is associated with spontaneous 
preterm birth at less than thirty-five weeks' gestation. National Institute 
of Child Health and Human Development Maternal-Fetal Medicine Units 
Network. Am J Obstet Gynecol 1996;175(5):1286-92. 
22. Muglia LJ, Katz M. CURRENT CONCEPTS The Enigma of Spontaneous Preterm 
Birth. New England Journal of Medicine 2010;362(6):529-35. 
23. Romero R, Espinoza J, Kusanovic JP, Gotsch F, Hassan S, Erez O, et al. The 
preterm parturition syndrome. Bjog 2006;3:17-42. 
24. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, 
Paraskevaidis E. Obstetric outcomes after conservative treatment for 
intraepithelial or early invasive cervical lesions: systematic review and 
meta-analysis. Lancet 2006;367(9509):489-98. 
25. Refuerzo JS. Impact of multiple births on late and moderate prematurity. 
Seminars in Fetal and Neonatal Medicine 2012;17(3):143-45. 
26. Albertsen K, Andersen AMN, Olsen J, Gronbaek M. Alcohol consumption 
during pregnancy and the risk of preterm delivery. Am. J. Epidemiol. 
2004;159(2):155-61. 
27. Bada HS, Das A, Bauer CR, Shankaran S, Lester BM, Gard CC, et al. Low birth 
weight and preterm births: etiologic fraction attributable to prenatal drug 
exposure. Journal of perinatology : official journal of the California 
Perinatal Association 2005;25(10):631-7. 
28. Henderson JJ, McWilliam OA, Newnham JP, Pennell CE. Preterm birth 
aetiology 2004-2008. Maternal factors associated with three phenotypes: 
spontaneous preterm labour, preterm pre-labour rupture of membranes 
and medically indicated preterm birth. J. Matern.-Fetal Neonatal Med. 
2012;25(6):642-47. 
29. Bhattacharya S, Raja EA, Mirazo ER, Campbell DM, Lee AJ, Norman JE. 
Inherited Predisposition to Spontaneous Preterm Delivery. Obstetrics and 
Gynecology 2010;115(6):1125-33. 
30. Kesmodel U, Olsen SF, Secher NJ. Does alcohol increase the risk of preterm 
delivery? Epidemiology 2000;11(5):512-18. 
31. Yuan W, Duffner A, Chen L, Hunt L, Sellers S, Bernal A. Analysis of preterm 
deliveries below 35 weeks' gestation in a tertiary referral hospital in the 
UK. A case-control survey. BMC Research Notes 2010;3(1):119. 
32. Hussain AA, Yakoob MY, Imdad A, Bhutta Z. Elective induction for 
pregnancies at or beyond 41 weeks of gestation and its impact on 
stillbirths: a systematic review with meta-analysis. BMC Public Health 
2011;11(Suppl 3):S5. 
33. Smith GCS. Life-table analysis of the risk of perinatal death at term and post 
term in singleton pregnancies. American Journal of Obstetrics and 
Gynecology 2001;184(3):489-96. 
34. Cotzias CS, Paterson-Brown S, Fisk NM. Prospective risk of unexplained 
stillbirth in singleton pregnancies at term: population based analysis. Br. 
Med. J. 1999;319(7205):287-88. 
 379 
35. Hilder L, Costeloe K, Thilaganathan B. Prolonged pregnancy: evaluating 
gestation-specific risks of fetal and infant mortality. Br. J. Obstet. 
Gynaecol. 1998;105(2):169-73. 
36. Hussain AA, Yakoob MY, Imdad A, Bhutta ZA. Elective induction for 
pregnancies at or beyond 41 weeks of gestation and its impact on 
stillbirths: a systematic review with meta-analysis. BMC Public Health 
2011;11:12. 
37. Gulmezoglu AM, Crowther CA, Middleton P. Induction of labour for improving 
birth outcomes for women at or beyond term. Cochrane Database Syst Rev 
2006;18(4). 
38. Gulmezoglu AM, Crowther CA, Middleton P, Heatley E. Induction of labour for 
improving birth outcomes for women at or beyond term. Cochrane 
Database Syst Rev 2012;2012(13). 
39. Nakling J, Backe B. Pregnancy risk increases from 41 weeks of gestation. 
Acta Obstetricia et Gynecologica Scandinavica 2006;85(6):663-68. 
40. Chantry AA, Lopez E. Fetal and neonatal complications related to prolonged 
pregnancy. J. Gynecol. Obstet. Biol. Reprod. 2011;40(8):717-25. 
41. Alexander JM, McIntire DD, Leveno KJ. Forty weeks and beyond: Pregnancy 
outcomes by week of gestation. Obstetrics and Gynecology 
2000;96(2):291-94. 
42. Caughey AB, Bishop JT. Maternal complications of pregnancy increase 
beyond 40 weeks of gestation in low-risk women. J. Perinatol. 
2006;26(9):540-45. 
43. Greve T, Lundbye-Christensen S, Nickelsen CN, Secher NJ. Maternal and 
perinatal complications by day of gestation after spontaneous labor at 40-
42 weeks of gestation. Acta Obstetricia et Gynecologica Scandinavica 
2011;90(8):852-56. 
44. NICE. Induction of Labour. 2nd ed. London: RCOG Press 2008. 
45. El Marroun H, Zeegers M, Steegers EA, van der Ende J, Schenk JJ, Hofman A, 
et al. Post-term birth and the risk of behavioural and emotional problems 
in early childhood. International Journal of Epidemiology 2012. 
46. Morken NH, Melve KK, Skjaerven R. Recurrence of prolonged and post-term 
gestational age across generations: maternal and paternal contribution. 
BJOG: An International Journal of Obstetrics & Gynaecology 
2011;118(13):1630-35. 
47. Harper LM, Caughey AB, Odibo AO, Roehl KA, Zhao Q, Cahill AG. Normal 
Progress of Induced Labor. Obstetrics & Gynecology 2012;119(6):1113-18 
10.097/AOG.0b013e318253d7aa. 
48. NHS Maternity Statistics, England:2004-2005. Leeds: The Information Centre 
CHS, 2006. 
49. Yeast JD, Jones A, Poskin M. Induction of labor and the relationship to 
cesarean delivery: A review of 7001 consecutive inductions. Am J Obstet 
Gynecol 1999;180(3 Pt 1):628-33. 
50. Seyb ST, Berka RJ, Socol ML, Dooley SL. Risk of cesarean delivery with 
elective induction of labor at term in nulliparous women. Obstet Gynecol 
1999;94(4):600-7. 
51. Cammu H, Martens G, Ruyssinck G, Amy JJ. Outcome after elective labor 
induction in nulliparous women: a matched cohort study. Am J Obstet 
Gynecol 2002;186(2):240-4. 
52. Dublin S, Lydon-Rochelle M, Kaplan RC, Watts DH, Critchlow CW. Maternal 
and neonatal outcomes after induction of labor without an identified 
indication. Am J Obstet Gynecol 2000;183(4):986-94. 
 380 
53. Maslow AS, Sweeny AL. Elective induction of labor as a risk factor for 
cesarean delivery among low-risk women at term. Obstet Gynecol 
2000;95(6 Pt 1):917-22. 
54. Grivell RM, Reilly AJ, Oakey H, Chan A, Dodd JM. Maternal and neonatal 
outcomes following induction of labor: a cohort study. Acta Obstetricia et 
Gynecologica Scandinavica 2011;91(2):198-203. 
55. Prysak M, Castronova FC. Elective induction versus spontaneous labor: a 
case-control analysis of safety and efficacy. Obstet Gynecol 
1998;92(1):47-52. 
56. Rane SM, Guirgis RR, Higgins B, Nicolaides KH. Models for the prediction of 
successful induction of labor based on pre-induction sonographic 
measurement of cervical length. J Matern Fetal Neonatal Med 
2005;17(5):315-22. 
57. Shetty A, Burt R, Rice P, Templeton A. Women's perceptions, expectations 
and satisfaction with induced labour--a questionnaire-based study. Eur J 
Obstet Gynecol Reprod Biol 2005;123(1):56-61. 
58. Leitch CR, Walker JJ. The rise in caesarean section rate: the same 
indications but a lower threshold. BJOG: An International Journal of 
Obstetrics & Gynaecology 1998;105(6):621-26. 
59. McIlwaine G, Boulton-Jones C, Cole S, Wilkinson C. Caesarean Section in 
Scotland 1994/5: a National Audit. Edinburgh: Scottish Programme for 
Clinical Effectiveness in Reproductive Health, 1998. 
60. EAGoCS. Report and Recommendations of the Expert Advisory Group on 
Caesarean Section in Scotland. Edinburgh: Scottish Programme for Clinical 
Effectiveness in Reproductive Health, 2001. 
61. Thomas J, Paranjothy S. The national sentinel caesarean section audit 
report. London: Royal College of Obstetricians and Gynaecologists Clinical 
Effectiveness Support Unit, 2001. 
62. Vahratian A, Zhang J, Troendle JF, Savitz DA, Siega-Riz AM. Maternal 
Prepregnancy Overweight and Obesity and the Pattern of Labor 
Progression in Term Nulliparous Women. Obstet Gynecol 2004;104(5):943-
51. 
63. N J Sebire, M Jolly, J P Harris, J Wadsworth, M Joffe, R W Beard, et al. 
Maternal obesity and pregnancy outcome: a study of 287 213 pregnancies 
in London. Int J Obes Relat Metab Disords 2001;25(8):1175-82. 
64. Graves BW, DeJoy SA, Heath A, Pekow P. Maternal Body Mass Index, Delivery 
Route, and Induction of Labor in a Midwifery Caseload. Journal of 
Midwifery & Women's Health 2006;51(4):254. 
65. Usha Kiran TS, Hemmadi S, Bethel J, Evans J. Outcome of pregnancy in a 
woman with an increased body mass index. BJOG: An International 
Journal of Obstetrics & Gynaecology 2005;112(6):768-72. 
66. Zhang J, Bricker L, Wray S, Quenby S. Poor uterine contractility in obese 
women. BJOG: An International Journal of Obstetrics & Gynaecology 
2007;114(3):343-8. 
67. Barau G, Robillard PY, Hulsey TC, Dedecker F, Laffite A, Gerardin P, et al. 
Linear association between maternal pre-pregnancy body mass index and 
risk of caesarean section in term deliveries. BJOG: An International 
Journal of Obstetrics & Gynaecology 2006;113(10):1173-7. 
68. Main DM, Main EK, Moore DH, 2nd. The relationship between maternal age 
and uterine dysfunction: a continuous effect throughout reproductive 
life.[see comment]. American Journal of Obstetrics & Gynecology 
2000;182(6):1312-20. 
69. Rosenthal AN, Paterson-Brown S. Is there an incremental rise in the risk of 
obstetric intervention with increasing maternal age? BJOG: An 
 381 
International Journal of Obstetrics and Gynaecology 1998;105(10):1064-
69. 
70. Ecker JL, Chen KT, Cohen AP, Riley LE, Lieberman ES. Increased risk of 
cesarean delivery with advancing maternal age: Indications and associated 
factors in nulliparous women. American Journal of Obstetrics and 
Gynecology 2001;185(4):883-87. 
71. Lialios G, Kaponis A, Adonakis G. Maternal age as an independent risk factor 
for cesarean delivery. International Journal of Gynecology &amp; 
Obstetrics 1999;67(3):187-88. 
72. Arulkumaran S, Gibb DMF, Lun KC, Heng SH, Ratnam SS. The effect of parity 
on uterine activity in labour. BJOG: An International Journal of Obstetrics 
and Gynaecology 1984;91(9):843-48. 
73. Rane SM, Guirgis RR, Higgins B, Nicolaides KH. The value of ultrasound in the 
prediction of successful induction of labor. Ultrasound in Obstetrics and 
Gynecology 2004;24(5):538-49. 
74. RCOG. Birth after Previous Caesarean Birth (Green-top Guideline No. 45). 
London: Royal College of Obstetricians and Gynaecologists, 2007. 
75. Guise J-M, McDonagh MS, Osterweil P, Nygren P, Chan BKS, Helfand M. 
Systematic review of the incidence and consequences of uterine rupture 
in women with previous caesarean section. BMJ 2004;329(7456):19. 
76. Kennare R, Tucker G, Heard A, Chan A. Risks of Adverse Outcomes in the 
Next Birth After a First Cesarean Delivery. Obstetrics & Gynecology 
2007;109(2, Part 1):270-76 10.1097/01.AOG.0000250469.23047.73. 
77. Hopkins F, Raine-Fenning N, Gee H. Prediction of vaginal delivery following 
caesarean section for failure to progress based on the initial aberrant 
labour pattern. European Journal of Obstetrics & Gynecology and 
Reproductive Biology 2002;101(2):121. 
78. Tahseen S, Griffiths M. Vaginal birth after two caesarean sections (VBAC-2)—
a systematic review with meta-analysis of success rate and adverse 
outcomes of VBAC-2 versus VBAC-1 and repeat (third) caesarean sections. 
BJOG: An International Journal of Obstetrics & Gynaecology 200;117(1):5-
19. 
79. Tita ATN, Lai Y, Bloom SL, Spong CY, Varner MW, Ramin SM, et al. Timing of 
delivery and pregnancy outcomes among laboring nulliparous women. 
American Journal of Obstetrics and Gynecology 2012;206(3):239.e1-39.e8. 
80. Bailit JL, Gregory KD, Reddy UM, Gonzalez-Quintero VH, Hibbard JU, Ramirez 
MM, et al. Maternal and neonatal outcomes by labor onset type and 
gestational age. American Journal of Obstetrics and Gynecology 
2010;202(3):245.e1-45.e12. 
81. Saving Mothers’ Lives: Reviewing maternal deaths to make motherhood 
safer: 2006–2008. BJOG: An International Journal of Obstetrics & 
Gynaecology 2011;118:1-203. 
82. Brace V, Kernaghan D, Penney G. Learning from adverse clinical outcomes: 
major obstetric haemorrhage in Scotland, 2003-05. Bjog-an International 
Journal of Obstetrics and Gynaecology 2007;114(11):1388-96. 
83. Lennox C M, L. Scottish Confidential Audit of Sever Maternal Morbidity, 7th 
Annual Report (Data from 2009). Edinburgh: Reproductive Health 
Programme, Healthcare Improvement Scotland, 2011. 
84. Moore KL, Agur AMR. Pelvis and Perineum. Essential clinical anatomy. 3rd 
edition ed. Baltimore: Williams & Wilkins, 1995. 
85. Ramsey EM. Anatomy of the uterus. In: Chard T, Grudzinskas JG, editors. The 
Uterus. Cambridge: Cambridge University Press, 1994:18-40. 
86. Young RC. Myocytes, Myometrium, and Uterine Contractions. Annals of the 
New York Academy of Sciences 2007;1101(1):72-84. 
 382 
87. Ellis H. Anatomy of the uterus. Anaesthesia &amp; Intensive Care Medicine 
2011;12(3):99-101. 
88. Gray H. Anatomy of the human body. 20th ed. Philadelphia: Bartleby, 2000. 
89. Calder AA. The cervix during pregnancy. In: Chard T, Grudzinskas JG, 
editors. The Uterus. Cambridge: Cambridge University Press, 1994:288-
307. 
90. Arrowsmith S, Quenby S, Weeks A, Burdyga T, Wray S. Poor spontaneous and 
oxytocin-stimulated contractility in human myometrium from postdates 
pregnancies. PLoS ONE 2012;7(5):10. 
91. Blanks AM, Vatish M, Allen MJ, Ladds G, de Wit NC, Slater DM, et al. 
Paracrine oxytocin and estradiol demonstrate a spatial increase in human 
intrauterine tissues with labor. J. Clin. Endocrinol. Metab. 
2003;88(7):3392-400. 
92. Luckas MJ, Wray S. A comparison of the contractile properties of human 
myometrium obtained from the upper and lower uterine segments. BJOG: 
An International Journal of Obstetrics & Gynaecology 2000;107(10):1309-
11. 
93. Ludmir J, Sehdev HM. Anatomy and physiology of the uterine cervix. Clin 
Obstet Gynecol 2000;43(3):433-9. 
94. Bauer M, Mazza E, Nava A, Zeck W, Eder M, Bajka M, et al. In vivo 
characterization of the mechanics of human uterine cervices. Ann N Y 
Acad Sci 2007:15. 
95. Oxlund B, Ortoft G, Bruel A, Danielsen C, Bor P, Oxlund H, et al. Collagen 
concentration and biomechanical properties of samples from the lower 
uterine cervix in relation to age and parity in non-pregnant women. 
Reproductive Biology and Endocrinology 2010;8(1):82. 
96. Timmons B, Akins M, Mahendroo M. Cervical remodeling during pregnancy 
and parturition. Trends Endocrinol. Metab. 2010;21(6):353-61. 
97. Nelson SM, Khan AH, Norman JE. Cervical and myometrial physiology and 
preterm labor. Expert Review of Obstetrics & Gynecology 2007;2(2):179-
92. 
98. Rorie DK, Newton M. Histologic and chemical studies of the smooth muscle in 
the human cervix and uterus. Am J Obstet Gynecol 1967;99(4):466-9. 
99. Garfield RE, Yallampalli C. Structure and function of uterine muscle. In: 
Chard T, Grudzinskas JG, editors. The Uterus. Cambridge: Cambridge 
University Press, 1994. 
100. Sokolowski P, Saison F, Giles W, McGrath S, Smith D, Smith J, et al. Human 
Uterine Wall Tension Trajectories and the Onset of Parturition. PLoS ONE 
2010;5(6):e11037. 
101. Garfield RE, Somlyo AP. Structure of Smooth Muscle. In: Grover AK, Daniel 
EE, editors. Calcium and Contractility: Smooth Muscle: Humana Press, 
1985. 
102. Favaro RR, Salgado RM, Raspantini PR, Fortes ZB, Zorn TM. Effects of long-
term diabetes on the structure and cell proliferation of the myometrium 
in the early pregnancy of mice. Int J Exp Pathol 2010;91(5):426-35. 
103. Lambert FL, Pelletier G, Dufour M, Fortier MA. Specific properties of 
smooth muscle cells from different layers of rabbit myometrium. Am J 
Physiol 1990;258(5 Pt 1):C794-802. 
104. Miller BF, O'Toole MT. Miller-Keane encyclopedia and dictionary of 
medicine, nursing, and allied health: Saunders, 2005. 
105. Weiss S, Jaermann T, Schmid P, Staempfli P, Boesiger P, Niederer P, et al. 
Three-dimensional fiber architecture of the nonpregnant human uterus 
determined ex vivo using magnetic resonance diffusion tensor imaging. 
 383 
The Anatomical Record Part A: Discoveries in Molecular, Cellular, and 
Evolutionary Biology 2006;288A(1):84-90. 
106. Aguilar HN, Mitchell BF. Physiological pathways and molecular mechanisms 
regulating uterine contractility. Human Reproduction Update 
2010;16(6):725-44. 
107. Brosens J, Barker F, deSouza N. Myometrial zonal differentiation and 
uterine junctional zone hyperplasia in the non-pregnant uterus. Human 
Reproduction Update 1998;4(5):496-502. 
108. Brosens JJ, de Souza NM, Barker FG. Uterine junctional zone: function and 
disease. Lancet 1995;346(8974):558-60. 
109. Nakai A, Togashi K, Yamaoka T, Fujiwara T, Ueda H, Koyama T, et al. 
Uterine peristalsis shown on cine MR imaging using ultrafast sequence. J 
Magn Reson Imaging 2003;18(6):726-33. 
110. Fujiwara T, Togashi K, Yamaoka T, Nakai A, Kido A, Nishio S, et al. 
Kinematics of the uterus: cine mode MR imaging. Radiographics 
2004;24(1):3. 
111. Scoutt LM, Flynn SD, Luthringer DJ, McCauley TR, McCarthy SM. Junctional 
zone of the uterus: correlation of MR imaging and histologic examination 
of hysterectomy specimens. Radiology 1991;179(2):403-7. 
112. Brown HK, Stoll BS, Nicosia SV, Fiorica JV, Hambley PS, Clarke LP, et al. 
Uterine junctional zone: correlation between histologic findings and MR 
imaging. Radiology 1991;179(2):409-13. 
113. Willms AB, Brown ED, Kettritz UI, Kuller JA, Semelka RC. Anatomic changes 
in the pelvis after uncomplicated vaginal delivery: evaluation with serial 
MR imaging. Radiology 1995;195(1):91-4. 
114. Aslanidi O, Atia J, Benson AP, van den Berg HA, Blanks AM, Choi C, et al. 
Towards a computational reconstruction of the electrodynamics of 
premature and full term human labour. Progress in Biophysics & Molecular 
Biology 2011;107(1):183-92. 
115. Taggart M, Blanks A, Kharche S, Holden A, Wang B, Zhang H. Towards 
understanding the myometrial physiome: approaches for the construction 
of a virtual physiological uterus. BMC Pregnancy and Childbirth 
2007;7(Suppl 1):S3. 
116. Blanks AM, Shmygol A, Thornton S. Myometrial function in prematurity. Best 
Practice &amp; Research Clinical Obstetrics &amp; Gynaecology 
2007;21(5):807-19. 
117. Taggart MJ, Morgan KG. Regulation of the uterine contractile apparatus and 
cytoskeleton. Semin. Cell Dev. Biol. 2007;18(3):296. 
118. Longbottom ER, Luckas MJM, Kupittayanant S, Badrick E, Shmigol T, Wray S. 
The effects of inhibiting myosin light chain kinase on contraction and 
calcium signalling in human and rat myometrium. Pflugers Archiv 
European Journal of Physiology 2000;440(2):315-21. 
119. Word RA, Stull JT, Casey ML, Kamm KE. Contractile elements and myosin 
light chain phosphorylation in myometrial tissue from nonpregnant and 
pregnant women. J Clin Invest 1993;92(1):29-37. 
120. Arrowsmith S, Kendrick A, Wray S. Drugs acting on the pregnant uterus. 
Obstetrics, Gynaecology &amp; Reproductive Medicine 2010;20(8):241-47. 
121. Somlyo AP, Somlyo AV. Signal transduction through the RhoA/Rho-kinase 
pathway in smooth muscle. Journal Of Muscle Research And Cell Motility 
2004;25(8):613-15. 
122. Moran CJ, Friel AM, Smith TJ, Cairns M, Morrison JJ. Expression and 
modulation of Rho kinase in human pregnant myometrium. Molecular 
Human Reproduction 2002;8(2):196-200. 
 384 
123. Woodcock NA, Taylor CW, Thornton S. Effect of an oxytocin receptor 
antagonist and rho kinase inhibitor on the [Ca++](i) sensitivity of human 
myometrium. American Journal of Obstetrics and Gynecology 
2004;190(1):222-28. 
124. Taggart MJ, Arthur P, Zielnik B, Mitchell BF. Molecular pathways regulating 
contractility in rat uterus through late gestation and parturition. 
American Journal of Obstetrics and Gynecology 2012;207(1):76.e15-
76.e24. 
125. Yasuda K, Nakamoto T, Yasuhara M, Okada H, Nakajima T, Kanzaki H, et al. 
Role of protein kinase Cβ in rhythmic contractions of human pregnant 
myometrium. Reproduction 2007;133(4):797-806. 
126. Webb BLJ, Hirst SJ, Giembycz MA. Protein kinase C isoenzymes: a review of 
their structure, regulation and role in regulating airways smooth muscle 
tone and mitogenesis. British Journal of Pharmacology 2000;130(7):1433-
52. 
127. Burdyga T, Wray S. Simultaneous measurements of electrical activity, 
intracellular [Ca2+] and force in intact smooth muscle. Pflugers Arch 
1997;435(1):182-4. 
128. Luckas MJM, Taggart MJ, Wray S. Intracellular calcium stores and agonist-
induced contractions in isolated human myometrium. American Journal of 
Obstetrics and Gynecology 1999;181(2):468-76. 
129. Parkington HC, Tonta MA, Brennecke SP, Coleman HA. Contractile activity, 
membrane potential, and cytoplasmic calcium in human uterine smooth 
muscle in the third trimester of pregnancy and during labor. American 
Journal of Obstetrics and Gynecology 1999;181(6):1445. 
130. Sanborn BM. Relationship of Ion Channel Activity to Control of Myometrial 
Calcium. J. Soc. Gynecol. Invest. 2000;7(1):4-11. 
131. Wray S, Jones K, Kupittayanant S, Li Y, Matthew A, Monir-Bishty E, et al. 
Calcium Signalling and Uterine Contractility. J Soc Gynecol Investig 
2003;10(5):252-64. 
132. Sanborn BM. Hormonal signaling and signal pathway crosstalk in the control 
of myometrial calcium dynamics. Semin. Cell Dev. Biol. 2007;18(3):305. 
133. Blanks AM, Zhao Z-H, Shmygol A, Bru-Mercier G, Astle S, Thornton S. 
Characterization of the molecular and electrophysiological properties of 
the T-type calcium channel in human myometrium. J Physiol 
2007;581(3):915-26. 
134. Arnaudeau S, Lepretre N, Mironneau J. Chloride and monovalent ion-
selective cation currents activated by oxytocin in pregnant rat myometrial 
cells. American Journal of Obstetrics and Gynecology 1994;171(2):491-
501. 
135. Eswaran H, Preissl H, Wilson JD, Murphy P, Robinson SE, Lowery CL. First 
magnetomyographic recordings of uterine activity with spatial-temporal 
information with a 151-channel sensor array. American Journal of 
Obstetrics and Gynecology 2002;187(1):145-51. 
136. Benson AP, Clayton RH, Holden AV, Kharche S, Tong WC. Endogenous 
driving and synchronization in cardiac and uterine virtual tissues: 
bifurcations and local coupling. Philos Transact A Math Phys Eng Sci 
2006;364(1842):1313-27. 
137. Garfield RE, Blennerhassett MG, Miller SM. Control of myometrial 
contractility: role and regulation of gap junctions. Oxf Rev Reprod Biol 
1988;10:436-90. 
138. Orsino A, Taylor CV, Lye SJ. Connexin-26 and connexin-43 are differentially 
expressed and regulated in the rat myometrium throughout late 
 385 
pregnancy and with the onset of labor. Endocrinology 1996;137(5):1545-
53. 
139. Chow L, Lye SJ. Expression of the gap junction proein connexin-43 is 
increased in the human myometrium toward term and with the onset of 
labor. American Journal of Obstetrics and Gynecology 1994;170(3):788-
95. 
140. Tattersall M, Engineer N, Khanjani S, Sooranna SR, Roberts VH, Grigsby PL, 
et al. Pro-labour myometrial gene expression: are preterm labour and 
term labour the same? Reproduction 2008;135(4):569-79. 
141. Lye SJ, Nicholson BJ, Mascarenhas M, Mackenzie L, Petrocelli T. Increased 
expression of connexin-43 in the rat myometrium during labor is 
associated with an increase in the plasma estrogen progesterone ratio. 
Endocrinology 1993;132(6):2380-86. 
142. Ou CW, Orsino A, Lye SJ. Expression of connexin-43 and connexin-26 in the 
rat myometrium during pregnancy and labor is differentially regulated by 
mechanical and hormonal signals. Endocrinology 1997;138(12):5398-407. 
143. Doring B, Shynlova O, Tsui P, Eckardt D, Janssen-Bienhold U, Hofmann F, et 
al. Ablation of connexin43 in uterine smooth muscle cells of the mouse 
causes delayed parturition. Journal of Cell Science 2006;119(9):1715-22. 
144. Chibbar R, Miller FD, Mitchell BF. Synthesis of oxytocin in amnion, chorion, 
and decidua may influence the timing of human parturition. The Journal 
of Clinical Investigation 1993;91(1):185-92. 
145. Chibbar R, Wong S, Miller FD, Mitchell BF. Estrogen stimulates oxytocin 
gene expression in human chorio-decidua. J. Clin. Endocrinol. Metab. 
1995;80(2):567-72. 
146. Dale HH. On some physiological actions of ergot. J. Physiol.-London 
1906;34(3):163-206. 
147. Dale HH. The action of extracts of the pituitary body. Biochemical Journal 
1909;4:427-47. 
148. Bell WB. The pituitary body and the therapeutic value of the infundibular 
extract in shock, uterine atony, and interstinal paresis. BMJ 
1909;2(2553):1609-13. 
149. Shmygol A, Gullam J, Blanks A, Thornton S. Multiple mechanisms involved in 
oxytocin-induced modulation of myometrial contractility. Acta 
Pharmacologica Sinica 2006;27(7):827-32. 
150. Thornton S, Smith SK. The physiological basis for administration of oxytocin 
antagonists in preterm labour. Journal of the Royal Society of Medicine 
1995;88(3):166P-70P. 
151. Blanks AM, Shmygol A, Thornton S. Regulation of oxytocin receptors and 
oxytocin receptor signaling. Seminars in Reproductive Medicine 
2007;25(1):52-9. 
152. Fuchs AR, Fuchs F, Husslein P, Soloff MS. Oxytocin receptors in the human-
uterus during pregnancy and parturition. American Journal of Obstetrics 
and Gynecology 1984;150(6):734-41. 
153. Soloff MS, Alexandrova M, Fernstrom MJ. Oxytocin receptors: triggers for 
parturition and lactation? Science 1979;204(4399):1313-5. 
154. Word RA, Stull JT, Casey ML, Kamm KE. Contractile elements and myosin 
light chain phosphorylation in myometrial tissue from nonpregnant and 
pregnant women. The Journal of Clinical Investigation 1993;92(1):29-37. 
155. Berridge MJ, Irvine RF. Inositol trisphosphate, a novel second messenger in 
cellular signal transduction. Nature 1984;312(5992):315-21. 
156. Berridge MJ. Inositol trisphosphate and calcium signalling. Nature 
1993;361(6410):315-25. 
 386 
157. Shlykov SG, Sanborn BM. Stimulation of intracellular Ca2+ oscillations by 
diacylglycerol in human myometrial cells. Cell Calcium 2004;36(2):157-64. 
158. Somlyo AP, Wu X, Walker LA, Somlyo AV. Pharmacomechanical coupling: 
the role of calcium, G-proteins, kinases and phosphatases. Reviews of 
physiology, biochemistry and pharmacology 1999;134:201-34. 
159. Kimura T, Tanizawa O, Mori K, Brownstein MJ, Okayama H. Structure and 
expression of a human oxytocin receptor. Nature 1992;356(6369):526-29. 
160. Gimpl G, Fahrenholz F. The Oxytocin Receptor System: Structure, Function, 
and Regulation. Physiol. Rev. 2001;81(2):629-83. 
161. Mitchell BF, Schmid B. Oxytocin and its Receptor in the Process of 
Parturition. J. Soc. Gynecol. Invest. 2001;8(3):122-33. 
162. Terzidou V, Blanks AM, Kim SH, Thornton S, Bennett PR. Labor and 
Inflammation Increase the Expression of Oxytocin Receptor in Human 
Amnion. Biology of Reproduction 2011;84(3):546-52. 
163. Terzidou V, Sooranna SR, Kim LU, Thornton S, Bennett PR, Johnson MR. 
Mechanical stretch up-regulates the human oxytocin receptor in primary 
human uterine myocytes. J. Clin. Endocrinol. Metab. 2005;90(1):237-46. 
164. Thornton S, Davison JM, Baylis PH. Plasma oxytocin during third stage of 
labour: comparison of natural and active management. Br. Med. J. 
1988;297(6642):167-69. 
165. Thornton S, Davison JM, Baylis PH. Plasma oxytocin during the first and 
second stages of spontaneous human labor. Acta Endocrinologica 
1992;126(5):425-29. 
166. Ferguson JKW. A study of the motility of the intact uterus at term. Surg 
Gynecol and Obstet 1941;73((3)):359-66. 
167. Fuchs AR, Romero R, Keefe D, Parra M, Oyarzun E, Behnke E. Oxytocin 
secretion and human parturition - pulse frequency and duration increase 
during spontaneous labor in women. American Journal of Obstetrics and 
Gynecology 1991;165(5):1515-23. 
168. Higuchi T, Uchide K, Honda K, Negoro H. Oxytocin release during 
parturition in the pelvic-neurectomized rat. J. Endocrinol. 
1986;109(2):149-54. 
169. O'Byrne KT, Ring JPG, Summerlee AJS. Plasma oxytocin and oxytocin neuron 
activity during delivery in rabbits. Journal of Physiology (Cambridge) 
1986;370:501-14. 
170. Summerlee AJ. Extracellular recordings from oxytocin neurones during the 
expulsive phase of birth in unanaesthetized rats. J Physiol 1981;321:1-9. 
171. Higuchi T, Okere CO. Role of the supraoptic nucleus in regulation of 
parturition and milk ejection revisited. Microsc Res Tech 2002;56(2):113-
21. 
172. Honnebier M, Mecenas CA, Jenkins SL, Nathanielsz PW. Comparison of the 
myometrial response to oxytocin during daylight with the response 
obtained during the early hours of darkness in the fetectomized rhesus-
Monkey at 160-172 days gestational-age. Biology of Reproduction 
1993;48(4):779-85. 
173. Vatish M, Steer PJ, Blanks AM, Hon M, Thornton S. Diurnal variation is lost 
in preterm deliveries before 28 weeks of gestation. Bjog-an International 
Journal of Obstetrics and Gynaecology 2010;117(6):765-67. 
174. Dickinson JE, Godfrey M, Evans SF. Antenatal patterns of uterine activity in 
low-risk women: A longitudinal study. Aust. N. Z. J. Obstet. Gynaecol. 
1997;37(2):149-52. 
175. Nageotte MP, Dorchester W, Porto M, Keegan KA, Freeman RK. Quantitation 
of uterine activity preceding preterm, term, and postterm labor. 
American Journal of Obstetrics and Gynecology 1988;158(6):1254-59. 
 387 
176. Main DM, Grisso JA, Wold T, Snyder ES, Holmes J, Chiu G. Extended 
longitudinal-study of uterine activity among low-risk women. American 
Journal of Obstetrics and Gynecology 1991;165(5):1317-22. 
177. Moore TR, Iams JD, Creasy RK, Burau KD, Davidson AL. Diurnal and 
gestationl patterns of uterine activity in normal human-pregnancy. 
Obstetrics and Gynecology 1994;83(4):517-23. 
178. Germain AM, Valenzuela GJ, Ivankovic M, Ducsay CA, Gabella C, Seronferre 
M. Relationship of circadian-rhythms of uterine activity with terma dn 
preterm delivery. American Journal of Obstetrics and Gynecology 
1993;168(4):1271-77. 
179. Fuchs AR, Behrens O, Liu HC. Correlation of nocturnal increase in plasma 
oxytocin with a decrease in plasma estradiol progesterone ratio in late 
pregnancy. American Journal of Obstetrics and Gynecology 
1992;167(6):1559-63. 
180. de Wit NCJ, Heck AJR, Thornton S. The effect of oxytocin and an oxytocin 
antagonist on the human myometrial proteome. Reproductive Sciences 
2010;17(1):40-6. 
181. Young WS, Shepard E, Amico J, Hennighausen L, Wagner KU, LaMarca ME, et 
al. Deficiency in mouse oxytocin prevents milk ejection, but not fertility 
or parturition. J. Neuroendocrinol. 1996;8(11):847-53. 
182. Kawamata M, Tonomura Y, Kimura T, Sugimoto Y, Yanagisawa T, Nishimori 
K. Oxytocin-induced phasic and tonic contractions are modulated by the 
contractile machinery rather than the quantity of oxytocin receptor. 
American Journal of Physiology - Endocrinology And Metabolism 
2007;292(4):E992-E99. 
183. Moonen P, Klok G, Keirse M. Immunohistochemical localization of 
prostaglandin endoperoxide synthase and prostacyclin synthase in 
pregnant human myometrium. Eur. J. Obstet. Gynecol. Reprod. Biol. 
1985;19(3):151-58. 
184. Moonen P, Klok G, Keirse M. Distribution of prostaglandin endoperoside 
synthase and prostacyclin synthase in the late pregnant uterus. Br. J. 
Obstet. Gynaecol. 1986;93(3):255-59. 
185. Moonen P, Klok G, Keirse M. Increase in concentrations of prostaglandin 
endoperoxide synthase and prostacyclin syntase in human myometrium in 
late pregnancy. Prostaglandins 1984;28(3):309-21. 
186. British National Formulary, http://bnf.org. 
187. McKay GR, JL. Walters MR. Lecture Notes: Clinical Pharmacology and 
Therapeutics. 8th ed: Wiley-Blackwell, 2010. 
188. Terzidou V. Biochemical and endocrinological preparation for parturition. 
Best Practice & Research Clinical Obstetrics & Gynaecology 
2007;21(5):729. 
189. Olson DM, Ammann C. Role of the prostaglandins in labour and 
prostaglandin receptor inhibitors in the prevention of preterm labour. 
Front. Biosci. 2007;12:1329-43. 
190. Olson DM. The role of prostaglandins in the initiation of parturition. Best 
Practice & Research in Clinical Obstetrics & Gynaecology 2003;17(5):717-
30. 
191. Kimura T, Ogita K, Kusui C, Ohashi K, Azuma C, Murata Y. What knockout 
mice can tell us about parturition. Reviews of Reproduction 1999;4(2):73-
80. 
192. Gross G, Imamura T, Muglia LJ. Gene knockout mice in the study of 
parturition. J. Soc. Gynecol. Invest. 2000;7(2):88-95. 
193. Grigsby PL, Sooranna SR, Adu-Amankwa B, Pitzer B, Brockman DE, Johnson 
MR, et al. Regional expression of prostaglandin E2 and F2 alpha receptors 
 388 
in human myometrium, amnion, and choriodecidua with advancing 
gestation and labor. Biology of Reproduction 2006;75(2):297-305. 
194. Myatt L, Lye SJ. Expression, localization and function of prostaglandin 
receptors in myometrium. Prostaglandins Leukot. Essent. Fatty Acids 
2004;70(2):137-48. 
195. Astle S, Thornton S, Slater DM. Identification and localization of 
prostaglandin E-2 receptors in upper and lower segment human 
myometrium during pregnancy. Molecular Human Reproduction 
2005;11(4):279-87. 
196. Arulkumaran S, Kandola MK, Hoffman B, Hanyaloglu AC, Johnson MR, 
Bennett PR. The Roles of Prostaglandin EP 1 and 3 Receptors in the 
Control of Human Myometrial Contractility. J. Clin. Endocrinol. Metab. 
2012;97(2):489-98. 
197. Olson DM, Zaragoza DB, Shallow MC, Cook JL, Mitchell BF, Grigsby P, et al. 
Myometrial activation and preterm labour: evidence supporting a role for 
the prostaglandin F receptor--a review. Placenta 2003;24 Suppl A:S47-54. 
198. Blesson CS, Buttner E, Masironi B, Sahlin L. Prostaglandin receptors EP and 
FP are regulated by estradiol and progesterone in the uterus of 
ovariectomized rats. Reproductive Biology and Endocrinology 2012;10:10. 
199. Keelan JA, Blumenstein M, Helliwell RJ, Sato TA, Marvin KW, Mitchell MD. 
Cytokines, prostaglandins and parturition--a review. Placenta 
2003;24(46):S33-46. 
200. Bennett PR, Slater D, Sullivan M, Elder MG, Moore GE. Changes in amniotic 
arachidonic-acid metabolism associated with increased cyclo-oxygenase 
gene-expression. Br. J. Obstet. Gynaecol. 1993;100(11):1037-42. 
201. Higuchi T, Uchide K, Honda K, Negoro H. Pelvic neurectomy abolishes the 
fetus-expulsion reflex and induces dystocia in the rat. Exp. Neurol. 
1987;96(2):443-55. 
202. Sugimoto Y, Yamasaki A, Segi E, Tsuboi K, Aze Y, Nishimura T, et al. Failure 
of parturition in mice lacking the prostaglandin F receptor. Science 
1997;277(5326):681-83. 
203. Blanks AM, Thornton S. Gene redundancy in parturition: lessonsfor tocolysis? 
Preterm Birth, 2007:56-59. 
204. Tsuboi K, Sugimoto Y, Iwane A, Yamamoto K, Yamamoto S, Ichikawa A. 
Uterine expression of prostaglandin H-2 synthase in late pregnancy and 
during parturition in prostaglandin F receptor-deficient mice. 
Endocrinology 2000;141(1):315-24. 
205. Gross GA, Imamura T, Luedke C, Vogt SK, Olson LM, Nelson DM, et al. 
Opposing actions of prostaglandins and oxytocin determine the onset of 
murine labor. Proceedings of the National Academy of Sciences of the 
United States of America 1998;95(20):11875-79. 
206. Blanks AM, Thornton S. The role of oxytocin in parturition. BJOG: An 
International Journal of Obstetrics & Gynaecology 2003;110 Suppl 20:46-
51. 
207. Grigsby PL, Poore KR, Hirst JJ, Jenkin G. Inhibition of premature labor in 
sheep by a combined treatment of nimesulide, a prostaglandin synthase 
type 2 inhibitor, and atosiban, an oxytocin receptor antagonist. American 
Journal of Obstetrics and Gynecology 2000;183(3):649-57. 
208. Scott JE, Grigsby PL, Hirst JJ, Jenkin G. Inhibition of prostaglandin 
synthesis and its effect on uterine activity during established premature 
labor in sheep. J. Soc. Gynecol. Invest. 2001;8(5):266-76. 
209. Blank V, Hirsch E, Challis JRG, Romero R, Lye SJ. Cytokine signaling, 
inflammation, innate immunity and preterm labour - A workshop report. 
Placenta 2008;29:S102-S04. 
 389 
210. Challis JR, Lockwood CJ, Myatt L, Norman JE, Strauss JF, Petraglia F. 
Inflammation and Pregnancy. Reproductive Sciences 2009;16(2):206-15. 
211. Bollopragada S, Youssef R, Jordan F, Greer I, Norman J, Nelson S. Term 
labor is associated with a core inflammatory response in human fetal 
membranes, myometrium, and cervix. American Journal of Obstetrics and 
Gynecology 2009;200(1):104.e1-04.e11. 
212. Haddad R, Tromp G, Kuivaniemi H, Chaiworapongsa T, Kim YM, Romero R. 
Spontaneous labor at term is characterized by a genomic signature of 
acute inflammation in the chorioamniotic membranes but not in the 
systemic circulation. American Journal Of Obstetrics And Gynecology 
2004;191(6):S138-S38. 
213. Mittal P, Romero R, Tarca AL, Gonzalez J, Draghici S, Xu Y, et al. 
Characterization of the myometrial transcriptome and biological pathways 
of spontaneous human labor at term. J. Perinat. Med. 2010;38(6):617-43. 
214. Catalano RD, Lannagan TRM, Gorowiec M, Denison FC, Norman JE, Jabbour 
HN. Prokineticins: novel mediators of inflammatory and contractile 
pathways at parturition? Molecular Human Reproduction 2010;16(5):311-
19. 
215. Liggins G. Cervical ripening as an inflammatory reaction. In: EllwoodDA A, 
editor. The Cervix in Pregnancy and Labor: Clinical and Biochemical 
Investigations. Edinburgh: Churchill-Livingstone, 1981:1-9. 
216. Bowen JM, Chamley L, Keelan JA, Mitchell MD. Cytokines of the Placenta 
and Extra-placental Membranes: Roles and Regulation During Human 
Pregnancy and Parturition. Placenta 2002;23(4):257-73. 
217. Yellon SM, Mackler AM, Kirby MA. The role of leukocyte traffic and 
activation in parturition. J. Soc. Gynecol. Invest. 2003;10(6):323-38. 
218. Liggins G. Cervical ripening as an inflammatory reaction. In: Ellwood DA, 
Anderson ABM, editors. The Cervix in pregnancy and labour: clinical and 
biochemical investigations. Edinburgh: Churchill Livingstone, 1981. 
219. Thomson AJ, Telfer JF, Young A, Campbell S, Stewart CJR, Cameron IT, et 
al. Leukocytes infiltrate the myometrium during human parturition: 
further evidence that labour is an inflammatory process. Hum. Reprod. 
1999;14(1):229-36. 
220. Osman I, Young A, Ledingham MA, Thomson AJ, Jordan F, Greer IA, et al. 
Leukocyte density and pro-inflammatory cytokine expression in human 
fetal membranes, decidua, cervix and myometrium before and during 
labour at term. Mol. Hum. Reprod. 2003;9(1):41-45. 
221. Winkler M. Role of cytokines and other inflammatory mediators. BJOG: An 
International Journal of Obstetrics & Gynaecology 2003;110:118-23. 
222. LEDINGHAM MA, THOMSON AJ, JORDAN F, YOUNG A, CRAWFORD M, NORMAN 
JE. Cell Adhesion Molecule Expression in the Cervix and Myometrium 
During Pregnancy and Parturition. Obstetrics & Gynecology 
2001;97(2):235-42. 
223. Young A, Thomson AJ, Ledingham M, Jordan F, Greer IA, Norman JE. 
Immunolocalization of Proinflammatory Cytokines in Myometrium, Cervix, 
and Fetal Membranes During Human Parturition at Term. Biology of 
Reproduction 2002;66(2):445-49. 
224. Hansen WR, Keelan JA, Skinner SJM, Mitchell MD. Key enzymes of 
prostaglandin biosynthesis and metabolism. Coordinate regulation of 
expression by cytokines in gestational tissues: a review. Prostaglandins 
&amp; Other Lipid Mediators 1999;57(4):243-57. 
225. Romero R, Mazor M, Tartakovsky B. Systemic administration of interleukin-1 
induces preterm parturition in mice. American Journal of Obstetrics and 
Gynecology 1991;165(4):969-71. 
 390 
226. Lindstrom TM, Bennett PR. The role of nuclear factor kappa B in human 
labour. Reproduction 2005;130(5):569-81. 
227. Newton R, Kuitert LME, Bergmann M, Adcock IM, Barnes PJ. Evidence for 
Involvement of NF-ÎºB in the Transcriptional Control of COX-2 Gene 
Expression by IL-1Î². Biochemical and Biophysical Research 
Communications 1997;237(1):28-32. 
228. Yang X, Sheares KK, Davie N, Upton PD, Taylor GW, Horsley J, et al. 
Hypoxic induction of cox-2 regulates proliferation of human pulmonary 
artery smooth muscle cells. American journal of respiratory cell and 
molecular biology 2002;27(6):688-96. 
229. Shimizu N, Ozawa Y, Yamaguchi M, Goseki T, Ohzeki K, Abiko Y. Induction 
of COX-2 expression by mechanical tension force in human periodontal 
ligament cells. Journal of periodontology 1998;69(6):670-77. 
230. Goldenberg RL, Hauth JC, Andrews WW. Mechanisms of disease - 
Intrauterine infection and preterm delivery. New England Journal of 
Medicine 2000;342(20):1500-07. 
231. Keelan JA. Pharmacological inhibition of inflammatory pathways for the 
prevention of preterm birth. Journal of Reproductive Immunology 
2011;88(2):176-84. 
232. Golightly E, Jabbour HN, Norman JE. Endocrine immune interactions in 
human parturition. Molecular and Cellular Endocrinology 2011;335(1):52-
59. 
233. Sykes L MD, Teoh TG, Bennett PR. Targeting Immune Activation in the 
Prevention of Pre-term Labour. European Obstetrics & Gynaecology 
2011;6(2):100-06. 
234. Romero R, Gotsch F, Pineles B, Kusanovic JP. Inflammation in pregnancy: 
Its roles in reproductive physiology, obstetrical complications, and fetal 
injury. Nutrition Reviews 2007;65(12):S194-S202. 
235. Romero R, Espinoza J, Goncalves LF, Kusanovic JP, Friel L, Hassan S. The 
role of inflammation and infection in preterm birth. Seminars in 
Reproductive Medicine 2007;25(1):21-39. 
236. Romero R, Espinoza J, GonÃ§alves LsF, Kusanovic JP, Friel LA, Nien JK. 
Inflammation in preterm and term labour and delivery. Seminars in Fetal 
and Neonatal Medicine 2006;11(5):317-26. 
237. MacIntyre DA, Sykes L, Teoh TG, Bennett PR. Prevention of pre-term labour 
via the modulation of inflammatory pathways. Journal of Maternal-Fetal 
and Neonatal Medicine 2012;0(ja):1-16. 
238. Elovitz MA. Anti-inflammatory interventions in pregnancy: Now and the 
future. Seminars in Fetal and Neonatal Medicine 2006;11(5):327-32. 
239. RCOG. Tocolysis for Women in Preterm Labour, Green-top Guideline No. 1b. 
London: Royal College of Obstetricians and Gynaecologists, 2011. 
240. Groom KM, Shennan AH, Jones BA, Seed P, Bennett PR. TOCOX—A 
randomised, double-blind, placebo-controlled trial of rofecoxib (a COX-2-
specific prostaglandin inhibitor) for the prevention of preterm delivery in 
women at high risk. BJOG: An International Journal of Obstetrics & 
Gynaecology 2005;112(6):725-30. 
241. King J, Flenady V, Cole S, Thornton S. Cyclo-oxygenase (COX) inhibitors for 
treating preterm labour. Cochrane database of systematic reviews 
(Online) 2005(2):CD001992. 
242. Haddad R, Tromp G, Kuivaniemi H, Chaiworapongsa T, Kim YM, Mazor M, et 
al. Human spontaneous labor without histologic chorioamnionitis is 
characterized by an acute inflammation gene expression signature. 
American Journal Of Obstetrics And Gynecology 2006;195(2):394-405. 
 391 
243. Bukowski R, Hankins GD, Saade GR, Anderson GD, Thornton S. Labor-
associated gene expression in the human uterine fundus, lower segment, 
and cervix.[see comment]. PLoS Medicine / Public Library of Science 
2006;3(6):e169. 
244. Bethin KE, Nagai Y, Sladek R, Asada M, Sadovsky Y, Hudson TJ, et al. 
Microarray Analysis of Uterine Gene Expression in Mouse and Human 
Pregnancy. Molecular Endocrinology 2003;17(8):1454-69. 
245. Aguan K, Carvajal JA, Thompson LP, Weiner CP. Application of a functional 
genomics approach to identify differentially expressed genes in human 
myometrium during pregnancy and labour. Molecular Human 
Reproduction 2000;6(12):1141-45. 
246. Weiner CP, Mason CW, Dong Y, Buhimschi IA, Swaan PW, Buhimschi CS. 
Human effector/initiator gene sets that regulate myometrial contractility 
during term and preterm labor. American Journal of Obstetrics and 
Gynecology 2010;202(5):474.e1-20. 
247. Holt R, Timmons BC, Akgul Y, Akins ML, Mahendroo M. The Molecular 
Mechanisms of Cervical Ripening Differ between Term and Preterm Birth. 
Endocrinology 2011;152(3):1036-46. 
248. Mahendroo M. Cervical remodeling in term and preterm birth: insights from 
an animal model. Reproduction 2012;143(4):429-38. 
249. Ohama T, Hori M, Momotani E, Iwakura Y, Guo F, Kishi H, et al. Intestinal 
inflammation downregulates smooth muscle CPI-17 through induction of 
TNF-alpha and causes motility disorders. American Journal of Physiology-
Gastrointestinal and Liver Physiology 2007;292(5):G1429-G38. 
250. Ohama T, Hori M, Sato K, Ozaki H, Karaki H. Chronic treatment with 
interleukin-1 beta attenuates contractions by decreasing the activities of 
CPI-17 and MYPT-1 in intestinal smooth muscle. Journal of Biological 
Chemistry 2003;278(49):48794-804. 
251. Uwe S. Anti-inflammatory interventions of NF-kappaB signaling: potential 
applications and risks. Biochem Pharmacol 2008;75(8):1567-79. 
252. Lim S, MacIntyre DA, Lee YS, Khanjani S, Terzidou V, Teoh TG, et al. 
Nuclear Factor Kappa B Activation Occurs in the Amnion Prior to Labour 
Onset and Modulates the Expression of Numerous Labour Associated 
Genes. PLoS ONE 2012;7(4):12. 
253. Khanjani S, Kandola MK, Lindstrom TM, Sooranna SR, Melchionda M, Lee YS, 
et al. NF-kappaB regulates a cassette of immune/inflammatory genes in 
human pregnant myometrium at term. J Cell Mol Med 2011;15(4):809-24. 
254. Hua R, Pease JE, Sooranna SR, Viney JM, Nelson SM, Myatt L, et al. Stretch 
and Inflammatory Cytokines Drive Myometrial Chemokine Expression Via 
NF-kappa B Activation. Endocrinology 2012;153(1):481-91. 
255. Cookson VJ, Chapman NR. NF-kappaB function in the human myometrium 
during pregnancy and parturition. Histol Histopathol 2010;25(7):945-56. 
256. Belt AR, Baldassare JJ, Molnar M, Romero R, Hertelendy F. The nuclear 
transcription factor NF-kappa B mediates interleukin-1 beta-induced 
expression of cyclooxygenase-2 in human myometrial cells. American 
Journal of Obstetrics and Gynecology 1999;181(2):359-66. 
257. Hardy DB, Janowski BA, Corey DR, Mendelson CR. Progesterone Receptor 
Plays a Major Antiinflammatory Role in Human Myometrial Cells by 
Antagonism of Nuclear Factor-ÎºB Activation of Cyclooxygenase 2 
Expression. Molecular Endocrinology 2006;20(11):2724-33. 
258. Eliopoulos AG, Dumitru CD, Wang C-C, Cho J, Tsichlis PN. Induction of COX-
2 by LPS in macrophages is regulated by Tpl2-dependent CREB activation 
signals. EMBO J 2002;21(18):4831-40. 
 392 
259. Wadleigh DJ, Reddy ST, Kopp E, Ghosh S, Herschman HR. Transcriptional 
Activation of the Cyclooxygenase-2 Gene in Endotoxin-treated RAW 264.7 
Macrophages. Journal of Biological Chemistry 2000;275(9):6259-66. 
260. Lamont RF. Infection in the prediction and antibiotics in the prevention of 
spontaneous preterm labour and preterm birth. Bjog-an International 
Journal of Obstetrics and Gynaecology 2003;110:71-75. 
261. Klein LL, Gibbs RS. Use of microbial cultures and antibiotics in the 
prevention of infection-associated preterm birth. American Journal of 
Obstetrics and Gynecology 2004;190(6):1493-502. 
262. Morken NH, Gunnes N, Magnus P, Jacobsson B. Risk of spontaneous preterm 
delivery in a low-risk population: the impact of maternal febrile episodes, 
urinary tract infection, pneumonia and ear-nose-throat infections. 
European Journal of Obstetrics & Gynecology and Reproductive Biology 
2011;159(2):310-14. 
263. Kaga N, Katsuki Y, Obata M, Shibutani Y. Repeated administration of low-
dose lipopolysaccharide induces preterm delivery in mice: A model for 
human preterm parturition and for assessment of the therapeutic ability 
of drugs against preterm delivery. American Journal of Obstetrics and 
Gynecology 1996;174(2):754-59. 
264. Ryan GB, Majno G. Acute inflammation. American Journal of Pathology 
1977;86(1):185-276. 
265. Playfair JHL. Immunology at a Glance. Sixth Edition ed. Oxford: Blackwell 
Science, 1996. 
266. Kenyon SL, Taylor DJ, Tarnow-Mordi W, Grp OC. Broad-spectrum antibiotics 
for spontaneous preterm labour: the ORACLE II randomised trial. Lancet 
2001;357(9261):989-94. 
267. King J, Flenady V. Prophylactic antibiotics for inhibiting preterm labour 
with intact membranes. Cochrane database of systematic reviews 
(Online) 2002(4):CD000246. 
268. Lamont RF. Infection in the prediction and antibiotics in the prevention of 
spontaneous preterm labour and preterm birth. BJOG: An International 
Journal of Obstetrics and Gynaecology 2003;110, Supplement 20(0):71-75. 
269. Romero R, Oyarzun E, Mazor M, Sirtori M, Hobbins JC, Bracken M. Meta-
analysis of the relationship between asymptomatic bacteriuria and 
preterm delivery low birth-weight. Obstetrics and Gynecology 
1989;73(4):576-82. 
270. McDonald HM, Brocklehurst P, Gordon A. Antibiotics for treating bacterial 
vaginosis in pregnancy. Cochrane Database of Systematic Reviews 
2007(1):66. 
271. Simcox R, Sin W-TA, Seed PT, Briley A, Shennan AH. Prophylactic antibiotics 
for the prevention of preterm birth in women at risk: A meta-analysis. 
Australian and New Zealand Journal of Obstetrics and Gynaecology 
2007;47(5):368-77. 
272. Saitoh M, Ishikawa T, Matsushima S, Naka M, Hidaka H. Selective inhibition 
of catalytic activity of smooth muscle myosin light chain kinase. Journal 
of Biological Chemistry 1987;262(16):7796-801. 
273. Sigma-Aldrich. ML-7 Product Details, 
http://www.sigmaaldrich.com/catalog/ProductDetail.do?D7=0&N5=SEARC
H_CONCAT_PNO|BRAND_KEY&N4=I2764|SIGMA&N25=0&QS=ON&F=SPEC. 
274. Cohen P. The effective use of protein kinase inhibitors. Sigma-Aldrich 
Application Notes 2003:20-23. 
275. Bain J, McLauchlan H, Elliott M, Cohen P. The specificities of protein kinase 
inhibitors: an update. Biochemical Journal 2003;371:199-204. 
 393 
276. King JF, Flenady VJ, Papatsonis DN, Dekker GA, Carbonne B. Calcium 
channel blockers for inhibiting preterm labour. Cochrane Database Syst 
Rev 2003;1. 
277. Anotayanonth S, Subhedar NV, Garner P, Neilson JP, Harigopal S. 
Betamimetics for inhibiting preterm labour. Cochrane Database Syst Rev 
2004;18(4). 
278. Whitworth M, Quenby S. Prophylactic oral betamimetics for preventing 
preterm labour in singleton pregnancies. Cochrane Database Syst Rev 
2008;23(1). 
279. Dodd JM, Crowther CA, Dare MR, Middleton P. Oral betamimetics for 
maintenance therapy after threatened preterm labour. Cochrane 
Database Syst Rev 2006;25(1). 
280. Morrison JJ, Ashford MLJ, Khan RN, Smith SK. The effects of potassium 
channel openers on isolated pregnant human myometrium before and 
after the onset of labor - potential for tocolysis. American Journal of 
Obstetrics and Gynecology 1993;169(5):1277-85. 
281. Suzuki S, Yano K, Kusano S, Hashimoto T. Antihypertensive effect of 
levcromakalim in patients with essential hypertension. Study by 24-h 
ambulatory blood pressure monitoring. Arzneimittelforschung 
1995;45(8):859-64. 
282. Galik M, Gaspar R, Kolarovszki-Sipiczki Z, Falkay G. Gestagen treatment 
enhances the tocolytic effect of salmeterol in hormone-induced preterm 
labor in the rat in vivo. Am J Obstet Gynecol 2008;198(3):e1-5. 
283. Chanrachakul B, Pipkin FB, Warren AY, Arulkumaran S, Khan RN. 
Progesterone enhances the tocolytic effect of ritodrine in isolated 
pregnant human myometrium. American Journal of Obstetrics and 
Gynecology 2005;192(2):458-63. 
284. Baumbach J, Shi SQ, Shi L, Balducci J, Coonrod DV, Garfield RE. Inhibition 
of uterine contractility with various tocolytics with and without 
progesterone: in vitro studies. Am J Obstet Gynecol 2012;206(3):16. 
285. Anderson L, Martin W, Higgins C, Nelson SM, Norman JE. The Effect of 
Progesterone on Myometrial Contractility, Potassium Channels, and 
Tocolytic Efficacy. Reproductive Sciences 2009;16(11):1052-61. 
286. Anderson L. The Myometrial Effects of Progesterone. University of Glasgow, 
2009. 
287. Norman JE, Mackenzie F, Owen P, Mactier H, Hanretty K, Cooper S, et al. 
Progesterone for the prevention of preterm birth in twin pregnancy 
(STOPPIT): a randomised, double-blind, placebo-controlled study and 
meta-analysis. Lancet 2009;373(9680):2034-40. 
288. Rozenberg P, Chauveaud A, Deruelle P, Capelle M, Winer N, DesbriÃ¨re R, 
et al. Prevention of preterm delivery after successful tocolysis in preterm 
labor by 17 alpha-hydroxyprogesterone caproate: A randomized controlled 
trial. American Journal of Obstetrics and Gynecology 2012;206(3):206.e1-
06.e9. 
289. Mackenzie R, Walker M, Armson A, Hannah ME. Progesterone for the 
prevention of preterm birth among women at increased risk: A systematic 
review and meta-analysis of randomized controlled trials. American 
Journal of Obstetrics and Gynecology 2006;194(5):1234-42. 
290. Dodd JM, Flenady VJ, Cincotta R, Crowther CA. Progesterone for the 
prevention of preterm birth - A systematic review. Obstetrics and 
Gynecology 2008;112(1):127-34. 
291. Thornton S, Terzidou V, Clark A, Blanks A. Progesterone metabolite and 
spontaneous myometrial contractions in vitro. Lancet 
1999;353(9161):1327-9. 
 394 
292. Wilson RJ, Allen MJ, Nandi M, Giles H, Thornton S. Spontaneous 
contractions of myometrium from humans, non-human primate and 
rodents are sensitive to selective oxytocin receptor antagonism in vitro. 
BJOG: An International Journal of Obstetrics & Gynaecology 
2001;108(9):960-6. 
293. Papatsonis D, Flenady V, Cole S, Liley H. Oxytocin receptor antagonists for 
inhibiting preterm labour.[see comment]. Cochrane Database of 
Systematic Reviews 2005(3):CD004452. 
294. Papatsonis D, Flenady V, Liley H. Maintenance therapy with oxytocin 
antagonists for inhibiting preterm birth after threatened preterm labour. 
Cochrane Database of Systematic Reviews 2009(1). 
295. Dennedy MC, Avalos G, O'Reilly MW, O'Sullivan EP, Gaffney G, Dunne F. 
ATLANTIC-DIP: Raised Maternal Body Mass Index (BMI) Adversely Affects 
Maternal and Fetal Outcomes in Glucose-Tolerant Women According to 
International Association of Diabetes and Pregnancy Study Groups 
(IADPSG) Criteria. J. Clin. Endocrinol. Metab. 2012;97(4):E608-E12. 
296. Cedergren MI. Maternal Morbid Obesity and the Risk of Adverse Pregnancy 
Outcome. Obstet Gynecol 2004;103(2):219-24. 
297. Dietz PM, Callaghan WM, Cogswell ME, Morrow B, Ferre C, Schieve LA. 
Combined effects of prepregnancy body mass index and weight gain 
during pregnancy on the risk of preterm delivery. Epidemiology 
2006;17(2):170-7. 
298. Stotland NE, Washington AE, Caughey AB. Prepregnancy body mass index 
and the length of gestation at term. American Journal of Obstetrics and 
Gynecology 2007;197(4):378.e1-78.e5. 
299. Smith RD, Babiychuk EB, Noble K, Draeger A, Wray S. Increased cholesterol 
decreases uterine activity: functional effects of cholesterol alteration in 
pregnant rat myometrium. Am J Physiol Cell Physiol 2005;288(5):C982-88. 
300. Zhang J, Kendrick A, Quenby S, Wray S. Contractility and Calcium Signalling 
of Human Myometrium Are Profoundly Affected by Cholesterol 
Manipulation: Implications for Labor? Reproductive Sciences 
2007;14(5):456-66. 
301. Moynihan AT, Hehir MP, Glavey SV, Smith TJ, Morrison JJ. Inhibitory effect 
of leptin on human uterine contractility in vitro. American Journal of 
Obstetrics and Gynecology 2006;195(2):504. 
302. Elmes MJ, Tan DSY, Cheng Z, Wathes DC, McMullen S. The effects of a high-
fat, high-cholesterol diet on markers of uterine contractility during 
parturition in the rat. Reproduction 2011;141(2):283-90. 
303. Vahratian A, Hoffman MK, Troendle JF, Zhang J. The impact of parity on 
course of labor in a contemporary population. Birth 2006;33(1):12-7. 
304. Martel M, Wacholder S, Lippman A, Brohan J, Hamilton E. Maternal age and 
primary cesarean section rates: a multivariate analysis. Am J Obstet 
Gynecol 1987;156(2):305-8. 
305. Heinberg EM, Wood RA, Chambers RB. Elective induction of labor in 
multiparous women. Does it increase the risk of cesarean section? J 
Reprod Med 2002;47(5):399-403. 
306. Fraser AM, Brockert JE, Ward RH. Association of Young Maternal Age with 
Adverse Reproductive Outcomes. New England Journal of Medicine 
1995;332(17):1113-18. 
307. Black C, Kaye JA, Jick H. Cesarean delivery in the United Kingdom - Time 
trends in the general practice research database. Obstetrics and 
Gynecology 2005;106(1):151-55. 
 395 
308. Marwick JC, Lynn R. High caesarean section rates among,women over 30 - 
Effect of age is continuous and international. Br. Med. J. 
2001;323(7307):284-84. 
309. Graseck AS, Odibo AO, Tuuli M, Roehl KA, Macones GA, Cahill AG. Normal 
first stage of labor in women undergoing trial of labor after cesarean 
delivery. Obstet Gynecol 2012;119(4):732-6. 
310. Stock S, Norman J. Preterm and term labour in multiple pregnancies. Semin 
Fetal Neonatal Med 2012;15(6):336-41. 
311. Many A, Hill LM, Lazebnik N, Martin JG. The association between 
polyhydramnios and preterm delivery. Obstet Gynecol 1995;86(3):389-91. 
312. Loudon JA, Sooranna SR, Bennett PR, Johnson MR. Mechanical stretch of 
human uterine smooth muscle cells increases IL-8 mRNA expression and 
peptide synthesis. Molecular Human Reproduction 2004;10(12):895-9. 
313. Shynlova O, Tsui P, Dorogin A, Lye SJ. Monocyte chemoattractant protein-1 
(CCL-2) integrates mechanical and endocrine signals that mediate term 
and preterm Labor. J. Immunol. 2008;181(2):1470-79. 
314. Sparey C, Robson SC, Bailey J, Lyall F, Nicholas Europe-Finner G. The 
Differential Expression of Myometrial Connexin-43, Cyclooxygenase-1 and 
-2, and GsÎ± Proteins in the Upper and Lower Segments of the Human 
Uterus during Pregnancy and Labor. J. Clin. Endocrinol. Metab. 
1999;84(5):1705-10. 
315. Menzies FM, Khan AH, Higgins CA, Nelson SM, Nibbs RJB. The Chemokine 
Receptor CCR2 Is Not Required for Successful Initiation of Labor in Mice. 
Biology of Reproduction 2012. 
316. Durnwald CP, Mercer BM. Myometrial thickness according to uterine site, 
gestational age and prior cesarean delivery. Journal of Maternal Fetal & 
Neonatal Medicine 2008;21(4):247-50. 
317. Crankshaw DJ, Morrison JJ. Methodology and pharmacological analysis of 
effects of uterotonic compounds in human myometrium in vitro. American 
Journal of Obstetrics and Gynecology 2011;205(2):6. 
318. Product 475981  Myosin Light Chain Kinase Inhibitor Peptide 18 
http://www.merck-chemicals.com/is-
bin/INTERSHOP.enfinity/WFS/Merck-GB-Site/en_US/-/GBP/ViewPDF-
Print.pdf?RenderPageType=ProductDetail&CatalogCategoryID=Dcib.s1OezA
AAAEjtRl9.zLX&ProductUUID=0eqb.s1OqV8AAAEaiMssKi67&PortalCatalogU
UID=ywGb.s1LAyMAAAEWzdUfVhTl. Nottingham: Merck Chemicals Limited, 
2010. 
319. McKendrick JD, Paisley K, Eason S, Mian KB, Martin W. Induction of nitric 
oxide synthase by endotoxin in rat isolated aorta but not in rat aortic 
smooth muscle cells grown in culture from explant. Archives 
Internationales de Pharmacodynamie et de Therapie 1995;330(2):206-24. 
320. Ferrari D, Pizzirani C, Adinolfi E, Forchap S, Sitta B, Turchet L, et al. The 
Antibiotic Polymyxin B Modulates P2X7 Receptor Function. J Immunol 
2004;173(7):4652-60. 
321. Pierce JG, Gordon S, Duvigneaud V. Further distribution studies on the 
oxytocic hormone of the posterior lobe of the pituitary glasnd and the 
preparation of an active crystalline flavianate. Journal of Biological 
Chemistry 1952;199(2):929-40. 
322. Vigneaud VD, Ressler C, Swan JM, Roberts CW, Katsoyannis PG, Gordon S. 
The synthesis of an octapeptide amide with the hormonal activity of 
oxytocin. Journal of the American Chemical Society 1953;75(19):4879-80. 
323. Vigneaud VD, Ressler C, Trippett S. The sequence of amino acids in 
oxytocin, with a proposal for the structure of oxytocin. Journal of 
Biological Chemistry 1953;205(2):949-57. 
 396 
324. Vigneaud VD. A Trail of Sulfa Research: From Insulin to Oxytocin. Nobel 
Lectures, Chemistry 1942-1962. Amsterdam: Elsevier Publishing Company, 
1964. 
325. Hicks J. On the contractions of the uterus throughout pregnancy: their 
physiological effects and their value in the diagnosis of pregnancy. 
Transactions of the Obstetrical Society of London 1871;13:216-31. 
326. Dunn PM. John Braxton Hicks (1823â€“97) and painless uterine contractions. 
Archives of Disease in Childhood - Fetal and Neonatal Edition 
1999;81(2):F157-F58. 
327. Park ES, Echetebu CO, Soloff S, Soloff MS. Oxytocin stimulation of RGS2 
mRNA expression in cultured human myometrial cells. American Journal 
of Physiology - Endocrinology & Metabolism 2002;282(3):E580-4. 
328. Lin SM, Du P, Huber W, Kibbe WA. Model-based variance-stabilizing 
transformation for Illumina microarray data. Nucleic Acids Research 
2008;36(2):e11. 
329. Smyth GK. Limma: linear models for microarray data. In: Gentleman V, 
Carey S, Dudoit R, Irizarry WH, editors. Bioinformatics and Computational 
Biology Solutions using R and Bioconductor, R. New York: Springer, 
2005:397-420. 
330. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical 
and Powerful Approach to Multiple Testing. Journal of the Royal 
Statistical Society. Series B (Methodological) 1995;57(1):289-300. 
331. Feise R. Do multiple outcome measures require p-value adjustment? BMC 
Medical Research Methodology 2002;2(1):8. 
332. Rothman KJ. No adjustments are needed for multiple comparisons. 
Epidemiology (Cambridge, Mass.) 1990;1(1):43-6. 
333. Bacchetti P. Peer review of statistics in medical research: the other 
problem. BMJ 2002;324(7348):1271-73. 
334. Goodman SN. Multiple Comparisons, Explained. Am. J. Epidemiol. 
1998;147(9):807-12. 
335. The Gene Ontology, http://www.geneontology.org/, 2012. 
336. KEGG: Kyoto Encyclopedia of Genes and Genomes, 
http://www.genome.jp/kegg/, 2012. 
337. NCBI. CCL3L3 chemokine (C-C motif) ligand 3-like 3 [ Homo sapiens ] Gene 
ID: 414062 http://www.ncbi.nlm.nih.gov/gene/414062, 2012. 
338. NCBI. CCL4L1 chemokine (C-C motif) ligand 4-like 1 [ Homo sapiens ] Gene 
ID: 9560 http://www.ncbi.nlm.nih.gov/gene/9560, 2012. 
339. Dhawan J, Helfman DM. Modulation of acto-myosin contractility in skeletal 
muscle myoblasts uncouples growth arrest from differentiation. Journal of 
Cell Science 2004;117(17):3735-48. 
340. Duran JM, Valderrama F, Castel S, Magdalena J, TomÃ¡s Mn, Hosoya H, et 
al. Myosin Motors and Not Actin Comets Are Mediators of the Actin-based 
Golgi-to-Endoplasmic Reticulum Protein Transport. Molecular Biology of 
the Cell 2003;14(2):445-59. 
341. Helfman DM, Pawlak G. Myosin light chain kinase and acto-myosin 
contractility modulate activation of the ERK cascade downstream of 
oncogenic Ras. Journal of Cellular Biochemistry 2005;95(5):1069-80. 
342. Mahoney DJ, Parise G, Melov S, Safdar A, Tarnopolsky MA. Analysis of global 
mRNA expression in human skeletal muscle during recovery from 
endurance exercise. The FASEB Journal 2005;19(11):1498-500. 
343. Chen Y-W, Hubal MJ, Hoffman EP, Thompson PD, Clarkson PM. Molecular 
responses of human muscle to eccentric exercise. Journal of Applied 
Physiology 2003;95(6):2485-94. 
 397 
344. Livak KJ, Schmittgen TD. Analysis of Relative Gene Expression Data Using 
Real-Time Quantitative PCR and the 2-KKCt Method. Methods 
2001;25(4):402-08. 
345. User Bulletin #2 ABI Prism 7700 Sequence Detection System, Relative 
Quantification of Gene Expression: Applied Biosystems, 2001. 
346. Baumbach J, Shi S-Q, Shi L, Balducci J, Coonrod DV, Garfield RE. Inhibition 
of uterine contractility with various tocolytics with and without 
progesterone: in vitro studies. American Journal of Obstetrics and 
Gynecology 2011;206(3):254.e1-54.e5. 
347. Norman JE, Yuan MF, Anderson L, Howie F, Harold G, Young A, et al. Effect 
of Prolonged In Vivo Administration of Progesterone in Pregnancy on 
Myometrial Gene Expression, Peripheral Blood Leukocyte Activation, and 
Circulating Steroid Hormone Levels. Reproductive Sciences 
2011;18(5):435-46. 
348. Critchley HOD, Jones RL, Lea RG, Drudy TA, Kelly RW, Williams ARW, et al. 
Role of inflammatory mediators in human endometrium during 
progesterone withdrawal and early pregnancy. J. Clin. Endocrinol. Metab. 
1999;84(1):240-48. 
349. Elovitz M, Wang Z. Medroxyprogesterone acetate, but not progesterone, 
protects against inflammation-induced parturition and intrauterine fetal 
demise. American Journal of Obstetrics and Gynecology 2004;190(3):693-
701. 
350. Hutzal CE, Boyle EM, Kenyon SL, Nash JV, Winsor S, Taylor DJ, et al. Use of 
antibiotics for the treatment of preterm parturition and prevention of 
neonatal morbidity: a metaanalysis. American Journal of Obstetrics and 
Gynecology 2008;199(6):620.e1-20.e8. 
351. Serhan CN. Novel Lipid Mediators and Resolution Mechanisms in Acute 
Inflammation: To Resolve or Not? The American Journal of Pathology 
2010;177(4):1576-91. 
352. Janeway C. Immunobiology: the immune system in health and disease: 
Current Biology Publications, 1999. 
353. Bochner BS. Road signs guiding leukocytes along the inflammation 
superhighway. The Journal of allergy and clinical immunology 
2000;106(5):817-28. 
354. Leong AS, Norman JE, Smith R. Vascular and myometrial changes in the 
human uterus at term. Reproductive Sciences 2008;15(1):59-65. 
355. BALLOCH AJ, CAUCHI MN. Reference ranges for haematology parameters in 
pregnancy derived from patient populations. Clinical & Laboratory 
Haematology 1993;15(1):7-14. 
356. Griffin JFT, Beck I. A longitudinal study of leucocyte numbers and 
mitogenesis during the last ten weeks of human pregnancy. Journal of 
Reproductive Immunology 1983;5(4):239-47. 
357. Lurie S, Rahamim E, Piper I, Golan A, Sadan O. Total and differential 
leukocyte counts percentiles in normal pregnancy. European Journal of 
Obstetrics &amp; Gynecology and Reproductive Biology 2008;136(1):16-
19. 
358. Valdimarsson H, Mulholland C, Fridriksdottir V, Coleman DV. A longitudinal 
study of leucocyte blood counts and lymphocyte responses in pregnancy: a 
marked early increase of monocyte-lymphocyte ratio. Clinical & 
Experimental Immunology 1983;53(2):437-43. 
359. Dawson DW. Eosinophils and pregnancy. Journal of Obstetrics & 
Gynaecology of the British Empire 1953;60(5):727-31. 
 398 
360. Luppi P, Haluszczak C, Betters D, Richard CAH, Trucco M, DeLoia JA. 
Monocytes are progressively activated in the circulation of pregnant 
women. Journal of Leukocyte Biology 2002;72(5):874-84. 
361. Kraus T, Engel S, Sperling R, Kellerman L, Lo Y, Wallenstein S, et al. 
Characterizing the Pregnancy Immune Phenotype: Results of the Viral 
Immunity and Pregnancy (VIP) Study. Journal of Clinical Immunology:1-
12. 
362. Delgado I, Neubert R, Dudenhausen JW. Changes in white blood cells during 
parturition in mothers and newborn. Gynecologic & Obstetric 
Investigation 1994;38(4):227-35. 
363. Rodriguez-Dennen F, Martinez-Ocana J, Kawa-Karasik S, Villanueva-Egan L, 
Reyes-Paredes N, Flisser A, et al. Comparison of hemodynamic, 
biochemical and hematological parameters of healthy pregnant women in 
the third trimester of pregnancy and the active labor phase. BMC 
Pregnancy and Childbirth 2011;11(1):33. 
364. Griffin JFT, Beck I. CHANGES IN MATERNAL PERIPHERAL LEUCOCYTES 
AROUND DELIVERY. BJOG: An International Journal of Obstetrics & 
Gynaecology 1980;87(5):402-07. 
365. Bass DA. Behavior of eosinophil leukocytes in acute inflammation. II. 
Eosinophil dynamics during acute inflammation. The Journal of Clinical 
Investigation 1975;56(4):870-79. 
366. van Ginhoven TM, Dik WA, Mitchell JR, Nijenhuis MAS-t, van Holten-Neelen 
C, Hooijkaas H, et al. Dietary Restriction Modifies Certain Aspects of the 
Postoperative Acute Phase Response. Journal of Surgical 
Research;171(2):582-89. 
367. Desborough JP. The stress response to trauma and surgery. British Journal 
of Anaesthesia 2000;85(1):109-17. 
368. Bartal I, Melamed R, Greenfeld K, Atzil S, Glasner A, Domankevich V, et al. 
Immune perturbations in patients along the perioperative period: 
Alterations in cell surface markers and leukocyte subtypes before and 
after surgery. Brain Behav. Immun. 2010;24(3):376-86. 
369. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. 
Definitions for sepsis and organ failure and guidelines for the use of 
innovative therapies in sepsis. The ACCP/SCCM Consensus Conference 
Committee. American College of Chest Physicians/Society of Critical Care 
Medicine. Chest 1992;101(6):1644-55. 
370. Thorley JD, Smith JW, Luby JP, Sanford JP. Peripheral blood lymphocyte 
response to acute infections in humans. Infection and Immunity 
1977;16(1):110-14. 
371. Levy MMMDF, Fink MPMDF, Marshall JCMD, Abraham EMD, Angus DMDMPHF, 
Cook DMDF, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis 
Definitions Conference. Critical Care Medicine 2003;31(4):1250-56. 
372. Yuan M, Jordan F, McInnes IB, Harnett MM, Norman JE. Leukocytes are 
primed in peripheral blood for activation during term and preterm labour. 
Molecular Human Reproduction 2009;15(11):713-24. 
373. Picklesimer AH, Jared HL, Moss K, Offenbacher S, Beck JD, Boggess KA. 
Racial differences in C-reactive protein levels during normal pregnancy. 
American Journal of Obstetrics and Gynecology 2008;199(5):523.e1-23.e6. 
374. Watts DHM, Krohn MAP, Wener MHM, Eschenbach DAM. C-Reactive Protein 
in Normal Pregnancy. Obstetrics & Gynecology 1991;77(2):176-80. 
375. Makhseed M, Raghupathy R, Azizieh F, Farhat R, Hassan N, Bandar A. 
Circulating cytokines and CD30 in normal human pregnancy and recurrent 
spontaneous abortions. Human Reproduction 2000;15(9):2011-17. 
 399 
376. Curry AE, Vogel I, Skogstrand K, Drews C, Schendel DE, Flanders WD, et al. 
Maternal plasma cytokines in early- and mid-gestation of normal human 
pregnancy and their association with maternal factors. Journal of 
Reproductive Immunology 2008;77(2):152-60. 
377. Kronborg CS, Gjedsted J, Vittinghus E, Hansen TK, Allen JIM, Knudsen UB. 
Longitudinal measurement of cytokines in pre-eclamptic and 
normotensive pregnancies. Acta Obstetricia et Gynecologica Scandinavica 
2011;90(7):791-96. 
378. Kraus TA, Sperling RS, Engel SM, Lo Y, Kellerman L, Singh T, et al. 
Peripheral Blood Cytokine Profiling During Pregnancy and Post-partum 
Periods. American Journal of Reproductive Immunology 2010;64(6):411-
26. 
379. Hamilton S, Oomomian Y, Stephen G, Shynlova O, Tower CL, Garrod A, et 
al. Macrophages Infiltrate the Human and Rat Decidua During Term and 
Preterm Labor: Evidence That Decidual Inflammation Precedes Labor. 
Biology of Reproduction. 
380. Gomez-Lopez N, Guilbert LJ, Olson DM. Invasion of the leukocytes into the 
fetal-maternal interface during pregnancy. Journal of Leukocyte 
Biology;88(4):625-33. 
381. Bisits AM, Smith R, Mesiano S, Yeo G, Kwek K, MacIntyre D, et al. 
Inflammatory Aetiology of Human Myometrial Activation Tested Using 
Directed Graphs. PLoS Comput Biol 2005;1(2):e19. 
382. Gorowiec MR, Catalano RD, Norman JE, Denison FC, Jabbour HN. 
Prokineticin 1 Induces Inflammatory Response in Human Myometrium A 
Potential Role in Initiating Term and Preterm Parturition. American 
Journal of Pathology;179(6):2709-19. 
383. Walsh NP, Gleeson M, Shephard RJ, Gleeson M, Woods JA, Bishop NC, et al. 
Position Statement Part one: Immune function and exercise. Exercise 
Immunology Review 2011;17:6-63. 
384. Pedersen BK. Exercise and cytokines. Immunol Cell Biol 2000;78(5):532-35. 
385. Pedersen BK, Toft AD. Effects of exercise on lymphocytes and cytokines. 
British Journal of Sports Medicine 2000;34(4):246-51. 
386. Clarkson PM, Hubal MJ. Exercise-induced muscle damage in humans. 
American Journal of Physical Medicine & Rehabilitation 2002;81(11 
Suppl):S52-69. 
387. Mair J, Koller A, Artner-Dworzak E, Haid C, Wicke K, Judmaier W, et al. 
Effects of exercise on plasma myosin heavy chain fragments and MRI of 
skeletal muscle. Journal of Applied Physiology 1992;72(2):656-63. 
388. Peake J, Wilson G, Hordern M, Suzuki K, Yamaya K, Nosaka K, et al. 
Changes in neutrophil surface receptor expression, degranulation, and 
respiratory burst activity after moderate- and high-intensity exercise. J 
Appl Physiol 2004;97(2):612-18. 
389. Smith LL. Acute inflammation: the underlying mechanism in delayed onset 
muscle soreness? Medicine & Science in Sports & Exercise 1991;23(5):542-
51. 
390. Shivvers SA, Wians FH, Jr., Keffer JH, Ramin SM. Maternal cardiac troponin I 
levels during normal labor and delivery. American Journal of Obstetrics & 
Gynecology 1999;180(1 Pt 1):122. 
391. Kosowicz J, Gryczyska M, Drews K. ELEVATION OF MATERNAL SERUM 
MYOGLOBIN CONCENTRATIONS DURING DELIVERY. BJOG: An International 
Journal of Obstetrics & Gynaecology 1981;88(6):628-31. 
392. Abramov Y, Abramov D, Abrahamov A, Durst R, Schenker J. Elevation of 
serum creatine phosphokinase and its MB isoenzyme during normal labor 
 400 
and early puerperium. Acta Obstetricia et Gynecologica Scandinavica 
1996;75(3):255-60. 
393. Rothenberg ME, Hogan SP. THE EOSINOPHIL. Annual Review of Immunology 
2006;24(1):147-74. 
394. Karasuyama H, Mukai K, Obata K, Tsujimura Y, Wada T. Nonredundant Roles 
of Basophils in Immunity. Annual Review of Immunology 2011;29(1):45-69. 
395. Rottman JB. Key Role of Chemokines and Chemokine Receptors in 
Inflammation, Immunity, Neoplasia, and Infectious Disease. Veterinary 
Pathology Online 1999;36(5):357-67. 
396. Baggiolini M. Chemokines in pathology and medicine. Journal of Internal 
Medicine 2001;250(2):91-104. 
397. Roberts PJ, Pizzey AR, Khwaja A, Carver JE, Mire-Sluis AR, Linch DC. The 
effects of interleukin-8 on neutrophil fMetLeuPhe receptors, CD11b 
expression and metabolic activity, in comparison and combination with 
other cytokines. British Journal of Haematology 1993;84(4):586-94. 
398. White JR, Lee JM, Young PR, Hertzberg RP, Jurewicz AJ, Chaikin MA, et al. 
Identification of a Potent, Selective Non-peptide CXCR2 Antagonist That 
Inhibits Interleukin-8-induced Neutrophil Migration. Journal of Biological 
Chemistry 1998;273(17):10095-98. 
399. Lippert U, Zachmann K, Henz BM, Neumann C. Human T lymphocytes and 
mast cells differentially express and regulate extra- and intracellular 
CXCR1 and CXCR2. Experimental Dermatology 2004;13(8):520-25. 
400. NCBI. CXCR1 chemokine (C-X-C motif) receptor 1 [ Homo sapiens ] Gene ID: 
3577 http://www.ncbi.nlm.nih.gov/gene/3577, 2012. 
401. NCBI. CXCR2 chemokine (C-X-C motif) receptor 2 [ Homo sapiens ] Gene ID: 
3579 http://www.ncbi.nlm.nih.gov/gene/3579, 2012. 
402. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998;392(6676):565-
68. 
403. NCBI. CCR2 chemokine (C-C motif) receptor 2 [ Homo sapiens ] Gene ID: 
729230 http://www.ncbi.nlm.nih.gov/gene/729230, 2012. 
404. Combadiere C, Ahuja SK, Van Damme J, Tiffany HL, Gao J-L, Murphy PM. 
Monocyte Chemoattractant Protein-3 Is a Functional Ligand for CC 
Chemokine Receptors 1 and 2B. Journal of Biological Chemistry 
1995;270(50):29671-75. 
405. Gong X, Gong W, Kuhns DB, Ben-Baruch A, Howard OMZ, Wang JM. 
Monocyte Chemotactic Protein-2 (MCP-2) Uses CCR1 AND CCR2B as Its 
Functional Receptors. Journal of Biological Chemistry 
1997;272(18):11682-85. 
406. Godiska R, Chantry D, Raport CJ, Schweickart VL, Trong HL, Gray PW. 
Monocyte chemotactic protein-4: tissue-specific expression and signaling 
through CC chemokine receptor-2. Journal of Leukocyte Biology 
1997;61(3):353-60. 
407. NCBI. CCR6 chemokine (C-C motif) receptor 6 [ Homo sapiens ] Gene ID: 
1235 http://www.ncbi.nlm.nih.gov/gene/1235, 2012. 
408. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. The Journal 
of Clinical Investigation 2003;111(12):1805-12. 
409. Laurence AS. Serum myoglobin and creatine kinase following surgery. 
British Journal of Anaesthesia 2000;84(6):763-6. 
410. Payne RM, Friedman DL, Grant JW, Perryman MB, Strauss AW. Creatine 
kinase isoenzymes are highly regulated during pregnancy in rat uterus and 
placenta. Am J Physiol Endocrinol Metab 1993;265(4):E624-35. 
411. Qiu Y, Sutton L, Riggs AF. Identification of myoglobin in human smooth 
muscle. Journal of Biological Chemistry 1998;273(36):23426-32. 
 401 
412. Stone MJ, Waterman MR, Harimoto D, Murray G, Willson N, Platt MR, et al. 
Serum myoglobin level as diagnostic test in patients with acute 
myocardial infarction. British Heart Journal 1977;39(4):375-80. 
413. McCracken S, Layton JE, Shorter SC, Starkey PM, Barlow DH, Mardon HJ. 
Expression of granulocyte-colony stimulating factor and its receptor is 
regulated during the development of the human placenta. J. Endocrinol. 
1996;149(2):249-58. 
414. Walter J, Fraga L, Orin M, Decker W, Gipps T, Stek A, et al. 
Immunomodulatory factors in cervicovaginal secretions from pregnant and 
non-pregnant women: A cross-sectional study. BMC Infectious Diseases 
2011;11(1):263. 
415. Nibbs R, Graham G, Rot A. Chemokines on the move: control by the 
chemokine â€œinterceptorsâ€  Duffy blood group antigen and D6. 
Seminars in Immunology 2003;15(5):287-94. 
416. Mantovani A, Bonecchi R, Locati M. Tuning inflammation and immunity by 
chemokine sequestration: decoys and more. Nat Rev Immunol 
2006;6(12):907-18. 
417. Hansell C, Simpson C, Nibbs R. Chemokine sequestration by atypical 
chemokine receptors. Biochem Soc Trans. 2006;34(Pt 6):1009-13. 
418. Graham GJ. D6 and the atypical chemokine receptor family: Novel 
regulators of immune and inflammatory processes. European Journal of 
Immunology 2009;39(2):342-51. 
419. Hansell C, Hurson C, Nibbs R. DARC and D6: silent partners in chemokine 
regulation? Immunol 2010;89(2):197-206. Epub 2010 Dec 14. 
420. Nibbs R, Wylie S, Yang J, Landau N, Graham G. Cloning and characterization 
of a novel promiscuous human beta-chemokine receptor D6. J Biol Chem. 
1997;272(51):32078-83. 
421. Novitzky-Basso I, Rot A. Duffy antigen receptor for chemokines and its 
involvement in patterning and control of inflammatory chemokines. Front 
2012;3:266. Epub 2012 Aug 17. 
422. Cochain C, Auvynet C, Poupel L, Vilar J, Dumeau E, Richart A, et al. The 
chemokine decoy receptor D6 prevents excessive inflammation and 
adverse ventricular remodeling after myocardial infarction. Arterioscler 
Thromb Vasc Biol 2012;32(9):2206-13. doi: 10.1161/ATVBAHA.112.254409. 
Epub 2012 Jul 12. 
423. Borroni E, Bonecchi R, Buracchi C, Savino B, Mantovani A, Locati M. 
Chemokine decoy receptors: new players in reproductive immunology. 
Immunol Invest 2008;37(5):483-97. 
424. Lanza A. Creatine kinase in serum after uterus contraction produced by 
oxytocin. Cellular and Molecular Life Sciences 1968;24(4):337-37. 
425. Pizza FX, Koh TJ, McGregor SJ, Brooks SV, Pizza FX, Koh TJ, et al. Muscle 
inflammatory cells after passive stretches, isometric contractions, and 
lengthening contractions. Journal of Applied Physiology 2002;92(5):1873-
8. 
426. Pizza FX, Mitchell JB, Davis BH, Starling RD, Holtz RW, Bigelow N. Exercise-
induced muscle damage: effect on circulating leukocyte and lymphocyte 
subsets. Medicine & Science in Sports & Exercise 1995;27(3):363-70. 
427. Smith LL, McKune AJ, Semple SJ, Sibanda E, Steel H, Anderson R, et al. 
Changes in serum cytokines after repeated bouts of downhill running. 
Applied Physiology, Nutrition, & Metabolism = Physiologie Appliquee, 
Nutrition et Metabolisme 2007;32(2):233-40. 
428. Smith LL, Anwar A, Fragen M, Rananto C, Johnson R, Holbert D. Cytokines 
and cell adhesion molecules associated with high-intensity eccentric 
exercise. European Journal of Applied Physiology 2000;82(1-2):61-7. 
 402 
429. Tidball JG. Inflammatory processes in muscle injury and repair. American 
Journal of Physiology - Regulatory, Integrative and Comparative 
Physiology 2005;288(2):R345-R53. 
430. Smith L, McCammon M, Smith S, Chamness M, Israel R, O'Brien K. White 
blood cell response to uphill walking and downhill jogging at similar 
metabolic loads. European Journal of Applied Physiology and 
Occupational Physiology 1989;58(8):833-37. 
431. Lu H, Huang D, Saederup N, Charo IF, Ransohoff RM, Zhou L. Macrophages 
recruited via CCR2 produce insulin-like growth factor-1 to repair acute 
skeletal muscle injury. Faseb J. 2011;25(1):358-69. 
432. Yahiaoui L, Gvozdic D, Danialou G, Mack M, Petrof BJ. CC family 
chemokines directly regulate myoblast responses to skeletal muscle 
injury. J Physiol 2008;586(16):3991-4004. 
433. Lu H, Huang D, Ransohoff RM, Zhou L. Acute skeletal muscle injury: CCL2 
expression by both monocytes and injured muscle is required for repair. 
Faseb J 2011;25(10):3344-55. 
434. Negishi H, Kishida T, Yamada H, Hirayama E, Mikuni M, Fujimoto S. Changes 
in uterine size after vaginal delivery and cesarean section determined by 
vaginal sonography in the puerperium. Archives of Gynecology & 
Obstetrics 1999;263(1-2):13-6. 
435. Mulic-Lutvica A, Axelsson O. Postpartum ultrasound in women with 
postpartum endometritis, after cesarean section and after manual 
evacuation of the placenta. Acta Obstetricia et Gynecologica Scandinavica 
2007;86(2):210-17. 
436. Hirani V. Chapter 5: Anthropometric Measures, Overweight, and Obesity. In: 
Bromley C, Sproston K, Shelton N, editors. The Scottish Health Survey 
2003 - Volume 2. Edinburgh: Scottish Executive, 2005:168-206. 
437. Hirani V. Chapter 6: Anthropometric measures, overweight, and obesity   
In: Sprotston K, Primatesta P, editors. Health Survey for England 2003.  
Volume 2: Risk factors for cardiovascular disease. London: Department of 
Health, 2004:143-80. 
438. Statistics on Obesity, Physical Activity and Diet: England, February 2009 
http://www.ic.nhs.uk/statistics-and-data-collections/health-and-
lifestyles/obesity/statistics-on-obesity-physical-activity-and-diet-england-
february-2009. 
439. Kanagalingam MG, Forouhi NG, Greer IA, Sattar N. Changes in booking body 
mass index over a decade: retrospective analysis from a Glasgow 
Maternity Hospital. BJOG: An International Journal of Obstetrics and 
Gynaecology 2005;112(10):1431-33. 
440. Heslehurst N, Ells LJ, Simpson H, Batterham A, Wilkinson J, Summerbell CD. 
Trends in maternal obesity incidence rates, demographic predictors, and 
health inequalities in 36 821 women over a 15-year period. BJOG: An 
International Journal of Obstetrics & Gynaecology 2007;114(2):187-94. 
441. Cnattingius S, Bergstrom R, Lipworth L, Kramer MS. Prepregnancy Weight 
and the Risk of Adverse Pregnancy Outcomes. N Engl J Med 
1998;338(3):147-52. 
442. Smith GC. A population study of birthweight and the risk of caesarean 
section: Scotland 1980-1996. BJOG: An International Journal of Obstetrics 
& Gynaecology 2000;107(6):740-4. 
443. Wischnik A, Lehmann K, Ziegler M, Georgi M, Melchert F. Does the 'fatty 
pelvis' exist?  Quantitative computer tomography studies. Z Geburtshilfe 
Perinatol 1992;196(6):247-52. 
 403 
444. Buhimschi CS, Buhimschi IA, Malinow AM, Weiner CP. Intrauterine Pressure 
During the Second Stage of Labor in Obese Women. Obstet Gynecol 
2004;103(2):225-30. 
445. Noble K, Zhang J, Wray S. Lipid rafts, the sarcoplasmic reticulum and 
uterine calcium signalling: an integrated approach. Journal of Physiology 
2006;570(Pt 1):29-35. 
446. Ramsay JE, Ferrell WR, Crawford L, Wallace AM, Greer IA, Sattar N. 
Maternal Obesity Is Associated with Dysregulation of Metabolic, Vascular, 
and Inflammatory Pathways. J Clin Endocrinol Metab 2002;87(9):4231-37. 
447. Pinheiro J, Bates, Douglas Mixed-Effects Models in S and S-PLUS. 1st ed ed. 
New York ; London: Springer, 2000. 
448. Efron BT, Robert J. An introduction to the bootstrap. 1 edition ed. London: 
Chapman & Hall/CRC, 1993. 
449. Mazurkiewicz JC, Watts GF, Warburton FG, Slavin BM, Lowy C, Koukkou E. 
Serum lipids, lipoproteins and apolipoproteins in pregnant non-diabetic 
patients. J Clin Pathol 1994;47(8):728-31. 
450. Gimpl G, Fahrenholz F. Cholesterol as stabilizer of the oxytocin receptor. 
Biochimica et Biophysica Acta (BBA) - Biomembranes 2002;1564(2):384. 
451. Bastiaanse EML, Hold KM, Van der Laarse A. The effect of membrane 
cholesterol content on ion transport processes in plasma membranes. 
Cardiovascular Research 1997;33(2):272. 
452. Sattar N, Greer IA, Louden J, Lindsay G, McConnell M, Shepherd J, et al. 
Lipoprotein Subfraction Changes in Normal Pregnancy: Threshold Effect of 
Plasma Triglyceride on Appearance of Small, Dense Low Density 
Lipoprotein. J Clin Endocrinol Metab 1997;82(8):2483-91. 
453. Turi A, Kiss AL, Mullner N. ESTROGEN DOWNREGULATES THE NUMBER OF 
CAVEOLAE AND THE LEVEL OF CAVEOLIN IN UTERINE SMOOTH MUSCLE. 
Cell Biology International 2001;25(8):785. 
454. Chiossi G, Costantine MM, Betancourt A, Hankins GDV, Longo M, Saade GR, 
et al. Effect of maternal body mass index on in vitro response to 
tocolytics in term myometrium. American Journal of Obstetrics and 
Gynecology 2010;203(3):5. 
455. Stewart FM, Freeman DJ, Ramsay JE, Greer IA, Caslake M, Ferrell WR. 
Longitudinal Assessment of Maternal Endothelial Function and Markers of 
Inflammation and Placental Function throughout Pregnancy in Lean and 
Obese Mothers. J Clin Endocrinol Metab 2007;92(3):969-75. 
456. Myers J, Hall C, Wareing M, Gillham J, Baker P. The effect of maternal 
characteristics on endothelial-dependent relaxation of myometrial 
arteries. European Journal of Obstetrics & Gynecology and Reproductive 
Biology 2006;124(2):158. 
457. Larcombe-McDouall J, Buttell N, Harrison N, Wray S. In vivo pH and 
metabolite changes during a single contraction in rat uterine smooth 
muscle. Journal of Physiology 1999;518(Pt 3):783-90. 
458. Quenby S, Pierce SJ, Brigham S, Wray S. Dysfunctional labor and 
myometrial lactic acidosis.[erratum appears in Obstet Gynecol. 2004 
Jun;103(6):1344]. Obstetrics & Gynecology 2004;103(4):718-23. 
459. Muller-Delp JM. Aging-induced adaptations of microvascular reactivity. 
Microcirculation 2006;13(4):301-14. 
460. Anim-Nyame N, Gamble J, Sooranna SR, Johnson MR, Sullivan MH, Steer PJ. 
Evidence of impaired microvascular function in pre-eclampsia: a non-
invasive study. Clin. Sci. 2003;104(4):405-12. 
461. Edwards C, Witter FR. Preeclampsia, labor duration and mode of delivery. 
International Journal of Gynecology & Obstetrics 1997;57(1):39. 
 404 
462. Griffiths AN, Hikary N, Sizer AR. Induction to delivery time interval in 
patients with and without preeclampsia: a retrospective analysis. Acta 
Obstetricia et Gynecologica Scandinavica 2002;81(9):867-9. 
463. Blanch G, Lavender T, Walkinshaw S, Alfirevic Z. Dysfunctional labour: a 
randomised trial. British Journal of Obstetrics & Gynaecology 
1998;105(1):117-20. 
464. Smith GCS, Celik E, To M, Khouri O, Nicolaides KH. Cervical Length at Mid-
Pregnancy and the Risk of Primary Cesarean Delivery. The New England 
Journal of Medicine 2008;358:In press. 
465. Gee H, Taylor EW, Hancox R. A model for the generation of intra-uterine 
pressure in the human parturient uterus which demonstrates the critical 
role of the cervix. Journal of Theoretical Biology 1988;133(3):281. 
466. Olah KSJ, Neilson JP. Failure to progress in the management of labour. 
BJOG: An International Journal of Obstetrics and Gynaecology 
1994;101(1):1-3. 
467. Moser K, Macfarlane A, Chow Y, Hilder L, Dattani N. Introducing new data 
on gestation-specific infant mortality among babies born in 2005 in 
England and Wales. Health Stat Q. 2007(35):13-27. 
468. Kramer M, Demissie K, Yang H, Platt R, Sauve R, Liston R. The contribution 
of mild and moderate preterm birth to infant mortality. Fetal and Infant 
Health Study Group of the Canadian Perinatal Surveillance System. JAMA. 
2000;284(7):843-9. 
469. Singer L, Salvator A, Guo S, Collin M, Lilien L, Baley J. Maternal 
psychological distress and parenting stress after the birth of a very low-
birth-weight infant. JAMA. 1999;281(9):799-805. 
470. Taylor HG, Klein N, Minich NM, Hack M. Long-term family outcomes for 
children with very low birth weights. Arch Pediatr Adolesc Med 
2001;155(2):155-61. 
471. Brennan DJ, McGee SF, Rexhepaj E, O'Connor DP, Robson M, O'Herlihy C. 
Identification of a myometrial molecular profile for dystocic labor. BMC 
Pregnancy and Childbirth 2011;11:10. 
472. King J, Flenady V. Prophylactic antibiotics for inhibiting preterm labour 
with intact membranes. Cochrane Database Syst Rev 2002;4. 
473. Nielsen S, Pedersen BK. Skeletal muscle as an immunogenic organ. Curr 
Opin Pharmacol 2008;8(3):346-51. 
474. White BG, Williams SJ, Highmore K, Macphee DJ. Small heat shock protein 
27 (Hsp27) expression is highly induced in rat myometrium during late 
pregnancy and labour. Reproduction 2005;129(1):115-26. 
475. MacIntyre DA, Tyson EK, Read M, Smith R, Yeo G, Kwek K, et al. 
Contraction in human myometrium is associated with changes in small 
heat shock proteins. Endocrinology 2008;149(1):245-52. 
476. White BG, MacPhee DJ. Distension of the uterus induces HspB1 expression in 
rat uterine smooth muscle. Am J Physiol Regul Integr Comp Physiol 
2011;301(5):7. 
477. MacIntyre DA, Tyson EK, Read M, Smith R, Yeo G, Kwek K, et al. 
Contraction in human myometrium is associated with changes in small 
heat shock proteins. Endocrinology 2008;149(1):245-52. 
478. Oldham RS, Menzies FM, Nibbs RJB, Nelson SM. Identification of a dominant 
T cell subpopulation in the uterine horn during postpartum remodelling. 
Immunology 2011;135:120-20. 
479. Thompson PD, Buchner D, PiÃ±a IL, Balady GJ, Williams MA, Marcus BH, et 
al. Exercise and Physical Activity in the Prevention and Treatment of 
Atherosclerotic Cardiovascular Disease. Arteriosclerosis, Thrombosis, and 
Vascular Biology 2003;23(8):e42-e49. 
 405 
480. Mandic S, Tymchak W, Kim D, Daub B, Quinney HA, Taylor D, et al. Effects 
of aerobic or aerobic and resistance training on cardiorespiratory and 
skeletal muscle function in heart failure: a randomized controlled pilot 
trial. Clinical Rehabilitation 2009;23(3):207-16. 
481. Melzer K, Schutz Y, Boulvain M, Kayser B. Physical Activity and Pregnancy 
Cardiovascular Adaptations, Recommendations and Pregnancy Outcomes. 
Sports Med. 2010;40(6):493-507. 
482. Jones AM, Carter H. The effect of endurance training on parameters of 
aerobic fitness. Sports Med. 2000;29(6):373-86. 
483. UPBEAT. UK Pregnancies Better Eating and Activity Trial (UPBEAT), 
http://www.medscinet.net/upbeat/default.aspx. London, 2012. 
 
 
